|
1A1M
MHC CLASS I MOLECULE B*5301 COMPLEXED WITH PEPTIDE TPYDINQML FROM GAG PROTEIN OF HIV2
Deposited 1997-12-11
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；18% PEG8000 0.1M SODIUM CACODYLATE PH6.5 0.2M CALCIUM ACETATE
|
Resolution 2.30 Å
|
|
1A1N
MHC CLASS I MOLECULE B*3501 COMPLEXED WITH PEPTIDE VPLRPMTY FROM THE NEF PROTEIN (75-82) OF HIV1
Deposited 1997-12-11
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；18% PEG8000 0.1M SODIUM CACODYLATE PH6.5 0.2M CALCIUM ACETATE
|
Resolution 2.00 Å
|
|
1A1O
MHC CLASS I MOLECULE B*5301 COMPLEXED WITH PEPTIDE LS6 (KPIVQYDNF) FROM THE MALARIA PARASITE P. FALCIPARUM
Deposited 1997-12-11
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；18% PEG8000 0.1M SODIUM CACODYLATE PH6.5 0.2M CALCIUM ACETATE
|
Resolution 2.30 Å
|
|
1A6Z
HFE (HUMAN) HEMOCHROMATOSIS PROTEIN
Deposited 1998-03-04
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；pH 6.5
|
Resolution 2.60 Å
R-free 0.277
|
|
1A6Z
HFE (HUMAN) HEMOCHROMATOSIS PROTEIN
Deposited 1998-03-04
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；pH 6.5
|
Resolution 2.60 Å
R-free 0.277
|
|
1A9B
DECAMER-LIKE CONFORMATION OF A NANO-PEPTIDE BOUND TO HLA-B3501 DUE TO NONSTANDARD POSITIONING OF THE C-TERMINUS
Deposited 1998-04-03
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.6；20% MPD, 20% PEG 6000, 1% GLYCEROL, 100 MM SODIUM CITRATE, PH 5.6
|
Resolution 3.20 Å
R-free 0.305
|
|
1A9B
DECAMER-LIKE CONFORMATION OF A NANO-PEPTIDE BOUND TO HLA-B3501 DUE TO NONSTANDARD POSITIONING OF THE C-TERMINUS
Deposited 1998-04-03
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.6；20% MPD, 20% PEG 6000, 1% GLYCEROL, 100 MM SODIUM CITRATE, PH 5.6
|
Resolution 3.20 Å
R-free 0.305
|
|
1A9E
DECAMER-LIKE CONFORMATION OF A NANO-PEPTIDE BOUND TO HLA-B3501 DUE TO NONSTANDARD POSITIONING OF THE C-TERMINUS
Deposited 1998-04-05
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.9；4 M SODIUM FORMATE, PH 7.9
|
Resolution 2.50 Å
R-free 0.260
|
|
1AGB
ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGRKKYKL-3R MUTATION)
Deposited 1997-03-24
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：EXTRACELLULAR
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；30% PEG 4000 0.1M SODIUM CITRATE, PH 6.5 0.2M AMMONIUM ACETATE
|
Resolution 2.20 Å
|
|
1AGC
ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGKKKYQL-7Q MUTATION)
Deposited 1997-03-24
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：EXTRACELLULAR
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；30% PEG 4000 0.1M SODIUM CITRATE, PH 6.5 0.03M AMMONIUM ACETATE
|
Resolution 2.10 Å
|
|
1AGD
ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGKKKYKL-INDEX PEPTIDE)
Deposited 1997-03-24
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：EXTRACELLULAR
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；30% PEG 4000 0.1M SODIUM CITRATE, PH 6.5 0.2M AMMONIUM ACETATE
|
Resolution 2.05 Å
|
|
1AGE
ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGKKKYRL-7R MUTATION)
Deposited 1997-03-24
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：EXTRACELLULAR
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；30% PEG 4000 0.1M SODIUM CITRATE, PH 6.5 0.03M AMMONIUM ACETATE
|
Resolution 2.30 Å
|
|
1AGF
ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGKKRYKL-5R MUTATION)
Deposited 1997-03-24
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：EXTRACELLULAR
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；30% PEG 4000 0.1M SODIUM CITRATE, PH 6.5 0.03M AMMONIUM ACETATE
|
Resolution 2.20 Å
|
|
1AKJ
COMPLEX OF THE HUMAN MHC CLASS I GLYCOPROTEIN HLA-A2 AND THE T CELL CORECEPTOR CD8
Deposited 1997-05-21
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：EXTRACELLULAR DOMAIN
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；PROTEIN WAS CRYSTALLIZED FROM 12% PEG 20000, 100 MM MES, PH 6.5
|
Resolution 2.65 Å
R-free 0.276
|
|
1AO7
COMPLEX BETWEEN HUMAN T-CELL RECEPTOR, VIRAL PEPTIDE (TAX), AND HLA-A 0201
Deposited 1997-07-21
|
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Mutation：Y67C, K91C
|
EMC ETHYL MERCURY ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；CRYSTALLIZED FROM 10% PEG 8000, 100 MM MGACETATE, 50 MM NACACODYLATE, PH 6.5
|
Resolution 2.60 Å
R-free 0.320
|
|
1AO7
COMPLEX BETWEEN HUMAN T-CELL RECEPTOR, VIRAL PEPTIDE (TAX), AND HLA-A 0201
Deposited 1997-07-21
|
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 10
PDB declaration: decameric
|
Chain B
21–119（99 aa）
|
Mutation：Y67C, K91C
|
EMC ETHYL MERCURY ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；CRYSTALLIZED FROM 10% PEG 8000, 100 MM MGACETATE, 50 MM NACACODYLATE, PH 6.5
|
Resolution 2.60 Å
R-free 0.320
|
|
1B0G
CLASS I HISTOCOMPATIBILITY ANTIGEN (HLA-A2.1)/BETA 2-MICROGLOBULIN/PEPTIDE P1049 COMPLEX
Deposited 1998-11-09
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
11–110（100 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；PROTEIN WAS CRYSTALLIZED IN THE HANGING DROP VAPOR DIFFUSION METHOD. THE RESERVOIR SOLUTION CONTAINED 12-16% PEG6000, 6% DIOXANE IN 25MM MES BUFFER, PH6.5. THE HANGING DROP WAS A 1:1 MIXTURE OF THE RESERVOIR SOLUTION AND THE PROTEIN SOLUTION WHICH CONTAINED 10MG/ML PROTEIN IN 25MM MES BUFFER, PH6.5., vapor diffusion - hanging drop
|
Resolution 2.50 Å
R-free 0.304
|
|
1B0G
CLASS I HISTOCOMPATIBILITY ANTIGEN (HLA-A2.1)/BETA 2-MICROGLOBULIN/PEPTIDE P1049 COMPLEX
Deposited 1998-11-09
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
11–110（100 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；PROTEIN WAS CRYSTALLIZED IN THE HANGING DROP VAPOR DIFFUSION METHOD. THE RESERVOIR SOLUTION CONTAINED 12-16% PEG6000, 6% DIOXANE IN 25MM MES BUFFER, PH6.5. THE HANGING DROP WAS A 1:1 MIXTURE OF THE RESERVOIR SOLUTION AND THE PROTEIN SOLUTION WHICH CONTAINED 10MG/ML PROTEIN IN 25MM MES BUFFER, PH6.5., vapor diffusion - hanging drop
|
Resolution 2.50 Å
R-free 0.304
|
|
1B0R
CRYSTAL STRUCTURE OF HLA-A*0201 COMPLEXED WITH A PEPTIDE WITH THE CARBOXYL-TERMINAL GROUP SUBSTITUTED BY A METHYL GROUP
Deposited 1998-11-12
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：BETA 2 MICROGLOBULIN
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；pH 6.50
|
Resolution 2.90 Å
R-free 0.314
|
|
1BD2
COMPLEX BETWEEN HUMAN T-CELL RECEPTOR B7, VIRAL PEPTIDE (TAX) AND MHC CLASS I MOLECULE HLA-A 0201
Deposited 1998-05-12
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.1；12% PEG8000, 20MM MOPS, 100MM MAGNESIUM ACETATE,PH7.1
|
Resolution 2.50 Å
R-free 0.312
|
|
1C16
CRYSTAL STRUCTURE ANALYSIS OF THE GAMMA/DELTA T CELL LIGAND T22
Deposited 1999-07-20
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 3.10 Å
R-free 0.334
|
|
1C16
CRYSTAL STRUCTURE ANALYSIS OF THE GAMMA/DELTA T CELL LIGAND T22
Deposited 1999-07-20
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 3.10 Å
R-free 0.334
|
|
1C16
CRYSTAL STRUCTURE ANALYSIS OF THE GAMMA/DELTA T CELL LIGAND T22
Deposited 1999-07-20
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain F
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 3.10 Å
R-free 0.334
|
|
1C16
CRYSTAL STRUCTURE ANALYSIS OF THE GAMMA/DELTA T CELL LIGAND T22
Deposited 1999-07-20
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain H
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 3.10 Å
R-free 0.334
|
|
1C16
CRYSTAL STRUCTURE ANALYSIS OF THE GAMMA/DELTA T CELL LIGAND T22
Deposited 1999-07-20
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 5
Protein heterocomplex
Heteromer；Protein × 8
PDB declaration: octameric
|
Chain B
21–119（99 aa）
Chain D
21–119（99 aa）
Chain F
21–119（99 aa）
Chain H
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 3.10 Å
R-free 0.334
|
|
1CE6
MHC CLASS I H-2DB COMPLEXED WITH A SENDAI VIRUS NUCLEOPROTEIN PEPTIDE
Deposited 1999-03-17
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5；pH 5.0
|
Resolution 2.90 Å
R-free 0.274
|
|
1CG9
COMPLEX RECOGNITION OF THE SUPERTYPIC BW6-DETERMINANT ON HLA-B AND-C MOLECULES BY THE MONOCLONAL ANTIBODY SFR8-B6
Deposited 1999-03-25
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
20–119（100 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.9；4 M SODIUM FORMATE, PH 7.9
|
Resolution 2.70 Å
R-free 0.253
|
|
1DE4
HEMOCHROMATOSIS PROTEIN HFE COMPLEXED WITH TRANSFERRIN RECEPTOR
Deposited 1999-11-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain B
21–119（99 aa）
Chain E
21–119（99 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2
CA CALCIUM ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；PEG 8000, TRIS, TRIMETHYLAMINE HCL, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.80 Å
R-free 0.265
|
|
1DE4
HEMOCHROMATOSIS PROTEIN HFE COMPLEXED WITH TRANSFERRIN RECEPTOR
Deposited 1999-11-12
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain H
21–119（99 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2
CA CALCIUM ION × 2
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；PEG 8000, TRIS, TRIMETHYLAMINE HCL, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.80 Å
R-free 0.265
|
|
1DUY
CRYSTAL STRUCTURE OF HLA-A*0201/OCTAMERIC TAX PEPTIDE COMPLEX
Deposited 2000-01-19
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；298 K；13-20% polyethylene glycol 6000, 25 mM MES buffer, pH 6.5, VAPOR DIFFUSION, temperature 298K
|
Resolution 2.15 Å
R-free 0.254
|
|
1DUY
CRYSTAL STRUCTURE OF HLA-A*0201/OCTAMERIC TAX PEPTIDE COMPLEX
Deposited 2000-01-19
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；298 K；13-20% polyethylene glycol 6000, 25 mM MES buffer, pH 6.5, VAPOR DIFFUSION, temperature 298K
|
Resolution 2.15 Å
R-free 0.254
|
|
1DUZ
HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN (HLA-A 0201) IN COMPLEX WITH A NONAMERIC PEPTIDE FROM HTLV-1 TAX PROTEIN
Deposited 2000-01-19
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；298 K；13-20% polyethylene glycol 6000, 25 mM MES buffer, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.80 Å
R-free 0.250
|
|
1DUZ
HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN (HLA-A 0201) IN COMPLEX WITH A NONAMERIC PEPTIDE FROM HTLV-1 TAX PROTEIN
Deposited 2000-01-19
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；298 K；13-20% polyethylene glycol 6000, 25 mM MES buffer, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.80 Å
R-free 0.250
|
|
1EFX
STRUCTURE OF A COMPLEX BETWEEN THE HUMAN NATURAL KILLER CELL RECEPTOR KIR2DL2 AND A CLASS I MHC LIGAND HLA-CW3
Deposited 2000-02-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；298 K；PEG 20000, calcium chloride, sodium cacodylate, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 3.00 Å
R-free 0.294
|
|
1EXU
CRYSTAL STRUCTURE OF THE HUMAN MHC-RELATED FC RECEPTOR
Deposited 2000-05-04
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
BME BETA-MERCAPTOETHANOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.2；295 K；ammonium sulfate, glycerol, tris, pH 8.2, VAPOR DIFFUSION, HANGING DROP, temperature 295.0K
|
Resolution 2.70 Å
R-free 0.247
|
|
1HHG
THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEPTIDES PRESENTED BY HLA-A2
Deposited 1993-06-30
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.60 Å
|
|
1HHG
THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEPTIDES PRESENTED BY HLA-A2
Deposited 1993-06-30
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.60 Å
|
|
1HHH
THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEPTIDES PRESENTED BY HLA-A2
Deposited 1993-06-30
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 3.00 Å
|
|
1HHI
THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEPTIDES PRESENTED BY HLA-A2
Deposited 1993-06-30
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.50 Å
|
|
1HHI
THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEPTIDES PRESENTED BY HLA-A2
Deposited 1993-06-30
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.50 Å
|
|
1HHJ
THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEPTIDES PRESENTED BY HLA-A2
Deposited 1993-06-30
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.50 Å
|
|
1HHJ
THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEPTIDES PRESENTED BY HLA-A2
Deposited 1993-06-30
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.50 Å
|
|
1HHK
THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEPTIDES PRESENTED BY HLA-A2
Deposited 1993-06-30
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.50 Å
|
|
1HHK
THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEPTIDES PRESENTED BY HLA-A2
Deposited 1993-06-30
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.50 Å
|
|
1HLA
STRUCTURE OF THE HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN, HLA-A2
Deposited 1987-10-15
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain M
21–117（97 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 3.50 Å
|
|
1HSA
THE THREE-DIMENSIONAL STRUCTURE OF HLA-B27 AT 2.1 ANGSTROMS RESOLUTION SUGGESTS A GENERAL MECHANISM FOR TIGHT PEPTIDE BINDING TO MHC
Deposited 1992-08-11
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
THE FRAGMENT CRYSTALLIZED WAS THE EXTRACELLULAR PORTION OF
THE PROTEIN CLEAVED FROM DETERGENT MICELLES WITH PAPAIN
|
Resolution 2.10 Å
|
|
1HSA
THE THREE-DIMENSIONAL STRUCTURE OF HLA-B27 AT 2.1 ANGSTROMS RESOLUTION SUGGESTS A GENERAL MECHANISM FOR TIGHT PEPTIDE BINDING TO MHC
Deposited 1992-08-11
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
THE FRAGMENT CRYSTALLIZED WAS THE EXTRACELLULAR PORTION OF
THE PROTEIN CLEAVED FROM DETERGENT MICELLES WITH PAPAIN
|
Resolution 2.10 Å
|
|
1HSB
DIFFERENT LENGTH PEPTIDES BIND TO HLA-AW68 SIMILARLY AT THEIR ENDS BUT BULGE OUT IN THE MIDDLE
Deposited 1993-03-30
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
ALA ALANINE × 1
ARG ARGININE × 1
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 1.90 Å
|
|
1I1F
Crystal structure of human class i mhc (hla-a2.1) complexed with beta 2-microglobulin and hiv-rt variant peptide i1y
Deposited 1999-04-16
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
12–110（99 aa）
Fragment：BETA 2-MICROGLOBULIN
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；PROTEIN WAS CRYSTALLIZED IN THE HANGING DROP VAPOR DIFFUSION METHOD. THE
RESERVOIR SOLUTION CONTAINED 16% PEG8000 IN 25MM MES BUFFER, PH6.5. THE
HANGING DROP WAS A 1:1 MIXTURE OF THE RESERVOIR SOLUTION AND THE PROTEIN
SOLUTION WHICH CONTAINED 10MG/ML PROTEIN IN 25MM MES BUFFER, PH6.5.
|
Resolution 2.80 Å
R-free 0.315
|
|
1I1F
Crystal structure of human class i mhc (hla-a2.1) complexed with beta 2-microglobulin and hiv-rt variant peptide i1y
Deposited 1999-04-16
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
12–110（99 aa）
Fragment：BETA 2-MICROGLOBULIN
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；PROTEIN WAS CRYSTALLIZED IN THE HANGING DROP VAPOR DIFFUSION METHOD. THE
RESERVOIR SOLUTION CONTAINED 16% PEG8000 IN 25MM MES BUFFER, PH6.5. THE
HANGING DROP WAS A 1:1 MIXTURE OF THE RESERVOIR SOLUTION AND THE PROTEIN
SOLUTION WHICH CONTAINED 10MG/ML PROTEIN IN 25MM MES BUFFER, PH6.5.
|
Resolution 2.80 Å
R-free 0.315
|
|
1I1Y
CRYSTAL STRUCTURE OF HUMAN CLASS I MHC (HLA-A2.1) COMPLEXED WITH BETA 2-MICROGLOBULIN AND HIV-RT VARIANT PEPTIDE I1Y
Deposited 1999-04-16
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
12–110（99 aa）
Fragment：BETA 2-MICROGLOBULIN
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；PROTEIN WAS CRYSTALLIZED IN THE HANGING DROP VAPOR DIFFUSION METHOD. THE
RESERVOIR SOLUTION CONTAINED 18% PEG8000, IN 25MM MES BUFFER, PH6.5. THE
HANGING DROP WAS A 1:1 MIXTURE OF THE RESERVOIR SOLUTION AND THE PROTEIN
SOLUTION WHICH CONTAINED 10MG/ML PROTEIN IN 25MM MES BUFFER, PH6.5., pH 6.50, VAPOR DIFFUSION, HANGING DROP
|
Resolution 2.20 Å
R-free 0.289
|
|
1I1Y
CRYSTAL STRUCTURE OF HUMAN CLASS I MHC (HLA-A2.1) COMPLEXED WITH BETA 2-MICROGLOBULIN AND HIV-RT VARIANT PEPTIDE I1Y
Deposited 1999-04-16
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
12–110（99 aa）
Fragment：BETA 2-MICROGLOBULIN
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；PROTEIN WAS CRYSTALLIZED IN THE HANGING DROP VAPOR DIFFUSION METHOD. THE
RESERVOIR SOLUTION CONTAINED 18% PEG8000, IN 25MM MES BUFFER, PH6.5. THE
HANGING DROP WAS A 1:1 MIXTURE OF THE RESERVOIR SOLUTION AND THE PROTEIN
SOLUTION WHICH CONTAINED 10MG/ML PROTEIN IN 25MM MES BUFFER, PH6.5., pH 6.50, VAPOR DIFFUSION, HANGING DROP
|
Resolution 2.20 Å
R-free 0.289
|
|
1I4F
CRYSTAL STRUCTURE OF HLA-A*0201/MAGE-A4-PEPTIDE COMPLEX
Deposited 2001-02-21
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
1PG 2-(2-{2-[2-(2-METHOXY-ETHOXY)-ETHOXY]-ETHOXY}-ETHOXY)-ETHANOL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；291 K；PEG 8000, Tris-HCl, NaCl. PEG 400 as cryo protectant., pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.40 Å
R-free 0.173
|
|
1IM3
Crystal Structure of the human cytomegalovirus protein US2 bound to the MHC class I molecule HLA-A2/tax
Deposited 2001-05-09
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
Fragment：recombinant residues 1-99
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.75；291 K；PEG 6000, MPD, Tris, pH 7.75, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.20 Å
R-free 0.240
|
|
1IM3
Crystal Structure of the human cytomegalovirus protein US2 bound to the MHC class I molecule HLA-A2/tax
Deposited 2001-05-09
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain F
21–119（99 aa）
Fragment：recombinant residues 1-99
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.75；291 K；PEG 6000, MPD, Tris, pH 7.75, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.20 Å
R-free 0.240
|
|
1IM3
Crystal Structure of the human cytomegalovirus protein US2 bound to the MHC class I molecule HLA-A2/tax
Deposited 2001-05-09
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain J
21–119（99 aa）
Fragment：recombinant residues 1-99
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.75；291 K；PEG 6000, MPD, Tris, pH 7.75, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.20 Å
R-free 0.240
|
|
1IM3
Crystal Structure of the human cytomegalovirus protein US2 bound to the MHC class I molecule HLA-A2/tax
Deposited 2001-05-09
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain N
21–119（99 aa）
Fragment：recombinant residues 1-99
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.75；291 K；PEG 6000, MPD, Tris, pH 7.75, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.20 Å
R-free 0.240
|
|
1IM9
Crystal structure of the human natural killer cell inhibitory receptor KIR2DL1 bound to its MHC ligand HLA-Cw4
Deposited 2001-05-10
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 7
PDB declaration: heptameric
|
Chain B
21–119（99 aa）
Chain F
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；PEG6000, magnesium chloride, ethylene glycol, N-(2-acetamindo)iminodiacetic acid , pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.80 Å
R-free 0.256
|
|
1JF1
Crystal structure of HLA-A2*0201 in complex with a decameric altered peptide ligand from the MART-1/Melan-A
Deposited 2001-06-19
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：BETA-CHAIN OF MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I MOLECULES
|
Not recorded
|
ZN ZINC ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；16% PEG, 25 mM MES and 0.10% NaN3, pH 6.5, VAPOR DIFFUSION, HANGING DROP, at 293K
|
Resolution 1.85 Å
R-free 0.225
|
|
1JGD
HLA-B*2709 bound to deca-peptide s10R
Deposited 2001-06-25
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；291 K；PEG 8000, Tris-HCl, NaCl; glycerol as cryo protectant, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.90 Å
R-free 0.194
|
|
1JGE
HLA-B*2705 bound to nona-peptide m9
Deposited 2001-06-25
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；291 K；PEG 8000, Tris-HCl, NaCl; PEG 400 as cryo protectant, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.10 Å
R-free 0.250
|
|
1JHT
Crystal structure of HLA-A2*0201 in complex with a nonameric altered peptide ligand (ALGIGILTV) from the MART-1/Melan-A.
Deposited 2001-06-28
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：BETA-CHAIN OF MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I MOLECULES
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；16% PEG, 25 mM MES, 0.10% NaN3, pH 6.5, VAPOR DIFFUSION, HANGING DROP, at 293K
|
Resolution 2.15 Å
R-free 0.252
|
|
1JNJ
NMR solution structure of the human beta2-microglobulin
Deposited 2001-07-24
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
SOLUTION NMR
NMR measurement conditions
pH 6.4；310 K；Ionic strength (raw mmCIF value) 100 mM NaCl, 70 mM phosphate buffer；Pressure ambient
NMR measurement conditions
pH 6.4；310 K；Ionic strength (raw mmCIF value) 100 mM NaCl, 70 mM phosphate buffer；Pressure ambient
NMR sample composition
0.68 mM beta2-m; 70 mM phosphate buffer NA, 100 mM NaCl. | 90% H2O/10% D2O
NMR sample composition
0.37 mM beta2-m; 70 mM phosphate buffer NA, 100 mM NaCl. | 100% D2O
|
Resolution not provided
|
|
1K5N
HLA-B*2709 BOUND TO NONA-PEPTIDE M9
Deposited 2001-10-11
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 9；291 K；PEG 8000, Bicine, NaCl, glycerol as cryo protectant, pH 9.00, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.09 Å
R-free 0.148
|
|
1KPR
The human non-classical major histocompatibility complex molecule HLA-E
Deposited 2002-01-02
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；295 K；ammonium sulfate, PEG 400, Tris, pH 8.0, VAPOR DIFFUSION, HANGING DROP at 295K
|
Resolution 2.80 Å
R-free 0.289
|
|
1KPR
The human non-classical major histocompatibility complex molecule HLA-E
Deposited 2002-01-02
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；295 K；ammonium sulfate, PEG 400, Tris, pH 8.0, VAPOR DIFFUSION, HANGING DROP at 295K
|
Resolution 2.80 Å
R-free 0.289
|
|
1KPR
The human non-classical major histocompatibility complex molecule HLA-E
Deposited 2002-01-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 12
PDB declaration: dodecameric
|
Chain B
21–119（99 aa）
Chain D
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；295 K；ammonium sulfate, PEG 400, Tris, pH 8.0, VAPOR DIFFUSION, HANGING DROP at 295K
|
Resolution 2.80 Å
R-free 0.289
|
|
1KPR
The human non-classical major histocompatibility complex molecule HLA-E
Deposited 2002-01-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain B
21–119（99 aa）
Chain D
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；295 K；ammonium sulfate, PEG 400, Tris, pH 8.0, VAPOR DIFFUSION, HANGING DROP at 295K
|
Resolution 2.80 Å
R-free 0.289
|
|
1LDS
Crystal Structure of monomeric human beta-2-microglobulin
Deposited 2002-04-09
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
21–119（99 aa）
|
Not recorded
|
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.7；289 K；4-8% (w/v) PEG4000, 20% Isopropanol, 100mM sodium citrate, pH 5.7, VAPOR DIFFUSION, SITTING DROP, temperature 289K
|
Resolution 1.80 Å
R-free 0.233
|
|
1LP9
Xenoreactive complex AHIII 12.2 TCR bound to p1049/HLA-A2.1
Deposited 2002-05-07
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；298 K；PEG3350, 25mM MES , pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.00 Å
R-free 0.253
|
|
1LP9
Xenoreactive complex AHIII 12.2 TCR bound to p1049/HLA-A2.1
Deposited 2002-05-07
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain I
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；298 K；PEG3350, 25mM MES , pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.00 Å
R-free 0.253
|
|
1M05
HLA B8 in complex with an Epstein Barr Virus determinant
Deposited 2002-06-11
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：residues 21-119
|
Not recorded
|
CD CADMIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；VAPOR DIFFUSION, HANGING DROP
|
Resolution 1.90 Å
R-free 0.283
|
|
1M05
HLA B8 in complex with an Epstein Barr Virus determinant
Deposited 2002-06-11
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
21–119（99 aa）
Fragment：residues 21-119
|
Not recorded
|
CD CADMIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；VAPOR DIFFUSION, HANGING DROP
|
Resolution 1.90 Å
R-free 0.283
|
|
1MHE
THE HUMAN NON-CLASSICAL MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULE HLA-E
Deposited 1998-08-24
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain B
21–119（99 aa）
Chain D
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.5；pH 8.5
|
Resolution 2.85 Å
R-free 0.235
|
|
1MI5
The crystal structure of LC13 TcR in complex with HLAB8-EBV peptide complex
Deposited 2002-08-21
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；PEG, ammonium acetate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.50 Å
R-free 0.288
|
|
1N2R
A natural selected dimorphism in HLA B*44 alters self, peptide reportoire and T cell recognition.
Deposited 2002-10-24
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
ACY ACETIC ACID × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.2；298 K；30% PEG 4K, 0.1M citrate, 0.2M ammonium acetate, pH 5.2, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.70 Å
R-free 0.261
|
|
1P7Q
Crystal Structure of HLA-A2 Bound to LIR-1, a Host and Viral MHC Receptor
Deposited 2003-05-05
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；298 K；PEG 4000, Sodium Acetate, Tris, L-Cysteine, Triton X-100, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 3.40 Å
R-free 0.309
|
|
1PY4
Beta2 microglobulin mutant H31Y displays hints for amyloid formations
Deposited 2003-07-08
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
21–119（99 aa）
Fragment：H31Y
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；300 K；PEG 4K 31%, glycerol 25%, ammonium acetate 0.2 M, pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 300K
|
Resolution 2.90 Å
R-free 0.313
|
|
1PY4
Beta2 microglobulin mutant H31Y displays hints for amyloid formations
Deposited 2003-07-08
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
21–119（99 aa）
Fragment：H31Y
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；300 K；PEG 4K 31%, glycerol 25%, ammonium acetate 0.2 M, pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 300K
|
Resolution 2.90 Å
R-free 0.313
|
|
1PY4
Beta2 microglobulin mutant H31Y displays hints for amyloid formations
Deposited 2003-07-08
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain C
21–119（99 aa）
Fragment：H31Y
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；300 K；PEG 4K 31%, glycerol 25%, ammonium acetate 0.2 M, pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 300K
|
Resolution 2.90 Å
R-free 0.313
|
|
1PY4
Beta2 microglobulin mutant H31Y displays hints for amyloid formations
Deposited 2003-07-08
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain D
21–119（99 aa）
Fragment：H31Y
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；300 K；PEG 4K 31%, glycerol 25%, ammonium acetate 0.2 M, pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 300K
|
Resolution 2.90 Å
R-free 0.313
|
|
1Q94
Structures of HLA-A*1101 in complex with immunodominant nonamer and decamer HIV-1 epitopes clearly reveal the presence of a middle anchor residue
Deposited 2003-08-22
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；PEG 4000,sodium acetate,sodium citrate, pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 100K
|
Resolution 2.40 Å
R-free 0.272
|
|
1Q94
Structures of HLA-A*1101 in complex with immunodominant nonamer and decamer HIV-1 epitopes clearly reveal the presence of a middle anchor residue
Deposited 2003-08-22
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；PEG 4000,sodium acetate,sodium citrate, pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 100K
|
Resolution 2.40 Å
R-free 0.272
|
|
1QQD
CRYSTAL STRUCTURE OF HLA-CW4, A LIGAND FOR THE KIR2D NATURAL KILLER CELL INHIBITORY RECEPTOR
Deposited 1999-06-03
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
11–109（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；291 K；PEG 8000,
calcium acetate,
sodium cacodylate, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 291.0K
|
Resolution 2.70 Å
R-free 0.275
|
|
1QR1
POOR BINDING OF A HER-2/NEU EPITOPE (GP2) TO HLA-A2.1 IS DUE TO A LACK OF INTERACTIONS IN THE CENTER OF THE PEPTIDE
Deposited 1999-06-17
|
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Mutation：B2M HAS AN ADDED METHIONINE FOR BACTERIAL EXPRESSION
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；295 K；14% PEG 6000, 25 mM MES, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 22K
|
Resolution 2.40 Å
R-free 0.284
|
|
1QR1
POOR BINDING OF A HER-2/NEU EPITOPE (GP2) TO HLA-A2.1 IS DUE TO A LACK OF INTERACTIONS IN THE CENTER OF THE PEPTIDE
Deposited 1999-06-17
|
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Mutation：B2M HAS AN ADDED METHIONINE FOR BACTERIAL EXPRESSION
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；295 K；14% PEG 6000, 25 mM MES, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 22K
|
Resolution 2.40 Å
R-free 0.284
|
|
1QRN
CRYSTAL STRUCTURE OF HUMAN A6 TCR COMPLEXED WITH HLA-A2 BOUND TO ALTERED HTLV-1 TAX PEPTIDE P6A
Deposited 1999-06-14
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；287 K；seeding with hanging drop vapor diffusion; 50 mM MOPS pH 7.0,
75 mM MgSO4, 13% PEG 8000, VAPOR DIFFUSION, HANGING DROP, temperature 287K
|
Resolution 2.80 Å
R-free 0.273
|
|
1QSE
STRUCTURE OF HUMAN A6-TCR BOUND TO HLA-A2 COMPLEXED WITH ALTERED HTLV-1 TAX PEPTIDE V7R
Deposited 1999-06-21
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
11–110（100 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；290 K；seeding with hanging drop vapor diffusion; 50 mM MOPS, pH 7.0, 75 mM MgSO4 and
13% PEG 8000, VAPOR DIFFUSION, HANGING DROP, temperature 290K
|
Resolution 2.80 Å
R-free 0.290
|
|
1QSF
STRUCTURE OF A6-TCR BOUND TO HLA-A2 COMPLEXED WITH ALTERED HTLV-1 TAX PEPTIDE Y8A
Deposited 1999-06-21
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
11–110（100 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；290 K；seeding with hanging drop vapor diffusion; 50 mM MOPS, pH 7.0, 75 mM MgSO4 and
13% PEG 8000, VAPOR DIFFUSION, HANGING DROP, temperature 290K
|
Resolution 2.80 Å
R-free 0.286
|
|
1QVO
STRUCTURES OF HLA-A*1101 IN COMPLEX WITH IMMUNODOMINANT NONAMER AND DECAMER HIV-1 EPITOPES CLEARLY REVEAL THE PRESENCE OF A MIDDLE ANCHOR RESIDUE
Deposited 2003-08-28
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；293 K；PEG 4000, ammonium acetate, sodium citrate, pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.22 Å
R-free 0.255
|
|
1QVO
STRUCTURES OF HLA-A*1101 IN COMPLEX WITH IMMUNODOMINANT NONAMER AND DECAMER HIV-1 EPITOPES CLEARLY REVEAL THE PRESENCE OF A MIDDLE ANCHOR RESIDUE
Deposited 2003-08-28
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；293 K；PEG 4000, ammonium acetate, sodium citrate, pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.22 Å
R-free 0.255
|
|
1R3H
Crystal Structure of T10
Deposited 2003-10-02
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.2；293 K；MPEG5000, MGCL2, pH 5.2, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.50 Å
R-free 0.272
|
|
1R3H
Crystal Structure of T10
Deposited 2003-10-02
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.2；293 K；MPEG5000, MGCL2, pH 5.2, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.50 Å
R-free 0.272
|
|
1R3H
Crystal Structure of T10
Deposited 2003-10-02
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain F
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.2；293 K；MPEG5000, MGCL2, pH 5.2, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.50 Å
R-free 0.272
|
|
1R3H
Crystal Structure of T10
Deposited 2003-10-02
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain H
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.2；293 K；MPEG5000, MGCL2, pH 5.2, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.50 Å
R-free 0.272
|
|
1S9W
Crystal Structure Analysis of NY-ESO-1 epitope, SLLMWITQC, in complex with HLA-A2
Deposited 2004-02-05
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；2.0M ammonium sulphate, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.20 Å
R-free 0.267
|
|
1S9X
Crystal Structure Analysis of NY-ESO-1 epitope analogue, SLLMWITQA, in complex with HLA-A2
Deposited 2004-02-05
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；2.0M ammonium sulphate, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.50 Å
R-free 0.279
|
|
1S9Y
Crystal Structure Analysis of NY-ESO-1 epitope analogue, SLLMWITQS, in complex with HLA-A2
Deposited 2004-02-05
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；2.0M ammonium sulphate, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.30 Å
R-free 0.273
|
|
1SYS
Crystal structure of HLA, B*4403, and peptide EEPTVIKKY
Deposited 2004-04-01
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.8；295 K；PEG 4000, 0.2M Ammonium Acetate, 0.2M Sodium Citrate, pH 5.8, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 2.40 Å
R-free 0.271
|
|
1SYV
HLA-B*4405 complexed to the dominant self ligand EEFGRAYGF
Deposited 2004-04-02
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.8；295 K；PEG 4000, SODIUM CITRATE, AMMONIUM ACETATE, pH 5.8, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 1.70 Å
R-free 0.224
|
|
1TMC
THE THREE-DIMENSIONAL STRUCTURE OF A CLASS I MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULE MISSING THE ALPHA3 DOMAIN OF THE HEAVY CHAIN
Deposited 1994-12-19
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.30 Å
|
|
1TVB
Crystal structure of Melanoma Antigen gp100(209-217) Bound to Human Class I MHC HLA-A2
Deposited 2004-06-29
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：beta-chain
|
Not recorded
|
GOL GLYCEROL × 9
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；PEG 3350, MES, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 1.80 Å
R-free 0.216
|
|
1TVB
Crystal structure of Melanoma Antigen gp100(209-217) Bound to Human Class I MHC HLA-A2
Deposited 2004-06-29
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
Fragment：beta-chain
|
Not recorded
|
GOL GLYCEROL × 13
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；PEG 3350, MES, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 1.80 Å
R-free 0.216
|
|
1TVH
Crystal structure of Modified Melanoma Antigen gp100(209-T2M) Bound to Human Class I MHC HLA-A2
Deposited 2004-06-29
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：beta-chain
|
Not recorded
|
GOL GLYCEROL × 13
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；PEG 3350, MES, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 1.80 Å
R-free 0.247
|
|
1TVH
Crystal structure of Modified Melanoma Antigen gp100(209-T2M) Bound to Human Class I MHC HLA-A2
Deposited 2004-06-29
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
Fragment：beta-chain
|
Not recorded
|
GOL GLYCEROL × 15
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；PEG 3350, MES, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 1.80 Å
R-free 0.247
|
|
1VGK
The crystal structure of class I Major histocompatibility complex, H-2Kd at 2.0 A resolution
Deposited 2004-04-27
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；291 K；PEG 2000, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.06 Å
R-free 0.240
|
|
1W0V
Crystal Structure Of HLA-B*2705 Complexed With the self-Peptide TIS from EGF-response factor 1
Deposited 2004-06-14
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：RESIDUES 21-119
|
Not recorded
|
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8；18% PEG8000, 0.1M TRIS PH 8.0
|
Resolution 2.27 Å
R-free 0.246
|
|
1W0W
Crystal Structure Of HLA-B*2709 Complexed With the self-Peptide TIS from EGF-response factor 1
Deposited 2004-06-14
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：RESIDUES 21-119
|
Not recorded
|
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.5；20% PEG8000, 0.1M TRIS PH 8.5
|
Resolution 2.11 Å
R-free 0.245
|
|
1W72
Crystal structure of HLA-A1:MAGE-A1 in complex with Fab-Hyb3
Deposited 2004-08-27
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：RESIDUES 21-119
|
Not recorded
|
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；MES PH 6.5, NACL 600MM, 19% PEG3350, 80MM DIOXANE
|
Resolution 2.15 Å
R-free 0.248
|
|
1W72
Crystal structure of HLA-A1:MAGE-A1 in complex with Fab-Hyb3
Deposited 2004-08-27
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain E
21–119（99 aa）
Fragment：RESIDUES 21-119
|
Not recorded
|
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；MES PH 6.5, NACL 600MM, 19% PEG3350, 80MM DIOXANE
|
Resolution 2.15 Å
R-free 0.248
|
|
1X7Q
Crystal structure of HLA-A*1101 with sars nucleocapsid peptide
Deposited 2004-08-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 3
GOL GLYCEROL × 7
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293.15 K；25% PEG 5000 MME, 0.2M AMMONIUM SULFATE, 0.1M MES PH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 293.15K
|
Resolution 1.45 Å
R-free 0.181
|
|
1XH3
Conformational Restraints and Flexibility of 14-Meric Peptides in Complex with HLA-B*3501
Deposited 2004-09-17
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；PEG4000, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.48 Å
R-free 0.208
|
|
1XR8
Crystal Structures of HLA-B*1501 in Complex with Peptides from Human UbcH6 and Epstein-Barr Virus EBNA-3
Deposited 2004-10-14
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
PG4 TETRAETHYLENE GLYCOL × 1
URE UREA × 1
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；0.2M MgAc4H20, 0.1M Na-cacodylate, pH 6.5, 20% w/v PEG8000, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.30 Å
R-free 0.245
|
|
1XR9
Crystal Structures of HLA-B*1501 in Complex with Peptides from Human UbcH6 and Epstein-Barr Virus EBNA-3
Deposited 2004-10-14
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 2
URE UREA × 1
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；277 K；0.2M NH4Ac, 0.1M tri-Sodium Citrate dihydrate, pH 5.6, 30% w/v PEG4000, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 1.79 Å
R-free 0.232
|
|
1XZ0
Crystal structure of CD1a in complex with a synthetic mycobactin lipopeptide
Deposited 2004-11-11
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
JH0 6-(HYDROXY-HEXADECANOYL-AMINO)-2-{[(4S)-2-(2-HYDROXY-PHENYL)-4,5-DIHYDRO-OXAZOLE-4-CARBONYL]-AMINO}-HEXANOIC ACID 2-[(3S)-1-(TERT-BUTYL-DIPHENYL-SILANYLOXY)-2-OXO-AZEPAN-3-YLCARBAMOYL]-(1S)-1-METHYL-ETHYL ESTER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；295 K；PEG 2000 MME, Tris, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 295K
|
Resolution 2.80 Å
R-free 0.277
|
|
1XZ0
Crystal structure of CD1a in complex with a synthetic mycobactin lipopeptide
Deposited 2004-11-11
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Other combination
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
JH0 6-(HYDROXY-HEXADECANOYL-AMINO)-2-{[(4S)-2-(2-HYDROXY-PHENYL)-4,5-DIHYDRO-OXAZOLE-4-CARBONYL]-AMINO}-HEXANOIC ACID 2-[(3S)-1-(TERT-BUTYL-DIPHENYL-SILANYLOXY)-2-OXO-AZEPAN-3-YLCARBAMOYL]-(1S)-1-METHYL-ETHYL ESTER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；295 K；PEG 2000 MME, Tris, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 295K
|
Resolution 2.80 Å
R-free 0.277
|
|
1YDP
1.9A crystal structure of HLA-G
Deposited 2004-12-25
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
CO COBALT (II) ION × 1
CL CHLORIDE ION × 2
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 1.90 Å
R-free 0.264
|
|
1YDP
1.9A crystal structure of HLA-G
Deposited 2004-12-25
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
CO COBALT (II) ION × 1
CL CHLORIDE ION × 2
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 1.90 Å
R-free 0.264
|
|
1YPZ
Immune receptor
Deposited 2005-01-31
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 8
PDB declaration: octameric
|
Chain B
19–118（100 aa）
Chain D
19–118（100 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 3.40 Å
R-free 0.330
|
|
1ZHK
Crystal structure of HLA-B*3501 presenting 13-mer EBV antigen LPEPLPQGQLTAY
Deposited 2005-04-26
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.6；277 K；0.2M Ammonium Acetate, 17% w/v PEG 3350, 100mM Cacodylate, pH 7.6, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 1.60 Å
R-free 0.231
|
|
1ZHL
Crystal structure of HLA-B*3508 presenting 13-mer EBV antigen LPEPLPQGQLTAY
Deposited 2005-04-26
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.6；277 K；0.2M Ammonium Acetate, 17% w/v PEG 3350, 100mM Cacodylate, pH 7.6, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 1.50 Å
R-free 0.227
|
|
1ZS8
Crystal Structure of the Murine MHC Class Ib Molecule M10.5
Deposited 2005-07-22
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；0.1 M imidazole, 20% PEG 1000, 0.2 M calcium acetate, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 3.00 Å
R-free 0.308
|
|
1ZS8
Crystal Structure of the Murine MHC Class Ib Molecule M10.5
Deposited 2005-07-22
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；0.1 M imidazole, 20% PEG 1000, 0.2 M calcium acetate, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 3.00 Å
R-free 0.308
|
|
1ZS8
Crystal Structure of the Murine MHC Class Ib Molecule M10.5
Deposited 2005-07-22
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain F
21–119（99 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；0.1 M imidazole, 20% PEG 1000, 0.2 M calcium acetate, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 3.00 Å
R-free 0.308
|
|
1ZS8
Crystal Structure of the Murine MHC Class Ib Molecule M10.5
Deposited 2005-07-22
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain H
21–119（99 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；0.1 M imidazole, 20% PEG 1000, 0.2 M calcium acetate, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 3.00 Å
R-free 0.308
|
|
1ZS8
Crystal Structure of the Murine MHC Class Ib Molecule M10.5
Deposited 2005-07-22
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 5
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain J
21–119（99 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；0.1 M imidazole, 20% PEG 1000, 0.2 M calcium acetate, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 3.00 Å
R-free 0.308
|
|
1ZS8
Crystal Structure of the Murine MHC Class Ib Molecule M10.5
Deposited 2005-07-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 6
Protein heterocomplex
Heteromer；Protein × 10
PDB declaration: decameric
|
Chain B
21–119（99 aa）
Chain D
21–119（99 aa）
Chain F
21–119（99 aa）
Chain H
21–119（99 aa）
Chain J
21–119（99 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；0.1 M imidazole, 20% PEG 1000, 0.2 M calcium acetate, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 3.00 Å
R-free 0.308
|
|
1ZSD
Crystal Structure Of HLA-B*3501 Presenting an 11-Mer EBV Antigen EPLPQGQLTAY
Deposited 2005-05-24
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：beta-2-microglobulin
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.6；0.2M ammonium acetate, 17% w/v PEG 3350, 100mM cacodylate, pH 7.6, VAPOR DIFFUSION, HANGING DROP
|
Resolution 1.70 Å
R-free 0.246
|
|
1ZT4
The crystal structure of human CD1d with and without alpha-Galactosylceramide
Deposited 2005-05-26
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
AGH N-{(1S,2R,3S)-1-[(ALPHA-D-GALACTOPYRANOSYLOXY)METHYL]-2,3-DIHYDROXYHEPTADECYL}HEXACOSANAMIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；PEG3350, potassium fluoride, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293.0K
|
Resolution 3.00 Å
R-free 0.326
|
|
1ZT4
The crystal structure of human CD1d with and without alpha-Galactosylceramide
Deposited 2005-05-26
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；PEG3350, potassium fluoride, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293.0K
|
Resolution 3.00 Å
R-free 0.326
|
|
1ZT4
The crystal structure of human CD1d with and without alpha-Galactosylceramide
Deposited 2005-05-26
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
Chain D
21–119（99 aa）
|
Not recorded
|
AGH N-{(1S,2R,3S)-1-[(ALPHA-D-GALACTOPYRANOSYLOXY)METHYL]-2,3-DIHYDROXYHEPTADECYL}HEXACOSANAMIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；PEG3350, potassium fluoride, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293.0K
|
Resolution 3.00 Å
R-free 0.326
|
|
1ZVS
Crystal structure of the first class MHC mamu and Tat-Tl8 complex
Deposited 2005-06-02
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；291 K；(NH4)2SO4, Tris-HCl, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.80 Å
R-free 0.257
|
|
1ZVS
Crystal structure of the first class MHC mamu and Tat-Tl8 complex
Deposited 2005-06-02
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；291 K；(NH4)2SO4, Tris-HCl, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.80 Å
R-free 0.257
|
|
2A83
Crystal structure of hla-b*2705 complexed with the glucagon receptor (gr) peptide (residues 412-420)
Deposited 2005-07-07
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：RESIDUES 21-119
|
Not recorded
|
GOL GLYCEROL × 6
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；14% PEG4000,100mM Tris/HCl, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.40 Å
R-free 0.150
|
|
2AK4
Crystal Structure of SB27 TCR in complex with HLA-B*3508-13mer peptide
Deposited 2005-08-03
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
IOD IODIDE ION × 7
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.7；277 K；200mM Potassium Iodide, 16% PEG 3350, 100mM Na Cacodylate, pH 6.7, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.50 Å
R-free 0.278
|
|
2AK4
Crystal Structure of SB27 TCR in complex with HLA-B*3508-13mer peptide
Deposited 2005-08-03
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
|
Not recorded
|
IOD IODIDE ION × 7
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.7；277 K；200mM Potassium Iodide, 16% PEG 3350, 100mM Na Cacodylate, pH 6.7, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.50 Å
R-free 0.278
|
|
2AK4
Crystal Structure of SB27 TCR in complex with HLA-B*3508-13mer peptide
Deposited 2005-08-03
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain L
21–119（99 aa）
|
Not recorded
|
IOD IODIDE ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.7；277 K；200mM Potassium Iodide, 16% PEG 3350, 100mM Na Cacodylate, pH 6.7, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.50 Å
R-free 0.278
|
|
2AK4
Crystal Structure of SB27 TCR in complex with HLA-B*3508-13mer peptide
Deposited 2005-08-03
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
21–119（99 aa）
|
Not recorded
|
IOD IODIDE ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.7；277 K；200mM Potassium Iodide, 16% PEG 3350, 100mM Na Cacodylate, pH 6.7, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.50 Å
R-free 0.278
|
|
2AV7
Crystal structure of HTLV-1 TAX peptide Bound to Human Class I MHC HLA-A2 with the K66A mutation in the heavy chain.
Deposited 2005-08-29
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 14
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；PEG3350 24%, MES 0.025M., pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 2.05 Å
R-free 0.234
|
|
2AV7
Crystal structure of HTLV-1 TAX peptide Bound to Human Class I MHC HLA-A2 with the K66A mutation in the heavy chain.
Deposited 2005-08-29
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 6
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；PEG3350 24%, MES 0.025M., pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 2.05 Å
R-free 0.234
|
|
2AXF
The Immunogenicity of a Viral Cytotoxic T Cell Epitope is controlled by its MHC-bound Conformation
Deposited 2005-09-05
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
ACY ACETIC ACID × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.6；277 K；200mM Ammonium Acetate, 17% W/V PEG 3350, 100mM Cacodylate, pH 7.6, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 1.80 Å
R-free 0.234
|
|
2AXG
The Immunogenicity of a Viral Cytotoxic T Cell Epitope is controlled by its MHC-bound Conformation
Deposited 2005-09-05
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
ACY ACETIC ACID × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.6；277 K；200mM Ammonium Acetate, 17% W/V PEG 3350, 100mM Cacodylate, pH 7.6, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.00 Å
R-free 0.234
|
|
2BCK
Crystal Structure of HLA-A*2402 Complexed with a telomerase peptide
Deposited 2005-10-19
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：residues 1-99
|
Not recorded
|
SO4 SULFATE ION × 5
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7；293 K；1.6M Ammonium Sulphate, 0.1M Sodium Chloride, 0.1M HEPES, 10% v/v Dioxane, pH 7.0, VAPOR DIFFUSION, temperature 293K
|
Resolution 2.80 Å
R-free 0.256
|
|
2BCK
Crystal Structure of HLA-A*2402 Complexed with a telomerase peptide
Deposited 2005-10-19
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
Fragment：residues 1-99
|
Not recorded
|
SO4 SULFATE ION × 3
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7；293 K；1.6M Ammonium Sulphate, 0.1M Sodium Chloride, 0.1M HEPES, 10% v/v Dioxane, pH 7.0, VAPOR DIFFUSION, temperature 293K
|
Resolution 2.80 Å
R-free 0.256
|
|
2BCK
Crystal Structure of HLA-A*2402 Complexed with a telomerase peptide
Deposited 2005-10-19
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain B
21–119（99 aa）
Fragment：residues 1-99
Chain E
21–119（99 aa）
Fragment：residues 1-99
|
Not recorded
|
SO4 SULFATE ION × 8
GOL GLYCEROL × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7；293 K；1.6M Ammonium Sulphate, 0.1M Sodium Chloride, 0.1M HEPES, 10% v/v Dioxane, pH 7.0, VAPOR DIFFUSION, temperature 293K
|
Resolution 2.80 Å
R-free 0.256
|
|
2BNQ
Structural and kinetic basis for heightened immunogenicity of T cell vaccines
Deposited 2005-03-31
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：BETA-2-MICROGLOBULIN, RESIDUES 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.2；pH 7.20
|
Resolution 1.70 Å
R-free 0.253
|
|
2BNR
Structural and kinetic basis for heightened immunogenicity of T cell vaccines
Deposited 2005-03-31
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：BETA-2-MICROGLOBULIN, RESIDUES 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.2；pH 7.20
|
Resolution 1.90 Å
|
|
2BSR
Crystal structures and KIR3DL1 recognition of three immunodominant viral peptides complexed to HLA-B2705
Deposited 2005-05-23
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；pH 6.50
|
Resolution 2.30 Å
R-free 0.280
|
|
2BSS
Crystal structures and KIR3DL1 recognition of three immunodominant viral peptides complexed to HLA-B2705
Deposited 2005-05-23
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
1–99（99 aa）
Fragment：IMMUNOGLOBULIN DOMAIN, RESIDUES 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；pH 6.50
|
Resolution 2.00 Å
|
|
2BST
Crystal structures and KIR3DL1 recognition of three immunodominant viral peptides complexed to HLA-B2705
Deposited 2005-05-23
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；pH 6.50
|
Resolution 2.10 Å
|
|
2BVO
Structures of Three HIV-1 HLA-B5703-Peptide Complexes and Identification of Related HLAs Potentially Associated with Long-Term Non-Progression
Deposited 2005-07-01
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：RESIDUES 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 1.65 Å
R-free 0.235
|
|
2BVP
Structures of Three HIV-1 HLA-B5703-Peptide Complexes and Identification of Related HLAs Potentially Associated with Long-Term Non-Progression
Deposited 2005-07-01
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 1.35 Å
R-free 0.215
|
|
2BVQ
Structures of Three HIV-1 HLA-B5703-Peptide Complexes and Identification of Related HLAs Potentially Associated with Long-Term Non-Progression
Deposited 2005-07-01
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：RESIDUES 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.00 Å
R-free 0.267
|
|
2C7U
Conflicting selective forces affect CD8 T-cell receptor contact sites in an HLA-A2 immunodominant HIV epitope.
Deposited 2005-11-29
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；pH 6.50
|
Resolution 2.38 Å
R-free 0.314
|
|
2C7U
Conflicting selective forces affect CD8 T-cell receptor contact sites in an HLA-A2 immunodominant HIV epitope.
Deposited 2005-11-29
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；pH 6.50
|
Resolution 2.38 Å
R-free 0.314
|
|
2CII
The crystal structure of H-2Db complexed with a partial peptide epitope suggests an MHC Class I assembly-intermediate
Deposited 2006-03-21
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5；25% PEG 6000, 100MM AMMONIUM SULFATE, 100 MM SODIUM CHLORIDE, 50 MM MES PH 5.0
|
Resolution 2.55 Å
R-free 0.297
|
|
2CIK
Insights Into Crossreactivity in Human Allorecognition: The Structure of HLA-B35011 Presenting an Epitope derived from Cytochrome P450.
Deposited 2006-03-22
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.6；0.105M AMMONIUM ACETATE, 0.0525M TRI-SODIUM CITRATE DIHYDRATE PH 5.6 AND 15.75% W/V PEG 4000
|
Resolution 1.75 Å
R-free 0.227
|
|
2CLR
THREE DIMENSIONAL STRUCTURE OF A PEPTIDE EXTENDING OUT ONE END OF A CLASS I MHC BINDING SITE
Deposited 1994-08-01
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.00 Å
|
|
2CLR
THREE DIMENSIONAL STRUCTURE OF A PEPTIDE EXTENDING OUT ONE END OF A CLASS I MHC BINDING SITE
Deposited 1994-08-01
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.00 Å
|
|
2D31
Crystal structure of disulfide-linked HLA-G dimer
Deposited 2005-09-23
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 10.5；293 K；CAPS, PEG8000, NaCl, pH 10.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 3.20 Å
R-free 0.298
|
|
2D31
Crystal structure of disulfide-linked HLA-G dimer
Deposited 2005-09-23
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 10.5；293 K；CAPS, PEG8000, NaCl, pH 10.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 3.20 Å
R-free 0.298
|
|
2D4D
The Crystal Structure of human beta2-microglobulin, L39W W60F W95F Mutant
Deposited 2005-10-17
|
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
21–119（99 aa）
|
Mutation：L39W, W60F, W95F
|
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；288 K；15% PEG4000, 25% glycerol, 0.2M ammonium acetate, 0.1M sodium acetate, pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 288K
|
Resolution 2.10 Å
R-free 0.265
|
|
2D4F
The Crystal Structure of human beta2-microglobulin
Deposited 2005-10-18
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
21–119（99 aa）
|
Not recorded
|
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；288 K；20% PEG4000, 25% glycerol, 0.2M ammonium acetate, 0.1M sodium acetate, pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 288K
|
Resolution 1.70 Å
R-free 0.233
|
|
2DYP
Crystal Structure of LILRB2(LIR2/ILT4/CD85d) complexed with HLA-G
Deposited 2006-09-15
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
Fragment：residues in data base 24-219
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；293 K；0.1M Tris-HCl pH8.0, 45% PEG400, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.50 Å
R-free 0.278
|
|
2E8D
3D Structure of amyloid protofilaments of beta2-microglobulin fragment probed by solid-state NMR
Deposited 2007-01-19
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 4
PDB declaration: tetrameric
|
Chain A
40–61（22 aa）
Fragment：residues 40-61 (in UniProt numbering)
Chain B
40–61（22 aa）
Fragment：residues 40-61 (in UniProt numbering)
Chain C
40–61（22 aa）
Fragment：residues 40-61 (in UniProt numbering)
Chain D
40–61（22 aa）
Fragment：residues 40-61 (in UniProt numbering)
|
Not recorded
|
No recorded non-water small molecule
|
SOLID-STATE NMR
NMR measurement conditions
245 K；Pressure ambient
NMR sample composition
myloid fiber in a solid state
|
Resolution not provided
|
|
2ESV
Structure of the HLA-E-VMAPRTLIL/KK50.4 TCR complex
Deposited 2005-10-27
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
IOD IODIDE ION × 5
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277 K；19-22% PEG 3350, 0.2M Potassium Iodide, pH 6.9-7.4, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.60 Å
R-free 0.292
|
|
2F53
Directed Evolution of Human T-cell Receptor CDR2 residues by phage display dramatically enhances affinity for cognate peptide-MHC without apparent cross-reactivity
Deposited 2005-11-25
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：Beta-2 Microglobulin, residues 21-119
|
Mutation：K91C
|
NA SODIUM ION × 1
GOL GLYCEROL × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；85 mM HEPES, 8.5% Iso-propanol, 17% PEG4000, 15% glycerol, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.10 Å
R-free 0.231
|
|
2F53
Directed Evolution of Human T-cell Receptor CDR2 residues by phage display dramatically enhances affinity for cognate peptide-MHC without apparent cross-reactivity
Deposited 2005-11-25
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：Beta-2 Microglobulin, residues 21-119
|
Mutation：K91C
|
NA SODIUM ION × 1
GOL GLYCEROL × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；85 mM HEPES, 8.5% Iso-propanol, 17% PEG4000, 15% glycerol, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.10 Å
R-free 0.231
|
|
2F54
Directed evolution of human T cell receptor CDR2 residues by phage display dramatically enhances affinity for cognate peptide-MHC without increasing apparent cross-reactivity
Deposited 2005-11-25
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：Beta-2-microglobulin, residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；85 mM HEPES, 8.5% iso-propanol, 17% PEG 4000, 15% glycerol, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.70 Å
R-free 0.286
|
|
2F54
Directed evolution of human T cell receptor CDR2 residues by phage display dramatically enhances affinity for cognate peptide-MHC without increasing apparent cross-reactivity
Deposited 2005-11-25
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
Fragment：Beta-2-microglobulin, residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；85 mM HEPES, 8.5% iso-propanol, 17% PEG 4000, 15% glycerol, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.70 Å
R-free 0.286
|
|
2F74
Murine MHC class I H-2Db in complex with human b2-microglobulin and LCMV-derived immunodminant peptide gp33
Deposited 2005-11-30
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 8；290 K；20% PEG 6K, pH 8, VAPOR DIFFUSION, temperature 290K
|
Resolution 2.70 Å
R-free 0.298
|
|
2F74
Murine MHC class I H-2Db in complex with human b2-microglobulin and LCMV-derived immunodminant peptide gp33
Deposited 2005-11-30
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 8；290 K；20% PEG 6K, pH 8, VAPOR DIFFUSION, temperature 290K
|
Resolution 2.70 Å
R-free 0.298
|
|
2F8O
A Native to Amyloidogenic Transition Regulated by a Backbone Trigger
Deposited 2005-12-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 4
PDB declaration: tetrameric
|
Chain A
21–119（99 aa）
Chain B
21–119（99 aa）
|
Mutation：P32A
Mutation：P32A
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；295 K；31% PEG 4000, 25% glycerol, 0.2M ammonium acetate, 0.1M sodium acetate; drops contained 1ul of ~19 mg/ml protein, 1ul of mother liquor, and 1ul of 0.05M sodium acetate pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 1.70 Å
R-free 0.227
|
|
2FYY
The role of T cell receptor alpha genes in directing human MHC restriction
Deposited 2006-02-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.6；277 K；17% PEG 3350, 100mM cacodylate, 200mM ammonium acetate, pH 7.6, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 1.50 Å
R-free 0.236
|
|
2FZ3
The role of T cell receptor alpha genes in directing human MHC restriction
Deposited 2006-02-09
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.6；277 K；17% PEG 3350, 100mM cacodylate, 200mM ammonium acetate, pH 7.6, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 1.90 Å
R-free 0.275
|
|
2GIT
Human Class I MHC HLA-A2 in complex with the modified HTLV-1 TAX (Y5K-4-[3-Indolyl]-butyric acid) peptide
Deposited 2006-03-29
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：beta-2-microglobulin
|
Not recorded
|
GOL GLYCEROL × 2
NA SODIUM ION × 1
FMT FORMIC ACID × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；PEG3350 24%, MES 0.025M, HCOOH 0.1M, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 1.70 Å
R-free 0.219
|
|
2GIT
Human Class I MHC HLA-A2 in complex with the modified HTLV-1 TAX (Y5K-4-[3-Indolyl]-butyric acid) peptide
Deposited 2006-03-29
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
Fragment：beta-2-microglobulin
|
Not recorded
|
GOL GLYCEROL × 4
FMT FORMIC ACID × 6
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；PEG3350 24%, MES 0.025M, HCOOH 0.1M, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 1.70 Å
R-free 0.219
|
|
2GJ6
The complex between TCR A6 and human Class I MHC HLA-A2 with the modified HTLV-1 TAX (Y5K-4-[3-Indolyl]-butyric acid) peptide
Deposited 2006-03-30
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 5
GOL GLYCEROL × 13
3IB 3-INDOLEBUTYRIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；297 K；PEG8000 30%, 0.1 M Sodium Cacodylate, 0.2 M Ammonium sulfate, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 297K
|
Resolution 2.56 Å
R-free 0.250
|
|
2GT9
Human Class I MHC HLA-A2 in complex with the decameric Melan-A/MART-1(26-35) peptide
Deposited 2006-04-27
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：Beta-2-microglobulin (Residues 21-119)
|
Not recorded
|
GOL GLYCEROL × 2
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；PEG3350 24%, MES 0.025M, NaCl 0.1M, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 1.75 Å
R-free 0.213
|
|
2GT9
Human Class I MHC HLA-A2 in complex with the decameric Melan-A/MART-1(26-35) peptide
Deposited 2006-04-27
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
Fragment：Beta-2-microglobulin (Residues 21-119)
|
Not recorded
|
GOL GLYCEROL × 3
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；PEG3350 24%, MES 0.025M, NaCl 0.1M, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 1.75 Å
R-free 0.213
|
|
2GTW
Human Class I MHC HLA-A2 in complex with the nonameric Melan-A/MART-1(27-35) peptide having A27L substitution
Deposited 2006-04-28
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 3
FMT FORMIC ACID × 3
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；PEG 3350 24%, MES 0.025M, HCOOK 0.1M, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 1.55 Å
R-free 0.218
|
|
2GTW
Human Class I MHC HLA-A2 in complex with the nonameric Melan-A/MART-1(27-35) peptide having A27L substitution
Deposited 2006-04-28
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 2
FMT FORMIC ACID × 1
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；PEG 3350 24%, MES 0.025M, HCOOK 0.1M, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 1.55 Å
R-free 0.218
|
|
2GTZ
Human Class I MHC HLA-A2 in complex with the nonameric Melan-A/MART-1(27-35) peptide having A28L substitution
Deposited 2006-04-28
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 4
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；PEG 3350 24%, MES 0.025M, NH4Cl 0.1M, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 1.70 Å
R-free 0.217
|
|
2GTZ
Human Class I MHC HLA-A2 in complex with the nonameric Melan-A/MART-1(27-35) peptide having A28L substitution
Deposited 2006-04-28
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 2
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；PEG 3350 24%, MES 0.025M, NH4Cl 0.1M, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 1.70 Å
R-free 0.217
|
|
2GUO
Human Class I MHC HLA-A2 in complex with the native nonameric Melan-A/MART-1(27-35) peptide
Deposited 2006-05-01
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：Beta-2-microglobulin (Residues 21-119)
|
Not recorded
|
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；PEG3350 24%, MES 0.025M, NaCl 0.1M, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 1.90 Å
R-free 0.244
|
|
2GUO
Human Class I MHC HLA-A2 in complex with the native nonameric Melan-A/MART-1(27-35) peptide
Deposited 2006-05-01
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
Fragment：Beta-2-microglobulin (Residues 21-119)
|
Not recorded
|
GOL GLYCEROL × 2
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；PEG3350 24%, MES 0.025M, NaCl 0.1M, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 1.90 Å
R-free 0.244
|
|
2H26
human CD1b in complex with endogenous phosphatidylcholine and spacer
Deposited 2006-05-18
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
6PL (4S,7R)-4-HYDROXY-N,N,N-TRIMETHYL-9-OXO-7-[(PALMITOYLOXY)METHYL]-3,5,8-TRIOXA-4-PHOSPHAHEXACOSAN-1-AMINIUM 4-OXIDE × 1
6UL TETRACOSYL PALMITATE × 1
GOL GLYCEROL × 1
SO4 SULFATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；1.5 M ammonium sulfate
5 % (v/v) isopropanol
0.1 M Na citrate, pH 5.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.80 Å
R-free 0.241
|
|
2H6P
Crystal structure of HLA-B*3501 presenting the human cytochrome P450 derived peptide, KPIVVLHGY
Deposited 2006-05-31
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.6；277 K；18% PEG 3350, 0.1M ammonium acetate, 0.1M cacodylate, pH 7.6, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 1.90 Å
R-free 0.239
|
|
2HJK
Crystal Structure of HLA-B5703 and HIV-1 peptide
Deposited 2006-06-30
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：Beta-2-microglobulin domain (Residues 21-119)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 1.85 Å
R-free 0.237
|
|
2HJL
Crystal Structure of HLA-B5703 and HIV-1 peptide
Deposited 2006-06-30
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：Beta-2-microglobulin domain (Residues 21-119)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 1.50 Å
R-free 0.226
|
|
2HLA
SPECIFICITY POCKETS FOR THE SIDE CHAINS OF PEPTIDE ANTIGENS IN HLA-AW68
Deposited 1989-10-05
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.60 Å
|
|
2HN7
HLA-A*1101 in complex with HBV peptide homologue
Deposited 2006-07-12
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293.15 K；25% PEG 5000 MME, 0.2M AMMONIUM SULFATE, 0.1M MES, pH 6.50, VAPOR DIFFUSION, HANGING DROP, temperature 293.15K
|
Resolution 1.60 Å
R-free 0.212
|
|
2J8U
Large CDR3a loop alteration as a function of MHC mutation.
Deposited 2006-10-27
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；1.0 M NACL 20% PEG 8000 MES, PH 6.5
|
Resolution 2.88 Å
R-free 0.293
|
|
2J8U
Large CDR3a loop alteration as a function of MHC mutation.
Deposited 2006-10-27
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain I
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；1.0 M NACL 20% PEG 8000 MES, PH 6.5
|
Resolution 2.88 Å
R-free 0.293
|
|
2JCC
AH3 recognition of mutant HLA-A2 W167A
Deposited 2006-12-21
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：RESIDUES 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；pH 6.5
|
Resolution 2.50 Å
R-free 0.292
|
|
2JCC
AH3 recognition of mutant HLA-A2 W167A
Deposited 2006-12-21
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain I
21–119（99 aa）
Fragment：RESIDUES 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；pH 6.5
|
Resolution 2.50 Å
R-free 0.292
|
|
2NW3
Crystal structure of HLA-B*3508 presenting EBV peptide EPLPQGQLTAY at 1.7A
Deposited 2006-11-14
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.6；277 K；0.2M Ammonium acetate, 0.1M Cacodylate (pH7.7), 16% PEG 3350, pH 7.6, vapor diffusion, hanging drop, temperature 277K
|
Resolution 1.70 Å
R-free 0.236
|
|
2NX5
Crystal structure of ELS4 TCR bound to HLA-B*3501 presenting EBV peptide EPLPQGQLTAY at 1.7A
Deposited 2006-11-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.4；277 K；0.1M Na Cacodylate (pH6.4), 0.2M CaCl2, 16% PEG 3350, 3% 1,6Hexanediol, vapor diffusion, hanging drop, temperature 277K
|
Resolution 2.70 Å
R-free 0.327
|
|
2NX5
Crystal structure of ELS4 TCR bound to HLA-B*3501 presenting EBV peptide EPLPQGQLTAY at 1.7A
Deposited 2006-11-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.4；277 K；0.1M Na Cacodylate (pH6.4), 0.2M CaCl2, 16% PEG 3350, 3% 1,6Hexanediol, vapor diffusion, hanging drop, temperature 277K
|
Resolution 2.70 Å
R-free 0.327
|
|
2NX5
Crystal structure of ELS4 TCR bound to HLA-B*3501 presenting EBV peptide EPLPQGQLTAY at 1.7A
Deposited 2006-11-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain L
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.4；277 K；0.1M Na Cacodylate (pH6.4), 0.2M CaCl2, 16% PEG 3350, 3% 1,6Hexanediol, vapor diffusion, hanging drop, temperature 277K
|
Resolution 2.70 Å
R-free 0.327
|
|
2NX5
Crystal structure of ELS4 TCR bound to HLA-B*3501 presenting EBV peptide EPLPQGQLTAY at 1.7A
Deposited 2006-11-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.4；277 K；0.1M Na Cacodylate (pH6.4), 0.2M CaCl2, 16% PEG 3350, 3% 1,6Hexanediol, vapor diffusion, hanging drop, temperature 277K
|
Resolution 2.70 Å
R-free 0.327
|
|
2P5E
Crystal Structures of High Affinity Human T-Cell Receptors Bound to pMHC Reveal Native Diagonal Binding Geometry
Deposited 2007-03-15
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：BETA-2 MICROGLOBULIN, RESIDUES 21-119
|
Not recorded
|
GOL GLYCEROL × 8
MG MAGNESIUM ION × 1
SO4 SULFATE ION × 5
IPA ISOPROPYL ALCOHOL × 1
EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5；293 K；85 mM HEPES, 8.5% Isopropanol, 17% PEG 4000, 15% Glycerol, pH 7.5, VAPOR DIFFUSION, temperature 293K, pH 7.50
|
Resolution 1.89 Å
R-free 0.236
|
|
2P5W
Crystal structures of high affinity human T-cell receptors bound to pMHC reveal native diagonal binding geometry
Deposited 2007-03-16
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：Beta-2 Microglobulin, RESIDUES 21-119
|
Not recorded
|
SO4 SULFATE ION × 6
GOL GLYCEROL × 11
CA CALCIUM ION × 1
MG MAGNESIUM ION × 1
EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5；293 K；85 MM HEPES, 8.5% ISO-PROPANOL, 17% PEG4000, 15% GLYCEROL, PH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K, pH 7.50
|
Resolution 2.20 Å
R-free 0.245
|
|
2PO6
Crystal structure of CD1d-lipid-antigen complexed with Beta-2-Microglobulin, NKT15 Alpha-Chain and NKT15 Beta-Chain
Deposited 2007-04-25
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
Fragment：beta-2-microglobulin
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2
AGH N-{(1S,2R,3S)-1-[(ALPHA-D-GALACTOPYRANOSYLOXY)METHYL]-2,3-DIHYDROXYHEPTADECYL}HEXACOSANAMIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；298 K；13% PEG 10K, 0.1M bis-tris propane, 0.2M tri-sodium citrate, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 3.20 Å
R-free 0.293
|
|
2PO6
Crystal structure of CD1d-lipid-antigen complexed with Beta-2-Microglobulin, NKT15 Alpha-Chain and NKT15 Beta-Chain
Deposited 2007-04-25
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Other combination
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain F
21–119（99 aa）
Fragment：beta-2-microglobulin
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
AGH N-{(1S,2R,3S)-1-[(ALPHA-D-GALACTOPYRANOSYLOXY)METHYL]-2,3-DIHYDROXYHEPTADECYL}HEXACOSANAMIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；298 K；13% PEG 10K, 0.1M bis-tris propane, 0.2M tri-sodium citrate, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 3.20 Å
R-free 0.293
|
|
2PYE
Crystal Structures of High Affinity Human T-Cell Receptors Bound to pMHC RevealNative Diagonal Binding Geometry TCR Clone C5C1 Complexed with MHC
Deposited 2007-05-16
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：BETA-2 MICROGLOBULIN, RESIDUES 21-119
|
Not recorded
|
SO4 SULFATE ION × 9
PGE TRIETHYLENE GLYCOL × 3
7PE 2-(2-(2-(2-(2-(2-ETHOXYETHOXY)ETHOXY)ETHOXY)ETHOXY)ETHOXY)ETHANOL × 1
GOL GLYCEROL × 11
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；85 mM Na HEPES buffer pH7.5, 8.5 % iso-propanol, 17% PEG 4000, 15% glycerol, pH 7.50, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.30 Å
R-free 0.283
|
|
2RFX
Crystal Structure of HLA-B*5701, presenting the self peptide, LSSPVTKSF
Deposited 2007-10-02
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 4
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.50 Å
R-free 0.268
|
|
2UWE
Large CDR3a loop alteration as a function of MHC mutation
Deposited 2007-03-20
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：RESIDUES 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.8；14% PEG 8000, 1 M NACL, 25 MM HEPES, PH 7.8
|
Resolution 2.40 Å
R-free 0.290
|
|
2UWE
Large CDR3a loop alteration as a function of MHC mutation
Deposited 2007-03-20
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain I
21–119（99 aa）
Fragment：RESIDUES 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.8；14% PEG 8000, 1 M NACL, 25 MM HEPES, PH 7.8
|
Resolution 2.40 Å
R-free 0.290
|
|
2V2W
T CELL CROSS-REACTIVITY AND CONFORMATIONAL CHANGES DURING TCR ENGAGEMENT
Deposited 2007-06-07
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；pH 6.5
|
Resolution 1.60 Å
R-free 0.237
|
|
2V2W
T CELL CROSS-REACTIVITY AND CONFORMATIONAL CHANGES DURING TCR ENGAGEMENT
Deposited 2007-06-07
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；pH 6.5
|
Resolution 1.60 Å
R-free 0.237
|
|
2V2X
T cell cross-reactivity and conformational changes during TCR engagement.
Deposited 2007-06-07
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；pH 6.5
|
Resolution 1.60 Å
R-free 0.238
|
|
2V2X
T cell cross-reactivity and conformational changes during TCR engagement.
Deposited 2007-06-07
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；pH 6.5
|
Resolution 1.60 Å
R-free 0.238
|
|
2VB5
Solution structure of W60G mutant of human beta2-microglobulin
Deposited 2007-09-06
|
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
21–119（99 aa）
|
Mutation：YES
|
No recorded non-water small molecule
|
SOLUTION NMR
NMR measurement conditions
pH 6.6；310 K；Ionic strength (raw mmCIF value) 100；Pressure 1.0
NMR sample composition
95% WATER/5% D2O
|
Resolution not provided
|
|
2VLJ
The Structural Dynamics and Energetics of an Immunodominant T-cell Receptor are Programmed by its Vbeta Domain
Deposited 2008-01-15
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.40 Å
R-free 0.272
|
|
2VLK
The Structural Dynamics and Energetics of an Immunodominant T-cell Receptor are Programmed by its Vbeta Domain
Deposited 2008-01-15
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.50 Å
R-free 0.288
|
|
2VLL
The Structural Dynamics and Energetics of an Immunodominant T-cell Receptor are Programmed by its Vbeta Domain
Deposited 2008-01-15
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：RESIDUES 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 1.60 Å
R-free 0.242
|
|
2VLL
The Structural Dynamics and Energetics of an Immunodominant T-cell Receptor are Programmed by its Vbeta Domain
Deposited 2008-01-15
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
Fragment：RESIDUES 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 1.60 Å
R-free 0.242
|
|
2VLR
The Structural Dynamics and Energetics of an Immunodominant T-cell Receptor are Programmed by its Vbeta Domain
Deposited 2008-01-15
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.30 Å
R-free 0.281
|
|
2VLR
The Structural Dynamics and Energetics of an Immunodominant T-cell Receptor are Programmed by its Vbeta Domain
Deposited 2008-01-15
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.30 Å
R-free 0.281
|
|
2X4N
Crystal structure of MHC CLass I HLA-A2.1 bound to residual fragments of a photocleavable peptide that is cleaved upon UV-light treatment
Deposited 2010-02-02
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；100 MM MES PH 5.5, 20% PEG 1500. CRYSTALS WERE FROZEN IN 100 MM MES, 30% PEG 1500, 10% GLYCEROL
|
Resolution 2.34 Å
R-free 0.274
|
|
2X4N
Crystal structure of MHC CLass I HLA-A2.1 bound to residual fragments of a photocleavable peptide that is cleaved upon UV-light treatment
Deposited 2010-02-02
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 7
MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；100 MM MES PH 5.5, 20% PEG 1500. CRYSTALS WERE FROZEN IN 100 MM MES, 30% PEG 1500, 10% GLYCEROL
|
Resolution 2.34 Å
R-free 0.274
|
|
2X4O
Crystal structure of MHC CLass I HLA-A2.1 bound to HIV-1 envelope peptide env120-128
Deposited 2010-02-02
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 5
MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；pH 6.5
|
Resolution 2.30 Å
R-free 0.239
|
|
2X4O
Crystal structure of MHC CLass I HLA-A2.1 bound to HIV-1 envelope peptide env120-128
Deposited 2010-02-02
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 1
MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；pH 6.5
|
Resolution 2.30 Å
R-free 0.239
|
|
2X4P
Crystal structure of MHC CLass I HLA-A2.1 bound to a photocleavable peptide
Deposited 2010-02-02
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 2
MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；0.1 M MES PH 6.5, 20% PEG1500
|
Resolution 2.30 Å
R-free 0.222
|
|
2X4P
Crystal structure of MHC CLass I HLA-A2.1 bound to a photocleavable peptide
Deposited 2010-02-02
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 4
MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；0.1 M MES PH 6.5, 20% PEG1500
|
Resolution 2.30 Å
R-free 0.222
|
|
2X4Q
Crystal structure of MHC CLass I HLA-A2.1 bound to a photocleavable peptide
Deposited 2010-02-02
|
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF)
|
MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；0.1M MES PH 6.5, 20% PEG1500
|
Resolution 1.90 Å
R-free 0.206
|
|
2X4Q
Crystal structure of MHC CLass I HLA-A2.1 bound to a photocleavable peptide
Deposited 2010-02-02
|
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF)
|
MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；0.1M MES PH 6.5, 20% PEG1500
|
Resolution 1.90 Å
R-free 0.206
|
|
2X4R
Crystal structure of MHC CLass I HLA-A2.1 bound to Cytomegalovirus (CMV) pp65 epitope
Deposited 2010-02-02
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
Fragment：RESIDUES 21-119
|
Not recorded
|
GOL GLYCEROL × 7
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；0.1 M MES PH 6.5, 20% PEG1500
|
Resolution 2.30 Å
R-free 0.220
|
|
2X4R
Crystal structure of MHC CLass I HLA-A2.1 bound to Cytomegalovirus (CMV) pp65 epitope
Deposited 2010-02-02
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：RESIDUES 21-119
|
Not recorded
|
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；0.1 M MES PH 6.5, 20% PEG1500
|
Resolution 2.30 Å
R-free 0.220
|
|
2X4S
Crystal structure of MHC CLass I HLA-A2.1 bound to a peptide representing the epitope of the H5N1 (Avian Flu) Nucleoprotein
Deposited 2010-02-02
|
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF)
|
GOL GLYCEROL × 1
MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；pH 6.5
|
Resolution 2.55 Å
R-free 0.247
|
|
2X4S
Crystal structure of MHC CLass I HLA-A2.1 bound to a peptide representing the epitope of the H5N1 (Avian Flu) Nucleoprotein
Deposited 2010-02-02
|
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF)
|
MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；pH 6.5
|
Resolution 2.55 Å
R-free 0.247
|
|
2X4T
Crystal structure of MHC CLass I HLA-A2.1 bound to a Peiodate- cleavable peptide
Deposited 2010-02-02
|
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF)
|
GOL GLYCEROL × 2
MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；0.1 M MES PH 6.5, 22% PEG1500
|
Resolution 2.30 Å
R-free 0.236
|
|
2X4T
Crystal structure of MHC CLass I HLA-A2.1 bound to a Peiodate- cleavable peptide
Deposited 2010-02-02
|
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF)
|
GOL GLYCEROL × 1
MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；0.1 M MES PH 6.5, 22% PEG1500
|
Resolution 2.30 Å
R-free 0.236
|
|
2X4U
Crystal structure of MHC CLass I HLA-A2.1 bound to HIV-1 Peptide RT468-476
Deposited 2010-02-02
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 5
MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；100 MM MES PH 5.5, 20% PEG 1500. CRYSTALS WERE FROZEN IN 100 MM MES, 30% PEG 1500, 10% GLYCEROL
|
Resolution 2.10 Å
R-free 0.234
|
|
2X4U
Crystal structure of MHC CLass I HLA-A2.1 bound to HIV-1 Peptide RT468-476
Deposited 2010-02-02
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 4
MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；100 MM MES PH 5.5, 20% PEG 1500. CRYSTALS WERE FROZEN IN 100 MM MES, 30% PEG 1500, 10% GLYCEROL
|
Resolution 2.10 Å
R-free 0.234
|
|
2X70
Crystal structure of MHC CLass I HLA-A2.1 bound to a photocleavable peptide
Deposited 2010-02-22
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：RESIDUES 21-119
|
Not recorded
|
GOL GLYCEROL × 2
MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；VAPOUR DIFFUSION HANGING DROP AT 293K: 2 MICROLITER OF 5 MG/ML PROTEIN IN 0.1 M MES PH 6.0 WAS MIXED WITH 2 MICROLITER OF 0.1 M MES PH 6.5, 20-22% PEG 1500. SEEDING WAS USED TO GET BIGGER CRYSTALS
|
Resolution 2.00 Å
R-free 0.225
|
|
2X70
Crystal structure of MHC CLass I HLA-A2.1 bound to a photocleavable peptide
Deposited 2010-02-22
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
Fragment：RESIDUES 21-119
|
Not recorded
|
GOL GLYCEROL × 3
MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；VAPOUR DIFFUSION HANGING DROP AT 293K: 2 MICROLITER OF 5 MG/ML PROTEIN IN 0.1 M MES PH 6.0 WAS MIXED WITH 2 MICROLITER OF 0.1 M MES PH 6.5, 20-22% PEG 1500. SEEDING WAS USED TO GET BIGGER CRYSTALS
|
Resolution 2.00 Å
R-free 0.225
|
|
2X89
Structure of the Beta2_microglobulin involved in amyloidogenesis
Deposited 2010-03-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain F
27–119（93 aa）
Fragment：RESIDUES 27-119
Chain G
27–119（93 aa）
Fragment：RESIDUES 27-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
6%PEG4000, 0.2M AMMONIUM SULPHATE, 0.1M NA-ACETEATE PH4.6
|
Resolution 2.16 Å
R-free 0.267
|
|
2X89
Structure of the Beta2_microglobulin involved in amyloidogenesis
Deposited 2010-03-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain D
27–119（93 aa）
Fragment：RESIDUES 27-119
Chain E
27–119（93 aa）
Fragment：RESIDUES 27-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
6%PEG4000, 0.2M AMMONIUM SULPHATE, 0.1M NA-ACETEATE PH4.6
|
Resolution 2.16 Å
R-free 0.267
|
|
2XKS
Prion-like conversion during amyloid formation at atomic resolution
Deposited 2010-07-12
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
SOLUTION NMR
NMR measurement conditions
pH 7.5；298 K；Ionic strength (raw mmCIF value) 0.04；Pressure 1.0
NMR sample composition
90% H2O/10% D2O
NMR sample composition
100% D2O
|
Resolution not provided
|
|
2XKU
Prion-like conversion during amyloid formation at atomic resolution
Deposited 2010-07-12
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
27–119（93 aa）
Fragment：IMMUNGLOBULIN, RESIDUES 27-119
|
Not recorded
|
No recorded non-water small molecule
|
SOLUTION NMR
NMR measurement conditions
pH 7.5；298 K；Ionic strength (raw mmCIF value) 0.04；Pressure 1.0
NMR measurement conditions
pH 7.5；298 K；Ionic strength (raw mmCIF value) 0.04；Pressure 1.0
NMR measurement conditions
pH 7.5；298 K；Ionic strength (raw mmCIF value) 0.04；Pressure 1.0
NMR measurement conditions
pH 7.5；298 K；Ionic strength (raw mmCIF value) 0.04；Pressure 1.0
NMR sample composition
90% H2O/10% D2O
NMR sample composition
100% D2O
|
Resolution not provided
|
|
2XPG
Crystal structure of a MHC class I-peptide complex
Deposited 2010-08-26
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
22–118（97 aa）
Fragment：BETA2-MICROGLOBULIN FORM PI 5.3, RESIDUES 22-118
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8；0.1 M BIS-TRIS-PROPANE, PH 8.0, 0.2 M NA/K PHOSPHATE, 20% (V/V) PEG3350
|
Resolution 2.60 Å
R-free 0.247
|
|
2YPK
Structural features underlying T-cell receptor sensitivity to concealed MHC class I micropolymorphisms
Deposited 2012-10-30
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：RESIDUES 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；16% PEG 8000, 50MM MES PH6.5
|
Resolution 1.95 Å
R-free 0.252
|
|
2YPL
Structural features underlying T-cell receptor sensitivity to concealed MHC class I micropolymorphisms
Deposited 2012-10-30
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.3；pH 7.3
|
Resolution 2.40 Å
R-free 0.277
|
|
2YXF
The high resolution crystal structure of beta2-microglobulin under physiological conditions
Deposited 2007-04-26
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；288 K；25% PEG 4000, 25% Glycerol, 0.06M ammoniumacetate, 0.1M MOPS, pH 7.00, VAPOR DIFFUSION, HANGING DROP, temperature 288K
|
Resolution 1.13 Å
R-free 0.195
|
|
2Z9T
Crystal structure of the human beta-2 microglobulin mutant W60G
Deposited 2007-09-26
|
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
21–119（99 aa）
|
Mutation：W60G
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；293 K；0.1M MES, PEG 4000, Ammonium acetate, glycerol, pH 6.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.80 Å
R-free 0.214
|
|
2Z9T
Crystal structure of the human beta-2 microglobulin mutant W60G
Deposited 2007-09-26
|
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
21–119（99 aa）
|
Mutation：W60G
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；293 K；0.1M MES, PEG 4000, Ammonium acetate, glycerol, pH 6.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.80 Å
R-free 0.214
|
|
3AM8
Crystal Structure of a Human Major Histocompatibilty complex
Deposited 2010-08-18
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain C
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.3；294 K；14-19% PEG 3350, 2% MPD, 0.2M MgCl2, 0.1M Tris, pH 7.3, VAPOR DIFFUSION, HANGING DROP, temperature 294K
|
Resolution 2.80 Å
R-free 0.251
|
|
3AM8
Crystal Structure of a Human Major Histocompatibilty complex
Deposited 2010-08-18
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.3；294 K；14-19% PEG 3350, 2% MPD, 0.2M MgCl2, 0.1M Tris, pH 7.3, VAPOR DIFFUSION, HANGING DROP, temperature 294K
|
Resolution 2.80 Å
R-free 0.251
|
|
3B3I
Citrullination-dependent differential presentation of a self-peptide by HLA-B27 subtypes
Deposited 2007-10-22
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：RESIDUES 21-119
|
Not recorded
|
GOL GLYCEROL × 6
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；291 K；0.1 M Tris, 25% PEG 8000, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.86 Å
R-free 0.233
|
|
3B6S
Crystal Structure of hla-b*2705 Complexed with the Citrullinated Vasoactive Intestinal Peptide Type 1 Receptor (vipr) Peptide (residues 400-408)
Deposited 2007-10-29
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：RESIDUES 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；281 K；0.1M Tris HCl, 24% PEG 8000, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 281K
|
Resolution 1.80 Å
R-free 0.223
|
|
3BGM
Crystal Structure of PKD2 Phosphopeptide Bound to Human Class I MHC HLA-A2
Deposited 2007-11-27
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；17% PEG 8000, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.60 Å
R-free 0.232
|
|
3BH8
Crystal Structure of RQA_M Phosphopeptide Bound to HUMAN Class I MHC HLA-A2
Deposited 2007-11-28
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；17% PEG 8000, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.65 Å
R-free 0.231
|
|
3BH9
Crystal Structure of RTY Phosphopeptide Bound to Human Class I MHC HLA-A2
Deposited 2007-11-28
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
NA SODIUM ION × 1
EDO 1,2-ETHANEDIOL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；21% PEG 3350, 0.1M sodium thiocyanate, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.70 Å
R-free 0.229
|
|
3BH9
Crystal Structure of RTY Phosphopeptide Bound to Human Class I MHC HLA-A2
Deposited 2007-11-28
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
NA SODIUM ION × 2
EDO 1,2-ETHANEDIOL × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；21% PEG 3350, 0.1M sodium thiocyanate, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.70 Å
R-free 0.229
|
|
3BHB
Crystal Structure of KMD Phosphopeptide Bound to Human Class I MHC HLA-A2
Deposited 2007-11-28
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
22–119（98 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；24% POLYACRYLIC ACID, 0.1M HEPES, 0.09M MgCl2, pH 7.5, VAPOR DIFFUSION, hanging drop, temperature 298K
|
Resolution 2.20 Å
R-free 0.256
|
|
3BO8
The High Resolution Crystal Structure of HLA-A1 Complexed with the MAGE-A1 Peptide
Deposited 2007-12-17
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；291 K；20% PEG 3350, 0.2M Sodium Fluoride, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 291K
|
Resolution 1.80 Å
R-free 0.225
|
|
3BP4
The high resolution crystal structure of HLA-B*2705 in complex with a Cathepsin A signal sequence peptide pCatA
Deposited 2007-12-18
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；23% PEG 8000, 0.1M Tris buffer pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.85 Å
R-free 0.222
|
|
3BP7
The high resolution crystal structure of HLA-B*2709 in complex with a Cathepsin A signal sequence peptide, pCatA
Deposited 2007-12-18
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；23.5% PEG 8000, 0.1M Tris buffer pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.80 Å
R-free 0.204
|
|
3BVN
High resolution crystal structure of HLA-B*1402 in complex with the latent membrane protein 2 peptide (LMP2) of Epstein-Barr virus
Deposited 2008-01-07
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；20-22%(w/v) PEG 20 000, 0.1 M HEPES buffer pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.55 Å
R-free 0.268
|
|
3BVN
High resolution crystal structure of HLA-B*1402 in complex with the latent membrane protein 2 peptide (LMP2) of Epstein-Barr virus
Deposited 2008-01-07
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；20-22%(w/v) PEG 20 000, 0.1 M HEPES buffer pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.55 Å
R-free 0.268
|
|
3BW9
Crystal Structure of HLA B*3508 in complex with a HCMV 12-mer peptide from the pp65 protein
Deposited 2008-01-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.6；277 K；0.2M ammonium acetate, 16% PEG 3350, pH 7.6, vapor diffusion, hanging drop, temperature 277K
|
Resolution 1.75 Å
R-free 0.235
|
|
3BWA
Crystal Structure of HLA B*3508 in complex with a HCMV 8-mer peptide from the pp65 protein
Deposited 2008-01-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.6；277 K；0.2M ammonium acetate, 16% PEG 3350, pH 7.6, vapor diffusion, hanging drop, temperature 277K
|
Resolution 1.30 Å
R-free 0.209
|
|
3BXN
The high resolution crystal structure of HLA-B*1402 complexed with a Cathepsin A signal sequence peptide, pCatA
Deposited 2008-01-14
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；24- 27%(w/v) PEG 20000, with 0.1 M HEPES pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.86 Å
R-free 0.219
|
|
3BZE
The human non-classical major histocompatibility complex molecule HLA-E
Deposited 2008-01-17
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.3；293 K；14-19% PEG 3350, 2% MPD, 0.2M MgCl2, 0.1M Tris, pH 7.3, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.50 Å
R-free 0.296
|
|
3BZE
The human non-classical major histocompatibility complex molecule HLA-E
Deposited 2008-01-17
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.3；293 K；14-19% PEG 3350, 2% MPD, 0.2M MgCl2, 0.1M Tris, pH 7.3, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.50 Å
R-free 0.296
|
|
3BZE
The human non-classical major histocompatibility complex molecule HLA-E
Deposited 2008-01-17
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain F
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.3；293 K；14-19% PEG 3350, 2% MPD, 0.2M MgCl2, 0.1M Tris, pH 7.3, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.50 Å
R-free 0.296
|
|
3BZE
The human non-classical major histocompatibility complex molecule HLA-E
Deposited 2008-01-17
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain H
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.3；293 K；14-19% PEG 3350, 2% MPD, 0.2M MgCl2, 0.1M Tris, pH 7.3, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.50 Å
R-free 0.296
|
|
3BZF
The human non-classical major histocompatibility complex molecule HLA-E
Deposited 2008-01-17
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
23–119（97 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.3；293 K；19% PEG 3350, 0.3M NaCl, 0.1M Tris, pH 7.3, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.50 Å
R-free 0.269
|
|
3BZF
The human non-classical major histocompatibility complex molecule HLA-E
Deposited 2008-01-17
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
23–119（97 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.3；293 K；19% PEG 3350, 0.3M NaCl, 0.1M Tris, pH 7.3, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.50 Å
R-free 0.269
|
|
3C9N
Crystal Structure of a SARS Corona Virus Derived Peptide Bound to the Human Major Histocompatibility Complex Class I molecule HLA-B*1501
Deposited 2008-02-18
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
PG4 TETRAETHYLENE GLYCOL × 1
EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5；273 K；0.2M Magnesium chloride hexahydrate, 0.1M HEPES sodium, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 273K, pH 7.50
|
Resolution 1.87 Å
R-free 0.227
|
|
3CDG
Human CD94/NKG2A in complex with HLA-E
Deposited 2008-02-26
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.9；291 K；Ammonium sulfate, pH 7.9, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 3.40 Å
R-free 0.279
|
|
3CDG
Human CD94/NKG2A in complex with HLA-E
Deposited 2008-02-26
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain D
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.9；291 K；Ammonium sulfate, pH 7.9, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 3.40 Å
R-free 0.279
|
|
3CII
Structure of NKG2A/CD94 bound to HLA-E
Deposited 2008-03-11
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；291 K；1.8M ammonium sulfate, 0.3-0.7% sucrose, 100 mM Tris (8.0), VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 4.41 Å
R-free 0.355
|
|
3CII
Structure of NKG2A/CD94 bound to HLA-E
Deposited 2008-03-11
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；291 K；1.8M ammonium sulfate, 0.3-0.7% sucrose, 100 mM Tris (8.0), VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 4.41 Å
R-free 0.355
|
|
3CIQ
A regulatable switch mediates self-association in an immunoglobulin fold
Deposited 2008-03-11
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 6
PDB declaration: hexameric
|
Chain G
21–119（99 aa）
Chain H
21–119（99 aa）
Chain I
21–119（99 aa）
Chain J
21–119（99 aa）
Chain K
21–119（99 aa）
Chain L
21–119（99 aa）
|
Mutation：H13F
Mutation：H13F
Mutation：H13F
Mutation：H13F
Mutation：H13F
Mutation：H13F
|
CU COPPER (II) ION × 6
TLA L(+)-TARTARIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；288 K；28% PEG 3350, 200 mM ammonium tartrate dibasic, pH 7.40, VAPOR DIFFUSION, SITTING DROP, temperature 288K
|
Resolution 2.90 Å
R-free 0.264
|
|
3CIQ
A regulatable switch mediates self-association in an immunoglobulin fold
Deposited 2008-03-11
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein homooligomer
Homooligomer；Protein × 6
PDB declaration: hexameric
|
Chain A
21–119（99 aa）
Chain B
21–119（99 aa）
Chain C
21–119（99 aa）
Chain D
21–119（99 aa）
Chain E
21–119（99 aa）
Chain F
21–119（99 aa）
|
Mutation：H13F
Mutation：H13F
Mutation：H13F
Mutation：H13F
Mutation：H13F
Mutation：H13F
|
CU COPPER (II) ION × 6
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；288 K；28% PEG 3350, 200 mM ammonium tartrate dibasic, pH 7.40, VAPOR DIFFUSION, SITTING DROP, temperature 288K
|
Resolution 2.90 Å
R-free 0.264
|
|
3CZF
Crystal structure of HLA-B*2709 complexed with the glucagon receptor (GR) peptide (residues 412-420)
Deposited 2008-04-29
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：RESIDUES 21-119
|
Not recorded
|
GOL GLYCEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5；291 K；14% (w/v) PEG 4000, 20mM Tris/HCl pH 7.5, 150mM NaCl, VAPOR DIFFUSION, HANGING DROP, temperature 291K, pH 7.50
|
Resolution 1.20 Å
R-free 0.149
|
|
3D18
Crystal structure of HLA-B*2709 complexed with a variant of the latent membrane protein 2 peptide (LMP2(L)) of epstein-barr virus
Deposited 2008-05-05
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：Residues 21-119
|
Not recorded
|
GOL GLYCEROL × 6
TRS 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1
MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；291 K；20% PEG 4000, 0.1M MES, pH 6, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.74 Å
R-free 0.233
|
|
3D25
Crystal structure of HA-1 minor histocompatibility antigen bound to human class I MHC HLA-A2
Deposited 2008-05-07
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
22–119（98 aa）
Fragment：UNP residues 22-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5；298 K；20 % PEG 10K, 0.1 M HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K, pH 7.50
|
Resolution 1.30 Å
R-free 0.204
|
|
3D2U
Structure of UL18, a Peptide-Binding Viral MHC Mimic, Bound to a Host Inhibitory Receptor
Deposited 2008-05-08
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 7
MAN alpha-D-mannopyranose × 1
BMA beta-D-mannopyranose × 1
FUC alpha-L-fucopyranose × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；0.4 M Mg(NO3)2, and 16~22% (w/v) PEG 33500, pH 5.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.21 Å
R-free 0.259
|
|
3D2U
Structure of UL18, a Peptide-Binding Viral MHC Mimic, Bound to a Host Inhibitory Receptor
Deposited 2008-05-08
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain F
21–119（99 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 6
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；0.4 M Mg(NO3)2, and 16~22% (w/v) PEG 33500, pH 5.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.21 Å
R-free 0.259
|
|
3D39
The complex between TCR A6 and human Class I MHC HLA-A2 with the modified HTLV-1 TAX (Y5(4-fluoroPhenylalanine)) peptide
Deposited 2008-05-09
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；297 K；TRIS 0.1 M, PEG4000 15%, MgCl2 0.2M, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 297K
|
Resolution 2.81 Å
R-free 0.269
|
|
3D3V
The complex between TCR A6 and human Class I MHC HLA-A2 with the modified HTLV-1 TAX (Y5(3,4-difluoroPhenylalanine)) peptide
Deposited 2008-05-12
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 6
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；297 K；TRIS 0.1 M, PEG4000 15%, MgCl2 0.2M, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 297K
|
Resolution 2.80 Å
R-free 0.278
|
|
3DBX
Structure of chicken CD1-2 with bound fatty acid
Deposited 2008-06-02
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3
PLM PALMITIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；277 K；20% PEG4000, 0.1M sodium citrate, 10% isopropanol, pH5.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 2.00 Å
R-free 0.266
|
|
3DHJ
Beta 2 microglobulin mutant W60C
Deposited 2008-06-18
|
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
21–119（99 aa）
|
Mutation：W60C
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.5；293 K；0.1M Na acetate, PEG 4000, Ammonium acetate, glycerol, pH 4.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.00 Å
R-free 0.212
|
|
3DHM
Beta 2 microglobulin mutant D59P
Deposited 2008-06-18
|
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
21–119（99 aa）
|
Mutation：D59P
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.5；293 K；0.1M Na acetate, PEG 4000, Ammonium acetate, glycerol, pH 4.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.80 Å
R-free 0.222
|
|
3DTX
Crystal structure of HLA-B*2705 complexed with the double citrullinated vasoactive intestinal peptide type 1 receptor (VIPR) peptide (residues 400-408)
Deposited 2008-07-16
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain B
21–119（99 aa）
Fragment：RESIDUES 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；291 K；0.1M TRIS HCL, 25% PEG 8000,, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.10 Å
R-free 0.262
|
|
3DTX
Crystal structure of HLA-B*2705 complexed with the double citrullinated vasoactive intestinal peptide type 1 receptor (VIPR) peptide (residues 400-408)
Deposited 2008-07-16
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：RESIDUES 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；291 K；0.1M TRIS HCL, 25% PEG 8000,, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.10 Å
R-free 0.262
|
|
3DX6
Crystal Structure of B*4402 presenting a 10mer EBV epitope
Deposited 2008-07-23
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
ACT ACETATE ION × 9
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；293 K；Citrate, Ammonium Acetate, PEG 4000, pH 5.6, vapor diffusion, hanging drop, temperature 293K
|
Resolution 1.70 Å
R-free 0.251
|
|
3DX7
Crystal Structure of HLA-B*4403 presenting 10mer EBV antigen
Deposited 2008-07-23
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
ACT ACETATE ION × 4
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；293 K；Citrate, Ammonium Acetate, PEG 4000, pH 5.6, vapor diffusion, hanging drop, temperature 293K
|
Resolution 1.60 Å
R-free 0.210
|
|
3DX8
Crystal Structure of B*4405 presenting a 10mer EBV epitope
Deposited 2008-07-23
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；293 K；Citrate, Ammonium Acetate, PEG 4000, pH 5.6, vapor diffusion, hanging drop, temperature 293K
|
Resolution 2.10 Å
R-free 0.255
|
|
3DXA
Crystal Structure of the DM1 TCR in complex with HLA-B*4405 and decamer EBV antigen
Deposited 2008-07-23
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 9；293 K；Bicine, Lithium Sulfate, PEG 3350, pH 9.0, vapor diffusion, hanging drop, temperature 293K
|
Resolution 3.50 Å
R-free 0.330
|
|
3DXA
Crystal Structure of the DM1 TCR in complex with HLA-B*4405 and decamer EBV antigen
Deposited 2008-07-23
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 9；293 K；Bicine, Lithium Sulfate, PEG 3350, pH 9.0, vapor diffusion, hanging drop, temperature 293K
|
Resolution 3.50 Å
R-free 0.330
|
|
3DXA
Crystal Structure of the DM1 TCR in complex with HLA-B*4405 and decamer EBV antigen
Deposited 2008-07-23
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain L
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 9；293 K；Bicine, Lithium Sulfate, PEG 3350, pH 9.0, vapor diffusion, hanging drop, temperature 293K
|
Resolution 3.50 Å
R-free 0.330
|
|
3EKC
structure of W60V beta-2 microglobulin mutant
Deposited 2008-09-19
|
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
21–119（99 aa）
|
Mutation：W60V
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.5；293 K；0.1M Na acetate, PEG 4000, Ammonium acetate, glycerol, pH 4.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.80 Å
R-free 0.240
|
|
3FFC
Crystal Structure of CF34 TCR in complex with HLA-B8/FLR
Deposited 2008-12-03
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
CD CADMIUM ION × 5
CL CHLORIDE ION × 6
NA SODIUM ION × 6
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.4；293 K；11% PEG 20000, 0.2M LiSO4, 0.1M Tris, 6mM CdCl, 4% ethylene glycol, 4% dioxane, pH 8.4, vapor diffusion, hanging drop, temperature 293K
|
Resolution 2.80 Å
R-free 0.268
|
|
3FFC
Crystal Structure of CF34 TCR in complex with HLA-B8/FLR
Deposited 2008-12-03
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
|
Not recorded
|
CD CADMIUM ION × 5
CL CHLORIDE ION × 5
NA SODIUM ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.4；293 K；11% PEG 20000, 0.2M LiSO4, 0.1M Tris, 6mM CdCl, 4% ethylene glycol, 4% dioxane, pH 8.4, vapor diffusion, hanging drop, temperature 293K
|
Resolution 2.80 Å
R-free 0.268
|
|
3FQN
Phosphorylation of self-peptides alters Human Leukocyte Antigen Class I-restricted antigen presentation and generates tumor specific epitopes
Deposited 2009-01-07
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
22–119（98 aa）
|
Not recorded
|
CD CADMIUM ION × 6
MG MAGNESIUM ION × 2
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；293 K；13% PEG3350, 5mM CdCl2, 5mM MgCl2, 0.1M NaCl, pH7.4, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.65 Å
R-free 0.197
|
|
3FQR
Phosphorylation of self-peptides alters Human Leukocyte Antigen Class I-restricted antigen presentation and generates tumor specific epitopes
Deposited 2009-01-07
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
22–119（98 aa）
|
Not recorded
|
GOL GLYCEROL × 3
MG MAGNESIUM ION × 2
CD CADMIUM ION × 6
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；293 K；13% PEG3350, 5mM CdCl2, 5mM MgCl2, 0.1M NaCl, pH7.4, temperature 293K, VAPOR DIFFUSION, HANGING DROP
|
Resolution 1.70 Å
R-free 0.189
|
|
3FQT
Phosphorylation of self-peptides alters Human Leukocyte Antigen Class I-restricted antigen presentation and generates tumor specific epitopes
Deposited 2009-01-07
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
22–119（98 aa）
|
Not recorded
|
CD CADMIUM ION × 6
MG MAGNESIUM ION × 1
GOL GLYCEROL × 6
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；293 K；13% PEG3350, 3mM CdCl2, 3mM MgCl2, 0.1M NaCl, pH7.4, temperature 293K, VAPOR DIFFUSION, HANGING DROP
|
Resolution 1.80 Å
R-free 0.204
|
|
3FQU
Phosphorylation of self-peptides alters Human Leukocyte Antigen Class I-restricted antigen presentation and generates tumor specific epitopes
Deposited 2009-01-07
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
22–119（98 aa）
|
Not recorded
|
GOL GLYCEROL × 4
CD CADMIUM ION × 6
MG MAGNESIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；293 K；13% PEG3350, 3mM CdCl2, 3mM MgCl2, 0.1M NaCl, pH7.4, temperature 293K, VAPOR DIFFUSION, HANGING DROP
|
Resolution 1.80 Å
R-free 0.202
|
|
3FQW
Phosphorylation of self-peptides alters Human Leukocyte Antigen Class I-restricted antigen presentation and generates tumor specific epitopes
Deposited 2009-01-07
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
22–119（98 aa）
|
Not recorded
|
CD CADMIUM ION × 5
CO COBALT (II) ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；293 K；13% PEG3350, 10mM CdCl2, 10mM CoCl2, 0.1M NaCl, pH7.4, temperature 293K, VAPOR DIFFUSION, HANGING DROP
|
Resolution 1.93 Å
R-free 0.196
|
|
3FQX
Phosphorylation of self-peptides alters Human Leukocyte Antigen Class I-restricted antigen presentation and generates tumor specific epitopes
Deposited 2009-01-07
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
22–119（98 aa）
|
Not recorded
|
CD CADMIUM ION × 5
MG MAGNESIUM ION × 2
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；293 K；13% PEG3350, 5mM CdCl2, 5mM MgCl2, 0.1M NaCl, pH7.4, temperature 293K, VAPOR DIFFUSION, HANGING DROP
|
Resolution 1.70 Å
R-free 0.197
|
|
3FT2
Crystal Structure of a citrulline peptide variant of the minor histocompatibility peptide HA-1 in complex with HLA-A2
Deposited 2009-01-12
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；12-15% w/v PEG 6000, 0.1 M NaCl and 0.1 M tri-sodium-citrate, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.80 Å
R-free 0.218
|
|
3FT3
Crystal Structure of the minor histocompatibility peptide HA-1His in complex with HLA-A2
Deposited 2009-01-12
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；12-15% w/v PEG 6000, 0.1 M NaCl and 0.1 M tri-sodium-citrate, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.95 Å
R-free 0.231
|
|
3FT4
Crystal Structure of the minor histocompatibility peptide HA-1Arg in complex with HLA-A2
Deposited 2009-01-12
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；12-15% w/v PEG 6000, 0.1 M NaCl and 0.1 M tri-sodium-citrate, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.90 Å
R-free 0.224
|
|
3GIV
Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance
Deposited 2009-03-06
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.00 Å
R-free 0.238
|
|
3GIV
Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance
Deposited 2009-03-06
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.00 Å
R-free 0.238
|
|
3GJF
Rational development of high-affinity T-cell receptor-like antibodies
Deposited 2009-03-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 1.90 Å
R-free 0.251
|
|
3GJF
Rational development of high-affinity T-cell receptor-like antibodies
Deposited 2009-03-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 1.90 Å
R-free 0.251
|
|
3GSN
Crystal structure of the public RA14 TCR in complex with the HCMV dominant NLV/HLA-A2 epitope
Deposited 2009-03-27
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain L
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 1
CL CHLORIDE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；18-24% PEG 3350, 0.3M LiSO4, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.80 Å
R-free 0.290
|
|
3GSO
Crystal structure of the binary complex between HLA-A2 and HCMV NLV peptide
Deposited 2009-03-27
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；9-20% PEG 6000, 0.1M tri-Na Citrate, 0-0.1M NaCl, pH 6.5, vapor diffusion, hanging drop, temperature 293K
|
Resolution 1.60 Å
R-free 0.229
|
|
3GSQ
Crystal structure of the binary complex between HLA-A2 and HCMV NLV-M5S peptide variant
Deposited 2009-03-27
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；9-20% PEG 6000, 0.1M tri-Na Citrate, 0-0.1M NaCl, pH 6.5, vapor diffusion, hanging drop, temperature 293K
|
Resolution 2.12 Å
R-free 0.246
|
|
3GSR
Crystal structure of the binary complex between HLA-A2 and HCMV NLV-M5V peptide variant
Deposited 2009-03-27
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；9-20% PEG 6000, 0.1M tri-Na Citrate, 0-0.1M NaCl, pH 6.5, vapor diffusion, hanging drop, temperature 293K
|
Resolution 1.95 Å
R-free 0.226
|
|
3GSU
Crystal structure of the binary complex between HLA-A2 and HCMV NLV-M5T peptide variant
Deposited 2009-03-27
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；9-20% PEG 6000, 0.1M tri-Na Citrate, 0-0.1M NaCl, pH 6.5, vapor diffusion, hanging drop, temperature 293K
|
Resolution 1.80 Å
R-free 0.242
|
|
3GSV
Crystal structure of the binary complex between HLA-A2 and HCMV NLV-M5Q peptide variant
Deposited 2009-03-27
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；9-20% PEG 6000, 0.1M tri-Na Citrate, 0-0.1M NaCl, pH 6.5, vapor diffusion, hanging drop, temperature 293K
|
Resolution 1.90 Å
R-free 0.242
|
|
3GSW
Crystal structure of the binary complex between HLA-A2 and HCMV NLV-T8A peptide variant
Deposited 2009-03-27
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；9-20% PEG 6000, 0.1M tri-Na Citrate, 0-0.1M NaCl, pH 6.5, vapor diffusion, hanging drop, temperature 293K
|
Resolution 1.81 Å
R-free 0.227
|
|
3GSX
Crystal structure of the binary complex between HLA-A2 and HCMV NLV-T8V peptide variant
Deposited 2009-03-27
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；9-20% PEG 6000, 0.1M tri-Na Citrate, 0-0.1M NaCl, pH 6.5, vapor diffusion, hanging drop, temperature 293K
|
Resolution 2.10 Å
R-free 0.247
|
|
3H7B
Human Class I MHC HLA-A2 in complex with the Tel1p peptide
Deposited 2009-04-24
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 5
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；PEG3350 24%, MES 0.025M, NaCl 0.1M, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 1.88 Å
R-free 0.242
|
|
3H7B
Human Class I MHC HLA-A2 in complex with the Tel1p peptide
Deposited 2009-04-24
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；PEG3350 24%, MES 0.025M, NaCl 0.1M, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 1.88 Å
R-free 0.242
|
|
3H9H
Human Class I MHC HLA-A2(A150P) in complex with the Tel1p peptide
Deposited 2009-04-30
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；PEG3350 24%, MES 0.025M, NaF 0.1M, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 2.00 Å
R-free 0.226
|
|
3H9H
Human Class I MHC HLA-A2(A150P) in complex with the Tel1p peptide
Deposited 2009-04-30
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；PEG3350 24%, MES 0.025M, NaF 0.1M, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 2.00 Å
R-free 0.226
|
|
3H9S
The complex between TCR A6 and human Class I MHC HLA-A2 with the bound Tel1p peptide
Deposited 2009-04-30
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 6
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；297 K；PEG4000 15%, TRIS 0.1M, MgCl2 0.2M, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 297K
|
Resolution 2.70 Å
R-free 0.289
|
|
3HAE
Rational development of high-affinity T-cell receptor-like antibodies
Deposited 2009-05-01
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.9；294 K；12% PEG 8000, 50mM Mes, pH 6.9, VAPOR DIFFUSION, temperature 294K
|
Resolution 2.90 Å
R-free 0.283
|
|
3HAE
Rational development of high-affinity T-cell receptor-like antibodies
Deposited 2009-05-01
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.9；294 K；12% PEG 8000, 50mM Mes, pH 6.9, VAPOR DIFFUSION, temperature 294K
|
Resolution 2.90 Å
R-free 0.283
|
|
3HAE
Rational development of high-affinity T-cell receptor-like antibodies
Deposited 2009-05-01
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain K
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.9；294 K；12% PEG 8000, 50mM Mes, pH 6.9, VAPOR DIFFUSION, temperature 294K
|
Resolution 2.90 Å
R-free 0.283
|
|
3HAE
Rational development of high-affinity T-cell receptor-like antibodies
Deposited 2009-05-01
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain Q
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.9；294 K；12% PEG 8000, 50mM Mes, pH 6.9, VAPOR DIFFUSION, temperature 294K
|
Resolution 2.90 Å
R-free 0.283
|
|
3HCV
Crystal structure of HLA-B*2709 complexed with the double citrullinated vasoactive intestinal peptide type 1 receptor (VIPR) peptide (residues 400-408)
Deposited 2009-05-06
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：RESIDUES 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；291 K；0.1M TRIS HCL,25% PEG 8000, , pH 8.000000, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.95 Å
R-free 0.245
|
|
3HG1
Germline-governed recognition of a cancer epitope by an immunodominant human T cell receptor
Deposited 2009-05-13
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：Residues 21-119
|
Not recorded
|
GOL GLYCEROL × 2
SO4 SULFATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；23% PEG 550 MME, 0.1M TRIS, 15% Glycerol, pH 7.4, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 3.00 Å
R-free 0.304
|
|
3HLA
HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN A2.1
Deposited 1989-10-06
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.60 Å
|
|
3HPJ
Human Class I MHC HLA-A2 in complex with the WT-1 (126-134) peptide
Deposited 2009-06-04
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：residues 21-119
|
Not recorded
|
GOL GLYCEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；277 K；PEG3350 24%, MES 0.025M, NaCl 0.1M, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 2.00 Å
R-free 0.236
|
|
3HPJ
Human Class I MHC HLA-A2 in complex with the WT-1 (126-134) peptide
Deposited 2009-06-04
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
Fragment：residues 21-119
|
Not recorded
|
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；277 K；PEG3350 24%, MES 0.025M, NaCl 0.1M, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 2.00 Å
R-free 0.236
|
|
3HUJ
Crystal structure of human CD1d-alpha-Galactosylceramide in complex with semi-invariant NKT cell receptor
Deposited 2009-06-14
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
AGH N-{(1S,2R,3S)-1-[(ALPHA-D-GALACTOPYRANOSYLOXY)METHYL]-2,3-DIHYDROXYHEPTADECYL}HEXACOSANAMIDE × 1
MG MAGNESIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 9；291 K；0.1M Tris-HCl, 0.2M magnesium chloride, 12% PEG 10000, pH 9.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.50 Å
R-free 0.279
|
|
3HUJ
Crystal structure of human CD1d-alpha-Galactosylceramide in complex with semi-invariant NKT cell receptor
Deposited 2009-06-14
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Other combination
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain D
21–119（99 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
AGH N-{(1S,2R,3S)-1-[(ALPHA-D-GALACTOPYRANOSYLOXY)METHYL]-2,3-DIHYDROXYHEPTADECYL}HEXACOSANAMIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 9；291 K；0.1M Tris-HCl, 0.2M magnesium chloride, 12% PEG 10000, pH 9.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.50 Å
R-free 0.279
|
|
3I6G
Newly identified epitope Mn2 from SARS-CoV M protein complexed withHLA-A*0201
Deposited 2009-07-07
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；277 K；0.1M Ammonium acetate, 0.1M BIS-TRIS, pH6.0, 13-17% Polyethylene glycol 10,000, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.20 Å
R-free 0.246
|
|
3I6G
Newly identified epitope Mn2 from SARS-CoV M protein complexed withHLA-A*0201
Deposited 2009-07-07
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；277 K；0.1M Ammonium acetate, 0.1M BIS-TRIS, pH6.0, 13-17% Polyethylene glycol 10,000, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.20 Å
R-free 0.246
|
|
3I6K
Newly identified epitope from SARS-CoV membrane protein complexed with HLA-A*0201
Deposited 2009-07-07
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；277 K；0.1M BIS-TRIS pH 5.5, 10% w/v Polyethylene glycol 3350, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.80 Å
R-free 0.243
|
|
3I6K
Newly identified epitope from SARS-CoV membrane protein complexed with HLA-A*0201
Deposited 2009-07-07
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain F
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；277 K；0.1M BIS-TRIS pH 5.5, 10% w/v Polyethylene glycol 3350, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.80 Å
R-free 0.243
|
|
3I6L
Newly identified epitope N1 derived from SARS-CoV N protein complexed with HLA-A*2402
Deposited 2009-07-07
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.9；277 K；0.2M Ammonium sulfate, 0.1M Tris pH 8.9, 25% w/v Polyethylene glycol 3350, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.40 Å
R-free 0.284
|
|
3IB4
The double mutant of Beta-2 microglobulin K58P-W60G
Deposited 2009-07-15
|
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
21–119（99 aa）
|
Mutation：K58P, W60G
Non-standard monomer：Yes (specific site not provided by mmCIF)
|
PE4 2-{2-[2-(2-{2-[2-(2-ETHOXY-ETHOXY)-ETHOXY]-ETHOXY}-ETHOXY)-ETHOXY]-ETHOXY}-ETHANOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；0.1M NaAcetate, 0.2M CH3COONH4, 20% Glycerol, 22% PEG 4000, pH 5.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.25 Å
R-free 0.181
|
|
3IXA
Human Class I MHC HLA-A2(A150P) in complex with the Tax peptide
Deposited 2009-09-03
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；277 K；PEG3350 24%, MES 0.025M, NaF 0.1M, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 2.10 Å
R-free 0.230
|
|
3IXA
Human Class I MHC HLA-A2(A150P) in complex with the Tax peptide
Deposited 2009-09-03
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；277 K；PEG3350 24%, MES 0.025M, NaF 0.1M, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 2.10 Å
R-free 0.230
|
|
3JTS
GY9-Mamu-A*02-hb2m
Deposited 2009-09-14
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
1–119（119 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；291 K；(i) 0.1M Tris-HCl pH 5.5, 0.12M ammonium sulfate, 38% polyethene glycol monomethyl ether 20000; (ii) 0.1M MES pH 6.5, 0.32M ammonium sulfate, 38% polyethene glycol monomethyl ether 20 000, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.80 Å
R-free 0.248
|
|
3JTS
GY9-Mamu-A*02-hb2m
Deposited 2009-09-14
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
1–119（119 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；291 K；(i) 0.1M Tris-HCl pH 5.5, 0.12M ammonium sulfate, 38% polyethene glycol monomethyl ether 20000; (ii) 0.1M MES pH 6.5, 0.32M ammonium sulfate, 38% polyethene glycol monomethyl ether 20 000, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.80 Å
R-free 0.248
|
|
3JTS
GY9-Mamu-A*02-hb2m
Deposited 2009-09-14
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain H
1–119（119 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；291 K；(i) 0.1M Tris-HCl pH 5.5, 0.12M ammonium sulfate, 38% polyethene glycol monomethyl ether 20000; (ii) 0.1M MES pH 6.5, 0.32M ammonium sulfate, 38% polyethene glycol monomethyl ether 20 000, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.80 Å
R-free 0.248
|
|
3KLA
Ca2+ release from the endoplasmic reticulum of NY-ESO-1 specific T cells is modulated by the affinity of T cell receptor and by the use of the CD8 co-receptor
Deposited 2009-11-07
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：beta-2-microglobulin
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；294 K；16% PEG 8K, 20mM MES, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 294K
|
Resolution 1.65 Å
R-free 0.239
|
|
3KLA
Ca2+ release from the endoplasmic reticulum of NY-ESO-1 specific T cells is modulated by the affinity of T cell receptor and by the use of the CD8 co-receptor
Deposited 2009-11-07
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
Fragment：beta-2-microglobulin
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；294 K；16% PEG 8K, 20mM MES, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 294K
|
Resolution 1.65 Å
R-free 0.239
|
|
3KPL
Crystal Structure of HLA B*4402 in complex with EEYLQAFTY a self peptide from the ABCD3 protein
Deposited 2009-11-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；277 K；0.2M ammonium acetate, 20-28% PEG 4000, 0.1M Na-citrate, pH 5.6, vapor diffusion, hanging drop, temperature 277K
|
Resolution 1.96 Å
R-free 0.253
|
|
3KPM
Crystal Structure of HLA B*4402 in complex with EEYLKAWTF, a mimotope
Deposited 2009-11-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；277 K；0.2M ammonium acetate, 20-28% PEG 4000, 0.1M Na-citrate, pH 5.6, vapor diffusion, hanging drop, temperature 277K
|
Resolution 1.60 Å
R-free 0.241
|
|
3KPN
Crystal Structure of HLA B*4403 in complex with EEYLQAFTY a self peptide from the ABCD3 protein
Deposited 2009-11-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；277 K；0.2M ammonium acetate, 20-28% PEG 4000, 0.1M Na-citrate, pH 5.6, vapor diffusion, hanging drop, temperature 277K
|
Resolution 2.00 Å
R-free 0.244
|
|
3KPO
Crystal Structure of HLA B*4403 in complex with EEYLKAWTF, a mimotope
Deposited 2009-11-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；277 K；0.2M ammonium acetate, 20-28% PEG 4000, 0.1M Na-citrate, pH 5.6, vapor diffusion, hanging drop, temperature 277K
|
Resolution 2.30 Å
R-free 0.263
|
|
3KPP
Crystal Structure of HLA B*4405 in complex with EEYLQAFTY a self peptide from the ABCD3 protein
Deposited 2009-11-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
PEG DI(HYDROXYETHYL)ETHER × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；277 K；0.2M ammonium acetate, 20-28% PEG 4000, 0.1M Na-citrate, pH 5.6, vapor diffusion, hanging drop, temperature 277K
|
Resolution 1.90 Å
R-free 0.230
|
|
3KPQ
Crystal Structure of HLA B*4405 in complex with EEYLKAWTF, a mimotope
Deposited 2009-11-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；277 K；0.2M ammonium acetate, 20-28% PEG 4000, 0.1M Na-citrate, pH 5.6, vapor diffusion, hanging drop, temperature 277K
|
Resolution 1.84 Å
R-free 0.269
|
|
3KPR
Crystal Structure of the LC13 TCR in complex with HLA B*4405 bound to EEYLKAWTF a mimotope
Deposited 2009-11-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；0.2M NaOAc, 12-18% PEG 4000, 0.1M Tris, pH 8.5, vapor diffusion, hanging drop, temperature 277K
|
Resolution 2.60 Å
R-free 0.279
|
|
3KPR
Crystal Structure of the LC13 TCR in complex with HLA B*4405 bound to EEYLKAWTF a mimotope
Deposited 2009-11-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；0.2M NaOAc, 12-18% PEG 4000, 0.1M Tris, pH 8.5, vapor diffusion, hanging drop, temperature 277K
|
Resolution 2.60 Å
R-free 0.279
|
|
3KPS
Crystal Structure of the LC13 TCR in complex with HLA B*4405 bound to EEYLQAFTY a self peptide from the ABCD3 protein
Deposited 2009-11-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；0.2M NaOAc, 12-18% PEG 4000, 0.1M Tris, pH 8.5, vapor diffusion, hanging drop, temperature 277K
|
Resolution 2.70 Å
R-free 0.269
|
|
3KWW
Crystal structure of the 'restriction triad' mutant of HLA B*3508, beta-2-microglobulin and EBV peptide
Deposited 2009-12-01
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
ACY ACETIC ACID × 7
GOL GLYCEROL × 1
PEG DI(HYDROXYETHYL)ETHER × 8
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.6；298 K；0.1M cacodlyate, 0.2M ammonium acetate, 18% PEG3350, pH 7.6, vapor diffusion, temperature 298K
|
Resolution 2.18 Å
R-free 0.251
|
|
3KXF
Crystal Structure of SB27 TCR in complex with the 'restriction triad' mutant HLA-B*3508-13mer
Deposited 2009-12-03
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
IOD IODIDE ION × 7
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.7；298 K；0.1M cacodlyate, 0.2M potassium iodide, 18% polyethylene glycol 3350, pH 6.7, vapor diffusion, temperature 298K
|
Resolution 3.10 Å
R-free 0.291
|
|
3KXF
Crystal Structure of SB27 TCR in complex with the 'restriction triad' mutant HLA-B*3508-13mer
Deposited 2009-12-03
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain F
21–119（99 aa）
|
Not recorded
|
IOD IODIDE ION × 7
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.7；298 K；0.1M cacodlyate, 0.2M potassium iodide, 18% polyethylene glycol 3350, pH 6.7, vapor diffusion, temperature 298K
|
Resolution 3.10 Å
R-free 0.291
|
|
3KXF
Crystal Structure of SB27 TCR in complex with the 'restriction triad' mutant HLA-B*3508-13mer
Deposited 2009-12-03
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain L
21–119（99 aa）
|
Not recorded
|
IOD IODIDE ION × 5
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.7；298 K；0.1M cacodlyate, 0.2M potassium iodide, 18% polyethylene glycol 3350, pH 6.7, vapor diffusion, temperature 298K
|
Resolution 3.10 Å
R-free 0.291
|
|
3KXF
Crystal Structure of SB27 TCR in complex with the 'restriction triad' mutant HLA-B*3508-13mer
Deposited 2009-12-03
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain J
21–119（99 aa）
|
Not recorded
|
IOD IODIDE ION × 5
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.7；298 K；0.1M cacodlyate, 0.2M potassium iodide, 18% polyethylene glycol 3350, pH 6.7, vapor diffusion, temperature 298K
|
Resolution 3.10 Å
R-free 0.291
|
|
3KYN
Crystal structure of HLA-G presenting KGPPAALTL peptide
Deposited 2009-12-06
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
CO COBALT (II) ION × 1
CL CHLORIDE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.8；277 K；18% PEG 3350, 0.2M potassium formate, 0.1M HEPES, 10mM cobalt chloride, pH 6.8, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.40 Å
R-free 0.299
|
|
3KYO
Crystal structure of HLA-G presenting KLPAQFYIL peptide
Deposited 2009-12-06
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
CO COBALT (II) ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.8；277 K；16% PEG 3350, 0.2M potassium formate, 0.1M HEPES, 10mM cobalt chloride, pH 6.8, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 1.70 Å
R-free 0.226
|
|
3KYO
Crystal structure of HLA-G presenting KLPAQFYIL peptide
Deposited 2009-12-06
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
CO COBALT (II) ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.8；277 K；16% PEG 3350, 0.2M potassium formate, 0.1M HEPES, 10mM cobalt chloride, pH 6.8, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 1.70 Å
R-free 0.226
|
|
3L3D
Crystal structure of HLA-B*4402 in complex with the F3A mutant of a self-peptide derived from DPA*0201
Deposited 2009-12-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
ACT ACETATE ION × 1
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；0.1M tri-sodium citrate dihydrate, 12-30% PEG 4000, 0.2M ammonium acetate, pH 5.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.80 Å
R-free 0.231
|
|
3L3G
Crystal structure of HLA-B*4402 in complex with the R5A mutant of a self-peptide derived from DPA*0201
Deposited 2009-12-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
ACT ACETATE ION × 2
GOL GLYCEROL × 5
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；0.1M tri-sodium citrate dihydrate, 12-30% PEG 4000, 0.2M ammonium acetate, pH 5.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.10 Å
R-free 0.264
|
|
3L3I
Crystal structure of HLA-B*4402 in complex with the F7A mutant of a self-peptide derived from DPA*0201
Deposited 2009-12-17
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；0.1M tri-sodium citrate dihydrate, 12-30% PEG 4000, 0.2M ammonium acetate , pH 5.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.70 Å
R-free 0.242
|
|
3L3J
Crystal structure of HLA-B*4402 in complex with the F3A/R5A double mutant of a self-peptide derived from DPA*0201
Deposited 2009-12-17
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
ACT ACETATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；0.1M tri-sodium citrate dihydrate, 12-30% PEG 4000, 0.2M ammonium acetate, pH 5.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.40 Å
R-free 0.289
|
|
3L3K
Crystal structure of HLA-B*4402 in complex with the R5A/F7A double mutant of a self-peptide derived from DPA*0201
Deposited 2009-12-17
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；0.1M tri-sodium citrate dihydrate, 12-30% PEG 4000, 0.2M ammonium acetate, pH 5.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.60 Å
R-free 0.275
|
|
3LKN
Crystal Structure of HLA B*3501 in complex with influenza NP418 epitope from 1918 strain
Deposited 2010-01-27
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；277 K；15-25% PEG 4000, 0.2M NH4Acetate, 0.1M Na-Citrate, pH 5.6, vapor diffusion, hanging drop, temperature 277K
|
Resolution 2.00 Å
R-free 0.252
|
|
3LKO
Crystal Structure of HLA B*3501 in complex with influenza NP418 epitope from 1934 strain
Deposited 2010-01-27
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；277 K；15-25% PEG 4000, 0.2M NH4Acetate, 0.1M Na-Citrate, pH 5.6, vapor diffusion, hanging drop, temperature 277K
|
Resolution 1.80 Å
R-free 0.238
|
|
3LKP
Crystal Structure of HLA B*3501 in complex with influenza NP418 epitope from 1972 strain
Deposited 2010-01-27
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；277 K；15-25% PEG 4000, 0.2M NH4Acetate, 0.1M Na-Citrate, pH 5.6, vapor diffusion, hanging drop, temperature 277K
|
Resolution 1.80 Å
R-free 0.244
|
|
3LKQ
Crystal Structure of HLA B*3501 in complex with influenza NP418 epitope from 1977 strain
Deposited 2010-01-27
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；277 K；15-25% PEG 4000, 0.2M NH4Acetate, 0.1M Na-Citrate, pH 5.6, vapor diffusion, hanging drop, temperature 277K
|
Resolution 1.80 Å
R-free 0.230
|
|
3LKR
Crystal Structure of HLA B*3501 in complex with influenza NP418 epitope from 2009 H1N1 swine origin strain
Deposited 2010-01-27
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；277 K；15-25% PEG 4000, 0.2M NH4Acetate, 0.1M Na-Citrate, pH 5.6, vapor diffusion, hanging drop, temperature 277K
|
Resolution 2.00 Å
R-free 0.266
|
|
3LKS
Crystal Structure of HLA B*3501 in complex with influenza NP418 epitope from 1980 strain
Deposited 2010-01-27
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；277 K；15-25% PEG 4000, 0.2M NH4Acetate, 0.1M Na-Citrate, pH 5.6, vapor diffusion, hanging drop, temperature 277K
|
Resolution 1.90 Å
R-free 0.260
|
|
3LN4
Crystal structure of HLA-B*4103 in complex with a 16mer self-peptide derived from heterogeneous nuclear ribonucleoproteins C1/C2
Deposited 2010-02-01
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
ACT ACETATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；294 K；0.1M citrate pH 5.6, 14-20% PEG 4000, 0.2M NH4OAc, VAPOR DIFFUSION, HANGING DROP, temperature 294K
|
Resolution 1.30 Å
R-free 0.177
|
|
3LN5
Crystal structure of HLA-B*4104 in complex with a 11mer self-peptide derived from S-methyl-5-thioadenosine phosphorylase
Deposited 2010-02-02
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；294 K；0.1M citrate pH 5.6, 14-20% PEG 4000, 0.2M NH4OAc, VAPOR DIFFUSION, HANGING DROP, temperature 294K
|
Resolution 1.90 Å
R-free 0.241
|
|
3LOW
Crystal structure of Beta 2 Microglobulin domain-swapped dimer
Deposited 2010-02-04
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
21–119（99 aa）
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 3
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.30 Å
R-free 0.266
|
|
3LOZ
Crystal structure of Beta 2 Microglobulin amyloidogenic segment LSFSKD
Deposited 2010-02-04
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 8
PDB declaration: octameric
|
Chain A
74–79（6 aa）
Chain B
74–79（6 aa）
Chain C
74–79（6 aa）
Chain D
74–79（6 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 1.80 Å
R-free 0.241
|
|
3LV3
Crystal structure of HLA-B*2705 complexed with a peptide derived from the human voltage-dependent calcium channel alpha1 subunit (residues 513-521)
Deposited 2010-02-19
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；291 K；20%(w/v) PEG 8000, 150mM NaCl, 20mM Tris-HCl, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.94 Å
R-free 0.224
|
|
3M17
Crystal structure of human FcRn with a monomeric peptide inhibitor
Deposited 2010-03-04
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.2；277 K；2uL protein:peptide with 2ul solution of 100mM sodium phosphate/citric acid, 20% PEG 3350, 8% ethanol, pH 4.2, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 2.60 Å
R-free 0.325
|
|
3M17
Crystal structure of human FcRn with a monomeric peptide inhibitor
Deposited 2010-03-04
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain D
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.2；277 K；2uL protein:peptide with 2ul solution of 100mM sodium phosphate/citric acid, 20% PEG 3350, 8% ethanol, pH 4.2, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 2.60 Å
R-free 0.325
|
|
3M17
Crystal structure of human FcRn with a monomeric peptide inhibitor
Deposited 2010-03-04
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 6
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain F
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.2；277 K；2uL protein:peptide with 2ul solution of 100mM sodium phosphate/citric acid, 20% PEG 3350, 8% ethanol, pH 4.2, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 2.60 Å
R-free 0.325
|
|
3M17
Crystal structure of human FcRn with a monomeric peptide inhibitor
Deposited 2010-03-04
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 8
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain H
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.2；277 K；2uL protein:peptide with 2ul solution of 100mM sodium phosphate/citric acid, 20% PEG 3350, 8% ethanol, pH 4.2, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 2.60 Å
R-free 0.325
|
|
3M1B
Crystal structure of human FcRn with a dimeric peptide inhibitor
Deposited 2010-03-04
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.2；294 K；2ul protein:peptide with 2ul buffer containing 100 mM phosphate/citric acid, 22% PEG 1000 and 8% ethanol , pH 4.2, VAPOR DIFFUSION, SITTING DROP, temperature 294K
|
Resolution 3.10 Å
R-free 0.397
|
|
3M1B
Crystal structure of human FcRn with a dimeric peptide inhibitor
Deposited 2010-03-04
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain D
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.2；294 K；2ul protein:peptide with 2ul buffer containing 100 mM phosphate/citric acid, 22% PEG 1000 and 8% ethanol , pH 4.2, VAPOR DIFFUSION, SITTING DROP, temperature 294K
|
Resolution 3.10 Å
R-free 0.397
|
|
3M1B
Crystal structure of human FcRn with a dimeric peptide inhibitor
Deposited 2010-03-04
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 6
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain F
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.2；294 K；2ul protein:peptide with 2ul buffer containing 100 mM phosphate/citric acid, 22% PEG 1000 and 8% ethanol , pH 4.2, VAPOR DIFFUSION, SITTING DROP, temperature 294K
|
Resolution 3.10 Å
R-free 0.397
|
|
3M1B
Crystal structure of human FcRn with a dimeric peptide inhibitor
Deposited 2010-03-04
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 8
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain H
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.2；294 K；2ul protein:peptide with 2ul buffer containing 100 mM phosphate/citric acid, 22% PEG 1000 and 8% ethanol , pH 4.2, VAPOR DIFFUSION, SITTING DROP, temperature 294K
|
Resolution 3.10 Å
R-free 0.397
|
|
3MGO
Crystal structure of a H5-specific CTL epitope derived from H5N1 influenza virus in complex with HLA-A*0201
Deposited 2010-04-07
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；291 K；25mM MES(pH 6.5), 16% PEG 6000, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.30 Å
R-free 0.247
|
|
3MGO
Crystal structure of a H5-specific CTL epitope derived from H5N1 influenza virus in complex with HLA-A*0201
Deposited 2010-04-07
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；291 K；25mM MES(pH 6.5), 16% PEG 6000, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.30 Å
R-free 0.247
|
|
3MGO
Crystal structure of a H5-specific CTL epitope derived from H5N1 influenza virus in complex with HLA-A*0201
Deposited 2010-04-07
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain H
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；291 K；25mM MES(pH 6.5), 16% PEG 6000, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.30 Å
R-free 0.247
|
|
3MGO
Crystal structure of a H5-specific CTL epitope derived from H5N1 influenza virus in complex with HLA-A*0201
Deposited 2010-04-07
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain K
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；291 K；25mM MES(pH 6.5), 16% PEG 6000, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.30 Å
R-free 0.247
|
|
3MGT
Crystal structure of a H5-specific CTL epitope variant derived from H5N1 influenza virus in complex with HLA-A*0201
Deposited 2010-04-07
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；291 K；25mM MES(pH 6.5), 16% PEG 6000, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.20 Å
R-free 0.237
|
|
3MGT
Crystal structure of a H5-specific CTL epitope variant derived from H5N1 influenza virus in complex with HLA-A*0201
Deposited 2010-04-07
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；291 K；25mM MES(pH 6.5), 16% PEG 6000, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.20 Å
R-free 0.237
|
|
3MGT
Crystal structure of a H5-specific CTL epitope variant derived from H5N1 influenza virus in complex with HLA-A*0201
Deposited 2010-04-07
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain H
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；291 K；25mM MES(pH 6.5), 16% PEG 6000, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.20 Å
R-free 0.237
|
|
3MGT
Crystal structure of a H5-specific CTL epitope variant derived from H5N1 influenza virus in complex with HLA-A*0201
Deposited 2010-04-07
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain K
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；291 K；25mM MES(pH 6.5), 16% PEG 6000, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.20 Å
R-free 0.237
|
|
3MR9
Crystal Structure of MHC class I HLA-A2 molecule complexed with HCMV pp65-495-503 nonapeptide M5A variant
Deposited 2010-04-29
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；12% PEG 6000, 0.1M NaCitrate, 0.15M NaCl, 3.5mg/ml protein conc., pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.93 Å
R-free 0.266
|
|
3MRB
Crystal Structure of MHC class I HLA-A2 molecule complexed with HCMV pp65-495-503 nonapeptide A7H variant
Deposited 2010-04-29
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；12% PEG 6000, 0.1M NaCacodylate, 5mg/ml protein conc., pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.40 Å
R-free 0.244
|
|
3MRC
Crystal Structure of MHC class I HLA-A2 molecule complexed with HCMV pp65-495-503 nonapeptide V6C variant
Deposited 2010-04-29
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；12% PEG 6000, 0.1M NaCitrate, 0.15M NaCl, 3.45mg/ml protein conc., pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.80 Å
R-free 0.223
|
|
3MRD
Crystal Structure of MHC class I HLA-A2 molecule complexed with HCMV pp65-495-503 nonapeptide V6G variant
Deposited 2010-04-29
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；10% PEG 6000, 0.1M MES, 5mg/ml protein conc., pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.70 Å
R-free 0.226
|
|
3MRE
Crystal Structure of MHC class I HLA-A2 molecule complexed with EBV bmlf1-280-288 nonapeptide
Deposited 2010-04-29
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；15% PEG 6000, 0.1M NaCitrate, 0.1M NaCl, 5mg/ml protein conc., pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.10 Å
R-free 0.204
|
|
3MRF
Crystal Structure of MHC class I HLA-A2 molecule complexed with EBV bmlf1-280-288 nonapeptide T4P variant
Deposited 2010-04-29
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；12% PEG 6000, 0.1M NaCacodylate, 0.1M NaCl, 7.5mg/ml protein conc., pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.30 Å
R-free 0.257
|
|
3MRG
Crystal Structure of MHC class I HLA-A2 molecule complexed with HCV NS3-1073-1081 nonapeptide
Deposited 2010-04-29
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
CIT CITRIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；17% PEG 6000, 0.1M NaCitrate, 0.05M NaCl, 5mg/ml protein conc., pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.30 Å
R-free 0.202
|
|
3MRH
Crystal Structure of MHC class I HLA-A2 molecule complexed with HCV NS3-1073-1081 nonapeptide N3S variant
Deposited 2010-04-29
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；9% PEG 6000, 0.1M NaCitrate, 5mg/ml protein conc., pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.40 Å
R-free 0.308
|
|
3MRI
Crystal Structure of MHC class I HLA-A2 molecule complexed with HCV NS3-1073-1081 nonapeptide G4M-V5W variant
Deposited 2010-04-29
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；9% PEG 6000, 0.1M NaCitrate, 0.1M NaCl, 5mg/ml protein conc., pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.10 Å
R-free 0.296
|
|
3MRJ
Crystal Structure of MHC class I HLA-A2 molecule complexed with HCV NS3-1073-1081 nonapeptide V5M variant
Deposited 2010-04-29
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；13% PEG 6000, 0.1M NaCitrate, 0.05M NaCl, 2.84mg/ml protein conc., pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.87 Å
R-free 0.230
|
|
3MRK
Crystal Structure of MHC class I HLA-A2 molecule complexed with AFP137 nonapeptide
Deposited 2010-04-29
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；10% PEG 6000, 0.1M NaCitrate, 5mg/ml protein conc., pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.40 Å
R-free 0.232
|
|
3MRL
Crystal Structure of MHC class I HLA-A2 molecule complexed with HCV NS3-1073-1081 nonapeptide C6V variant
Deposited 2010-04-29
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；15% PEG 6000, 0.1M NaCitrate, 3.6mg/ml protein conc., pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.41 Å
R-free 0.279
|
|
3MRM
Crystal Structure of MHC class I HLA-A2 molecule complexed with HCV NS3-1406-1415 decapeptide
Deposited 2010-04-29
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；18% PEG 6000, 0.1M NaCitrate, 0.02M NaCl, 5mg/ml protein conc., pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.90 Å
R-free 0.250
|
|
3MRN
Crystal Structure of MHC class I HLA-A2 molecule complexed with HCV NS4b-1807-1816 decapeptide
Deposited 2010-04-29
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；18% PEG 6000, 0.1M NaCitrate, 0.1M NaCl, 5mg/ml protein conc., pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.30 Å
R-free 0.298
|
|
3MRO
Crystal Structure of MHC class I HLA-A2 molecule complexed with Melan-A MART1 decapeptide variant
Deposited 2010-04-29
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；12% PEG 6000, 0.1M NaCitrate, 0.1M NaCl, 3mg/ml protein conc., pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.35 Å
R-free 0.279
|
|
3MRP
Crystal Structure of MHC class I HLA-A2 molecule complexed with Melan-A MART1 decapeptide variant
Deposited 2010-04-29
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；13% PEG 6000, 0.1M NaCitrate, 0.1M NaCl, 2.61mg/ml protein conc., pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.10 Å
R-free 0.227
|
|
3MRQ
Crystal Structure of MHC class I HLA-A2 molecule complexed with Melan-A MART1 decapeptide variant
Deposited 2010-04-29
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；17% PEG 6000, 0.1M NaCitrate, 0.1M NaCl, 2.61mg/ml protein conc., pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.20 Å
R-free 0.235
|
|
3MRR
Crystal Structure of MHC class I HLA-A2 molecule complexed with Human Prostaglandin Transporter decapeptide
Deposited 2010-04-29
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；15% PEG 6000, 0.1M NaCitrate, 0.1M NaCl, 3mg/ml protein conc., pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.60 Å
R-free 0.224
|
|
3MV7
Crystal Structure of the TK3 TCR in complex with HLA-B*3501/HPVG
Deposited 2010-05-03
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；277 K；15%PEG 3350, 0.2M LiSO4, 0.1M Na-citrate, pH 5.6, vapor diffusion, hanging drop, temperature 277K
|
Resolution 2.00 Å
R-free 0.286
|
|
3MV8
Crystal Structure of the TK3-Gln55His TCR in complex with HLA-B*3501/HPVG
Deposited 2010-05-03
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；277 K；15%PEG 3350, 0.2M LiSO4, 0.1M Na-citrate, pH 5.6, vapor diffusion, hanging drop, temperature 277K
|
Resolution 2.10 Å
R-free 0.276
|
|
3MV9
Crystal Structure of the TK3-Gln55Ala TCR in complex with HLA-B*3501/HPVG
Deposited 2010-05-03
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；277 K；15%PEG 3350, 0.2M LiSO4, 0.1M Na-citrate, pH 5.6, vapor diffusion, hanging drop, temperature 277K
|
Resolution 2.70 Å
R-free 0.331
|
|
3MYJ
Human Class I MHC HLA-A2 in complex with the WT-1 (126-134) (R1Y) peptide variant.
Deposited 2010-05-10
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：residues 21-119
|
Not recorded
|
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；PEG3350 24%, MES 0.025M, KCl 0.1M, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 1.89 Å
R-free 0.230
|
|
3MYJ
Human Class I MHC HLA-A2 in complex with the WT-1 (126-134) (R1Y) peptide variant.
Deposited 2010-05-10
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
Fragment：residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；PEG3350 24%, MES 0.025M, KCl 0.1M, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 1.89 Å
R-free 0.230
|
|
3MYZ
Protein induced photophysical changes to the amyloid indicator dye, thioflavin T
Deposited 2010-05-11
|
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
21–119（99 aa）
|
Mutation：H13F
|
HG MERCURY (II) ION × 1
TFX 2-[4-(dimethylamino)phenyl]-3,6-dimethyl-1,3-benzothiazol-3-ium × 2
TLA L(+)-TARTARIC ACID × 1
ACT ACETATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；298 K；25% PEG 3350, 50mM diammonium tartrate, 5mM Thioflavin T, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.60 Å
R-free 0.223
|
|
3MYZ
Protein induced photophysical changes to the amyloid indicator dye, thioflavin T
Deposited 2010-05-11
|
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
21–119（99 aa）
|
Mutation：H13F
|
TFX 2-[4-(dimethylamino)phenyl]-3,6-dimethyl-1,3-benzothiazol-3-ium × 1
ACT ACETATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；298 K；25% PEG 3350, 50mM diammonium tartrate, 5mM Thioflavin T, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.60 Å
R-free 0.223
|
|
3MZT
Protein-induced photophysical changes to the amyloid indicator dye, thioflavin T
Deposited 2010-05-13
|
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
21–119（99 aa）
|
Mutation：H13F
|
CU COPPER (II) ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；298 K；5mM ThT, 50mM diammonium tartrate, 22.5% PEG 3350, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.70 Å
R-free 0.256
|
|
3MZT
Protein-induced photophysical changes to the amyloid indicator dye, thioflavin T
Deposited 2010-05-13
|
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
21–119（99 aa）
|
Mutation：H13F
|
CU COPPER (II) ION × 1
TFX 2-[4-(dimethylamino)phenyl]-3,6-dimethyl-1,3-benzothiazol-3-ium × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；298 K；5mM ThT, 50mM diammonium tartrate, 22.5% PEG 3350, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.70 Å
R-free 0.256
|
|
3MZT
Protein-induced photophysical changes to the amyloid indicator dye, thioflavin T
Deposited 2010-05-13
|
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain C
21–119（99 aa）
|
Mutation：H13F
|
CU COPPER (II) ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；298 K；5mM ThT, 50mM diammonium tartrate, 22.5% PEG 3350, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.70 Å
R-free 0.256
|
|
3MZT
Protein-induced photophysical changes to the amyloid indicator dye, thioflavin T
Deposited 2010-05-13
|
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain D
21–119（99 aa）
|
Mutation：H13F
|
CU COPPER (II) ION × 1
TFX 2-[4-(dimethylamino)phenyl]-3,6-dimethyl-1,3-benzothiazol-3-ium × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；298 K；5mM ThT, 50mM diammonium tartrate, 22.5% PEG 3350, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.70 Å
R-free 0.256
|
|
3MZT
Protein-induced photophysical changes to the amyloid indicator dye, thioflavin T
Deposited 2010-05-13
|
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 5
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain E
21–119（99 aa）
|
Mutation：H13F
|
CU COPPER (II) ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；298 K；5mM ThT, 50mM diammonium tartrate, 22.5% PEG 3350, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.70 Å
R-free 0.256
|
|
3MZT
Protein-induced photophysical changes to the amyloid indicator dye, thioflavin T
Deposited 2010-05-13
|
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 6
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain F
21–119（99 aa）
|
Mutation：H13F
|
CU COPPER (II) ION × 1
TFX 2-[4-(dimethylamino)phenyl]-3,6-dimethyl-1,3-benzothiazol-3-ium × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；298 K；5mM ThT, 50mM diammonium tartrate, 22.5% PEG 3350, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.70 Å
R-free 0.256
|
|
3NA4
D53P beta-2 microglobulin mutant
Deposited 2010-06-01
|
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
21–119（99 aa）
|
Mutation：D53P
Non-standard monomer：Yes (specific site not provided by mmCIF)
|
PE4 2-{2-[2-(2-{2-[2-(2-ETHOXY-ETHOXY)-ETHOXY]-ETHOXY}-ETHOXY)-ETHOXY]-ETHOXY}-ETHANOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；293 K；PEG 4000, Sodium Acetate, Glycerol, Ammonium Acetate, pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.90 Å
R-free 0.269
|
|
3NFN
Recognition of peptide-MHC by a V-delta/V-beta TCR
Deposited 2010-06-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；288 K；0.1M MES monohydrate, pH 6.5, 12% w/v PEG 20000, VAPOR DIFFUSION, HANGING DROP, temperature 288K
|
Resolution 2.39 Å
R-free 0.222
|
|
3O3A
Human Class I MHC HLA-A2 in complex with the Peptidomimetic ELA-1
Deposited 2010-07-23
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 5
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；PEG3350 24%, MES 0.025M, KCl 0.1M, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 1.80 Å
R-free 0.212
|
|
3O3A
Human Class I MHC HLA-A2 in complex with the Peptidomimetic ELA-1
Deposited 2010-07-23
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；PEG3350 24%, MES 0.025M, KCl 0.1M, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 1.80 Å
R-free 0.212
|
|
3O3B
Human Class I MHC HLA-A2 in complex with the Peptidomimetic ELA-1.1
Deposited 2010-07-23
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 6
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；PEG3350 24%, MES 0.025M, KCl 0.1M, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 1.90 Å
R-free 0.238
|
|
3O3B
Human Class I MHC HLA-A2 in complex with the Peptidomimetic ELA-1.1
Deposited 2010-07-23
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；PEG3350 24%, MES 0.025M, KCl 0.1M, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 1.90 Å
R-free 0.238
|
|
3O3D
Human Class I MHC HLA-A2 in complex with the Peptidomimetic ELA-2
Deposited 2010-07-23
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；PEG3350 24%, MES 0.025M, KCl 0.1M, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 1.70 Å
R-free 0.219
|
|
3O3D
Human Class I MHC HLA-A2 in complex with the Peptidomimetic ELA-2
Deposited 2010-07-23
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；PEG3350 24%, MES 0.025M, KCl 0.1M, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 1.70 Å
R-free 0.219
|
|
3O3E
Human Class I MHC HLA-A2 in complex with the Peptidomimetic ELA-2.1
Deposited 2010-07-23
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；PEG3350 24%, MES 0.025M, NaF 0.1M, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 1.85 Å
R-free 0.230
|
|
3O3E
Human Class I MHC HLA-A2 in complex with the Peptidomimetic ELA-2.1
Deposited 2010-07-23
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；PEG3350 24%, MES 0.025M, NaF 0.1M, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 1.85 Å
R-free 0.230
|
|
3O4L
Genetic and structural basis for selection of a ubiquitous T cell receptor deployed in Epstein-Barr virus
Deposited 2010-07-27
|
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Mutation：K111C
|
GOL GLYCEROL × 11
SO4 SULFATE ION × 7
MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；291 K；0.16 M Ca Acetate, 0.08 M Na Cacodylate, 12.5% PEG 8000, 20% Glycerol, pH 6.0, VAPOR DIFFUSION, SITTING DROP, temperature 291K
|
Resolution 2.54 Å
R-free 0.296
|
|
3OV6
CD1c in complex with MPM (mannosyl-beta1-phosphomycoketide)
Deposited 2010-09-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
21–119（99 aa）
Fragment：beta-2-microglobulin
|
Mutation：C-terminal fusion to CD1c ectodomain, N52Q, N57Q, K108G, N128Q, N241Q, W242G, CD1c a3 domain replaced with CD1b a3 domain
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
D12 DODECANE × 1
MK0 1-O-[(S)-hydroxy{[(4S,8S,16S,20S)-4,8,12,16,20-pentamethylheptacosyl]oxy}phosphoryl]-beta-D-mannopyranose × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 9.45；291 K；0.1M CHES pH 9.45, 1.05M sodium citrate, 25 mM triglycine, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.50 Å
R-free 0.273
|
|
3OX8
Crystal Structure of HLA A*02:03 Bound to HBV Core 18-27
Deposited 2010-09-21
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；0.1M HEPSE pH7.5, 1.4M sodium citrate tribasic dihydrate, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.16 Å
R-free 0.234
|
|
3OX8
Crystal Structure of HLA A*02:03 Bound to HBV Core 18-27
Deposited 2010-09-21
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；0.1M HEPSE pH7.5, 1.4M sodium citrate tribasic dihydrate, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.16 Å
R-free 0.234
|
|
3OXR
Crystal Structure of HLA A*02:06 Bound to HBV Core 18-27
Deposited 2010-09-21
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；0.1M HEPES pH 7.5, 10% w/v Polyethylene glycol 6,000, 5% v/v (+/-)-2-Methyl-2,4-pentanediol, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.70 Å
R-free 0.214
|
|
3OXS
Crystal Structure of HLA A*02:07 Bound to HBV Core 18-27
Deposited 2010-09-22
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.6；298 K；0.1M sodium acetate tridydrate pH 4.6, 8% w/v polyethylene 4000, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.75 Å
R-free 0.207
|
|
3PWJ
Human Class I MHC HLA-A2 in complex with the HuD (G2L,I9V) peptide variant
Deposited 2010-12-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；PEG3350 24%, MES 0.025M, NaCl 0.1M, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 1.70 Å
R-free 0.215
|
|
3PWJ
Human Class I MHC HLA-A2 in complex with the HuD (G2L,I9V) peptide variant
Deposited 2010-12-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；PEG3350 24%, MES 0.025M, NaCl 0.1M, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 1.70 Å
R-free 0.215
|
|
3PWL
Human Class I MHC HLA-A2 in complex with the HuD peptide
Deposited 2010-12-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 5
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；PEG3350 24%, MES 0.025M, NaCl 0.1M, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 1.65 Å
R-free 0.195
|
|
3PWL
Human Class I MHC HLA-A2 in complex with the HuD peptide
Deposited 2010-12-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；PEG3350 24%, MES 0.025M, NaCl 0.1M, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 1.65 Å
R-free 0.195
|
|
3PWN
Human Class I MHC HLA-A2 in complex with the HuD (G2L) peptide variant
Deposited 2010-12-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；PEG3350 24%, MES 0.025M, NaCl 0.1M, pH 6.5, vapor diffusion, sitting drop, temperature 277K
|
Resolution 1.60 Å
R-free 0.214
|
|
3PWN
Human Class I MHC HLA-A2 in complex with the HuD (G2L) peptide variant
Deposited 2010-12-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；PEG3350 24%, MES 0.025M, NaCl 0.1M, pH 6.5, vapor diffusion, sitting drop, temperature 277K
|
Resolution 1.60 Å
R-free 0.214
|
|
3PWP
The complex between TCR A6 and human Class I MHC HLA-A2 with the bound HuD peptide
Deposited 2010-12-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 7
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；298 K；30% PEG3350, 0.1M TRIS, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.69 Å
R-free 0.259
|
|
3QDA
Crystal structure of W95L beta-2 microglobulin
Deposited 2011-01-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
21–119（99 aa）
Fragment：Form pI 5.3 (UNP residues 21-119)
|
Mutation：W95L
|
PGE TRIETHYLENE GLYCOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；293 K；19-20% PEG4000, 20% glycerol, 0.2 M ammonium acetate, 0.1 M MES, pH 6.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.57 Å
R-free 0.198
|
|
3QDG
The complex between TCR DMF5 and human Class I MHC HLA-A2 with the bound MART-1(26-35)(A27L) peptide
Deposited 2011-01-18
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；297 K；PEG 30%, TRIS 0.1M, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 297K
|
Resolution 2.69 Å
R-free 0.278
|
|
3QDJ
The complex between TCR DMF5 and human Class I MHC HLA-A2 with the bound MART-1(27-35) nonameric peptide
Deposited 2011-01-18
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；297 K；PEG 24%, TRIS 0.1M, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 297K
|
Resolution 2.30 Å
R-free 0.299
|
|
3QDM
The complex between TCR DMF4 and human Class I MHC HLA-A2 with the bound MART-1(26-35)(A27L) decameric peptide
Deposited 2011-01-18
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；297 K；PEG 24%, TRIS 0.1, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 297K
|
Resolution 2.80 Å
R-free 0.284
|
|
3QEQ
The complex between TCR DMF4 and human Class I MHC HLA-A2 with the bound MART-1(27-35) nonameric peptide
Deposited 2011-01-20
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；297 K；PEG 24%, TRIS 0.1M, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 297K
|
Resolution 2.59 Å
R-free 0.269
|
|
3QFD
Human Class I MHC HLA-A2 in complex with Mart-1(27-35) nonameric peptide
Deposited 2011-01-21
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 4
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；PEG3350 24%, MES 0.025M, NaCl 0.1M, pH 6.5, vapor diffusion, sitting drop, temperature 277K
|
Resolution 1.68 Å
R-free 0.211
|
|
3QFD
Human Class I MHC HLA-A2 in complex with Mart-1(27-35) nonameric peptide
Deposited 2011-01-21
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 2
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；PEG3350 24%, MES 0.025M, NaCl 0.1M, pH 6.5, vapor diffusion, sitting drop, temperature 277K
|
Resolution 1.68 Å
R-free 0.211
|
|
3QFJ
The complex between TCR A6 and human Class I MHC HLA-A2 with the modified TAX (Y5F) peptide
Deposited 2011-01-21
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 11
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.5；297 K；PEG 24%, TRIS 0.1 M, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 297K
|
Resolution 2.29 Å
R-free 0.271
|
|
3QZW
Plasticity of human CD8 binding to peptide-HLA-A*2402
Deposited 2011-03-07
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；288 K；0.1M MES monohydrate, pH 6.5, 12% w/v PEG 20000, VAPOR DIFFUSION, HANGING DROP, temperature 288K
|
Resolution 2.80 Å
R-free 0.260
|
|
3QZW
Plasticity of human CD8 binding to peptide-HLA-A*2402
Deposited 2011-03-07
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；288 K；0.1M MES monohydrate, pH 6.5, 12% w/v PEG 20000, VAPOR DIFFUSION, HANGING DROP, temperature 288K
|
Resolution 2.80 Å
R-free 0.260
|
|
3REW
Crystal structure of an lmp2a-derived peptide bound to human class i mhc hla-a2
Deposited 2011-04-05
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
IOD IODIDE ION × 5
EDO 1,2-ETHANEDIOL × 2
CL CHLORIDE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；22% PEG 3350, 0.2M AMMONIUM IODIDE, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K
|
Resolution 1.90 Å
R-free 0.239
|
|
3REW
Crystal structure of an lmp2a-derived peptide bound to human class i mhc hla-a2
Deposited 2011-04-05
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
IOD IODIDE ION × 3
CL CHLORIDE ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；22% PEG 3350, 0.2M AMMONIUM IODIDE, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K
|
Resolution 1.90 Å
R-free 0.239
|
|
3RL1
HIV RT derived peptide complexed to HLA-A*0301
Deposited 2011-04-19
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；291 K；pH 5.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.00 Å
R-free 0.222
|
|
3RL2
HIV Nef derived peptide Nef73 complexed to HLA-A*0301
Deposited 2011-04-19
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；291 K；0.2M calcium acetate hydrate, 0.1M Sodium cacodylate trihydrate, 18%(w/v) Polyethylene glycol 8000, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.39 Å
R-free 0.265
|
|
3RWJ
Rhesus macaque MHC class I molecule Mamu-B*17-HW8
Deposited 2011-05-09
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.70 Å
R-free 0.256
|
|
3S6C
Structure of human CD1e
Deposited 2011-05-25
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
21–119（99 aa）
Fragment：P61769 residues 21-119, P15812 residues 32-303
|
Not recorded
|
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 3.6；293 K；10% PEG 6000, 0.2 M Sodium malonate, 0.1 M magnesium valerate, 0.1 M sodium borate , pH 3.6, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.90 Å
R-free 0.296
|
|
3SDX
Crystal structure of human autoreactive-Valpha24 NKT TCR in complex with CD1d-beta-galactosylceramide
Deposited 2011-06-09
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GCY N-[(2S,3R)-1-(beta-D-galactopyranosyloxy)-3-hydroxyoctadec-4-en-2-yl]tetracosanamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；293 K；30% PEG 400, 0.1M Tris, 0.1M MgCl2, pH 8.5, vapor diffusion, hanging drop, temperature 293K
|
Resolution 3.12 Å
R-free 0.273
|
|
3SDX
Crystal structure of human autoreactive-Valpha24 NKT TCR in complex with CD1d-beta-galactosylceramide
Deposited 2011-06-09
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain D
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GCY N-[(2S,3R)-1-(beta-D-galactopyranosyloxy)-3-hydroxyoctadec-4-en-2-yl]tetracosanamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；293 K；30% PEG 400, 0.1M Tris, 0.1M MgCl2, pH 8.5, vapor diffusion, hanging drop, temperature 293K
|
Resolution 3.12 Å
R-free 0.273
|
|
3SJV
Crystal structure of the RL42 TCR in complex with HLA-B8-FLR
Deposited 2011-06-22
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；277 K；0.2M ammonium tartrate, 14% PEG 3350, 7% ethylene glycol, pH 8, vapor diffusion, hanging drop, temperature 277K
|
Resolution 3.10 Å
R-free 0.321
|
|
3SJV
Crystal structure of the RL42 TCR in complex with HLA-B8-FLR
Deposited 2011-06-22
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；277 K；0.2M ammonium tartrate, 14% PEG 3350, 7% ethylene glycol, pH 8, vapor diffusion, hanging drop, temperature 277K
|
Resolution 3.10 Å
R-free 0.321
|
|
3SJV
Crystal structure of the RL42 TCR in complex with HLA-B8-FLR
Deposited 2011-06-22
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain L
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；277 K；0.2M ammonium tartrate, 14% PEG 3350, 7% ethylene glycol, pH 8, vapor diffusion, hanging drop, temperature 277K
|
Resolution 3.10 Å
R-free 0.321
|
|
3SJV
Crystal structure of the RL42 TCR in complex with HLA-B8-FLR
Deposited 2011-06-22
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain Q
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；277 K；0.2M ammonium tartrate, 14% PEG 3350, 7% ethylene glycol, pH 8, vapor diffusion, hanging drop, temperature 277K
|
Resolution 3.10 Å
R-free 0.321
|
|
3SKM
Crystal structure of the HLA-B8FLRGRAYVL, mutant G8V of the FLR peptide
Deposited 2011-06-22
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；277 K；0.2M ammonium acetate, 20% PEG 4000, 0.1M tri-Na citrate, pH 5.6, vapor diffusion, hanging drop, temperature 277K
|
Resolution 1.80 Å
R-free 0.212
|
|
3SKO
Crystal structure of the HLA-B8-A66-FLR, mutant A66 of the HLA B8
Deposited 2011-06-22
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；277 K；0.2M ammonium acetate, 20% PEG 4000, 0.1M tri-Na citrate, pH 5.6, vapor diffusion, hanging drop, temperature 277K
|
Resolution 1.60 Å
R-free 0.234
|
|
3SPV
Crystal structure of a peptide-HLA complex
Deposited 2011-07-04
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
ACT ACETATE ION × 2
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 5.6；298 K；15-20% PEG 4000, 0.2M ammonium acetate, 0.1M Na-Citrate, pH 5.6, vapor diffusion, temperature 298K
|
Resolution 1.30 Å
R-free 0.219
|
|
3T8X
Crystal structure of human CD1b in complex with synthetic antigenic diacylsulfoglycolipid SGL12 and endogenous spacer
Deposited 2011-08-02
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 1
ACT ACETATE ION × 1
T8X 2-O-sulfo-alpha-D-glucopyranosyl 2-O-hexadecanoyl-3-O-[(2E,4S,6S,8S)-2,4,6,8-tetramethyltetracos-2-enoyl]-alpha-D-glucopyranoside × 1
ULI tetracontane × 1
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.6；293 K；1.9 M Ammonium sulfate, 0.2 M Ammonium acetate, pH 6.6, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.90 Å
R-free 0.211
|
|
3T8X
Crystal structure of human CD1b in complex with synthetic antigenic diacylsulfoglycolipid SGL12 and endogenous spacer
Deposited 2011-08-02
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Other combination
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 4
T8X 2-O-sulfo-alpha-D-glucopyranosyl 2-O-hexadecanoyl-3-O-[(2E,4S,6S,8S)-2,4,6,8-tetramethyltetracos-2-enoyl]-alpha-D-glucopyranoside × 1
ULI tetracontane × 1
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.6；293 K；1.9 M Ammonium sulfate, 0.2 M Ammonium acetate, pH 6.6, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.90 Å
R-free 0.211
|
|
3TID
Crystal structure of the LCMV derived peptide GP34 in complex with the murine mhc class I H-2 Kb
Deposited 2011-08-20
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
ACT ACETATE ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；PEG 8K, Cacodylate, Magnesium Acetate, DTT, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.65 Å
R-free 0.192
|
|
3TIE
Crystal structure of the vaccinia derived peptide A11R in complex with the murine MHC CLASS I H-2 KB
Deposited 2011-08-20
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；298 K；PEG 8K, Cacodylate, Magnesium Acetate, DTT, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.25 Å
R-free 0.219
|
|
3TIE
Crystal structure of the vaccinia derived peptide A11R in complex with the murine MHC CLASS I H-2 KB
Deposited 2011-08-20
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；298 K；PEG 8K, Cacodylate, Magnesium Acetate, DTT, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.25 Å
R-free 0.219
|
|
3TLR
Crystal Structure of the tetrameric Beta-2 microglobulin DIMC20 mutant
Deposited 2011-08-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 4
PDB declaration: tetrameric
|
Chain A
21–119（99 aa）
Chain B
21–119（99 aa）
Chain C
21–119（99 aa）
Chain D
21–119（99 aa）
|
Mutation：S20C
Mutation：S20C
Mutation：S20C
Mutation：S20C
|
CD CADMIUM ION × 10
NA SODIUM ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.7；293 K；Hepes 0.1 M pH 7.7, CdSO4 0.12 M, sodium acetate 2.4 M, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.45 Å
R-free 0.266
|
|
3TM6
Crystal structure of the beta-2 microglobulin DIMC50 disulphide-linked homodimer mutant
Deposited 2011-08-31
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 4
PDB declaration: tetrameric
|
Chain A
21–119（99 aa）
Fragment：Full-length Beta-2 microglobulin
Chain B
21–119（99 aa）
Fragment：Full-length Beta-2 microglobulin
Chain C
21–119（99 aa）
Fragment：Full-length Beta-2 microglobulin
Chain D
21–119（99 aa）
Fragment：Full-length Beta-2 microglobulin
|
Mutation：E50C
Mutation：E50C
Mutation：E50C
Mutation：E50C
|
PEG DI(HYDROXYETHYL)ETHER × 3
PO4 PHOSPHATE ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；imidazole-malate 0.2 M, pH 5.5, PEG 600 24%, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.70 Å
R-free 0.263
|
|
3TM6
Crystal structure of the beta-2 microglobulin DIMC50 disulphide-linked homodimer mutant
Deposited 2011-08-31
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein homooligomer
Homooligomer；Protein × 4
PDB declaration: tetrameric
|
Chain E
21–119（99 aa）
Fragment：Full-length Beta-2 microglobulin
Chain F
21–119（99 aa）
Fragment：Full-length Beta-2 microglobulin
Chain G
21–119（99 aa）
Fragment：Full-length Beta-2 microglobulin
Chain H
21–119（99 aa）
Fragment：Full-length Beta-2 microglobulin
|
Mutation：E50C
Mutation：E50C
Mutation：E50C
Mutation：E50C
|
PEG DI(HYDROXYETHYL)ETHER × 2
PO4 PHOSPHATE ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；imidazole-malate 0.2 M, pH 5.5, PEG 600 24%, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.70 Å
R-free 0.263
|
|
3TO2
Structure of HLA-A*0201 complexed with peptide Md3-C9 derived from a clustering region of restricted cytotoxic T lymphocyte epitope from SARS-CoV M protein
Deposited 2011-09-03
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；0.1M Ammonium acetate, 0.1M BIS-Tris pH6.5, 17% polyethylene glycol 10000, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.60 Å
R-free 0.230
|
|
3TZV
Crystal structure of an iNKT TCR in complex with CD1d-lysophosphatidylcholine
Deposited 2011-09-27
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain D
21–119（99 aa）
|
Not recorded
|
LSC (4R,7R,18E)-4,7-dihydroxy-N,N,N-trimethyl-10-oxo-3,5,9-trioxa-4-phosphaheptacos-18-en-1-aminium 4-oxide × 1
HEX HEXANE × 1
D12 DODECANE × 1
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；291 K；0.1 M Hepes, 17% PEG 4000, 0.1 MgCl2, pH 7.0, VAPOR DIFFUSION, SITTING DROP, temperature 291K
|
Resolution 3.06 Å
R-free 0.288
|
|
3U0P
Crystal structure of human CD1d-lysophosphatidylcholine
Deposited 2011-09-28
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
LSC (4R,7R,18E)-4,7-dihydroxy-N,N,N-trimethyl-10-oxo-3,5,9-trioxa-4-phosphaheptacos-18-en-1-aminium 4-oxide × 1
HEX HEXANE × 1
SO4 SULFATE ION × 3
GOL GLYCEROL × 4
UND UNDECANE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；291 K；0.1 M Tris-HCl, 2.0 M Ammonium Sulfate, 0.03 M glycyl-glycyl-glycine, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 291K
|
Resolution 2.80 Å
R-free 0.259
|
|
3U0P
Crystal structure of human CD1d-lysophosphatidylcholine
Deposited 2011-09-28
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Other combination
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
LSC (4R,7R,18E)-4,7-dihydroxy-N,N,N-trimethyl-10-oxo-3,5,9-trioxa-4-phosphaheptacos-18-en-1-aminium 4-oxide × 1
SO4 SULFATE ION × 7
GOL GLYCEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；291 K；0.1 M Tris-HCl, 2.0 M Ammonium Sulfate, 0.03 M glycyl-glycyl-glycine, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 291K
|
Resolution 2.80 Å
R-free 0.259
|
|
3U0P
Crystal structure of human CD1d-lysophosphatidylcholine
Deposited 2011-09-28
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Other combination
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain F
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 1
NBU N-BUTANE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；291 K；0.1 M Tris-HCl, 2.0 M Ammonium Sulfate, 0.03 M glycyl-glycyl-glycine, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 291K
|
Resolution 2.80 Å
R-free 0.259
|
|
3UPR
HLA-B*57:01 complexed to pep-V and Abacavir
Deposited 2011-11-18
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
1KX {(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol × 1
CL CHLORIDE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；289 K；0.1M NaCacodylate, 0.1MNaAcetate, 25%PEG 8,000, 15% Glycerol, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 289K
|
Resolution 2.00 Å
R-free 0.228
|
|
3UPR
HLA-B*57:01 complexed to pep-V and Abacavir
Deposited 2011-11-18
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
1KX {(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol × 1
CL CHLORIDE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；289 K；0.1M NaCacodylate, 0.1MNaAcetate, 25%PEG 8,000, 15% Glycerol, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 289K
|
Resolution 2.00 Å
R-free 0.228
|
|
3UTQ
Human HLA-A*0201-ALWGPDPAAA
Deposited 2011-11-26
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；291 K；20% w/v PEG3350, 0.2 M potassium/sodium tartrate, 0.1 M Bis-tris propane, pH 6.5, VAPOR DIFFUSION, temperature 291K
|
Resolution 1.67 Å
R-free 0.244
|
|
3UTS
1E6-A*0201-ALWGPDPAAA Complex, Monoclinic
Deposited 2011-11-26
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
SO4 SULFATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；291 K；20% w/v PEG3350, 0.2 M sodium citrate, 0.1 M Bis-tris propane, pH 6.5, VAPOR DIFFUSION, temperature 291K
|
Resolution 2.71 Å
R-free 0.269
|
|
3UTS
1E6-A*0201-ALWGPDPAAA Complex, Monoclinic
Deposited 2011-11-26
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
SO4 SULFATE ION × 1
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；291 K；20% w/v PEG3350, 0.2 M sodium citrate, 0.1 M Bis-tris propane, pH 6.5, VAPOR DIFFUSION, temperature 291K
|
Resolution 2.71 Å
R-free 0.269
|
|
3UTT
1E6-A*0201-ALWGPDPAAA Complex, Triclinic
Deposited 2011-11-26
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；291 K；20% w/v PEG3350, 0.2 M sodium citrate, 0.1 M Bis-tris propane, pH 6.5, VAPOR DIFFUSION, temperature 291K
|
Resolution 2.60 Å
R-free 0.274
|
|
3UTT
1E6-A*0201-ALWGPDPAAA Complex, Triclinic
Deposited 2011-11-26
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；291 K；20% w/v PEG3350, 0.2 M sodium citrate, 0.1 M Bis-tris propane, pH 6.5, VAPOR DIFFUSION, temperature 291K
|
Resolution 2.60 Å
R-free 0.274
|
|
3V5D
HLA-A2.1 KVAELVHFL
Deposited 2011-12-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；25 mM MES pH 6.5, 12% PEG 8000, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.00 Å
R-free 0.264
|
|
3V5D
HLA-A2.1 KVAELVHFL
Deposited 2011-12-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；25 mM MES pH 6.5, 12% PEG 8000, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.00 Å
R-free 0.264
|
|
3V5H
HLA-A2.1 KVAEIVHFL
Deposited 2011-12-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；25 mM MES pH6.5, 12% PEG 8000, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.63 Å
R-free 0.214
|
|
3V5H
HLA-A2.1 KVAEIVHFL
Deposited 2011-12-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；25 mM MES pH6.5, 12% PEG 8000, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.63 Å
R-free 0.214
|
|
3V5K
HLA2.1 KVAELVWFL
Deposited 2011-12-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；25 mM MES pH6.5 12% PEG 8000, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.31 Å
R-free 0.228
|
|
3V5K
HLA2.1 KVAELVWFL
Deposited 2011-12-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；25 mM MES pH6.5 12% PEG 8000, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.31 Å
R-free 0.228
|
|
3VCL
Crystal Structure of HLA-B7 with the HCMV pp65 peptide RPHERNGFTVL
Deposited 2012-01-04
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
NI NICKEL (II) ION × 4
GOL GLYCEROL × 8
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；293 K；18% PEG2000-MME, 5-10mM NiCl2, 0.1M HEPES, pH 7.4, VAPOR DIFFUSION, HANGING DROP, temperature 293.0K
|
Resolution 1.70 Å
R-free 0.217
|
|
3VFM
crystal structure of HLA B*3508 LPEP155A, HLA mutant Ala155
Deposited 2012-01-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；293 K；0.2M ammonium acetate, 16% PEG 4K, 0.1M sodium citrate pH5.6, vapor diffusion, hanging drop, temperature 293K
|
Resolution 1.90 Å
R-free 0.241
|
|
3VFN
crystal structure of HLA B*3508LPEP151A, HLA mutant Ala151
Deposited 2012-01-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；293 K；0.2M ammonium acetate, 16% PEG 4K, 0.1M sodium citrate pH5.6, vapor diffusion, hanging drop, temperature 293K
|
Resolution 1.50 Å
R-free 0.211
|
|
3VFO
crystal structure of HLA B*3508 LPEP157A, HLA mutant Ala157
Deposited 2012-01-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；293 K；0.2M ammonium acetate, 16% PEG 4K, 0.1M sodium citrate pH5.6, vapor diffusion, hanging drop, temperature 293K
|
Resolution 1.70 Å
R-free 0.279
|
|
3VFP
crystal structure of HLA B*3508 LPEP158G, HLA mutant Gly158
Deposited 2012-01-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
ACT ACETATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；293 K；0.2M ammonium acetate, 16% PEG 4K, 0.1M sodium citrate pH5.6, vapor diffusion, hanging drop, temperature 293K
|
Resolution 1.85 Å
R-free 0.266
|
|
3VFR
crystal structure of HLA B*3508LPEP-P4Ala, peptide mutant P4-ala
Deposited 2012-01-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；293 K；0.2M ammonium acetate, 16% PEG 4K, 0.1M sodium citrate pH5.6, vapor diffusion, hanging drop, temperature 293K
|
Resolution 1.85 Å
R-free 0.232
|
|
3VFS
crystal structure of HLA B*3508LPEP-P5Ala , peptide mutant P5-ala
Deposited 2012-01-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；293 K；0.2M ammonium acetate, 16% PEG 4K, 0.1M sodium citrate pH5.6, vapor diffusion, hanging drop, temperature 293K
|
Resolution 1.85 Å
R-free 0.216
|
|
3VFT
crystal structure of HLA B*3508LPEP-P6Ala, peptide mutant P6-ala
Deposited 2012-01-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；293 K；0.2M ammonium acetate, 16% PEG 4K, 0.1M sodium citrate pH5.6, vapor diffusion, hanging drop, temperature 293K
|
Resolution 1.95 Å
R-free 0.223
|
|
3VFU
crystal structure of HLA B*3508 LPEP-P7Ala, peptide mutant P7-ala
Deposited 2012-01-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；293 K；0.2M ammonium acetate, 16% PEG 4K, 0.1M sodium citrate pH5.6, vapor diffusion, hanging drop, temperature 293K
|
Resolution 1.65 Å
R-free 0.226
|
|
3VFV
crystal structure of HLA B*3508 LPEP-P9Ala, peptide mutant P9-ala
Deposited 2012-01-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；293 K；0.2M ammonium acetate, 16% PEG 4K, 0.1M sodium citrate pH5.6, vapor diffusion, hanging drop, temperature 293K
|
Resolution 1.55 Å
R-free 0.204
|
|
3VFW
crystal structure of HLA B*3508 LPEP-P10Ala, peptide mutant P10-ala
Deposited 2012-01-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；293 K；0.2M ammonium acetate, 16% PEG 4K, 0.1M sodium citrate pH5.6, vapor diffusion, hanging drop, temperature 293K
|
Resolution 2.30 Å
R-free 0.279
|
|
3VH8
KIR3DL1 in complex with HLA-B*5701
Deposited 2011-08-24
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；294 K；16% PEG 3350, 2% tacsimate pH 5.0, 0.1M tri-sodium citrate pH 5.6., VAPOR DIFFUSION, HANGING DROP, temperature 294K
|
Resolution 1.80 Å
R-free 0.237
|
|
3VH8
KIR3DL1 in complex with HLA-B*5701
Deposited 2011-08-24
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain E
21–119（99 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；294 K；16% PEG 3350, 2% tacsimate pH 5.0, 0.1M tri-sodium citrate pH 5.6., VAPOR DIFFUSION, HANGING DROP, temperature 294K
|
Resolution 1.80 Å
R-free 0.237
|
|
3VRI
HLA-B*57:01-RVAQLENVYI in complex with abacavir
Deposited 2012-04-11
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
1KX {(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol × 1
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.25；293 K；28% PEG 8000, 0.2M ammonium sulfate, 0.1M cacodylate, pH 6.25, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.60 Å
R-free 0.218
|
|
3VRJ
HLA-B*57:01-LTTKLTNTNI in complex with abacavir
Deposited 2012-04-11
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
1KX {(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.25；293 K；28% PEG 8000, 0.2M ammonium sulfate, 0.1M cacodylate, pH 6.25, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.90 Å
R-free 0.213
|
|
3VWJ
Ternary crystal structure of the human NKT TCR-CD1d-C20:2 complex
Deposited 2012-08-24
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2
DB3 (11Z,14E)-N-[(2S,3S,4R)-1-(alpha-D-galactopyranosyloxy)-3,4-dihydroxyoctadecan-2-yl]icosa-11,14-dienamide × 1
MG MAGNESIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.8；295 K；8% PEG 10000, 0.2M magnesium chloride, 0.1M Tris, pH 8.8, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 3.09 Å
R-free 0.292
|
|
3VWK
Ternary crystal structure of the human NKT TCR-CD1d-4'deoxy-alpha-galactosylceramide complex
Deposited 2012-08-24
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2
4GH N-{(2S,3R)-1-[(4-deoxy-alpha-D-xylo-hexopyranosyl)oxy]-3-hydroxyoctadecan-2-yl}hexacosanamide × 1
MG MAGNESIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 10；295 K；9% PEG 10000, 0.2M magnesium chloride, 0.1M glycine, pH 10.0, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 2.94 Å
R-free 0.250
|
|
3VXM
The complex between C1-28 TCR and HLA-A24 bound to HIV-1 Nef134-10(2F) peptide
Deposited 2012-09-20
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
CO COBALT (II) ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；80mM HEPES, 8mM Cobalt(II) chloride hexahydrate, 8% PEG 6000, 4% 2-Methyl-2,4-pentanediol (MPD), 8mM betaine hydrochloride, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.50 Å
R-free 0.267
|
|
3VXN
HLA-A24 in complex with HIV-1 Nef134-10(wt)
Deposited 2012-09-20
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；5% PEG 8000, 50mM ammonium formate, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.95 Å
R-free 0.246
|
|
3VXO
HLA-A24 in complex with HIV-1 Nef134-10(2F)
Deposited 2012-09-20
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；20% PEG 8000, 200mM ammonium acetate, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.61 Å
R-free 0.242
|
|
3VXO
HLA-A24 in complex with HIV-1 Nef134-10(2F)
Deposited 2012-09-20
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；20% PEG 8000, 200mM ammonium acetate, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.61 Å
R-free 0.242
|
|
3VXP
HLA-A24 in complex with HIV-1 Nef134-10(6L)
Deposited 2012-09-20
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；20% PEG 3350, 200mM NaCl, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.50 Å
R-free 0.269
|
|
3VXP
HLA-A24 in complex with HIV-1 Nef134-10(6L)
Deposited 2012-09-20
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；20% PEG 3350, 200mM NaCl, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.50 Å
R-free 0.269
|
|
3VXR
The complex between H27-14 TCR and HLA-A24 bound to HIV-1 Nef134-10(wt) peptide
Deposited 2012-09-20
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；20% PEG3350, 0.1M ammonium phosphate dibasic, 10mM barium chloride dihydrate, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.40 Å
R-free 0.242
|
|
3VXS
The complex between H27-14 TCR and HLA-A24 bound to HIV-1 Nef134-10(6L) peptide
Deposited 2012-09-20
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；9% PEG 3350, 10mM iron(III) chloride hexahydrate, 100mM sodium fluoride, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.80 Å
R-free 0.230
|
|
3VXU
The complex between T36-5 TCR and HLA-A24 bound to HIV-1 Nef134-10(2F) peptide
Deposited 2012-09-20
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；10% PEG3350, 0.1M sodium nitrate, 0.1M MES, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.70 Å
R-free 0.323
|
|
3VXU
The complex between T36-5 TCR and HLA-A24 bound to HIV-1 Nef134-10(2F) peptide
Deposited 2012-09-20
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；10% PEG3350, 0.1M sodium nitrate, 0.1M MES, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.70 Å
R-free 0.323
|
|
3W0W
The complex between T36-5 TCR and HLA-A24 bound to HIV-1 Nef134-10(2F) peptide in space group P212121
Deposited 2012-11-05
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；293 K；16% PEG 3350, 0.1 M diammonium tartrate, 0.2% n-dodecyl-N,N-dimethylamine-N-oxide (LDAO) 0.1M HEPES, pH 7.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.60 Å
R-free 0.250
|
|
3W39
Crystal structure of HLA-B*5201 in complexed with HIV immunodominant epitope (TAFTIPSI)
Deposited 2012-12-13
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；20% PEG 3350, 0.2M sodium acetate, 0.1M Bis Tris propane, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 3.10 Å
R-free 0.347
|
|
3W39
Crystal structure of HLA-B*5201 in complexed with HIV immunodominant epitope (TAFTIPSI)
Deposited 2012-12-13
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；20% PEG 3350, 0.2M sodium acetate, 0.1M Bis Tris propane, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 3.10 Å
R-free 0.347
|
|
3WL9
HLA-A24 in complex with HIV-1 Nef126-10(8I10F)
Deposited 2013-11-08
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；20%(w/v) PEG3350, 200mM sodium nitrate, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.66 Å
R-free 0.226
|
|
3WLB
HLA-A24 in complex with HIV-1 Nef126-10(8T10F)
Deposited 2013-11-08
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；20%(w/v) PEG3350, 200 mM sodium phosphate dibasic, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.00 Å
R-free 0.245
|
|
3WUW
KIR3DL1 in complex with HLA-B*57:01.I80T
Deposited 2014-05-06
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
22–119（98 aa）
Fragment：Beta 2 Microglobulin, UNP residues 22-119
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；293 K；16% PEG3350, 2% tacsimate(pH 5.0), 0.1M tri-sodium citrate pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.00 Å
R-free 0.239
|
|
3X11
Crystal structure of HLA-B*57:01.I80N.L82R.R83G
Deposited 2014-10-24
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.4；298 K；12-20% PEG4000, 0.2M ammonium acetate, 0.1M tri-sodium citrate pH 5.4., VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.15 Å
R-free 0.231
|
|
3X12
Crystal structure of HLA-B*57:01.I80N
Deposited 2014-10-24
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.4；298 K；12-20% PEG4000, 0.2M ammonium acetate, 0.1M tri-sodium citrate pH 5.4., VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.80 Å
R-free 0.219
|
|
3X13
Crystal structure of HLA-B*0801.N80I
Deposited 2014-10-24
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.4；298 K；12-20% PEG4000, 0.2M ammonium acetate, 0.1M tri-sodium citrate pH 5.4., VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.80 Å
R-free 0.207
|
|
3X14
Crystal structure of HLA-B*0801.N80I.R82L.G83R
Deposited 2014-10-25
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.4；298 K；12-20% PEG4000, 0.2M ammonium acetate, 0.1M tri-sodium citrate pH 5.4., VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.00 Å
R-free 0.229
|
|
4E5X
Crystal structure of a complex between the human adenovirus type 2 E3-19K protein and MHC class I molecule HLA-A2/Tax
Deposited 2012-03-14
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
Fragment：Beta 2-microglobulin
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；290 K；0.8M succinic acid pH7.0
0.1M calcium chloride dihydrate, VAPOR DIFFUSION, HANGING DROP, temperature 290K
|
Resolution 1.95 Å
R-free 0.241
|
|
4E5X
Crystal structure of a complex between the human adenovirus type 2 E3-19K protein and MHC class I molecule HLA-A2/Tax
Deposited 2012-03-14
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain E
21–119（99 aa）
Fragment：Beta 2-microglobulin
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；290 K；0.8M succinic acid pH7.0
0.1M calcium chloride dihydrate, VAPOR DIFFUSION, HANGING DROP, temperature 290K
|
Resolution 1.95 Å
R-free 0.241
|
|
4EN3
Crystal structure of a human Valpha24(-) NKT TCR in complex with CD1d/alpha-galactosylceramide
Deposited 2012-04-12
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain D
21–119（99 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5
AGH N-{(1S,2R,3S)-1-[(ALPHA-D-GALACTOPYRANOSYLOXY)METHYL]-2,3-DIHYDROXYHEPTADECYL}HEXACOSANAMIDE × 1
FUC alpha-L-fucopyranose × 1
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5；291 K；17 % PEG 4000, 0.1 M ammnonium acetate, 0.1 M sodium acetate pH 5.0, VAPOR DIFFUSION, SITTING DROP, temperature 291K
|
Resolution 2.57 Å
R-free 0.266
|
|
4EUP
The complex between TCR JKF6 and human Class I MHC HLA-A2 presenting the MART-1(27-35)(A27L) peptide
Deposited 2012-04-25
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain E
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；298 K；0.1 M Bis-Tris, 16% PEG10000, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.88 Å
R-free 0.295
|
|
4EUP
The complex between TCR JKF6 and human Class I MHC HLA-A2 presenting the MART-1(27-35)(A27L) peptide
Deposited 2012-04-25
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；298 K；0.1 M Bis-Tris, 16% PEG10000, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.88 Å
R-free 0.295
|
|
4F7M
Crystal Structure of HLA-A*2402 Complexed with a Newly Identified Peptide from 2009 H1N1 PA (649-658)
Deposited 2012-05-16
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：unp residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；0.2 M sodium nitrate and 20% (w/v) polyethylene glycol 3,350, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.40 Å
R-free 0.289
|
|
4F7M
Crystal Structure of HLA-A*2402 Complexed with a Newly Identified Peptide from 2009 H1N1 PA (649-658)
Deposited 2012-05-16
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
Fragment：unp residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；0.2 M sodium nitrate and 20% (w/v) polyethylene glycol 3,350, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.40 Å
R-free 0.289
|
|
4F7P
Crystal Structure of HLA-A*2402 Complexed with a Newly Identified Peptide from 2009H1N1 PB1 (496-505)
Deposited 2012-05-16
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：unp residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5；293 K；0.1 M Bis-Tris and 10% (w/v) polyethylene glycol 3,350, pH 5.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.90 Å
R-free 0.216
|
|
4F7T
Crystal Structure of HLA-A*2402 Complexed with a Newly Identified Peptide from 2009 H1N1 PB1 (498-505)
Deposited 2012-05-16
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：unp residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5；293 K；0.1 M Bis-Tris and 10% (w/v) polyethylene glycol 3,350, pH 5.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.70 Å
R-free 0.227
|
|
4F7T
Crystal Structure of HLA-A*2402 Complexed with a Newly Identified Peptide from 2009 H1N1 PB1 (498-505)
Deposited 2012-05-16
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
Fragment：unp residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5；293 K；0.1 M Bis-Tris and 10% (w/v) polyethylene glycol 3,350, pH 5.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.70 Å
R-free 0.227
|
|
4FTV
The complex between the high affinity version of A6 TCR (A6c134) and human Class I MHC HLA-A2 with the bound TAX nonameric peptide
Deposited 2012-06-28
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 10
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；PEG3350 24%, MES 0.025M, NaCl 0.1M, pH 6.5, vapor diffusion, sitting drop, temperature 277K
|
Resolution 2.74 Å
R-free 0.260
|
|
4FXL
Crystal structure of the D76N Beta-2 Microglobulin mutant
Deposited 2012-07-03
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
21–119（99 aa）
Fragment：UNP residues 21-119
|
Mutation：D76N
|
NA SODIUM ION × 1
ACT ACETATE ION × 1
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；18-20% PEG 4000, 20% glycerol, 0.2M ammonium acetate, 0.1 M MES, pH 5.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.40 Å
R-free 0.186
|
|
4G8G
Crystal Structure of C12C TCR-HA B2705-KK10
Deposited 2012-07-23
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；16% PEG 8000 and 0.1M MES pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.40 Å
R-free 0.257
|
|
4G8I
Crystal Structure of HLA B2705-KK10-L6M
Deposited 2012-07-23
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
TRS 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；24% PEG 3350 and 0.3M Na2SO4, pH 8, vapor diffusion, hanging drop, temperature 298K
|
Resolution 1.60 Å
R-free 0.225
|
|
4G9D
Crystal Structure of HLA B2705-KK10
Deposited 2012-07-23
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；24% PEG 3350 and 0.3M Na2SO4, pH 8, vapor diffusion, hanging drop, temperature 298K
|
Resolution 1.60 Å
R-free 0.233
|
|
4G9F
Crystal Structure of C12C TCR-HLAB2705-KK10-L6M
Deposited 2012-07-23
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
SO4 SULFATE ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；16% PEG 8000 and 0.1M MES, pH 7, vapor diffusion, hanging drop, temperature 298K
|
Resolution 1.90 Å
R-free 0.238
|
|
4GKN
A2-MHC Complex carrying FATGIGIITV
Deposited 2012-08-13
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；293 K；25% PEG 8000, 200 mM Ammonium Sulphate, 200 mM MES Buffer, pH 7, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.75 Å
R-free 0.299
|
|
4GKN
A2-MHC Complex carrying FATGIGIITV
Deposited 2012-08-13
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；293 K；25% PEG 8000, 200 mM Ammonium Sulphate, 200 mM MES Buffer, pH 7, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.75 Å
R-free 0.299
|
|
4GKS
A2-MHC Complex carrying FLTGIGIITV
Deposited 2012-08-13
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 7
SO4 SULFATE ION × 1
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；25% PEG 8000, 200 mM Ammonium Sulphate, 200 mM Cacodylate Buffer, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.35 Å
R-free 0.285
|
|
4GKS
A2-MHC Complex carrying FLTGIGIITV
Deposited 2012-08-13
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 6
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；25% PEG 8000, 200 mM Ammonium Sulphate, 200 mM Cacodylate Buffer, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.35 Å
R-free 0.285
|
|
4GUP
Structure of MHC-class I related molecule MR1
Deposited 2012-08-29
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
6FP 2-amino-4-oxo-3,4-dihydropteridine-6-carbaldehyde × 1
CL CHLORIDE ION × 1
PO4 PHOSPHATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；277 K；0.02M MgCl2, 0.1M HEPES, 22% polyacrylic acid 5100 sodium salt, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 3.20 Å
R-free 0.260
|
|
4GUP
Structure of MHC-class I related molecule MR1
Deposited 2012-08-29
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
6FP 2-amino-4-oxo-3,4-dihydropteridine-6-carbaldehyde × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；277 K；0.02M MgCl2, 0.1M HEPES, 22% polyacrylic acid 5100 sodium salt, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 3.20 Å
R-free 0.260
|
|
4HKJ
Structure of Cowpox CPXV203 in complex with MHCI (H-2Kb)
Deposited 2012-10-15
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.55；293 K；10% PEG6000, 4% glucose, 2% ethylene glycol, 0.1 M tri-potassium citrate, 0.01% azide, pH 5.55, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 3.00 Å
R-free 0.253
|
|
4HKJ
Structure of Cowpox CPXV203 in complex with MHCI (H-2Kb)
Deposited 2012-10-15
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain F
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.55；293 K；10% PEG6000, 4% glucose, 2% ethylene glycol, 0.1 M tri-potassium citrate, 0.01% azide, pH 5.55, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 3.00 Å
R-free 0.253
|
|
4HKJ
Structure of Cowpox CPXV203 in complex with MHCI (H-2Kb)
Deposited 2012-10-15
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain J
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.55；293 K；10% PEG6000, 4% glucose, 2% ethylene glycol, 0.1 M tri-potassium citrate, 0.01% azide, pH 5.55, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 3.00 Å
R-free 0.253
|
|
4HKJ
Structure of Cowpox CPXV203 in complex with MHCI (H-2Kb)
Deposited 2012-10-15
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain N
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.55；293 K；10% PEG6000, 4% glucose, 2% ethylene glycol, 0.1 M tri-potassium citrate, 0.01% azide, pH 5.55, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 3.00 Å
R-free 0.253
|
|
4HWZ
Structure of HLA-A68 complexed with an HIV derived peptide
Deposited 2012-11-09
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；291 K；0.1M HEPES, 30%(v/v) Jeffamine ED-2001, pH 7.0, VAPOR DIFFUSION, SITTING DROP, temperature 291K
|
Resolution 2.40 Å
R-free 0.233
|
|
4HX1
Structure of HLA-A68 complexed with a tumor antigen derived peptide
Deposited 2012-11-09
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；291 K；100mM Tris, 8% PEG8000, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.80 Å
R-free 0.226
|
|
4I48
Structure of HLA-A68 complexed with an HIV Env derived peptide
Deposited 2012-11-27
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；291 K；0.1M ammonium acetate, 0.1M Bis-Tris, 17%(w/v) PEG10000, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 291K
|
Resolution 2.80 Å
R-free 0.281
|
|
4I4W
Peptide length determines the outcome of T cell receptor/peptide-MHCI engagement
Deposited 2012-11-28
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 18
GOL GLYCEROL × 3
SO4 SULFATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5；291 K；0.2M Ammonium sulphate, 22.5% PEG 8K, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, temperature 291K
|
Resolution 1.77 Å
R-free 0.222
|
|
4JFD
Preservation of peptide specificity during TCR-MHC contact dominated affinity enhancement of a melanoma-specific TCR
Deposited 2013-02-28
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
TAM TRIS(HYDROXYETHYL)AMINOMETHANE × 1
SO4 SULFATE ION × 11
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；291 K；0.1 M TRIS, 15% PEG 4000, 17.4% glycerol, pH 7.5, vapor diffusion, sitting drop, temperature 291K
|
Resolution 2.46 Å
R-free 0.248
|
|
4JFE
Preservation of peptide specificity during TCR-MHC contact dominated affinity enhancement of a melanoma-specific TCR
Deposited 2013-02-28
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 4
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；291 K；0.1 M BIS TRIS Propane, 20% PEG 4000, 0.2M Ammonium sulphate, 17.4% glycerol, pH 7.0, vapor diffusion, sitting drop, temperature 291K
|
Resolution 2.70 Å
R-free 0.250
|
|
4JFF
Preservation of peptide specificity during TCR-MHC contact dominated affinity enhancement of a melanoma-specific TCR
Deposited 2013-02-28
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 2
SO4 SULFATE ION × 7
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；291 K；0.1 M TRIS, 15% PEG 4000, 17.4% Glycerol, pH 7.0, vapor diffusion, sitting drop, temperature 291K
|
Resolution 2.43 Å
R-free 0.263
|
|
4JFO
A2 HLA complex with E1A heteroclitic variant of Melanoma peptide
Deposited 2013-02-28
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 6
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；291 K；25 mM MES, 24% PEG 3350, 10 mM NaCl, pH 6.5, vapor diffusion, sitting drop, temperature 291K
|
Resolution 2.11 Å
R-free 0.296
|
|
4JFO
A2 HLA complex with E1A heteroclitic variant of Melanoma peptide
Deposited 2013-02-28
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；291 K；25 mM MES, 24% PEG 3350, 10 mM NaCl, pH 6.5, vapor diffusion, sitting drop, temperature 291K
|
Resolution 2.11 Å
R-free 0.296
|
|
4JFP
A2 HLA complex with G4A heteroclitic variant of Melanoma peptide
Deposited 2013-02-28
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 5
EDO 1,2-ETHANEDIOL × 3
SO4 SULFATE ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；291 K；0.1 M sodium cacodylate, 20% PEG 8000, 0.2 M ammonium sulphate, pH 6.0, vapor diffusion, sitting drop, temperature 291K
|
Resolution 1.91 Å
R-free 0.228
|
|
4JFP
A2 HLA complex with G4A heteroclitic variant of Melanoma peptide
Deposited 2013-02-28
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 2
EDO 1,2-ETHANEDIOL × 3
EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；291 K；0.1 M sodium cacodylate, 20% PEG 8000, 0.2 M ammonium sulphate, pH 6.0, vapor diffusion, sitting drop, temperature 291K
|
Resolution 1.91 Å
R-free 0.228
|
|
4JFQ
A2 HLA complex with L8A heteroclitic variant of Melanoma peptide
Deposited 2013-02-28
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 11
MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；291 K；25 mM MES, 24% PEG 3350, 10 mM NaCl, pH 6.5, vapor diffusion, sitting drop, temperature 291K
|
Resolution 1.90 Å
R-free 0.297
|
|
4JFQ
A2 HLA complex with L8A heteroclitic variant of Melanoma peptide
Deposited 2013-02-28
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 8
MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；291 K；25 mM MES, 24% PEG 3350, 10 mM NaCl, pH 6.5, vapor diffusion, sitting drop, temperature 291K
|
Resolution 1.90 Å
R-free 0.297
|
|
4JQV
HLA-B*18:01 in complex with Epstein-Barr virus BZLF1-derived peptide (residues 173-180)
Deposited 2013-03-20
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain C
21–119（99 aa）
Fragment：mature protein (UNP residues 21-119)
|
Not recorded
|
ACT ACETATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；293 K；0.1 M citrate, pH 5.6, 0.2 M ammonium acetate, 16-26% PEG4000, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.50 Å
R-free 0.214
|
|
4JQX
HLA-B*44:03 in complex with Epstein-Barr virus BZLF1-derived peptide (residues 169-180)
Deposited 2013-03-20
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain C
21–119（99 aa）
Fragment：mature protein (UNP residues 21-119)
|
Not recorded
|
GOL GLYCEROL × 1
ACT ACETATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；293 K；0.1 M citrate, pH 5.6, 0.2 M ammonium acetate, 16-26% PEG4000, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.90 Å
R-free 0.231
|
|
4JRX
Crystal Structure of CA5 TCR-HLA B*3505-LPEP complex
Deposited 2013-03-22
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
NA SODIUM ION × 3
IOD IODIDE ION × 8
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.7；298 K；16% PEG 3350, 0.2M KI, 0.1M Na-cacodylate pH 6.7, vapor diffusion, hanging drop, temperature 298K
|
Resolution 2.30 Å
R-free 0.257
|
|
4JRY
Crystal Structure of SB47 TCR-HLA B*3505-LPEP complex
Deposited 2013-03-22
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
NA SODIUM ION × 1
MG MAGNESIUM ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；12% PEG 10K, 0.2M Na tartrate, 10mM HEPES pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.80 Å
R-free 0.233
|
|
4K71
Crystal structure of a high affinity Human Serum Albumin variant bound to the Neonatal Fc Receptor
Deposited 2013-04-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain C
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 11
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.9；293 K；1.7 M ammonium sulfate, 0.1 M sodium citrate, pH 4.9, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.40 Å
R-free 0.255
|
|
4K71
Crystal structure of a high affinity Human Serum Albumin variant bound to the Neonatal Fc Receptor
Deposited 2013-04-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain F
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 8
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.9；293 K；1.7 M ammonium sulfate, 0.1 M sodium citrate, pH 4.9, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.40 Å
R-free 0.255
|
|
4K71
Crystal structure of a high affinity Human Serum Albumin variant bound to the Neonatal Fc Receptor
Deposited 2013-04-16
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 12
PDB declaration: dodecameric
|
Chain C
21–119（99 aa）
Chain F
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 38
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.9；293 K；1.7 M ammonium sulfate, 0.1 M sodium citrate, pH 4.9, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.40 Å
R-free 0.255
|
|
4K7F
Newly identified epitope V60 from HBV core protein complexed with HLA-A*0201
Deposited 2013-04-17
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；291 K；0.1M Bis-Tris, 20%(wt/vol) polyethylene glycol 3350, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.00 Å
R-free 0.259
|
|
4K7F
Newly identified epitope V60 from HBV core protein complexed with HLA-A*0201
Deposited 2013-04-17
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；291 K；0.1M Bis-Tris, 20%(wt/vol) polyethylene glycol 3350, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.00 Å
R-free 0.259
|
|
4KDT
Structure of an early native-like intermediate of beta2-microglobulin amyloidosis
Deposited 2013-04-25
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain D
21–119（99 aa）
Fragment：unp residues 21-119
|
Not recorded
|
SO4 SULFATE ION × 4
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；0.1 M MES, 1.6 M MgSO4, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.60 Å
R-free 0.274
|
|
4KDT
Structure of an early native-like intermediate of beta2-microglobulin amyloidosis
Deposited 2013-04-25
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain C
21–119（99 aa）
Fragment：unp residues 21-119
|
Not recorded
|
SO4 SULFATE ION × 2
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；0.1 M MES, 1.6 M MgSO4, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.60 Å
R-free 0.274
|
|
4L29
Structure of wtMHC class I with NY-ESO1 double mutant
Deposited 2013-06-04
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP RESIDUES 21-119
|
Not recorded
|
CL CHLORIDE ION × 2
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；1.9 M ammonium sulphate, 2% PEG 6K, 100 mM Tris-HCl, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 3.09 Å
R-free 0.201
|
|
4L29
Structure of wtMHC class I with NY-ESO1 double mutant
Deposited 2013-06-04
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 10
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain T
21–119（99 aa）
Fragment：UNP RESIDUES 21-119
|
Not recorded
|
CL CHLORIDE ION × 2
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；1.9 M ammonium sulphate, 2% PEG 6K, 100 mM Tris-HCl, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 3.09 Å
R-free 0.201
|
|
4L29
Structure of wtMHC class I with NY-ESO1 double mutant
Deposited 2013-06-04
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 11
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain V
21–119（99 aa）
Fragment：UNP RESIDUES 21-119
|
Not recorded
|
CL CHLORIDE ION × 2
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；1.9 M ammonium sulphate, 2% PEG 6K, 100 mM Tris-HCl, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 3.09 Å
R-free 0.201
|
|
4L29
Structure of wtMHC class I with NY-ESO1 double mutant
Deposited 2013-06-04
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 12
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain X
21–119（99 aa）
Fragment：UNP RESIDUES 21-119
|
Not recorded
|
CL CHLORIDE ION × 1
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；1.9 M ammonium sulphate, 2% PEG 6K, 100 mM Tris-HCl, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 3.09 Å
R-free 0.201
|
|
4L29
Structure of wtMHC class I with NY-ESO1 double mutant
Deposited 2013-06-04
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 13
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain Z
21–119（99 aa）
Fragment：UNP RESIDUES 21-119
|
Not recorded
|
CL CHLORIDE ION × 2
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；1.9 M ammonium sulphate, 2% PEG 6K, 100 mM Tris-HCl, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 3.09 Å
R-free 0.201
|
|
4L29
Structure of wtMHC class I with NY-ESO1 double mutant
Deposited 2013-06-04
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 14
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain b
21–119（99 aa）
Fragment：UNP RESIDUES 21-119
|
Not recorded
|
CL CHLORIDE ION × 2
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；1.9 M ammonium sulphate, 2% PEG 6K, 100 mM Tris-HCl, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 3.09 Å
R-free 0.201
|
|
4L29
Structure of wtMHC class I with NY-ESO1 double mutant
Deposited 2013-06-04
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
21–119（99 aa）
Fragment：UNP RESIDUES 21-119
|
Not recorded
|
CL CHLORIDE ION × 2
GOL GLYCEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；1.9 M ammonium sulphate, 2% PEG 6K, 100 mM Tris-HCl, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 3.09 Å
R-free 0.201
|
|
4L29
Structure of wtMHC class I with NY-ESO1 double mutant
Deposited 2013-06-04
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain F
21–119（99 aa）
Fragment：UNP RESIDUES 21-119
|
Not recorded
|
CL CHLORIDE ION × 2
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；1.9 M ammonium sulphate, 2% PEG 6K, 100 mM Tris-HCl, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 3.09 Å
R-free 0.201
|
|
4L29
Structure of wtMHC class I with NY-ESO1 double mutant
Deposited 2013-06-04
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain H
21–119（99 aa）
Fragment：UNP RESIDUES 21-119
|
Not recorded
|
CL CHLORIDE ION × 2
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；1.9 M ammonium sulphate, 2% PEG 6K, 100 mM Tris-HCl, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 3.09 Å
R-free 0.201
|
|
4L29
Structure of wtMHC class I with NY-ESO1 double mutant
Deposited 2013-06-04
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 5
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain J
21–119（99 aa）
Fragment：UNP RESIDUES 21-119
|
Not recorded
|
CL CHLORIDE ION × 4
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；1.9 M ammonium sulphate, 2% PEG 6K, 100 mM Tris-HCl, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 3.09 Å
R-free 0.201
|
|
4L29
Structure of wtMHC class I with NY-ESO1 double mutant
Deposited 2013-06-04
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 6
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain L
21–119（99 aa）
Fragment：UNP RESIDUES 21-119
|
Not recorded
|
CL CHLORIDE ION × 2
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；1.9 M ammonium sulphate, 2% PEG 6K, 100 mM Tris-HCl, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 3.09 Å
R-free 0.201
|
|
4L29
Structure of wtMHC class I with NY-ESO1 double mutant
Deposited 2013-06-04
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 7
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain N
21–119（99 aa）
Fragment：UNP RESIDUES 21-119
|
Not recorded
|
CL CHLORIDE ION × 2
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；1.9 M ammonium sulphate, 2% PEG 6K, 100 mM Tris-HCl, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 3.09 Å
R-free 0.201
|
|
4L29
Structure of wtMHC class I with NY-ESO1 double mutant
Deposited 2013-06-04
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 8
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain P
21–119（99 aa）
Fragment：UNP RESIDUES 21-119
|
Not recorded
|
CL CHLORIDE ION × 2
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；1.9 M ammonium sulphate, 2% PEG 6K, 100 mM Tris-HCl, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 3.09 Å
R-free 0.201
|
|
4L29
Structure of wtMHC class I with NY-ESO1 double mutant
Deposited 2013-06-04
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 9
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain R
21–119（99 aa）
Fragment：UNP RESIDUES 21-119
|
Not recorded
|
CL CHLORIDE ION × 3
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；1.9 M ammonium sulphate, 2% PEG 6K, 100 mM Tris-HCl, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 3.09 Å
R-free 0.201
|
|
4L3C
Structure of HLA-A2 in complex with D76N b2m mutant and NY-ESO1 double mutant
Deposited 2013-06-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP RESIDUES 21-119
|
Mutation：D76N
|
CL CHLORIDE ION × 3
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；1.9 M ammonium sulphate, 2% PEG 6K, 100 mM Tris-HCl, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.64 Å
R-free 0.218
|
|
4L3C
Structure of HLA-A2 in complex with D76N b2m mutant and NY-ESO1 double mutant
Deposited 2013-06-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 10
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain T
21–119（99 aa）
Fragment：UNP RESIDUES 21-119
|
Mutation：D76N
|
CL CHLORIDE ION × 2
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；1.9 M ammonium sulphate, 2% PEG 6K, 100 mM Tris-HCl, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.64 Å
R-free 0.218
|
|
4L3C
Structure of HLA-A2 in complex with D76N b2m mutant and NY-ESO1 double mutant
Deposited 2013-06-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 11
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain V
21–119（99 aa）
Fragment：UNP RESIDUES 21-119
|
Mutation：D76N
|
CL CHLORIDE ION × 2
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；1.9 M ammonium sulphate, 2% PEG 6K, 100 mM Tris-HCl, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.64 Å
R-free 0.218
|
|
4L3C
Structure of HLA-A2 in complex with D76N b2m mutant and NY-ESO1 double mutant
Deposited 2013-06-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 12
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain X
21–119（99 aa）
Fragment：UNP RESIDUES 21-119
|
Mutation：D76N
|
CL CHLORIDE ION × 3
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；1.9 M ammonium sulphate, 2% PEG 6K, 100 mM Tris-HCl, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.64 Å
R-free 0.218
|
|
4L3C
Structure of HLA-A2 in complex with D76N b2m mutant and NY-ESO1 double mutant
Deposited 2013-06-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 13
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain Z
21–119（99 aa）
Fragment：UNP RESIDUES 21-119
|
Mutation：D76N
|
CL CHLORIDE ION × 2
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；1.9 M ammonium sulphate, 2% PEG 6K, 100 mM Tris-HCl, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.64 Å
R-free 0.218
|
|
4L3C
Structure of HLA-A2 in complex with D76N b2m mutant and NY-ESO1 double mutant
Deposited 2013-06-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 14
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain b
21–119（99 aa）
Fragment：UNP RESIDUES 21-119
|
Mutation：D76N
|
CL CHLORIDE ION × 2
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；1.9 M ammonium sulphate, 2% PEG 6K, 100 mM Tris-HCl, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.64 Å
R-free 0.218
|
|
4L3C
Structure of HLA-A2 in complex with D76N b2m mutant and NY-ESO1 double mutant
Deposited 2013-06-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
21–119（99 aa）
Fragment：UNP RESIDUES 21-119
|
Mutation：D76N
|
CL CHLORIDE ION × 3
GOL GLYCEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；1.9 M ammonium sulphate, 2% PEG 6K, 100 mM Tris-HCl, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.64 Å
R-free 0.218
|
|
4L3C
Structure of HLA-A2 in complex with D76N b2m mutant and NY-ESO1 double mutant
Deposited 2013-06-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain F
21–119（99 aa）
Fragment：UNP RESIDUES 21-119
|
Mutation：D76N
|
CL CHLORIDE ION × 2
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；1.9 M ammonium sulphate, 2% PEG 6K, 100 mM Tris-HCl, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.64 Å
R-free 0.218
|
|
4L3C
Structure of HLA-A2 in complex with D76N b2m mutant and NY-ESO1 double mutant
Deposited 2013-06-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain H
21–119（99 aa）
Fragment：UNP RESIDUES 21-119
|
Mutation：D76N
|
CL CHLORIDE ION × 2
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；1.9 M ammonium sulphate, 2% PEG 6K, 100 mM Tris-HCl, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.64 Å
R-free 0.218
|
|
4L3C
Structure of HLA-A2 in complex with D76N b2m mutant and NY-ESO1 double mutant
Deposited 2013-06-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 5
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain J
21–119（99 aa）
Fragment：UNP RESIDUES 21-119
|
Mutation：D76N
|
CL CHLORIDE ION × 5
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；1.9 M ammonium sulphate, 2% PEG 6K, 100 mM Tris-HCl, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.64 Å
R-free 0.218
|
|
4L3C
Structure of HLA-A2 in complex with D76N b2m mutant and NY-ESO1 double mutant
Deposited 2013-06-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 6
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain L
21–119（99 aa）
Fragment：UNP RESIDUES 21-119
|
Mutation：D76N
|
CL CHLORIDE ION × 2
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；1.9 M ammonium sulphate, 2% PEG 6K, 100 mM Tris-HCl, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.64 Å
R-free 0.218
|
|
4L3C
Structure of HLA-A2 in complex with D76N b2m mutant and NY-ESO1 double mutant
Deposited 2013-06-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 7
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain N
21–119（99 aa）
Fragment：UNP RESIDUES 21-119
|
Mutation：D76N
|
CL CHLORIDE ION × 3
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；1.9 M ammonium sulphate, 2% PEG 6K, 100 mM Tris-HCl, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.64 Å
R-free 0.218
|
|
4L3C
Structure of HLA-A2 in complex with D76N b2m mutant and NY-ESO1 double mutant
Deposited 2013-06-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 8
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain P
21–119（99 aa）
Fragment：UNP RESIDUES 21-119
|
Mutation：D76N
|
CL CHLORIDE ION × 2
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；1.9 M ammonium sulphate, 2% PEG 6K, 100 mM Tris-HCl, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.64 Å
R-free 0.218
|
|
4L3C
Structure of HLA-A2 in complex with D76N b2m mutant and NY-ESO1 double mutant
Deposited 2013-06-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 9
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain R
21–119（99 aa）
Fragment：UNP RESIDUES 21-119
|
Mutation：D76N
|
CL CHLORIDE ION × 5
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；1.9 M ammonium sulphate, 2% PEG 6K, 100 mM Tris-HCl, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.64 Å
R-free 0.218
|
|
4L3E
The complex between high affinity TCR DMF5(alpha-D26Y,beta-L98W) and human Class I MHC HLA-A2 with the bound MART-1(26-35)(A27L) peptide
Deposited 2013-06-05
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；12% PEG3350, 0.1 M Tris-HCl, 0.25 M magnesium chloride, pH 8, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.56 Å
R-free 0.266
|
|
4L4T
Structure of human MAIT TCR in complex with human MR1-6-FP
Deposited 2013-06-09
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
6FP 2-amino-4-oxo-3,4-dihydropteridine-6-carbaldehyde × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；293 K；pH 6, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.00 Å
R-free 0.225
|
|
4L4T
Structure of human MAIT TCR in complex with human MR1-6-FP
Deposited 2013-06-09
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain F
21–119（99 aa）
|
Not recorded
|
6FP 2-amino-4-oxo-3,4-dihydropteridine-6-carbaldehyde × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；293 K；pH 6, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.00 Å
R-free 0.225
|
|
4L4V
Structure of human MAIT TCR in complex with human MR1-RL-6-Me-7-OH
Deposited 2013-06-09
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
1VY 1-deoxy-1-(7-hydroxy-6-methyl-2,4-dioxo-3,4-dihydropteridin-8(2H)-yl)-D-ribitol × 1
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.3；293 K；pH 6.3, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.90 Å
R-free 0.209
|
|
4L4V
Structure of human MAIT TCR in complex with human MR1-RL-6-Me-7-OH
Deposited 2013-06-09
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain F
21–119（99 aa）
|
Not recorded
|
1VY 1-deoxy-1-(7-hydroxy-6-methyl-2,4-dioxo-3,4-dihydropteridin-8(2H)-yl)-D-ribitol × 1
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.3；293 K；pH 6.3, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.90 Å
R-free 0.209
|
|
4LCW
The structure of human MAIT TCR in complex with MR1-K43A-RL-6-Me-7OH
Deposited 2013-06-24
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 1
1VY 1-deoxy-1-(7-hydroxy-6-methyl-2,4-dioxo-3,4-dihydropteridin-8(2H)-yl)-D-ribitol × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；0.2M sodium acetate, 0.1M Bis-Tris-Propane pH 6.5 and 20% PEG 3350, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.40 Å
R-free 0.227
|
|
4LCW
The structure of human MAIT TCR in complex with MR1-K43A-RL-6-Me-7OH
Deposited 2013-06-24
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain F
21–119（99 aa）
|
Not recorded
|
1VY 1-deoxy-1-(7-hydroxy-6-methyl-2,4-dioxo-3,4-dihydropteridin-8(2H)-yl)-D-ribitol × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；0.2M sodium acetate, 0.1M Bis-Tris-Propane pH 6.5 and 20% PEG 3350, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.40 Å
R-free 0.227
|
|
4LCY
Crystal structure of HLA-b46 at 1.6 angstrom resolution
Deposited 2013-06-24
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；0.1M BIS-TRIS pH 5.5, 25% POLYETHYLENE GLYCOL 3350 , VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.60 Å
R-free 0.201
|
|
4LCY
Crystal structure of HLA-b46 at 1.6 angstrom resolution
Deposited 2013-06-24
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 5
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain H
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；0.1M BIS-TRIS pH 5.5, 25% POLYETHYLENE GLYCOL 3350 , VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.60 Å
R-free 0.201
|
|
4LCY
Crystal structure of HLA-b46 at 1.6 angstrom resolution
Deposited 2013-06-24
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 7
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
NA SODIUM ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；0.1M BIS-TRIS pH 5.5, 25% POLYETHYLENE GLYCOL 3350 , VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.60 Å
R-free 0.201
|
|
4LCY
Crystal structure of HLA-b46 at 1.6 angstrom resolution
Deposited 2013-06-24
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 8
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain H
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
NA SODIUM ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；0.1M BIS-TRIS pH 5.5, 25% POLYETHYLENE GLYCOL 3350 , VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.60 Å
R-free 0.201
|
|
4LHU
Crystal Structure of 9C2 TCR bound to CD1d
Deposited 2013-07-01
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
BMA beta-D-mannopyranose × 1
MG MAGNESIUM ION × 1
JLS (15Z)-N-[(2S,3S,4R)-1-(alpha-D-galactopyranosyloxy)-3,4-dihydroxyoctadecan-2-yl]tetracos-15-enamide × 1
CL CHLORIDE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；277 K；12% PEG8000, 0.1 M Tris-HCl, pH 7.0, 0.2 M magnesium chloride, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.87 Å
R-free 0.243
|
|
4LNR
The structure of HLA-B*35:01 in complex with the peptide (RPQVPLRPMTY)
Deposited 2013-07-12
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；291 K；0.1M MES monohydrate pH 6.5, 12% w/v Polyethylene glycol 20,000, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.00 Å
R-free 0.208
|
|
4M8V
Crystal structure of Human double mutant beta2-microglobulin Q8H-L65T
Deposited 2013-08-14
|
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
21–119（99 aa）
|
Mutation：Q8H, L65T
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.7；289 K；20%(w/v) PEG 3350, 0.1M Bis-tris, 0.2M Ammonium acetate, pH 5.7, VAPOR DIFFUSION, HANGING DROP, temperature 289K
|
Resolution 1.95 Å
R-free 0.240
|
|
4M8V
Crystal structure of Human double mutant beta2-microglobulin Q8H-L65T
Deposited 2013-08-14
|
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
21–119（99 aa）
|
Mutation：Q8H, L65T
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.7；289 K；20%(w/v) PEG 3350, 0.1M Bis-tris, 0.2M Ammonium acetate, pH 5.7, VAPOR DIFFUSION, HANGING DROP, temperature 289K
|
Resolution 1.95 Å
R-free 0.240
|
|
4MJ5
Crystal Structure of HLA-A*1101 in complex with H1-22, an influenza A(H1N1) virus epitope
Deposited 2013-09-03
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；277 K；0.1M Ammonium acetate, 0.1M BIS0TRIS PH5.5, 17% w/v Polyethylene glycol 10K, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 2.40 Å
R-free 0.245
|
|
4MJ6
Crystal Structure of HLA-A*1101 in complex with H7-22, an influenza A(H7N9) virus epitope
Deposited 2013-09-03
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；277 K；0.1M Ammonium acetate, 0.1M BIS0TRIS PH5.5, 17% w/v Polyethylene glycol 10K, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 2.57 Å
R-free 0.247
|
|
4MJI
T cell response to a HIV reverse transcriptase epitope presented by the protective allele HLA-B*51:01
Deposited 2013-09-03
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；291 K；20% PEG 3350, 0.2M NaSO4, 0.1M Bis-Tris Propane, pH 6.5, VAPOR DIFFUSION, temperature 291K
|
Resolution 2.99 Å
R-free 0.304
|
|
4MJI
T cell response to a HIV reverse transcriptase epitope presented by the protective allele HLA-B*51:01
Deposited 2013-09-03
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；291 K；20% PEG 3350, 0.2M NaSO4, 0.1M Bis-Tris Propane, pH 6.5, VAPOR DIFFUSION, temperature 291K
|
Resolution 2.99 Å
R-free 0.304
|
|
4MNQ
TCR-peptide specificity overrides affinity enhancing TCR-MHC interactions
Deposited 2013-09-11
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 1
EDO 1,2-ETHANEDIOL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；291 K；TRIS 0.02M, 20% PEG 4000, 0.01M NaCl, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 291K
|
Resolution 2.74 Å
R-free 0.284
|
|
4N0F
Human FcRn complexed with human serum albumin
Deposited 2013-10-01
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：unp residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 5.2；298 K；4% Tacsimate, pH 4.0, 12% PEG3350, 30 mM Sodium Acetate, pH 5.2, HSA/FcRn 10 mg/ml, VAPOR DIFFUSION, temperature 298K
|
Resolution 3.02 Å
R-free 0.260
|
|
4N0F
Human FcRn complexed with human serum albumin
Deposited 2013-10-01
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain F
21–119（99 aa）
Fragment：unp residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 5.2；298 K；4% Tacsimate, pH 4.0, 12% PEG3350, 30 mM Sodium Acetate, pH 5.2, HSA/FcRn 10 mg/ml, VAPOR DIFFUSION, temperature 298K
|
Resolution 3.02 Å
R-free 0.260
|
|
4N0F
Human FcRn complexed with human serum albumin
Deposited 2013-10-01
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain I
21–119（99 aa）
Fragment：unp residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 5.2；298 K；4% Tacsimate, pH 4.0, 12% PEG3350, 30 mM Sodium Acetate, pH 5.2, HSA/FcRn 10 mg/ml, VAPOR DIFFUSION, temperature 298K
|
Resolution 3.02 Å
R-free 0.260
|
|
4N0F
Human FcRn complexed with human serum albumin
Deposited 2013-10-01
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain L
21–119（99 aa）
Fragment：unp residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 5.2；298 K；4% Tacsimate, pH 4.0, 12% PEG3350, 30 mM Sodium Acetate, pH 5.2, HSA/FcRn 10 mg/ml, VAPOR DIFFUSION, temperature 298K
|
Resolution 3.02 Å
R-free 0.260
|
|
4N0U
Ternary complex between Neonatal Fc receptor, serum albumin and Fc
Deposited 2013-10-02
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 8
PDB declaration: octameric
|
Chain B
21–119（99 aa）
Fragment：beta-2 microglobulin, unp residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 5.2；298 K；4% Tacsimate, pH 4.0, 12% PEG 3350, VAPOR DIFFUSION, temperature 298K
|
Resolution 3.80 Å
R-free 0.303
|
|
4N8V
Crystal structure of killer cell immunoglobulin-like receptor KIR2DS2 in complex with HLA-A
Deposited 2013-10-18
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；298 K；16% PEG 3350, 2% TACSIMATE, 0.1M TRI-SODIUM CITRATE, pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.50 Å
R-free 0.257
|
|
4N8V
Crystal structure of killer cell immunoglobulin-like receptor KIR2DS2 in complex with HLA-A
Deposited 2013-10-18
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；298 K；16% PEG 3350, 2% TACSIMATE, 0.1M TRI-SODIUM CITRATE, pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.50 Å
R-free 0.257
|
|
4NNX
Crystal structure of PKD2 phosphopeptide bound to HLA-A2
Deposited 2013-11-19
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
CD CADMIUM ION × 4
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；11% PEG3350, 0.1 M HEPES, pH 7.5, 0.15 M sodium chloride, 0.003 M magnesium chloride, 0.003 M cadmium chloride, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.10 Å
R-free 0.236
|
|
4NNY
Crystal structure of non-phosphorylated form of PKD2 phosphopeptide bound to HLA-A2
Deposited 2013-11-19
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
CD CADMIUM ION × 3
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；15% PEG3350, 0.1 M HEPES, 0.2 M sodium chloride, 0.003 M magnesium chloride, 0.003 M cadmium chloride, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.90 Å
R-free 0.229
|
|
4NO0
Crystal structure of non-phosphorylated form of RQA_V phosphopeptide bound to HLA-A2 in complex with LILRB1
Deposited 2013-11-19
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；18% PEG3350, 0.1 M HEPES, pH 7.4, 0.2 M ammonium acetate, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.70 Å
R-free 0.309
|
|
4NO2
Crystal structure of RQA_V phosphopeptide bound to HLA-A2
Deposited 2013-11-19
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 3
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；20% PEG8000, 0.1 M HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.00 Å
R-free 0.249
|
|
4NO3
Crystal structure of AMPD2 phosphopeptide bound to HLA-A2
Deposited 2013-11-19
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；12% PEG3350, 8% tacsimate, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.70 Å
R-free 0.232
|
|
4NO5
Crystal structure of non-phosphorylated form of AMPD2 phosphopeptide bound to HLA-A2
Deposited 2013-11-19
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
22–119（98 aa）
Fragment：UNP residues 22-119
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 3
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；298 K；19% PEG3350, 0.1 M Bis-Tris propane, 0.1 M sodium tartrate, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.10 Å
R-free 0.237
|
|
4NQC
Crystal structure of TCR-MR1 ternary complex and covalently bound 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil
Deposited 2013-11-25
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
2LJ 1-deoxy-1-({2,6-dioxo-5-[(E)-propylideneamino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-ribitol × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.3；293 K；12% (w/v) PEG3350, 0.2 M sodium citrate, 0.1 M bis-tris propane, pH 6.3, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.50 Å
R-free 0.216
|
|
4NQC
Crystal structure of TCR-MR1 ternary complex and covalently bound 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil
Deposited 2013-11-25
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain F
21–119（99 aa）
|
Not recorded
|
2LJ 1-deoxy-1-({2,6-dioxo-5-[(E)-propylideneamino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-ribitol × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.3；293 K；12% (w/v) PEG3350, 0.2 M sodium citrate, 0.1 M bis-tris propane, pH 6.3, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.50 Å
R-free 0.216
|
|
4NQD
Crystal structure of TCR-MR1 ternary complex and non-covalently bound 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil
Deposited 2013-11-25
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
Q87 1-deoxy-1-({2,6-dioxo-5-[(E)-(2-oxopropylidene)amino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-ribitol × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.3；293 K；12% (w/v) PEG3350, 0.2 M sodium citrate, 0.1 M bis-tris propane, pH 6.3, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.20 Å
R-free 0.227
|
|
4NQD
Crystal structure of TCR-MR1 ternary complex and non-covalently bound 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil
Deposited 2013-11-25
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain F
21–119（99 aa）
|
Not recorded
|
Q87 1-deoxy-1-({2,6-dioxo-5-[(E)-(2-oxopropylidene)amino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-ribitol × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.3；293 K；12% (w/v) PEG3350, 0.2 M sodium citrate, 0.1 M bis-tris propane, pH 6.3, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.20 Å
R-free 0.227
|
|
4NQD
Crystal structure of TCR-MR1 ternary complex and non-covalently bound 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil
Deposited 2013-11-25
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 5
Protein heterocomplex
Heteromer；Protein × 8
PDB declaration: octameric
|
Chain B
21–119（99 aa）
Chain F
21–119（99 aa）
|
Not recorded
|
Q87 1-deoxy-1-({2,6-dioxo-5-[(E)-(2-oxopropylidene)amino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-ribitol × 2
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.3；293 K；12% (w/v) PEG3350, 0.2 M sodium citrate, 0.1 M bis-tris propane, pH 6.3, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.20 Å
R-free 0.227
|
|
4NQE
Crystal structure of TCR-MR1 ternary complex bound to 5-(2-oxoethylideneamino)-6-D-ribitylaminouracil
Deposited 2013-11-25
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
2L4 1-deoxy-1-({2,6-dioxo-5-[(E)-(2-oxoethylidene)amino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-ribitol × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.3；12% (w/v) PEG3350, 0.2 M sodium citrate, 0.1 M bis-tris propane, pH 6.3, VAPOR DIFFUSION, HANGING DROP
|
Resolution 2.10 Å
R-free 0.222
|
|
4NQE
Crystal structure of TCR-MR1 ternary complex bound to 5-(2-oxoethylideneamino)-6-D-ribitylaminouracil
Deposited 2013-11-25
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain F
21–119（99 aa）
|
Not recorded
|
2L4 1-deoxy-1-({2,6-dioxo-5-[(E)-(2-oxoethylidene)amino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-ribitol × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.3；12% (w/v) PEG3350, 0.2 M sodium citrate, 0.1 M bis-tris propane, pH 6.3, VAPOR DIFFUSION, HANGING DROP
|
Resolution 2.10 Å
R-free 0.222
|
|
4NQV
Crystal Structure of HLA A*0101 in complex with NP44, an 9-mer influenza epitope
Deposited 2013-11-25
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；pH 5.6；277 K；0.2M MgCl, 0.1M Na-citrate pH 5.6, 15-20% PEG 6K, EVAPORATION, temperature 277K
|
Resolution 2.39 Å
R-free 0.291
|
|
4NQV
Crystal Structure of HLA A*0101 in complex with NP44, an 9-mer influenza epitope
Deposited 2013-11-25
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；pH 5.6；277 K；0.2M MgCl, 0.1M Na-citrate pH 5.6, 15-20% PEG 6K, EVAPORATION, temperature 277K
|
Resolution 2.39 Å
R-free 0.291
|
|
4NQV
Crystal Structure of HLA A*0101 in complex with NP44, an 9-mer influenza epitope
Deposited 2013-11-25
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain F
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；pH 5.6；277 K；0.2M MgCl, 0.1M Na-citrate pH 5.6, 15-20% PEG 6K, EVAPORATION, temperature 277K
|
Resolution 2.39 Å
R-free 0.291
|
|
4NQV
Crystal Structure of HLA A*0101 in complex with NP44, an 9-mer influenza epitope
Deposited 2013-11-25
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain H
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；pH 5.6；277 K；0.2M MgCl, 0.1M Na-citrate pH 5.6, 15-20% PEG 6K, EVAPORATION, temperature 277K
|
Resolution 2.39 Å
R-free 0.291
|
|
4NQV
Crystal Structure of HLA A*0101 in complex with NP44, an 9-mer influenza epitope
Deposited 2013-11-25
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 5
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain J
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；pH 5.6；277 K；0.2M MgCl, 0.1M Na-citrate pH 5.6, 15-20% PEG 6K, EVAPORATION, temperature 277K
|
Resolution 2.39 Å
R-free 0.291
|
|
4NQV
Crystal Structure of HLA A*0101 in complex with NP44, an 9-mer influenza epitope
Deposited 2013-11-25
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 6
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain L
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；pH 5.6；277 K；0.2M MgCl, 0.1M Na-citrate pH 5.6, 15-20% PEG 6K, EVAPORATION, temperature 277K
|
Resolution 2.39 Å
R-free 0.291
|
|
4NQX
Crystal Structure of HLA A*0101 in complex with NP44-S7N, an 9-mer influenza epitope
Deposited 2013-11-26
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；pH 5.6；277 K；0.2M MgCl, 0.1M Na-citrate pH 5.6, 15-20% PEG 6K, EVAPORATION, temperature 277K
|
Resolution 2.00 Å
R-free 0.283
|
|
4NQX
Crystal Structure of HLA A*0101 in complex with NP44-S7N, an 9-mer influenza epitope
Deposited 2013-11-26
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；pH 5.6；277 K；0.2M MgCl, 0.1M Na-citrate pH 5.6, 15-20% PEG 6K, EVAPORATION, temperature 277K
|
Resolution 2.00 Å
R-free 0.283
|
|
4NQX
Crystal Structure of HLA A*0101 in complex with NP44-S7N, an 9-mer influenza epitope
Deposited 2013-11-26
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain F
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；pH 5.6；277 K；0.2M MgCl, 0.1M Na-citrate pH 5.6, 15-20% PEG 6K, EVAPORATION, temperature 277K
|
Resolution 2.00 Å
R-free 0.283
|
|
4NQX
Crystal Structure of HLA A*0101 in complex with NP44-S7N, an 9-mer influenza epitope
Deposited 2013-11-26
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain H
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；pH 5.6；277 K；0.2M MgCl, 0.1M Na-citrate pH 5.6, 15-20% PEG 6K, EVAPORATION, temperature 277K
|
Resolution 2.00 Å
R-free 0.283
|
|
4NQX
Crystal Structure of HLA A*0101 in complex with NP44-S7N, an 9-mer influenza epitope
Deposited 2013-11-26
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 5
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain J
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；pH 5.6；277 K；0.2M MgCl, 0.1M Na-citrate pH 5.6, 15-20% PEG 6K, EVAPORATION, temperature 277K
|
Resolution 2.00 Å
R-free 0.283
|
|
4NQX
Crystal Structure of HLA A*0101 in complex with NP44-S7N, an 9-mer influenza epitope
Deposited 2013-11-26
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 6
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain L
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；pH 5.6；277 K；0.2M MgCl, 0.1M Na-citrate pH 5.6, 15-20% PEG 6K, EVAPORATION, temperature 277K
|
Resolution 2.00 Å
R-free 0.283
|
|
4NT6
HLA-C*0801 Crystal Structure
Deposited 2013-12-01
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–118（98 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；291 K；0.05M CALCIUM CHLORIDE DIHYDRATE, 0.1M BIS-TRIS, 30%(V/V) POLYETHYLENE GLYCOL MONOMETHYL ETHER 550, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.84 Å
R-free 0.229
|
|
4O2C
An Nt-acetylated peptide complexed with HLA-B*3901
Deposited 2013-12-17
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；0.1M ammonium acetate, 0.1M Bis-Tris (pH 6.5), 17% (w/v) PEG 10000, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 1.80 Å
R-free 0.202
|
|
4O2E
A peptide complexed with HLA-B*3901
Deposited 2013-12-17
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；0.1M ammonium acetate, 0.1M Bis-Tris (pH 6.5), 20% (w/v) PEG 10000, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 1.98 Å
R-free 0.208
|
|
4O2E
A peptide complexed with HLA-B*3901
Deposited 2013-12-17
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；0.1M ammonium acetate, 0.1M Bis-Tris (pH 6.5), 20% (w/v) PEG 10000, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 1.98 Å
R-free 0.208
|
|
4O2F
A peptide complexed with HLA-B*3901
Deposited 2013-12-17
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；277 K；0.2M sodium formate, 20% (w/v) PEG 3350, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 1.90 Å
R-free 0.213
|
|
4O2F
A peptide complexed with HLA-B*3901
Deposited 2013-12-17
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；277 K；0.2M sodium formate, 20% (w/v) PEG 3350, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 1.90 Å
R-free 0.213
|
|
4ONO
CD1c in complex with PM (phosphomycoketide)
Deposited 2014-01-28
|
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
21–119（99 aa）
|
Mutation：N52Q, N57Q, K108G, N128Q, N241Q, W242G
|
PMK (4R,8S,16S,20R)-4,8,12,16,20-pentamethylheptacosyl dihydrogen phosphate × 1
CL CHLORIDE ION × 6
MLI MALONATE ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 9.4；291 K；1.05 M sodium citrate, 100 mM CHES (pH 9.4), and 25 mM triglycine, VAPOR DIFFUSION, SITTING DROP, temperature 291K
|
Resolution 2.71 Å
R-free 0.271
|
|
4PJ5
Structure of human MR1-Ac-6-FP in complex with human MAIT TRBV6-1 TCR
Deposited 2014-05-12
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
30W N-(6-formyl-4-oxo-3,4-dihydropteridin-2-yl)acetamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG 3350, sodium acetate, bis-tris-propane
|
Resolution 2.00 Å
R-free 0.220
|
|
4PJ5
Structure of human MR1-Ac-6-FP in complex with human MAIT TRBV6-1 TCR
Deposited 2014-05-12
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain F
21–119（99 aa）
|
Not recorded
|
30W N-(6-formyl-4-oxo-3,4-dihydropteridin-2-yl)acetamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG 3350, sodium acetate, bis-tris-propane
|
Resolution 2.00 Å
R-free 0.220
|
|
4PJ7
Structure of human MR1-5-OP-RU in complex with human MAIT TRBV6-4 TCR
Deposited 2014-05-12
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
2LJ 1-deoxy-1-({2,6-dioxo-5-[(E)-propylideneamino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-ribitol × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；294 K；PEG 3350, Bis-tris propane, sodium acetate
|
Resolution 2.50 Å
R-free 0.219
|
|
4PJ7
Structure of human MR1-5-OP-RU in complex with human MAIT TRBV6-4 TCR
Deposited 2014-05-12
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain D
21–119（99 aa）
|
Not recorded
|
2LJ 1-deoxy-1-({2,6-dioxo-5-[(E)-propylideneamino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-ribitol × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；294 K；PEG 3350, Bis-tris propane, sodium acetate
|
Resolution 2.50 Å
R-free 0.219
|
|
4PJ8
Structure of human MR1-5-OP-RU in complex with human MAIT TRBV20 TCR
Deposited 2014-05-12
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
2LJ 1-deoxy-1-({2,6-dioxo-5-[(E)-propylideneamino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-ribitol × 1
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG 3350, Bis-tris propane, sodium acetate
|
Resolution 3.30 Å
R-free 0.213
|
|
4PJ9
Structure of human MR1-5-OP-RU in complex with human MAIT TRAJ20 TCR
Deposited 2014-05-12
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
2LJ 1-deoxy-1-({2,6-dioxo-5-[(E)-propylideneamino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-ribitol × 1
GOL GLYCEROL × 2
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG 3350, Bis-tris propane, sodium acetate
|
Resolution 2.00 Å
R-free 0.199
|
|
4PJA
Structure of human MR1-5-OP-RU in complex with human MAIT B-B10 TCR
Deposited 2014-05-12
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
2LJ 1-deoxy-1-({2,6-dioxo-5-[(E)-propylideneamino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-ribitol × 1
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG 3350, Bis-tris propane, sodium acetate
|
Resolution 2.68 Å
R-free 0.216
|
|
4PJA
Structure of human MR1-5-OP-RU in complex with human MAIT B-B10 TCR
Deposited 2014-05-12
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain D
21–119（99 aa）
|
Not recorded
|
2LJ 1-deoxy-1-({2,6-dioxo-5-[(E)-propylideneamino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-ribitol × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG 3350, Bis-tris propane, sodium acetate
|
Resolution 2.68 Å
R-free 0.216
|
|
4PJB
Structure of human MR1-5-OP-RU in complex with human MAIT B-F3-C1 TCR
Deposited 2014-05-12
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
2LJ 1-deoxy-1-({2,6-dioxo-5-[(E)-propylideneamino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-ribitol × 1
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG 3350, Bis-tris propane, sodium acetate
|
Resolution 2.85 Å
R-free 0.225
|
|
4PJB
Structure of human MR1-5-OP-RU in complex with human MAIT B-F3-C1 TCR
Deposited 2014-05-12
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain D
21–119（99 aa）
|
Not recorded
|
2LJ 1-deoxy-1-({2,6-dioxo-5-[(E)-propylideneamino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-ribitol × 1
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG 3350, Bis-tris propane, sodium acetate
|
Resolution 2.85 Å
R-free 0.225
|
|
4PJC
Structure of human MR1-5-OP-RU in complex with human MAIT C-A11 TCR
Deposited 2014-05-12
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
2LJ 1-deoxy-1-({2,6-dioxo-5-[(E)-propylideneamino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-ribitol × 1
B3P 2-[3-(2-HYDROXY-1,1-DIHYDROXYMETHYL-ETHYLAMINO)-PROPYLAMINO]-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG 3350, Bis-tris propane, sodium acetate
|
Resolution 2.50 Å
R-free 0.213
|
|
4PJC
Structure of human MR1-5-OP-RU in complex with human MAIT C-A11 TCR
Deposited 2014-05-12
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain D
21–119（99 aa）
|
Not recorded
|
2LJ 1-deoxy-1-({2,6-dioxo-5-[(E)-propylideneamino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-ribitol × 1
B3P 2-[3-(2-HYDROXY-1,1-DIHYDROXYMETHYL-ETHYLAMINO)-PROPYLAMINO]-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG 3350, Bis-tris propane, sodium acetate
|
Resolution 2.50 Å
R-free 0.213
|
|
4PJD
Structure of human MR1-5-OP-RU in complex with human MAIT C-C10 TCR
Deposited 2014-05-12
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
2LJ 1-deoxy-1-({2,6-dioxo-5-[(E)-propylideneamino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-ribitol × 1
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG 3350, Bis-tris propane, sodium acetate
|
Resolution 2.78 Å
R-free 0.226
|
|
4PJD
Structure of human MR1-5-OP-RU in complex with human MAIT C-C10 TCR
Deposited 2014-05-12
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain D
21–119（99 aa）
|
Not recorded
|
2LJ 1-deoxy-1-({2,6-dioxo-5-[(E)-propylideneamino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-ribitol × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG 3350, Bis-tris propane, sodium acetate
|
Resolution 2.78 Å
R-free 0.226
|
|
4PJE
Structure of human MR1-Ac-6-FP in complex with human MAIT B-B10 TCR
Deposited 2014-05-12
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
CL CHLORIDE ION × 2
GOL GLYCEROL × 6
ACT ACETATE ION × 3
30W N-(6-formyl-4-oxo-3,4-dihydropteridin-2-yl)acetamide × 1
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG 3350, Bis-tris propane, sodium acetate
|
Resolution 1.95 Å
R-free 0.197
|
|
4PJE
Structure of human MR1-Ac-6-FP in complex with human MAIT B-B10 TCR
Deposited 2014-05-12
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain D
21–119（99 aa）
|
Not recorded
|
CL CHLORIDE ION × 1
GOL GLYCEROL × 2
30W N-(6-formyl-4-oxo-3,4-dihydropteridin-2-yl)acetamide × 1
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG 3350, Bis-tris propane, sodium acetate
|
Resolution 1.95 Å
R-free 0.197
|
|
4PJF
Structure of human MR1-Ac-6-FP in complex with human MAIT B-C10 TCR
Deposited 2014-05-12
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
30W N-(6-formyl-4-oxo-3,4-dihydropteridin-2-yl)acetamide × 1
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG 3350, Bis-tris propane, sodium acetate
|
Resolution 2.45 Å
R-free 0.212
|
|
4PJF
Structure of human MR1-Ac-6-FP in complex with human MAIT B-C10 TCR
Deposited 2014-05-12
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain D
21–119（99 aa）
|
Not recorded
|
30W N-(6-formyl-4-oxo-3,4-dihydropteridin-2-yl)acetamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG 3350, Bis-tris propane, sodium acetate
|
Resolution 2.45 Å
R-free 0.212
|
|
4PJG
Structure of human MR1-Ac-6-FP in complex with human MAIT B-F3-C1 TCR
Deposited 2014-05-12
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
30W N-(6-formyl-4-oxo-3,4-dihydropteridin-2-yl)acetamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG 3350, Bis-tris propane, sodium acetate
|
Resolution 2.40 Å
R-free 0.213
|
|
4PJG
Structure of human MR1-Ac-6-FP in complex with human MAIT B-F3-C1 TCR
Deposited 2014-05-12
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain D
21–119（99 aa）
|
Not recorded
|
30W N-(6-formyl-4-oxo-3,4-dihydropteridin-2-yl)acetamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG 3350, Bis-tris propane, sodium acetate
|
Resolution 2.40 Å
R-free 0.213
|
|
4PJH
Structure of human MR1-Ac-6-FP in complex with human MAIT B-G8 TCR
Deposited 2014-05-12
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 2
30W N-(6-formyl-4-oxo-3,4-dihydropteridin-2-yl)acetamide × 1
NA SODIUM ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG 3350, Bis-tris propane, sodium acetate
|
Resolution 2.00 Å
R-free 0.198
|
|
4PJH
Structure of human MR1-Ac-6-FP in complex with human MAIT B-G8 TCR
Deposited 2014-05-12
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain D
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 2
30W N-(6-formyl-4-oxo-3,4-dihydropteridin-2-yl)acetamide × 1
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG 3350, Bis-tris propane, sodium acetate
|
Resolution 2.00 Å
R-free 0.198
|
|
4PJI
Structure of human MR1-Ac-6-FP in complex with human MAIT C-C10 TCR
Deposited 2014-05-12
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
30W N-(6-formyl-4-oxo-3,4-dihydropteridin-2-yl)acetamide × 1
GOL GLYCEROL × 1
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG 3350, Bis-tris propane, sodium acetate
|
Resolution 2.50 Å
R-free 0.228
|
|
4PJI
Structure of human MR1-Ac-6-FP in complex with human MAIT C-C10 TCR
Deposited 2014-05-12
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain D
21–119（99 aa）
|
Not recorded
|
30W N-(6-formyl-4-oxo-3,4-dihydropteridin-2-yl)acetamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG 3350, Bis-tris propane, sodium acetate
|
Resolution 2.50 Å
R-free 0.228
|
|
4PJX
Structure of human MR1-Ac-6-FP in complex with human MAIT C-A11 TCR
Deposited 2014-05-12
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
30W N-(6-formyl-4-oxo-3,4-dihydropteridin-2-yl)acetamide × 1
CL CHLORIDE ION × 1
GOL GLYCEROL × 4
B3P 2-[3-(2-HYDROXY-1,1-DIHYDROXYMETHYL-ETHYLAMINO)-PROPYLAMINO]-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG 3350, Bis-tris propane, sodium acetate
|
Resolution 2.25 Å
R-free 0.203
|
|
4PJX
Structure of human MR1-Ac-6-FP in complex with human MAIT C-A11 TCR
Deposited 2014-05-12
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain D
21–119（99 aa）
|
Not recorded
|
30W N-(6-formyl-4-oxo-3,4-dihydropteridin-2-yl)acetamide × 1
GOL GLYCEROL × 2
B3P 2-[3-(2-HYDROXY-1,1-DIHYDROXYMETHYL-ETHYLAMINO)-PROPYLAMINO]-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG 3350, Bis-tris propane, sodium acetate
|
Resolution 2.25 Å
R-free 0.203
|
|
4PR5
Crystal structure of a HLA-B*35:01-HPVG-D5
Deposited 2014-03-05
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 5.6；298 K；16% PEG 4000, 0.2M ammonium acetate and 0.1M Na-Citrate pH 5.6, vapor diffusion, temperature 298K
|
Resolution 1.80 Å
R-free 0.213
|
|
4PRA
Crystal structure of a HLA-B*35:01-HPVG-Q5
Deposited 2014-03-05
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 5.6；298 K；16% PEG 4000, 0.2M ammonium acetate and 0.1M Na-Citrate, pH 5.6, VAPOR DIFFUSION, temperature 298K
|
Resolution 1.85 Å
R-free 0.225
|
|
4PRB
Crystal structure of a HLA-B*35:08-HPVG-A4
Deposited 2014-03-05
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
ACT ACETATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 5.6；298 K；16% PEG 4000, 0.2M ammonium acetate and 0.1M Na-Citrate, pH 5.6, VAPOR DIFFUSION, temperature 298K
|
Resolution 1.75 Å
R-free 0.234
|
|
4PRD
Crystal structure of a HLA-B*35:08-HPVG-D5
Deposited 2014-03-05
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
ACT ACETATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 5.6；298 K；16% PEG 4000, 0.2M ammonium acetate and 0.1M Na-Citrate pH 5.6, vapor diffusion, temperature 298K
|
Resolution 1.75 Å
R-free 0.234
|
|
4PRE
Crystal structure of a HLA-B*35:08-HPVG-Q5
Deposited 2014-03-05
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 5.6；298 K；16% PEG 4000, 0.2M ammonium acetate and 0.1M Na-Citrate, pH 5.6, VAPOR DIFFUSION, temperature 298K
|
Resolution 1.65 Å
R-free 0.202
|
|
4PRH
Crystal structure of TK3 TCR-HLA-B*35:08-HPVG-D5 complex
Deposited 2014-03-05
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
23–119（97 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.6；298 K；18% PEG 3350, 0.2M LiSO4 and 0.1M Na-Citrate pH 5.6, vapor diffusion, temperature 298K
|
Resolution 2.50 Å
R-free 0.253
|
|
4PRI
Crystal structure of TK3 TCR-HLA-B*35:08-HPVG complex
Deposited 2014-03-05
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
CL CHLORIDE ION × 2
NA SODIUM ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 5.6；298 K；18% PEG 3350, 0.2M LiSO4 and 0.1M Na-Citrate pH 5.6, vapor diffusion, temperature 298K
|
Resolution 2.40 Å
R-free 0.261
|
|
4PRN
Crystal structure of a HLA-B*35:01-HPVG-A4
Deposited 2014-03-06
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
ACT ACETATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 5.6；298 K；16% PEG 4000, 0.2M ammonium acetate and 0.1M Na-Citrate pH 5.6, vapor diffusion, temperature 298K
|
Resolution 1.65 Å
R-free 0.222
|
|
4PRP
Crystal structure of TK3 TCR-HLA-B*35:01-HPVG-Q5 complex
Deposited 2014-03-06
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 5.6；298 K；18% PEG 3350, 0.2M LiSO4 and 0.1M Na-Citrate, pH 5.6, VAPOR DIFFUSION, temperature 298K
|
Resolution 2.50 Å
R-free 0.229
|
|
4QOK
Structural basis for ineffective T-cell responses to MHC anchor residue improved heteroclitic peptides
Deposited 2014-06-20
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；291 K；0.1 M Sodium Cacodylate, pH 6.5, 15% PEG 4000, 15% Glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 291K
|
Resolution 3.00 Å
R-free 0.262
|
|
4QRP
Crystal Structure of HLA B*0801 in complex with HSKKKCDEL and DD31 TCR
Deposited 2014-07-02
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
IOD IODIDE ION × 3
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；277 K；0.2M ammonium acetate, 16% PEG 4K, 0.1 tri-Na citrate, pH 5.6, vapor diffusion, hanging drop, temperature 277K
|
Resolution 2.90 Å
R-free 0.248
|
|
4QRP
Crystal Structure of HLA B*0801 in complex with HSKKKCDEL and DD31 TCR
Deposited 2014-07-02
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
|
Not recorded
|
IOD IODIDE ION × 4
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；277 K；0.2M ammonium acetate, 16% PEG 4K, 0.1 tri-Na citrate, pH 5.6, vapor diffusion, hanging drop, temperature 277K
|
Resolution 2.90 Å
R-free 0.248
|
|
4QRP
Crystal Structure of HLA B*0801 in complex with HSKKKCDEL and DD31 TCR
Deposited 2014-07-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 12
PDB declaration: dodecameric
|
Chain B
21–119（99 aa）
Chain G
21–119（99 aa）
|
Not recorded
|
IOD IODIDE ION × 12
NA SODIUM ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；277 K；0.2M ammonium acetate, 16% PEG 4K, 0.1 tri-Na citrate, pH 5.6, vapor diffusion, hanging drop, temperature 277K
|
Resolution 2.90 Å
R-free 0.248
|
|
4QRQ
Crystal Structure of HLA B*0801 in complex with HSKKKCDEL
Deposited 2014-07-02
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；277 K；0.2M ammonium acetate, 16% PEG 4K, 0.1 tri-Na citrate, pH 5.6, vapor diffusion, hanging drop, temperature 277K
|
Resolution 1.70 Å
R-free 0.209
|
|
4QRR
Crystal Structure of HLA B*3501-IPS in complex with a Delta-Beta TCR, clone 12 TCR
Deposited 2014-07-02
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；277 K；0.3 M KCN, 24% PEG 3350, 2% EG, 10 mM spermidine, 10 mM L-Proline, pH 8, vapor diffusion, hanging drop, temperature 277K
|
Resolution 3.00 Å
R-free 0.258
|
|
4QRS
Crystal Structure of HLA B*0801 in complex with ELK_IYM, ELKRKMIYM
Deposited 2014-07-02
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
22–119（98 aa）
|
Not recorded
|
ACT ACETATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；277 K；0.2M ammonium acetate, 16% PEG 4K, 0.1 tri-Na citrate, pH 5.6, vapor diffusion, hanging drop, temperature 277K
|
Resolution 1.40 Å
R-free 0.216
|
|
4QRT
Crystal Structure of HLA B*0801 in complex with ELN_YYM, ELNRKMIYM
Deposited 2014-07-02
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；277 K；0.2M ammonium acetate, 16% PEG 4K, 0.1 tri-Na citrate, pH 5.6, vapor diffusion, hanging drop, temperature 277K
|
Resolution 1.40 Å
R-free 0.204
|
|
4QRU
Crystal Structure of HLA B*0801 in complex with ELR_MYM, ELRRKMMYM
Deposited 2014-07-02
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
ACT ACETATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；277 K；0.2M ammonium acetate, 16% PEG 4K, 0.1 tri-Na citrate, pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 1.60 Å
R-free 0.202
|
|
4R9H
Crystal structure of dimeric S33C beta-2 microglobulin mutant at 1.9 Angstrom resolution
Deposited 2014-09-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
21–119（99 aa）
Fragment：UNP residues 21-119
Chain D
21–119（99 aa）
Fragment：UNP residues 21-119
|
Mutation：S33C
Mutation：S33C
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；293 K；25% PEG4000, 0.2 M imidazole-malate, pH 7.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.90 Å
R-free 0.247
|
|
4R9H
Crystal structure of dimeric S33C beta-2 microglobulin mutant at 1.9 Angstrom resolution
Deposited 2014-09-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
Chain C
21–119（99 aa）
Fragment：UNP residues 21-119
|
Mutation：S33C
Mutation：S33C
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；293 K；25% PEG4000, 0.2 M imidazole-malate, pH 7.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.90 Å
R-free 0.247
|
|
4RA3
Crystal structure of dimeric S33C beta-2 microglobulin mutant in complex with Thioflavin (ThT) at 2.8 Angstrom resolution
Deposited 2014-09-09
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
21–119（99 aa）
Fragment：UNP residues 21-119
Chain C
21–119（99 aa）
Fragment：UNP residues 21-119
|
Mutation：S33C
Mutation：S33C
|
TFX 2-[4-(dimethylamino)phenyl]-3,6-dimethyl-1,3-benzothiazol-3-ium × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；25% v/v PEG4000, 0.1 M sodium chloride, 5 mM thioflavin, 0.1 M HEPES sodium, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.80 Å
R-free 0.206
|
|
4RA3
Crystal structure of dimeric S33C beta-2 microglobulin mutant in complex with Thioflavin (ThT) at 2.8 Angstrom resolution
Deposited 2014-09-09
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
Chain D
21–119（99 aa）
Fragment：UNP residues 21-119
|
Mutation：S33C
Mutation：S33C
|
TFX 2-[4-(dimethylamino)phenyl]-3,6-dimethyl-1,3-benzothiazol-3-ium × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；25% v/v PEG4000, 0.1 M sodium chloride, 5 mM thioflavin, 0.1 M HEPES sodium, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.80 Å
R-free 0.206
|
|
4RAH
Crystal structure of dimeric S33C beta-2 microglobulin mutant at 1.4 Angstrom resolution
Deposited 2014-09-10
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
21–119（99 aa）
Fragment：UNP residues 21-119
|
Mutation：S33C
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；28% v/v PEG400, 0.2 M calcium chloride dihydrate, 0.1 M HEPES sodium, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.40 Å
R-free 0.209
|
|
4RMQ
Crystal structure of the D59N Beta-2 Microglobulin mutant
Deposited 2014-10-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
21–119（99 aa）
Fragment：UNP residues 21-119
|
Mutation：D59N
|
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5；293 K；27% PEG4000, 15% glycerol, 0.2 M ammonium acetate, 0.1 M sodium acetate, pH 5.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.46 Å
R-free 0.193
|
|
4RMR
Crystal structure of the D38N Beta-2 Microglobulin mutant
Deposited 2014-10-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
21–119（99 aa）
Fragment：UNP residues 21-119
|
Mutation：D38N
|
PEG DI(HYDROXYETHYL)ETHER × 1
ACT ACETATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5；293 K；21% PEG4000, 15% glycerol, 0.2 M ammonium acetate, 0.1 M sodium acetate, pH 5.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.53 Å
R-free 0.248
|
|
4RMS
Crystal structure of the D53N Beta-2 Microglobulin mutant
Deposited 2014-10-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
21–119（99 aa）
Fragment：UNP residues 21-119
|
Mutation：D53N
|
PEG DI(HYDROXYETHYL)ETHER × 1
ACT ACETATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；27% PEG4000, 15% glycerol, 0.2 M ammonium acetate, 0.1 M sodium acetate, pH 5.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.70 Å
R-free 0.249
|
|
4RMT
Crystal structure of the D98N Beta-2 Microglobulin mutant
Deposited 2014-10-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
21–119（99 aa）
Fragment：UNP residues 21-119
|
Mutation：D98N
|
PGE TRIETHYLENE GLYCOL × 1
PEG DI(HYDROXYETHYL)ETHER × 1
ACT ACETATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；27% PEG4000, 15% glycerol, 0.2 M ammonium acetate, 0.1 M MES, pH 6.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.24 Å
R-free 0.199
|
|
4RMU
Crystal structure of the D76E Beta-2 Microglobulin mutant
Deposited 2014-10-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
21–119（99 aa）
Fragment：UNP residues 21-119
|
Mutation：D76E
|
PGE TRIETHYLENE GLYCOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；24% PEG4000, 15% glycerol, 0.2 M ammonium acetate, 0.1 M MES, pH 6.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.40 Å
R-free 0.192
|
|
4RMV
Crystal structure of the D76H Beta-2 Microglobulin mutant
Deposited 2014-10-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
21–119（99 aa）
Fragment：UNP residues 21-119
|
Mutation：D76H
|
ACT ACETATE ION × 1
PGE TRIETHYLENE GLYCOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；30% PEG4000, 15% glycerol, 0.2 M ammonium acetate, 0.1 M MES, pH 6.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.46 Å
R-free 0.229
|
|
4RMW
Crystal structure of the D76A Beta-2 Microglobulin mutant
Deposited 2014-10-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
21–119（99 aa）
Fragment：UNP residues 21-119
|
Mutation：D76A
|
PGE TRIETHYLENE GLYCOL × 1
ACT ACETATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；21% PEG4000, 15% glycerol, 0.2 M ammonium acetate, 0.1 M sodium acetate, pH 5.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.40 Å
R-free 0.213
|
|
4U1H
HLA class I micropolymorphisms determine peptide-HLA landscape and dictate differential HIV-1 escape through identical epitopes
Deposited 2014-07-15
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: Trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 11
GOL GLYCEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；291 K；22% PEG 4000 and 0.2 M ammonium sulphate, 0.1M sodium acetate
|
Resolution 1.59 Å
R-free 0.194
|
|
4U1I
HLA class I micropolymorphisms determine peptide-HLA landscape and dictate differential HIV-1 escape through identical epitopes
Deposited 2014-07-15
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: Trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 6
GOL GLYCEROL × 1
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；291 K；0.1 M HEPES pH 7.0, 20% PEG 4000 and 0.2 M ammonium sulphate
|
Resolution 1.92 Å
R-free 0.207
|
|
4U1J
HLA class I micropolymorphisms determine peptide-HLA landscape and dictate differential HIV-1 escape through identical epitopes
Deposited 2014-07-15
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: Trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 7
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；291 K；10% PEG 6000, 10mM magnesium chloride
|
Resolution 1.38 Å
R-free 0.196
|
|
4U1K
HLA class I micropolymorphisms determine peptide-HLA landscape and dictate differential HIV-1 escape through identical epitopes
Deposited 2014-07-15
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: Trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 3
EDO 1,2-ETHANEDIOL × 3
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；291 K；0.1 M Sodium Cacodylate, pH 6, 15% PEG 8000, 15% Glycerol
|
Resolution 2.09 Å
R-free 0.226
|
|
4U1K
HLA class I micropolymorphisms determine peptide-HLA landscape and dictate differential HIV-1 escape through identical epitopes
Deposited 2014-07-15
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: Trimeric
|
Chain E
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 5
EDO 1,2-ETHANEDIOL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；291 K；0.1 M Sodium Cacodylate, pH 6, 15% PEG 8000, 15% Glycerol
|
Resolution 2.09 Å
R-free 0.226
|
|
4U1L
HLA class I micropolymorphisms determine peptide-HLA landscape and dictate differential HIV-1 escape through identical epitopes
Deposited 2014-07-15
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: Trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 2
EDO 1,2-ETHANEDIOL × 6
SO4 SULFATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；291 K；0.1 M TRIS pH 8.0, 15% PEG 4000 and 15% glycerol
|
Resolution 2.06 Å
R-free 0.209
|
|
4U1L
HLA class I micropolymorphisms determine peptide-HLA landscape and dictate differential HIV-1 escape through identical epitopes
Deposited 2014-07-15
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: Trimeric
|
Chain E
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 1
EDO 1,2-ETHANEDIOL × 12
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；291 K；0.1 M TRIS pH 8.0, 15% PEG 4000 and 15% glycerol
|
Resolution 2.06 Å
R-free 0.209
|
|
4U1M
HLA class I micropolymorphisms determine peptide-HLA landscape and dictate differential HIV-1 escape through identical epitopes
Deposited 2014-07-15
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：Beta 2 Microglobulin
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 26
GOL GLYCEROL × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；291 K；10% PEG 6000, 10mM magnesium chloride
|
Resolution 1.18 Å
R-free 0.180
|
|
4U1N
HLA class I micropolymorphisms determine peptide-HLA landscape and dictate differential HIV-1 escape through identical epitopes
Deposited 2014-07-15
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: TRIMERIC
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 12
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；291 K；10% PEG 6000, 10mM magnesium chloride
|
Resolution 1.77 Å
R-free 0.199
|
|
4U1S
HLA class I micropolymorphisms determine peptide-HLA landscape and dictate differential HIV-1 escape through identical epitopes
Deposited 2014-07-16
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: Trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 12
SO4 SULFATE ION × 1
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；291 K；0.2 M Lithium Chloride, pH 8, 20% PEG 6000
|
Resolution 1.76 Å
R-free 0.207
|
|
4U6X
Crystal Structure of HLA-A*0201 in complex with ALQDA, a 15 mer self-peptide
Deposited 2014-07-30
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
CL CHLORIDE ION × 4
PEG DI(HYDROXYETHYL)ETHER × 3
MG MAGNESIUM ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；pH 7.5；277 K；18-22.5% PEG 3350, Hepes pH 7.5, 0.1M MgCl2
|
Resolution 1.68 Å
R-free 0.202
|
|
4U6Y
Crystal Structure of HLA-A*0201 in complex with FLNDK, a 15 mer self-peptide
Deposited 2014-07-30
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
PEG DI(HYDROXYETHYL)ETHER × 2
CL CHLORIDE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；pH 7.5；277 K；18-225 PEG 3350, Hepes pH 7.5, 0.1M MgCl2
|
Resolution 1.47 Å
R-free 0.189
|
|
4UQ2
Crystal structure of HLA-A1101 in complex with an azobenzene- containing peptide
Deposited 2014-06-19
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
21–119（99 aa）
Fragment：RESIDUES 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
0.2 M AMMONIUM SULFATE, 15% W/V PEG4000, 0.1M TRI-SODIUM CITRATE PH5.6
|
Resolution 2.43 Å
R-free 0.251
|
|
4UQ2
Crystal structure of HLA-A1101 in complex with an azobenzene- containing peptide
Deposited 2014-06-19
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：RESIDUES 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
0.2 M AMMONIUM SULFATE, 15% W/V PEG4000, 0.1M TRI-SODIUM CITRATE PH5.6
|
Resolution 2.43 Å
R-free 0.251
|
|
4UQ3
Crystal structure of HLA-A0201 in complex with an azobenzene- containing peptide
Deposited 2014-06-19
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
IPA ISOPROPYL ALCOHOL × 4
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.10 Å
R-free 0.221
|
|
4UQ3
Crystal structure of HLA-A0201 in complex with an azobenzene- containing peptide
Deposited 2014-06-19
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
IPA ISOPROPYL ALCOHOL × 4
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.10 Å
R-free 0.221
|
|
4WDI
Weak TCR binding to an unstable insulin epitope drives type 1 diabetes
Deposited 2014-09-08
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：Human beta2-microglobulin, residues 21-219
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 1
SO4 SULFATE ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；291 K；20% PEG 3350, 0.2 M Sodium malonate, and 0.1 M Bis-Tris Propane, pH 6.5
|
Resolution 2.31 Å
R-free 0.283
|
|
4WDI
Weak TCR binding to an unstable insulin epitope drives type 1 diabetes
Deposited 2014-09-08
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
Fragment：Human beta2-microglobulin, residues 21-219
|
Not recorded
|
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；291 K；20% PEG 3350, 0.2 M Sodium malonate, and 0.1 M Bis-Tris Propane, pH 6.5
|
Resolution 2.31 Å
R-free 0.283
|
|
4WJ5
Structure of HLA-A2 in complex with an altered peptide ligands based on Mart-1 variant epitope
Deposited 2014-09-29
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Mutation：Methionine residue is introduced as start codon
|
GOL GLYCEROL × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；295 K；Good diffracting crystals were obtained by streak seeding
|
Resolution 1.65 Å
R-free 0.179
|
|
4WJ5
Structure of HLA-A2 in complex with an altered peptide ligands based on Mart-1 variant epitope
Deposited 2014-09-29
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
Fragment：UNP residues 21-119
|
Mutation：Methionine residue is introduced as start codon
|
GOL GLYCEROL × 9
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；295 K；Good diffracting crystals were obtained by streak seeding
|
Resolution 1.65 Å
R-free 0.179
|
|
4WO4
The molecular bases of Delta/Alpha beta T cell-mediated antigen recognition.
Deposited 2014-10-15
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
JLS (15Z)-N-[(2S,3S,4R)-1-(alpha-D-galactopyranosyloxy)-3,4-dihydroxyoctadecan-2-yl]tetracos-15-enamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.1；293 K；27% PEG1500
0.1M Sodium Malonate-imidazole-borate (2:3:3 molar ratio)
3% PEG3350
|
Resolution 2.50 Å
R-free 0.237
|
|
4WU5
HLA-A24 in complex with HIV-1 Nef134-8(wt)
Deposited 2014-10-31
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；20% PEG 3350, 200 mM sodium nitrate
|
Resolution 2.40 Å
R-free 0.271
|
|
4WU5
HLA-A24 in complex with HIV-1 Nef134-8(wt)
Deposited 2014-10-31
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；20% PEG 3350, 200 mM sodium nitrate
|
Resolution 2.40 Å
R-free 0.271
|
|
4WU7
HLA-A24 in complex with HIV-1 Nef134-8(2F)
Deposited 2014-10-31
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；200mM sodium nitrate, 20%PEG3350
|
Resolution 2.30 Å
R-free 0.287
|
|
4WU7
HLA-A24 in complex with HIV-1 Nef134-8(2F)
Deposited 2014-10-31
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；200mM sodium nitrate, 20%PEG3350
|
Resolution 2.30 Å
R-free 0.287
|
|
4WUU
Structure of ESK1 in complex with HLA-A*0201/WT1
Deposited 2014-11-03
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.25；291 K；0.1 M Bis-Tris HCl pH 5.5, 25 percent PEG 3350
|
Resolution 3.05 Å
R-free 0.254
|
|
4WW2
Crystal structure of human TCR Alpha Chain-TRAV21-TRAJ8, Beta Chain-TRBV7-8, Antigen-presenting glycoprotein CD1d, and Beta-2-microglobulin
Deposited 2014-11-10
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain F
21–119（99 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2
JLS (15Z)-N-[(2S,3S,4R)-1-(alpha-D-galactopyranosyloxy)-3,4-dihydroxyoctadecan-2-yl]tetracos-15-enamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；293 K；9-10% PEG 6K
0.1M MES 6.0
4% Ethylene Glycol
|
Resolution 2.48 Å
R-free 0.244
|
|
4WWK
Crystal structure of human TCR Alpha Chain-TRAV12-3, Beta Chain-TRBV6-5, Antigen-presenting molecule CD1d, and Beta-2-microglobulin
Deposited 2014-11-11
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain D
1–119（119 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2
JLS (15Z)-N-[(2S,3S,4R)-1-(alpha-D-galactopyranosyloxy)-3,4-dihydroxyoctadecan-2-yl]tetracos-15-enamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 9.5；293 K；18% PEG8000
0.1M CHES 9.5
|
Resolution 3.10 Å
R-free 0.256
|
|
4X6C
CD1a ternary complex with lysophosphatidylcholine and BK6 TCR
Deposited 2014-12-08
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2
42H (4R,7R,18Z)-4,7-dihydroxy-N,N,N-trimethyl-10-oxo-3,5,9-trioxa-4-phosphaheptacos-18-en-1-aminium 4-oxide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；sodium citrate, bis-tris propane, PEG 3350
|
Resolution 2.80 Å
R-free 0.236
|
|
4X6C
CD1a ternary complex with lysophosphatidylcholine and BK6 TCR
Deposited 2014-12-08
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain D
21–119（99 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
42H (4R,7R,18Z)-4,7-dihydroxy-N,N,N-trimethyl-10-oxo-3,5,9-trioxa-4-phosphaheptacos-18-en-1-aminium 4-oxide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；sodium citrate, bis-tris propane, PEG 3350
|
Resolution 2.80 Å
R-free 0.236
|
|
4X6D
CD1a ternary complex with endogenous lipids and BK6 TCR
Deposited 2014-12-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
OLA OLEIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；sodium citrate, bis-tris propane, PEG 3350
|
Resolution 2.98 Å
R-free 0.229
|
|
4X6D
CD1a ternary complex with endogenous lipids and BK6 TCR
Deposited 2014-12-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Other combination
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain D
21–119（99 aa）
|
Not recorded
|
PAM PALMITOLEIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；sodium citrate, bis-tris propane, PEG 3350
|
Resolution 2.98 Å
R-free 0.229
|
|
4X6E
CD1a binary complex with lysophosphatidylcholine
Deposited 2014-12-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
MLT D-MALATE × 1
42H (4R,7R,18Z)-4,7-dihydroxy-N,N,N-trimethyl-10-oxo-3,5,9-trioxa-4-phosphaheptacos-18-en-1-aminium 4-oxide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；20 mM DL-malic acid, 40 mM MES, 40 mM tris, PEG 1500
|
Resolution 2.10 Å
R-free 0.234
|
|
4X6F
CD1a binary complex with sphingomyelin
Deposited 2014-12-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
3XU (4S,7S,23Z)-4-hydroxy-7-[(1S,2Z)-1-hydroxyhexadec-2-en-1-yl]-N,N,N-trimethyl-9-oxo-3,5-dioxa-8-aza-4-phosphadotriacont- 23-en-1-aminium 4-oxide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；20 mM DL-malic acid, 40 mM MES, 40 mM tris, PEG 1500
|
Resolution 1.91 Å
R-free 0.224
|
|
4XXC
HLA-B*1801 in complex with a self-peptide, DELEIKAY
Deposited 2015-01-30
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain C
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
ACT ACETATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；pH 5.6；273 K；14-20% PEG 4K, 0.2 M NH4Ac
|
Resolution 1.43 Å
R-free 0.235
|
|
4Z76
Weak TCR binding to an unstable insulin epitope drives type 1 diabetes
Deposited 2015-04-06
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 5
GOL GLYCEROL × 2
SO4 SULFATE ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 8；291 K；G9V crystals were grown in 20% PEG 6000, 0.2 M calcium chloride, 0.1 M Tris propane pH 8.0
|
Resolution 1.88 Å
R-free 0.230
|
|
4Z76
Weak TCR binding to an unstable insulin epitope drives type 1 diabetes
Deposited 2015-04-06
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 1
GOL GLYCEROL × 1
SO4 SULFATE ION × 11
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 8；291 K；G9V crystals were grown in 20% PEG 6000, 0.2 M calcium chloride, 0.1 M Tris propane pH 8.0
|
Resolution 1.88 Å
R-free 0.230
|
|
4Z77
Weak TCR binding to an unstable insulin epitope drives type 1 diabetes
Deposited 2015-04-06
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 4
15P POLYETHYLENE GLYCOL (N=34) × 1
EDO 1,2-ETHANEDIOL × 7
SO4 SULFATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；291 K；20% PEG 6000, 0.2 M calcium chloride, 0.1 M Tris propane pH 8.0
|
Resolution 1.85 Å
R-free 0.253
|
|
4Z77
Weak TCR binding to an unstable insulin epitope drives type 1 diabetes
Deposited 2015-04-06
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 3
15P POLYETHYLENE GLYCOL (N=34) × 2
EDO 1,2-ETHANEDIOL × 5
SO4 SULFATE ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；291 K；20% PEG 6000, 0.2 M calcium chloride, 0.1 M Tris propane pH 8.0
|
Resolution 1.85 Å
R-free 0.253
|
|
4Z78
Weak TCR binding to an unstable insulin epitope drives type 1 diabetes
Deposited 2015-04-06
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 3
GOL GLYCEROL × 2
SO4 SULFATE ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；291 K；4% PEG 4000, 0.1 M sodium acetate pH 4.6
|
Resolution 2.30 Å
R-free 0.233
|
|
4Z78
Weak TCR binding to an unstable insulin epitope drives type 1 diabetes
Deposited 2015-04-06
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 1
GOL GLYCEROL × 2
SO4 SULFATE ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；291 K；4% PEG 4000, 0.1 M sodium acetate pH 4.6
|
Resolution 2.30 Å
R-free 0.233
|
|
4Z78
Weak TCR binding to an unstable insulin epitope drives type 1 diabetes
Deposited 2015-04-06
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain H
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 1
GOL GLYCEROL × 2
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；291 K；4% PEG 4000, 0.1 M sodium acetate pH 4.6
|
Resolution 2.30 Å
R-free 0.233
|
|
5B38
KIR3DL1*005 in complex with HLA-B*57:01
Deposited 2016-02-12
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；294 K；14 to 18% PEG 3350, 2% tacsimate pH 5.0, 0.1 M tri-sodium citrate pH 5.6
|
Resolution 2.30 Å
R-free 0.251
|
|
5B39
KIR3DL1*015 in complex with HLA-B*57:01
Deposited 2016-02-12
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；294 K；14 to 18% PEG 3350, 2% tacsimate pH 5.0, 0.1 M tri-sodium citrate pH 5.6
|
Resolution 2.50 Å
R-free 0.229
|
|
5BJT
Crystal structure of human FcRn with a peptide inhibitor at multiple sites
Deposited 2016-10-23
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.7；277 K；1.6 M ammonium sulfate, 20% glycerol, 0.8 M sodium acetate
|
Resolution 3.20 Å
R-free 0.339
|
|
5BJT
Crystal structure of human FcRn with a peptide inhibitor at multiple sites
Deposited 2016-10-23
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain D
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.7；277 K；1.6 M ammonium sulfate, 20% glycerol, 0.8 M sodium acetate
|
Resolution 3.20 Å
R-free 0.339
|
|
5BJT
Crystal structure of human FcRn with a peptide inhibitor at multiple sites
Deposited 2016-10-23
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain F
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.7；277 K；1.6 M ammonium sulfate, 20% glycerol, 0.8 M sodium acetate
|
Resolution 3.20 Å
R-free 0.339
|
|
5BJT
Crystal structure of human FcRn with a peptide inhibitor at multiple sites
Deposited 2016-10-23
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain H
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.7；277 K；1.6 M ammonium sulfate, 20% glycerol, 0.8 M sodium acetate
|
Resolution 3.20 Å
R-free 0.339
|
|
5BRZ
MAGE-A3 reactive TCR in complex with MAGE-A3 in HLA-A1
Deposited 2015-06-01
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 7
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.2M ammonium chloride, 0.1M HEPES pH7, 15% PEG 8000
|
Resolution 2.62 Å
R-free 0.268
|
|
5BS0
MAGE-A3 Reactive TCR in complex with Titin Epitope in HLA-A1
Deposited 2015-06-01
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 1
SO4 SULFATE ION × 11
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；291 K；0.2M Ammonium Chloride, 0.1M MES, 20% PEG 4000
|
Resolution 2.40 Å
R-free 0.262
|
|
5BXF
Apo FcRn Structure at pH 4.5
Deposited 2015-06-08
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
1–119（119 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；.1M sodium citrate pH 4.5, 20% PEG (4000)
|
Resolution 2.85 Å
R-free 0.314
|
|
5BXF
Apo FcRn Structure at pH 4.5
Deposited 2015-06-08
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain D
1–119（119 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；.1M sodium citrate pH 4.5, 20% PEG (4000)
|
Resolution 2.85 Å
R-free 0.314
|
|
5C07
1E6 TCR in complex with HLA-A02 carrying YQFGPDFPIA
Deposited 2015-06-12
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
SO4 SULFATE ION × 3
EDO 1,2-ETHANEDIOL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.2M sodium cholride, 0.1M HEPES pH7, 20% PEG 3350
|
Resolution 2.11 Å
R-free 0.237
|
|
5C07
1E6 TCR in complex with HLA-A02 carrying YQFGPDFPIA
Deposited 2015-06-12
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
SO4 SULFATE ION × 3
EDO 1,2-ETHANEDIOL × 6
GOL GLYCEROL × 7
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.2M sodium cholride, 0.1M HEPES pH7, 20% PEG 3350
|
Resolution 2.11 Å
R-free 0.237
|
|
5C08
1E6 TCR in Complex with HLA-A0e carrying RQWGPDPAAV
Deposited 2015-06-12
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 12
GOL GLYCEROL × 3
SO4 SULFATE ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.2M sodium cholride, 0.1M MES pH6, 20% PEG 6000
|
Resolution 2.33 Å
R-free 0.272
|
|
5C08
1E6 TCR in Complex with HLA-A0e carrying RQWGPDPAAV
Deposited 2015-06-12
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 13
SO4 SULFATE ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.2M sodium cholride, 0.1M MES pH6, 20% PEG 6000
|
Resolution 2.33 Å
R-free 0.272
|
|
5C09
HLA class I histocompatibility antigen
Deposited 2015-06-12
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
SO4 SULFATE ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.1M sodium cacodylate pH6.5, 15% PEG 4000, 0.2M sodium acetate
|
Resolution 2.48 Å
R-free 0.259
|
|
5C09
HLA class I histocompatibility antigen
Deposited 2015-06-12
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
SO4 SULFATE ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.1M sodium cacodylate pH6.5, 15% PEG 4000, 0.2M sodium acetate
|
Resolution 2.48 Å
R-free 0.259
|
|
5C0A
1E6 TCR in complex with HLA-A02 carrying MVW peptide
Deposited 2015-06-12
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 5
SO4 SULFATE ION × 5
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.1M HEPES pH7.5, 15% PEG 4000, 0.2M sodium acetate
|
Resolution 2.46 Å
R-free 0.232
|
|
5C0A
1E6 TCR in complex with HLA-A02 carrying MVW peptide
Deposited 2015-06-12
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 8
SO4 SULFATE ION × 3
GOL GLYCEROL × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.1M HEPES pH7.5, 15% PEG 4000, 0.2M sodium acetate
|
Resolution 2.46 Å
R-free 0.232
|
|
5C0B
1E6 TCR in complex with HLA-A02 carrying RQFGPDFPTI
Deposited 2015-06-12
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 30
GOL GLYCEROL × 3
SO4 SULFATE ION × 5
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.1M HEPES, pH 7.5, 15% PEG 4000, 0.2M sodium acetate
|
Resolution 2.03 Å
R-free 0.231
|
|
5C0B
1E6 TCR in complex with HLA-A02 carrying RQFGPDFPTI
Deposited 2015-06-12
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 25
GOL GLYCEROL × 3
SO4 SULFATE ION × 3
PG4 TETRAETHYLENE GLYCOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.1M HEPES, pH 7.5, 15% PEG 4000, 0.2M sodium acetate
|
Resolution 2.03 Å
R-free 0.231
|
|
5C0C
1E6 TCR in complex with HLA-A02 carrying RQFGPDWIVA
Deposited 2015-06-12
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 15
PG4 TETRAETHYLENE GLYCOL × 2
SO4 SULFATE ION × 4
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.1M HEPES pH7, 15% PEG 4000, 0.2M sodium acetate
|
Resolution 1.97 Å
R-free 0.227
|
|
5C0C
1E6 TCR in complex with HLA-A02 carrying RQFGPDWIVA
Deposited 2015-06-12
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 18
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.1M HEPES pH7, 15% PEG 4000, 0.2M sodium acetate
|
Resolution 1.97 Å
R-free 0.227
|
|
5C0D
HLA-A02 carrying AQWGPDPAAA
Deposited 2015-06-12
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.2M sodium malonate, 0.1M BIS TRIS propane, pH 6.5, 20% PEG3350
|
Resolution 1.68 Å
R-free 0.214
|
|
5C0E
HLA-A02 carrying YLGGPDFPTI
Deposited 2015-06-12
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：RESIDUES 21-119
|
Not recorded
|
BR BROMIDE ION × 1
EDO 1,2-ETHANEDIOL × 17
GOL GLYCEROL × 4
PG4 TETRAETHYLENE GLYCOL × 11
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.1M TRIS pH8, 25% PEG 4000, 15% glycerol
|
Resolution 1.49 Å
R-free 0.179
|
|
5C0F
HLA-A02 carrying RQWGPDPAAV
Deposited 2015-06-12
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：residues 21-119
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 18
GOL GLYCEROL × 1
MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1
SO4 SULFATE ION × 4
ACY ACETIC ACID × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.1M TRIS, pH 8, 20% PEG 8000, 15% glycerol
|
Resolution 1.46 Å
R-free 0.181
|
|
5C0G
HLA-A02 carrying YLGGPDFPTI
Deposited 2015-06-12
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：residues 21-119
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 14
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.2M sodium nitrate, 0.1M BIS TRIS propane pH6.5, 20% PEG 3350
|
Resolution 1.37 Å
R-free 0.188
|
|
5C0I
HAL-A02 carrying RQFGPDFPTI
Deposited 2015-06-12
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：residues 21-119
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 10
GOL GLYCEROL × 4
SO4 SULFATE ION × 2
CA CALCIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.2M potassium/sodium tartrate, 0.1M BIS TRIS propane, pH 8.5, 20% PEG 3350
|
Resolution 1.53 Å
R-free 0.191
|
|
5C0J
HLA-A02 carrying RQFGPDWIVA
Deposited 2015-06-12
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：residues 21-119
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 11
SO4 SULFATE ION × 2
CA CALCIUM ION × 1
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.2M sodium sulphate, 0.1M BIS TRIS propane, pH 6.5, 20% PEG 3350
|
Resolution 1.64 Å
R-free 0.214
|
|
5C9J
Human CD1c with ligands in A' and F' channel
Deposited 2015-06-27
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–118（98 aa）
|
Not recorded
|
DAO LAURIC ACID × 2
STE STEARIC ACID × 1
GOL GLYCEROL × 4
PO4 PHOSPHATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293.15 K；0.2M Magnesium chloride, 0.1M Tris pH 8, 10% PEG 8000, 1:1 protein to precipitant ratio.
|
Resolution 2.40 Å
R-free 0.200
|
|
5CFH
human beta-2 microglobulin double mutant W60G-Y63W
Deposited 2015-07-08
|
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
21–119（99 aa）
|
Mutation：W60G, Y63W
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；PEG 10000, HEPES
|
Resolution 1.49 Å
R-free 0.230
|
|
5CKA
Human beta-2 microglobulin double mutant W60G-N83V
Deposited 2015-07-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
21–119（99 aa）
Fragment：resideus 21-119
|
Mutation：W60G, N83V
|
GOL GLYCEROL × 2
ACT ACETATE ION × 2
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；0.1 M MES, 21% w/v PEG 4000, 15%
glycerol, 0.2 M ammonium acetate
|
Resolution 1.70 Å
R-free 0.226
|
|
5CKG
Human beta-2 microglobulin mutant V85E
Deposited 2015-07-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
21–119（99 aa）
Fragment：RESIDUES 21-119
|
Mutation：V85E
|
ACT ACETATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；0.1 M sodium acetate, 30% w/v PEG 4000, 15% glycerol, 0.2 M ammonium acetate
|
Resolution 1.75 Å
R-free 0.232
|
|
5CKG
Human beta-2 microglobulin mutant V85E
Deposited 2015-07-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
21–119（99 aa）
Fragment：RESIDUES 21-119
|
Mutation：V85E
|
ACT ACETATE ION × 1
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；0.1 M sodium acetate, 30% w/v PEG 4000, 15% glycerol, 0.2 M ammonium acetate
|
Resolution 1.75 Å
R-free 0.232
|
|
5CS7
The crystal structure of wt beta2-microglobulin at room temperature
Deposited 2015-07-23
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.5；293 K；30% PEG 4000, 0.1M sodium acetate, 15% glycerol, 0.2M ammonium acetate
|
Resolution 2.10 Å
R-free 0.238
|
|
5CSB
The crystal structure of beta2-microglobulin D76N mutant at room temperature
Deposited 2015-07-23
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
21–119（99 aa）
Fragment：UNP residues 21-119
|
Mutation：D76N
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.5；293 K；30% PEG 4000, 0.1M sodium acetate, 15% glycerol, 0.2M ammonium acetate
|
Resolution 1.72 Å
R-free 0.223
|
|
5CSG
The crystal structure of beta2-microglobulin R97Q mutant
Deposited 2015-07-23
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
21–119（99 aa）
Fragment：UNP residues 21-119
|
Mutation：R97Q
|
ACT ACETATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；27% PEG 4000, 0.1 M sodium acetate, 15% glycerol, 0.2 M ammonium acetate
|
Resolution 1.50 Å
R-free 0.225
|
|
5D2L
Crystal structure of TCR C7 in complex with HCMV NLV epitope presented by HLA-A2
Deposited 2015-08-05
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；293 K；30% PEG 400, 0.1M Tris-HCl pH 8.5, 0.2M MgCl2
|
Resolution 3.51 Å
R-free 0.355
|
|
5D2L
Crystal structure of TCR C7 in complex with HCMV NLV epitope presented by HLA-A2
Deposited 2015-08-05
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain H
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；293 K；30% PEG 400, 0.1M Tris-HCl pH 8.5, 0.2M MgCl2
|
Resolution 3.51 Å
R-free 0.355
|
|
5D2L
Crystal structure of TCR C7 in complex with HCMV NLV epitope presented by HLA-A2
Deposited 2015-08-05
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain N
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；293 K；30% PEG 400, 0.1M Tris-HCl pH 8.5, 0.2M MgCl2
|
Resolution 3.51 Å
R-free 0.355
|
|
5D2L
Crystal structure of TCR C7 in complex with HCMV NLV epitope presented by HLA-A2
Deposited 2015-08-05
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain D
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；293 K；30% PEG 400, 0.1M Tris-HCl pH 8.5, 0.2M MgCl2
|
Resolution 3.51 Å
R-free 0.355
|
|
5D2N
Crystal structure of C25-NLV-HLA-A2 complex
Deposited 2015-08-05
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain L
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
IMD IMIDAZOLE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；293 K；PEG3000, Imidazole, Calcium Acetate
|
Resolution 2.10 Å
R-free 0.253
|
|
5D2N
Crystal structure of C25-NLV-HLA-A2 complex
Deposited 2015-08-05
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
IMD IMIDAZOLE × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；293 K；PEG3000, Imidazole, Calcium Acetate
|
Resolution 2.10 Å
R-free 0.253
|
|
5D5M
Structure of human MR1-5-OP-RU in complex with human MAIT M33.64 TCR
Deposited 2015-08-11
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
2LJ 1-deoxy-1-({2,6-dioxo-5-[(E)-propylideneamino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-ribitol × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；294 K；BTP, PEG 3350, NaAc
|
Resolution 2.20 Å
R-free 0.222
|
|
5D5M
Structure of human MR1-5-OP-RU in complex with human MAIT M33.64 TCR
Deposited 2015-08-11
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
2LJ 1-deoxy-1-({2,6-dioxo-5-[(E)-propylideneamino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-ribitol × 1
GOL GLYCEROL × 1
ACT ACETATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；294 K；BTP, PEG 3350, NaAc
|
Resolution 2.20 Å
R-free 0.222
|
|
5D7I
Structure of human MR1-Ac-6-FP in complex with human MAIT M33.64 TCR
Deposited 2015-08-14
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
PRO PROLINE × 1
30W N-(6-formyl-4-oxo-3,4-dihydropteridin-2-yl)acetamide × 1
GOL GLYCEROL × 7
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；294 K；BTP, PEG 3350, NaAc
|
Resolution 2.00 Å
R-free 0.220
|
|
5D7I
Structure of human MR1-Ac-6-FP in complex with human MAIT M33.64 TCR
Deposited 2015-08-14
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain D
21–119（99 aa）
|
Not recorded
|
PRO PROLINE × 1
30W N-(6-formyl-4-oxo-3,4-dihydropteridin-2-yl)acetamide × 1
GOL GLYCEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；294 K；BTP, PEG 3350, NaAc
|
Resolution 2.00 Å
R-free 0.220
|
|
5D7J
Structure of human MR1-5-OP-RU in complex with human MAIT M33.64(Y95alphaF) TCR
Deposited 2015-08-14
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain F
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 1
2LJ 1-deoxy-1-({2,6-dioxo-5-[(E)-propylideneamino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-ribitol × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；294 K；BTP, PEG 3350, NaAc
|
Resolution 1.97 Å
R-free 0.222
|
|
5D7J
Structure of human MR1-5-OP-RU in complex with human MAIT M33.64(Y95alphaF) TCR
Deposited 2015-08-14
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain D
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 3
2LJ 1-deoxy-1-({2,6-dioxo-5-[(E)-propylideneamino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-ribitol × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；294 K；BTP, PEG 3350, NaAc
|
Resolution 1.97 Å
R-free 0.222
|
|
5D7L
Structure of human MR1-5-OP-RU in complex with human MAV36 TCR
Deposited 2015-08-14
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
2LJ 1-deoxy-1-({2,6-dioxo-5-[(E)-propylideneamino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-ribitol × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；294 K；BTP, PEG 3350, NaAc
|
Resolution 3.40 Å
R-free 0.337
|
|
5D7L
Structure of human MR1-5-OP-RU in complex with human MAV36 TCR
Deposited 2015-08-14
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain F
21–119（99 aa）
|
Not recorded
|
2LJ 1-deoxy-1-({2,6-dioxo-5-[(E)-propylideneamino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-ribitol × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；294 K；BTP, PEG 3350, NaAc
|
Resolution 3.40 Å
R-free 0.337
|
|
5D9S
Structure of HLA-A2:01 with the 11-mer peptide F11V
Deposited 2015-08-19
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293.15 K；30% PEG 5000 MME, 0.1M Tris-HCl pH 8.0, 0.2M lithium sulfate
|
Resolution 1.87 Å
R-free 0.223
|
|
5DDH
Structure of HLA-A2:01 with the 12-mer peptide F12K
Deposited 2015-08-24
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293.15 K；30% PEG 4000, 0.1M Tris-HCl 8.0, 0.2M lithium sulfate
|
Resolution 1.50 Å
R-free 0.218
|
|
5DEF
Crystal structure of B*27:04 complex bound to the pVIPR peptide
Deposited 2015-08-25
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 4
CL CHLORIDE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；291 K；28%(w/v) PEG 8000, 100 mM Tris-HCl pH 7.0
|
Resolution 1.60 Å
R-free 0.174
|
|
5DEG
Crystal structure of B*27:06 bound to the pVIPR peptide
Deposited 2015-08-25
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；291 K；20%(w/v) PEG 8000, 100 mM Tris-HCl pH 7.0
|
Resolution 1.83 Å
R-free 0.193
|
|
5E00
Structure of HLA-A2 P130
Deposited 2015-09-26
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；291 K；0.1mol/liter bis-Tris (pH 6.5), 20% (wt/vol) polyethylene glycol 3350
|
Resolution 1.70 Å
R-free 0.205
|
|
5E6I
Crystal structure of TCR PF8 in complex with flu MP(58-66) epitope presented by HLA-A2
Deposited 2015-10-09
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain J
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；293 K；0.1M immidazole pH8, 0.2M calcium acetate, 10%(v/v) PEG8000
|
Resolution 4.00 Å
R-free 0.338
|
|
5E6I
Crystal structure of TCR PF8 in complex with flu MP(58-66) epitope presented by HLA-A2
Deposited 2015-10-09
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain D
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；293 K；0.1M immidazole pH8, 0.2M calcium acetate, 10%(v/v) PEG8000
|
Resolution 4.00 Å
R-free 0.338
|
|
5E6I
Crystal structure of TCR PF8 in complex with flu MP(58-66) epitope presented by HLA-A2
Deposited 2015-10-09
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain N
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；293 K；0.1M immidazole pH8, 0.2M calcium acetate, 10%(v/v) PEG8000
|
Resolution 4.00 Å
R-free 0.338
|
|
5E6I
Crystal structure of TCR PF8 in complex with flu MP(58-66) epitope presented by HLA-A2
Deposited 2015-10-09
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain U
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；293 K；0.1M immidazole pH8, 0.2M calcium acetate, 10%(v/v) PEG8000
|
Resolution 4.00 Å
R-free 0.338
|
|
5E9D
RD-1 Mart-1 High bound to Mart-1 decameric peptide (ELA) in complex with HLA-A2
Deposited 2015-10-15
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；300 K；PEG 4000, 0.002 M Zinc Acetate, 5% 2- propanol.
|
Resolution 2.51 Å
R-free 0.232
|
|
5E9D
RD-1 Mart-1 High bound to Mart-1 decameric peptide (ELA) in complex with HLA-A2
Deposited 2015-10-15
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；300 K；PEG 4000, 0.002 M Zinc Acetate, 5% 2- propanol.
|
Resolution 2.51 Å
R-free 0.232
|
|
5ENW
Structure of HLA-A2:01 with peptide G9L
Deposited 2015-11-09
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293.15 K；30% PEG 4000, 0.1M Tris-HCl pH 8.0, 0.2M lithium sulfate
|
Resolution 1.85 Å
R-free 0.244
|
|
5EO0
Crystal Structure of HLA-B0702-RFL9
Deposited 2015-11-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；298 K；18% PEG 4000 and 0.1 M Ammonium acetate, 0.1 M Na-cacodylate
|
Resolution 1.70 Å
R-free 0.212
|
|
5EO1
Crystal Structure of HLA-B0702-RL9
Deposited 2015-11-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG4K, Ammonium acetate, Na-cacodylate
|
Resolution 1.85 Å
R-free 0.259
|
|
5EOT
Structure of HLA-A2:01 with peptide G13E
Deposited 2015-11-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293.15 K；30% PEG 5000 MME, 0.1M Tris-HCl pH 8.0, 0.2M lithium sulfate
|
Resolution 2.10 Å
R-free 0.237
|
|
5EU3
HLA Class I antigen
Deposited 2015-11-18
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 1
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；294 K；0.1 M Hepes pH 7.5, 0.2 M Ammonium Sulphate, 25 % PEG 4000
|
Resolution 1.97 Å
R-free 0.255
|
|
5EU4
HLA Class I antigen
Deposited 2015-11-18
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 1
EDO 1,2-ETHANEDIOL × 4
SO4 SULFATE ION × 5
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；294 K；0.1 M Tris pH 8.0, 15 % Glycerol, 20 % PEG 4000
|
Resolution 2.12 Å
R-free 0.211
|
|
5EU4
HLA Class I antigen
Deposited 2015-11-18
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 2
SO4 SULFATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；294 K；0.1 M Tris pH 8.0, 15 % Glycerol, 20 % PEG 4000
|
Resolution 2.12 Å
R-free 0.211
|
|
5EU5
HLA Class I antigen
Deposited 2015-11-18
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 18
GOL GLYCEROL × 10
SO4 SULFATE ION × 8
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；294 K；0.1 M Hepes pH 7.5, 0.2 M Ammonium Sulphate, 25 % PEG 4000
|
Resolution 1.54 Å
R-free 0.201
|
|
5EU6
HLA Class I antigen
Deposited 2015-11-18
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 10
GOL GLYCEROL × 3
SO4 SULFATE ION × 8
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；294 K；0.2 M sodium sulphate, 0.1 M Bis Tris propane pH 6.5, 20% w/v PEG 3350.
|
Resolution 2.02 Å
R-free 0.222
|
|
5EUO
PF6-M1-HLA-A2
Deposited 2015-11-18
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；PEG3350, Imidazole
|
Resolution 2.10 Å
R-free 0.281
|
|
5EUO
PF6-M1-HLA-A2
Deposited 2015-11-18
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain D
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
IMD IMIDAZOLE × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；PEG3350, Imidazole
|
Resolution 2.10 Å
R-free 0.281
|
|
5F7D
Structure of HLA-A2:01 with peptide G11N
Deposited 2015-12-07
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293.15 K；30% PEG 4000, 0.1M Tris-HCl pH 8.0, 0.2M lithium sulfate
|
Resolution 2.30 Å
R-free 0.257
|
|
5F9J
Structure of HLA-A2:01 with peptide Y9L
Deposited 2015-12-09
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–118（98 aa）
|
Not recorded
|
GOL GLYCEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293.15 K；30% PEG 4000, 0.1M Tris-HCl pH 8.0, 0.2M lithium sulfate
|
Resolution 2.51 Å
R-free 0.276
|
|
5FA3
Structure of HLA-A2:01 with peptide G9V
Deposited 2015-12-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293.15 K；30% PEG 4000, 0.1M Tris-HCl pH 8.0, 0.2 M lithium sulfate
|
Resolution 1.86 Å
R-free 0.235
|
|
5FA4
Structure of HLA-A2:01 with peptide Y16R
Deposited 2015-12-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 2
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293.15 K；30% PEG 4000, 0.1M Tris-HCl pH 8.0, 0.1M lithium sulfate
|
Resolution 2.40 Å
R-free 0.259
|
|
5FDW
Structure of HLA-A2:01 with peptide Y10L
Deposited 2015-12-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293.15 K；30% PEG 4000, 0.1M Tris-HCl pH 8.0, 0.2M lithium sulfate
|
Resolution 2.70 Å
R-free 0.285
|
|
5GR7
Mouse MHC class I H-2Kd with a MERS-CoV-derived peptide 37-1
Deposited 2016-08-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；291 K；0.1M Sodium citrate tribasic dihydrate pH 5.5, 16% w/v Polyethylene glycol 8000
|
Resolution 2.40 Å
R-free 0.257
|
|
5GRD
Crystal structure of 10-mer peptide from EBV in complex with HLA-A1101.
Deposited 2016-08-10
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.6；290 K；0.2 M ammonium acetate, 0.1 M Sodium acetate trihydrate, 30% PEG4000
|
Resolution 1.80 Å
R-free 0.226
|
|
5GRG
Crystal structure of dual peptide from EBV in complex with HLA-A*11:01
Deposited 2016-08-11
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；290 K；0.1 M Ammonium acetate, 0.1 M Bis-Tris, 22% PEG 4000
|
Resolution 1.94 Å
R-free 0.243
|
|
5GSB
Mouse MHC class I H-2Kd with a MERS-CoV-derived peptide 37-3
Deposited 2016-08-15
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；291 K；0.1M Sodium citrate tribasic dihydrate pH 5.5 , 16% w v Polyethylene glycol 8000
|
Resolution 1.80 Å
R-free 0.222
|
|
5GSD
Crystal structure of LMP2 peptide from EBV in complex with HLA-A*11:01
Deposited 2016-08-15
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 5
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；290 K；0.2 M Ammonium acetate, 20% PEG4000
|
Resolution 2.30 Å
R-free 0.273
|
|
5GSR
Mouse MHC class I H-2Kd with a MERS-CoV-derived peptide I5A
Deposited 2016-08-17
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
20–119（100 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.2 M Magnesium chloride hexahydrate, 0.1 M Sodium HEPES 7.5, 30 % v/v 2-Propanol
|
Resolution 2.20 Å
R-free 0.231
|
|
5GSR
Mouse MHC class I H-2Kd with a MERS-CoV-derived peptide I5A
Deposited 2016-08-17
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
20–119（100 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.2 M Magnesium chloride hexahydrate, 0.1 M Sodium HEPES 7.5, 30 % v/v 2-Propanol
|
Resolution 2.20 Å
R-free 0.231
|
|
5GSV
Mouse MHC class I H-2Kd with a MERS-CoV-derived peptide 142-5
Deposited 2016-08-17
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5；291 K；0.1M Sodium citrate tribasic dihydrate pH 5.0, 10% w/v Polyethylene glycol 6000
|
Resolution 2.00 Å
R-free 0.252
|
|
5GSX
Mouse MHC class I H-2Kd with a MERS-CoV-derived peptide 142-2
Deposited 2016-08-17
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5；291 K；0.1M Sodium citrate tribasic dihydrate pH 5.0, 10% w/v Polyethylene glycol 6000
|
Resolution 2.50 Å
R-free 0.242
|
|
5GSX
Mouse MHC class I H-2Kd with a MERS-CoV-derived peptide 142-2
Deposited 2016-08-17
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5；291 K；0.1M Sodium citrate tribasic dihydrate pH 5.0, 10% w/v Polyethylene glycol 6000
|
Resolution 2.50 Å
R-free 0.242
|
|
5HGA
HLA*A2402 complex with HIV nef138 Y2F-8mer mutant epitope
Deposited 2016-01-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；pH 6.5；291 K；0.1M MES monohydrate pH 6.5, 12% w/v Polyethylene glycol 20000
|
Resolution 2.20 Å
R-free 0.250
|
|
5HGA
HLA*A2402 complex with HIV nef138 Y2F-8mer mutant epitope
Deposited 2016-01-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；pH 6.5；291 K；0.1M MES monohydrate pH 6.5, 12% w/v Polyethylene glycol 20000
|
Resolution 2.20 Å
R-free 0.250
|
|
5HGB
HLA*A2402 complexed with HIV nef138 8mer epitope
Deposited 2016-01-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；291 K；0.1 M MES monohydrate pH 6.5, 12% w/v Polyethylene glycol 20000
|
Resolution 2.40 Å
R-free 0.218
|
|
5HGB
HLA*A2402 complexed with HIV nef138 8mer epitope
Deposited 2016-01-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；291 K；0.1 M MES monohydrate pH 6.5, 12% w/v Polyethylene glycol 20000
|
Resolution 2.40 Å
R-free 0.218
|
|
5HGB
HLA*A2402 complexed with HIV nef138 8mer epitope
Deposited 2016-01-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain H
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；291 K；0.1 M MES monohydrate pH 6.5, 12% w/v Polyethylene glycol 20000
|
Resolution 2.40 Å
R-free 0.218
|
|
5HGB
HLA*A2402 complexed with HIV nef138 8mer epitope
Deposited 2016-01-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain K
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；291 K；0.1 M MES monohydrate pH 6.5, 12% w/v Polyethylene glycol 20000
|
Resolution 2.40 Å
R-free 0.218
|
|
5HGD
HLA*A2402 complexed with HIV nef138 Y2F mutant 10mer epitope
Deposited 2016-01-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；291 K；0.1 M MES monohydrate pH 6.5, 12% w/v Polyethylene glycol 20000
|
Resolution 2.07 Å
R-free 0.224
|
|
5HGD
HLA*A2402 complexed with HIV nef138 Y2F mutant 10mer epitope
Deposited 2016-01-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；291 K；0.1 M MES monohydrate pH 6.5, 12% w/v Polyethylene glycol 20000
|
Resolution 2.07 Å
R-free 0.224
|
|
5HGH
HLA*A2402 complexed with HIV nef138 10mer epitope
Deposited 2016-01-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；291 K；0.1 M MES monohydrate pH 6.5, 12% w/v Polyethylene glycol 20000
|
Resolution 2.39 Å
R-free 0.222
|
|
5HHM
Crystal Structure of the JM22 TCR in complex with HLA-A*0201 in complex with M1-F5L
Deposited 2016-01-11
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；50mM Tris-HCl, 70mM NaCl, 16%PEG10K, 14% glycerol
|
Resolution 2.50 Å
R-free 0.289
|
|
5HHM
Crystal Structure of the JM22 TCR in complex with HLA-A*0201 in complex with M1-F5L
Deposited 2016-01-11
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；50mM Tris-HCl, 70mM NaCl, 16%PEG10K, 14% glycerol
|
Resolution 2.50 Å
R-free 0.289
|
|
5HHN
Crystal Structure of HLA-A*0201 in complex with M1-F5L
Deposited 2016-01-11
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；18-22% PEG 3350, Na citrate pH 6.5, 0.1M MgCl2
|
Resolution 2.03 Å
R-free 0.215
|
|
5HHO
Crystal Structure of the JM22 TCR in complex with HLA-A*0201 in complex with M1-G4E
Deposited 2016-01-11
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；50mM Tris-HCl, 70mM NaCl, 16%PEG10K, 14% glycerol
|
Resolution 2.95 Å
R-free 0.279
|
|
5HHP
Crystal Structure of HLA-A*0201 in complex with M1-G4E
Deposited 2016-01-11
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；18-22% PEG 3350, Na citrate pH 6.5, 0.1M MgCl2
|
Resolution 1.90 Å
R-free 0.209
|
|
5HHQ
Crystal Structure of HLA-A*0201 in complex with M1-L3W
Deposited 2016-01-11
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；18-22% PEG 3350, Na citrate pH 6.5, 0.1M MgCl2
|
Resolution 2.10 Å
R-free 0.227
|
|
5HYJ
1E6 TCR in Complex with HLA-A02 carrying AQWGPDPAAA
Deposited 2016-02-01
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；291 K；0.2M sodium citrate, 0.1M BIS TRIS propane pH6.5, 20% PEG 3350
|
Resolution 3.06 Å
R-free 0.293
|
|
5HYJ
1E6 TCR in Complex with HLA-A02 carrying AQWGPDPAAA
Deposited 2016-02-01
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；291 K；0.2M sodium citrate, 0.1M BIS TRIS propane pH6.5, 20% PEG 3350
|
Resolution 3.06 Å
R-free 0.293
|
|
5IB1
Crystal structure of HLA-B*27:05 complexed with the self-peptide pVIPR measured at 295 K
Deposited 2016-02-22
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；291 K；0.1 M Tris HCl, 16% (w/v) PEG 8000
|
Resolution 1.91 Å
R-free 0.192
|
|
5IB2
Crystal structure of HLA-B*27:05 complexed with the self-peptide pVIPR
Deposited 2016-02-22
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K
|
Resolution 1.44 Å
R-free 0.161
|
|
5IB3
Crystal structure of HLA-B*27:05 complexed with the self-peptide pVIPR and Copper
Deposited 2016-02-22
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
CU COPPER (II) ION × 2
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；291 K；0.1 M Tris HCl, 16% (w/v) PEG 8000
|
Resolution 1.91 Å
R-free 0.204
|
|
5IB4
Crystal structure of HLA-B*27:05 complexed with the self-peptide pVIPR and Nickel
Deposited 2016-02-22
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
NI NICKEL (II) ION × 2
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；291 K；0.1 M Tris HCl, 16% (w/v) PEG 8000
|
Resolution 1.95 Å
R-free 0.202
|
|
5IB5
Crystal structure of HLA-B*27:09 complexed with the self-peptide pVIPR and Copper
Deposited 2016-02-22
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
CU COPPER (II) ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；291 K；0.1 M Tris HCl, 16% (w/v) PEG 8000
|
Resolution 2.49 Å
R-free 0.272
|
|
5IB5
Crystal structure of HLA-B*27:09 complexed with the self-peptide pVIPR and Copper
Deposited 2016-02-22
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
CU COPPER (II) ION × 3
GOL GLYCEROL × 1
CL CHLORIDE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；291 K；0.1 M Tris HCl, 16% (w/v) PEG 8000
|
Resolution 2.49 Å
R-free 0.272
|
|
5IEH
Structure of HLA-B*40:02 in complex with the phosphorylated endogenous peptide REF(p)SKEPEL
Deposited 2016-02-25
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；294 K；150 mM Tris 8.0, 20% PEG5K, 8% ethylene glycol
|
Resolution 1.50 Å
R-free 0.183
|
|
5IEK
Structure of HLA-B*40:02 in complex with the endogenous peptide REFSKEPEL
Deposited 2016-02-25
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；294 K；150 mM Tris 8.5, 23% PEG8K, 70 mM potassium thiocyanate
|
Resolution 1.80 Å
R-free 0.188
|
|
5IM7
Crystal structure of HLA-B5801, a protective HLA allele for HIV-1 infection
Deposited 2016-03-05
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；291 K；0.1M MES pH 6.5, 15% PEG4K, 20% 2-proponal
|
Resolution 2.50 Å
R-free 0.233
|
|
5IM7
Crystal structure of HLA-B5801, a protective HLA allele for HIV-1 infection
Deposited 2016-03-05
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；291 K；0.1M MES pH 6.5, 15% PEG4K, 20% 2-proponal
|
Resolution 2.50 Å
R-free 0.233
|
|
5INC
Crystal structure of HLA-B5801, a protective HLA allele for HIV-1 infection
Deposited 2016-03-07
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；291 K；291
|
Resolution 2.88 Å
R-free 0.248
|
|
5INC
Crystal structure of HLA-B5801, a protective HLA allele for HIV-1 infection
Deposited 2016-03-07
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；291 K；291
|
Resolution 2.88 Å
R-free 0.248
|
|
5IND
Crystal structure of HLA-B5801, a protective HLA allele for HIV-1 infection
Deposited 2016-03-07
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；291 K；0.1M MES pH 6.5, 15% PEG4K, 20% 2-proponal
|
Resolution 2.13 Å
R-free 0.229
|
|
5IND
Crystal structure of HLA-B5801, a protective HLA allele for HIV-1 infection
Deposited 2016-03-07
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；291 K；0.1M MES pH 6.5, 15% PEG4K, 20% 2-proponal
|
Resolution 2.13 Å
R-free 0.229
|
|
5IRO
Crystal structure of a complex between the Human adenovirus type 4 E3-19K protein and MHC class molecule HLA-A2/TAX
Deposited 2016-03-14
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain C
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；pH 6.5；291 K；1.5M (NH4)2SO4,0.1M Bis-Tris pH6.5, 0.1MNaCI
|
Resolution 2.64 Å
R-free 0.288
|
|
5IRO
Crystal structure of a complex between the Human adenovirus type 4 E3-19K protein and MHC class molecule HLA-A2/TAX
Deposited 2016-03-14
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain G
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；pH 6.5；291 K；1.5M (NH4)2SO4,0.1M Bis-Tris pH6.5, 0.1MNaCI
|
Resolution 2.64 Å
R-free 0.288
|
|
5IRO
Crystal structure of a complex between the Human adenovirus type 4 E3-19K protein and MHC class molecule HLA-A2/TAX
Deposited 2016-03-14
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain K
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；pH 6.5；291 K；1.5M (NH4)2SO4,0.1M Bis-Tris pH6.5, 0.1MNaCI
|
Resolution 2.64 Å
R-free 0.288
|
|
5IRO
Crystal structure of a complex between the Human adenovirus type 4 E3-19K protein and MHC class molecule HLA-A2/TAX
Deposited 2016-03-14
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain O
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；pH 6.5；291 K；1.5M (NH4)2SO4,0.1M Bis-Tris pH6.5, 0.1MNaCI
|
Resolution 2.64 Å
R-free 0.288
|
|
5IRO
Crystal structure of a complex between the Human adenovirus type 4 E3-19K protein and MHC class molecule HLA-A2/TAX
Deposited 2016-03-14
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 5
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain S
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；pH 6.5；291 K；1.5M (NH4)2SO4,0.1M Bis-Tris pH6.5, 0.1MNaCI
|
Resolution 2.64 Å
R-free 0.288
|
|
5IRO
Crystal structure of a complex between the Human adenovirus type 4 E3-19K protein and MHC class molecule HLA-A2/TAX
Deposited 2016-03-14
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 6
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain W
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；pH 6.5；291 K；1.5M (NH4)2SO4,0.1M Bis-Tris pH6.5, 0.1MNaCI
|
Resolution 2.64 Å
R-free 0.288
|
|
5ISZ
Crystal structure of LS01-TCR/M1-HLA-A*02 complex
Deposited 2016-03-15
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
22–119（98 aa）
|
Not recorded
|
GOL GLYCEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；277 K；14% (w/v) PEG 4000, 100 mM Na-HEPES pH 7.0, 200 mM ammonium sulfate
|
Resolution 2.06 Å
R-free 0.200
|
|
5IUE
Human leukocyte antigen F (HLA-F) presents peptides and regulates immunity through interactions with NK-cell receptors
Deposited 2016-03-17
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
19–119（101 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG 10000, tris-HCl
|
Resolution 2.62 Å
R-free 0.241
|
|
5IUE
Human leukocyte antigen F (HLA-F) presents peptides and regulates immunity through interactions with NK-cell receptors
Deposited 2016-03-17
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain F
19–119（101 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG 10000, tris-HCl
|
Resolution 2.62 Å
R-free 0.241
|
|
5IUE
Human leukocyte antigen F (HLA-F) presents peptides and regulates immunity through interactions with NK-cell receptors
Deposited 2016-03-17
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain H
19–119（101 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG 10000, tris-HCl
|
Resolution 2.62 Å
R-free 0.241
|
|
5IUE
Human leukocyte antigen F (HLA-F) presents peptides and regulates immunity through interactions with NK-cell receptors
Deposited 2016-03-17
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain J
19–119（101 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG 10000, tris-HCl
|
Resolution 2.62 Å
R-free 0.241
|
|
5J1A
Antigen presenting molecule
Deposited 2016-03-29
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
1–119（119 aa）
|
Not recorded
|
6F8 3-[(8Z,11Z)-pentadeca-8,11-dien-1-yl]benzene-1,2-diol × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；20-25% PEG 1500 / 10% MMT buffer pH 5-6
|
Resolution 1.86 Å
R-free 0.217
|
|
5JHD
Crystal structure of LS10-TCR/M1-HLA-A*02 complex
Deposited 2016-04-20
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDT {[-(BIS-CARBOXYMETHYL-AMINO)-ETHYL]-CARBOXYMETHYL-AMINO}-ACETIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；294 K；10%(W/V) PEG8000, 100mM Tris-Cl, 200mM Magnesium chloirde
|
Resolution 2.46 Å
R-free 0.223
|
|
5JHD
Crystal structure of LS10-TCR/M1-HLA-A*02 complex
Deposited 2016-04-20
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
|
Not recorded
|
EDT {[-(BIS-CARBOXYMETHYL-AMINO)-ETHYL]-CARBOXYMETHYL-AMINO}-ACETIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；294 K；10%(W/V) PEG8000, 100mM Tris-Cl, 200mM Magnesium chloirde
|
Resolution 2.46 Å
R-free 0.223
|
|
5JZI
Crystal structure of 1406 TCR bound to HLA-A2 with HCV 1406-1415 antigen peptide
Deposited 2016-05-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.1；298 K；13% PEG 3350, 0.1M Sodium Cacodylate, 0.2m Ammonium Sulfate, 3% w/v 1,5-Diaminopentane dihydrochloride
|
Resolution 2.50 Å
R-free 0.232
|
|
5JZI
Crystal structure of 1406 TCR bound to HLA-A2 with HCV 1406-1415 antigen peptide
Deposited 2016-05-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.1；298 K；13% PEG 3350, 0.1M Sodium Cacodylate, 0.2m Ammonium Sulfate, 3% w/v 1,5-Diaminopentane dihydrochloride
|
Resolution 2.50 Å
R-free 0.232
|
|
5KNM
Human leukocyte antigen F (HLA-F) presents peptides and regulates immunity through interactions with NK-cell receptors
Deposited 2016-06-28
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
Fragment：UNP rrsidues 21-119
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；295 K；27% PEG 550 MME
.1 M Tris-HCl
300 mM NaCl
|
Resolution 3.30 Å
R-free 0.326
|
|
5L2J
Crystal Structure of human CD1b in complex with C36-GMM
Deposited 2016-08-02
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–118（98 aa）
|
Not recorded
|
6UL TETRACOSYL PALMITATE × 1
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
ACT ACETATE ION × 2
CL CHLORIDE ION × 2
70E 6-O-[(2R,3R)-3-hydroxy-2-tetradecyldocosanoyl]-alpha-L-idopyranose × 1
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；277 K；20-30 PEG 4000, 0.2M NaI, 2% EG
|
Resolution 1.65 Å
R-free 0.199
|
|
5L2K
Crystal structure of GEM42 TCR-CD1b-GMM complex
Deposited 2016-08-02
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–118（98 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3
SO4 SULFATE ION × 5
CL CHLORIDE ION × 4
NA SODIUM ION × 2
6UL TETRACOSYL PALMITATE × 1
CS CESIUM ION × 1
70E 6-O-[(2R,3R)-3-hydroxy-2-tetradecyldocosanoyl]-alpha-L-idopyranose × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；1.5-2M NH4SO4, 0.1M Tris-HCl pH8.5, 10mM MgCl2, 10mM CeCl2
|
Resolution 3.20 Å
R-free 0.239
|
|
5L2K
Crystal structure of GEM42 TCR-CD1b-GMM complex
Deposited 2016-08-02
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 16
PDB declaration: hexadecameric
|
Chain B
21–118（98 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 12
SO4 SULFATE ION × 20
CL CHLORIDE ION × 16
NA SODIUM ION × 8
6UL TETRACOSYL PALMITATE × 4
CS CESIUM ION × 4
70E 6-O-[(2R,3R)-3-hydroxy-2-tetradecyldocosanoyl]-alpha-L-idopyranose × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；1.5-2M NH4SO4, 0.1M Tris-HCl pH8.5, 10mM MgCl2, 10mM CeCl2
|
Resolution 3.20 Å
R-free 0.239
|
|
5MEN
Human Leukocyte Antigen A02 presenting ILAKFLHWL, in complex with cognate T-Cell Receptor
Deposited 2016-11-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 5
GOL GLYCEROL × 1
SO4 SULFATE ION × 5
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2M ammonium sulphate, 0.1M HEPES pH7, 20% PEG 8000
|
Resolution 2.81 Å
R-free 0.272
|
|
5MEO
Human Leukocyte Antigen presenting ILGKFLHRL
Deposited 2016-11-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 15
GOL GLYCEROL × 4
SO4 SULFATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M ammonium sulphate, 0.1 M Tris pH 7.5, 25% PEG 8000
|
Resolution 1.77 Å
R-free 0.214
|
|
5MEP
Human Leukocyte Antigen A02 presenting ILGKFLHWL
Deposited 2016-11-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 6
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2M ammonium sulphate, 0.1M MES pH7, 15% PEG 8000
|
Resolution 2.71 Å
R-free 0.239
|
|
5MEP
Human Leukocyte Antigen A02 presenting ILGKFLHWL
Deposited 2016-11-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 5
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2M ammonium sulphate, 0.1M MES pH7, 15% PEG 8000
|
Resolution 2.71 Å
R-free 0.239
|
|
5MEQ
Human Leukocyte Antigen A02 presenting ILAKFLHTL
Deposited 2016-11-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 1
EDO 1,2-ETHANEDIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2M ammonium sulphate, 0.1M HEPES pH7, 20% PEG 8000
|
Resolution 2.27 Å
R-free 0.264
|
|
5MER
Human Leukocyte Antigen A02 presenting ILAKFLHEL
Deposited 2016-11-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 10
CA CALCIUM ION × 1
MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 2
SO4 SULFATE ION × 3
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2M ammonium sulphate, 0.1M MES pH7, 25% PEG 8000
|
Resolution 1.88 Å
R-free 0.224
|
|
5MER
Human Leukocyte Antigen A02 presenting ILAKFLHEL
Deposited 2016-11-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 10
CA CALCIUM ION × 1
MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 2
SO4 SULFATE ION × 7
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2M ammonium sulphate, 0.1M MES pH7, 25% PEG 8000
|
Resolution 1.88 Å
R-free 0.224
|
|
5N1Y
HLA-A02 carrying MVWGPDPLYV
Deposited 2017-02-06
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 10
GOL GLYCEROL × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2M ammonium chloride, 0.1M TRIS pH8, 20% PEG 6000
|
Resolution 1.39 Å
R-free 0.201
|
|
5N6B
Human Leukocyte Antigen Class I A02 Carrying LLWNPGMAV
Deposited 2017-02-14
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 7
EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 1
PEG DI(HYDROXYETHYL)ETHER × 2
SO4 SULFATE ION × 5
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.2M ammonium sulphate, 0.1M HEPES pH7, 20% PEG 4000
|
Resolution 1.71 Å
R-free 0.214
|
|
5N6B
Human Leukocyte Antigen Class I A02 Carrying LLWNPGMAV
Deposited 2017-02-14
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 4
EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 1
PEG DI(HYDROXYETHYL)ETHER × 1
SO4 SULFATE ION × 1
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.2M ammonium sulphate, 0.1M HEPES pH7, 20% PEG 4000
|
Resolution 1.71 Å
R-free 0.214
|
|
5NHT
human 199.54-16 TCR in complex with Melan-A/MART-1 (26-35) peptide and HLA-A2
Deposited 2017-03-22
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain L
21–119（99 aa）
Fragment：UNP Residues 25-300
|
Not recorded
|
SCN THIOCYANATE ION × 1
K POTASSIUM ION × 2
CL CHLORIDE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；PEG3350 8 %, K Thiocyanate 0.1 M, Bis-Tris propane pH 6.5 0.1 M, protein concentration 3.5 mg/ml
|
Resolution 3.20 Å
R-free 0.299
|
|
5NME
868 TCR in complex with HLA A02 presenting SLYNTVATL
Deposited 2017-04-05
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 4
SO4 SULFATE ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.1 M Sodium Cacodylate, pH 6.0, 15% PEG 4000, 0.2 M Ammonium Sulphate
|
Resolution 2.94 Å
R-free 0.263
|
|
5NME
868 TCR in complex with HLA A02 presenting SLYNTVATL
Deposited 2017-04-05
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 4
SO4 SULFATE ION × 4
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.1 M Sodium Cacodylate, pH 6.0, 15% PEG 4000, 0.2 M Ammonium Sulphate
|
Resolution 2.94 Å
R-free 0.263
|
|
5NMF
868 TCR in complex with HLA A02 presenting SLYNTIATL
Deposited 2017-04-05
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 5
GOL GLYCEROL × 2
SO4 SULFATE ION × 8
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.1 M Sodium Cacodylate, pH 6.0, 15% PEG 4000, 0.2 M Ammonium Sulphate
|
Resolution 2.89 Å
R-free 0.255
|
|
5NMF
868 TCR in complex with HLA A02 presenting SLYNTIATL
Deposited 2017-04-05
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 14
GOL GLYCEROL × 1
SO4 SULFATE ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.1 M Sodium Cacodylate, pH 6.0, 15% PEG 4000, 0.2 M Ammonium Sulphate
|
Resolution 2.89 Å
R-free 0.255
|
|
5NMG
868 TCR in complex with HLA A02 presenting SLYFNTIAVL
Deposited 2017-04-05
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 13
GOL GLYCEROL × 3
SO4 SULFATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.1 M Sodium Cacodylate, pH 5.5, 15% PEG 4000, 0.2 M Ammonium Sulphate
|
Resolution 2.75 Å
R-free 0.254
|
|
5NMG
868 TCR in complex with HLA A02 presenting SLYFNTIAVL
Deposited 2017-04-05
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 3
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.1 M Sodium Cacodylate, pH 5.5, 15% PEG 4000, 0.2 M Ammonium Sulphate
|
Resolution 2.75 Å
R-free 0.254
|
|
5NMH
HLA A02 presenting SLYNTIATL
Deposited 2017-04-05
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 7
GOL GLYCEROL × 5
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.1 M Sodium Cacodylate, pH 6.0, 25% PEG 4000, 0.2 M Ammonium Sulphate
|
Resolution 1.55 Å
R-free 0.196
|
|
5NMK
HLA A02 presenting SLFNTIAVL
Deposited 2017-04-06
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 9
GOL GLYCEROL × 1
SO4 SULFATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.1 M Sodium Cacodylate, pH 6.0, 25% PEG 4000, 0.2 M Ammonium Sulphate
|
Resolution 1.66 Å
R-free 0.210
|
|
5NQ1
Porcine (Sus scrofa) Major Histocompatibility Complex, class I, with human beta2 micro globulin, presenting DFEREGYSL
Deposited 2017-04-19
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；PACT screen, condition D02: 0.1M MMT Buffer, pH 5.0, 25% PEG1500
|
Resolution 2.14 Å
R-free 0.283
|
|
5NQ1
Porcine (Sus scrofa) Major Histocompatibility Complex, class I, with human beta2 micro globulin, presenting DFEREGYSL
Deposited 2017-04-19
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 1
GOL GLYCEROL × 1
SO4 SULFATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；PACT screen, condition D02: 0.1M MMT Buffer, pH 5.0, 25% PEG1500
|
Resolution 2.14 Å
R-free 0.283
|
|
5NQ3
'Porcine (Sus scrofa) Major Histocompatibility Complex, class I, with human beta2 micro globulin, presenting EFEDLTFLA
Deposited 2017-04-19
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；JBS screen, condition A07: 30% MPD, 100 mM Na Citrate, pH 5.6, 200 mM Ammonium Acetate
|
Resolution 1.57 Å
R-free 0.262
|
|
5NQ3
'Porcine (Sus scrofa) Major Histocompatibility Complex, class I, with human beta2 micro globulin, presenting EFEDLTFLA
Deposited 2017-04-19
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 1
GOL GLYCEROL × 2
EDO 1,2-ETHANEDIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；JBS screen, condition A07: 30% MPD, 100 mM Na Citrate, pH 5.6, 200 mM Ammonium Acetate
|
Resolution 1.57 Å
R-free 0.262
|
|
5NQK
human 199.16 TCR in complex with Melan-A/MART-1 (26-35) peptide and HLA-A2
Deposited 2017-04-20
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain L
21–119（99 aa）
|
Not recorded
|
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；PEG3350 11%, bis-tris propane pH 6.5 0.1M, KNa tartrate 0.1M
|
Resolution 3.25 Å
R-free 0.316
|
|
5OPI
Crystal structure of the TAPBPR-MHC I peptide editing complex
Deposited 2017-08-09
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291.15 K；19% PEG400, 5% poly-gamma-glutamic acid, and 450 mM sodium cacodylate pH 6.5
|
Resolution 3.30 Å
R-free 0.303
|
|
5SWQ
Crystal Structure of HLA-A*0201 in complex with NA231, an influenza epitope
Deposited 2016-08-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；20%PEG6K, 0.1M Na-Citrate pH6.5, 0.2M NaCl
|
Resolution 2.00 Å
R-free 0.258
|
|
5T6W
HLA-B*57:01 presenting SSTRGISQLW
Deposited 2016-09-01
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；298 K；12 -20 % PEG 4000, 0.2 M ammonium acetate and 0.1 M tri-sodium citrate pH 5.6
|
Resolution 1.90 Å
R-free 0.263
|
|
5T6X
HLA-B*57:01 presenting TSTTSVASSW
Deposited 2016-09-02
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP resiudes 21-119
|
Not recorded
|
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；298 K；12 -20 % PEG 4000, 0.2 M ammonium acetate and 0.1 M tri-sodium citrate pH 5.6
|
Resolution 1.69 Å
R-free 0.244
|
|
5T6Y
HLA-B*57:01 presenting TSTFEDVKILAF
Deposited 2016-09-02
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 3
ACT ACETATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；298 K；12 -20 % PEG 4000, 0.2 M ammonium acetate and 0.1 M tri-sodium citrate pH 5.6
|
Resolution 1.76 Å
R-free 0.219
|
|
5T6Z
KIR3DL1 in complex with HLA-B*57:01-TW10
Deposited 2016-09-02
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；298 K；16% PEG 3350, 2% tacsimate pH 5.0 and 0.1M tri-sodium citrate pH 5.6
|
Resolution 2.00 Å
R-free 0.240
|
|
5T70
KIR3DL1 in complex with HLA-B*57:01 presenting TSNLQEQIGW
Deposited 2016-09-02
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；298 K；16% PEG 3350, 2% tacsimate pH 5.0 and 0.1M tri-sodium citrate pH 5.6
|
Resolution 2.10 Å
R-free 0.225
|
|
5TEZ
TCR F50 recgonizing M1-HLA-A2
Deposited 2016-09-23
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
20–119（100 aa）
Fragment：UNP residues 20-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；295 K；PEG 3350, 0.1 M imidazole (pH 8.0), and 0.2 M sodium malonate
|
Resolution 1.70 Å
R-free 0.224
|
|
5TRZ
Crystal structure of MHC-I H2-KD complexed with peptides of Mycobacterial tuberculosis (YQSGLSIVM)
Deposited 2016-10-27
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
Chain D
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 3
EDO 1,2-ETHANEDIOL × 8
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；14% PEG 4000, 0.1M MES buffer, 5% MPD
|
Resolution 2.25 Å
R-free 0.198
|
|
5TS1
Crystal structure of MHC-I H2-KD complexed with peptides of Mycobacterial tuberculosis (YYQSGLSIV)
Deposited 2016-10-27
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：residues 21-119
|
Not recorded
|
GOL GLYCEROL × 2
EDO 1,2-ETHANEDIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；14% PEG 4000, 0.1M MES buffer, 5% MPD
|
Resolution 2.30 Å
R-free 0.224
|
|
5TS1
Crystal structure of MHC-I H2-KD complexed with peptides of Mycobacterial tuberculosis (YYQSGLSIV)
Deposited 2016-10-27
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
21–119（99 aa）
Fragment：residues 21-119
|
Not recorded
|
GOL GLYCEROL × 1
EDO 1,2-ETHANEDIOL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；14% PEG 4000, 0.1M MES buffer, 5% MPD
|
Resolution 2.30 Å
R-free 0.224
|
|
5TS1
Crystal structure of MHC-I H2-KD complexed with peptides of Mycobacterial tuberculosis (YYQSGLSIV)
Deposited 2016-10-27
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain F
21–119（99 aa）
Fragment：residues 21-119
|
Not recorded
|
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；14% PEG 4000, 0.1M MES buffer, 5% MPD
|
Resolution 2.30 Å
R-free 0.224
|
|
5TS1
Crystal structure of MHC-I H2-KD complexed with peptides of Mycobacterial tuberculosis (YYQSGLSIV)
Deposited 2016-10-27
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain H
21–119（99 aa）
Fragment：residues 21-119
|
Not recorded
|
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；14% PEG 4000, 0.1M MES buffer, 5% MPD
|
Resolution 2.30 Å
R-free 0.224
|
|
5TXS
Crystal structure of an anaplastic lymphoma kinase-derived neuroblastoma tumor antigen bound to the Human Major Histocompatibility Complex Class I molecule HLA-B*1501
Deposited 2016-11-17
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；295 K；0.1 M HEPES (6.5)
20% PEG 6000
|
Resolution 1.70 Å
R-free 0.196
|
|
5U16
Structure of human MR1-2-OH-1-NA in complex with human MAIT A-F7 TCR
Deposited 2016-11-27
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
7WO 2-hydroxynaphthalene-1-carbaldehyde × 1
GOL GLYCEROL × 2
CL CHLORIDE ION × 2
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；294 K；BTP, PEG 3350, NaAc
|
Resolution 2.00 Å
R-free 0.219
|
|
5U16
Structure of human MR1-2-OH-1-NA in complex with human MAIT A-F7 TCR
Deposited 2016-11-27
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain D
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
7WO 2-hydroxynaphthalene-1-carbaldehyde × 1
GOL GLYCEROL × 3
CL CHLORIDE ION × 1
NA SODIUM ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；294 K；BTP, PEG 3350, NaAc
|
Resolution 2.00 Å
R-free 0.219
|
|
5U17
Structure of human MR1-DA-6-FP in complex with human MAIT A-F7 TCR
Deposited 2016-11-28
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain H
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
7WP 2,4-diaminopteridine-6-carbaldehyde × 1
GOL GLYCEROL × 4
NA SODIUM ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；294 K；BTP, PEG 3350, NaAc
|
Resolution 2.15 Å
R-free 0.224
|
|
5U17
Structure of human MR1-DA-6-FP in complex with human MAIT A-F7 TCR
Deposited 2016-11-28
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain F
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
7WP 2,4-diaminopteridine-6-carbaldehyde × 1
GOL GLYCEROL × 5
ACT ACETATE ION × 2
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；294 K；BTP, PEG 3350, NaAc
|
Resolution 2.15 Å
R-free 0.224
|
|
5U1R
Structure of human MR1-diclofenac in complex with human MAIT A-F7 TCR
Deposited 2016-11-28
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain F
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
NA SODIUM ION × 2
ACT ACETATE ION × 1
GOL GLYCEROL × 2
DIF 2-[2,6-DICHLOROPHENYL)AMINO]BENZENEACETIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；294 K；BTP, PEG 3350, NaAc
|
Resolution 2.70 Å
R-free 0.237
|
|
5U1R
Structure of human MR1-diclofenac in complex with human MAIT A-F7 TCR
Deposited 2016-11-28
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain H
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
ACT ACETATE ION × 2
GOL GLYCEROL × 1
DIF 2-[2,6-DICHLOROPHENYL)AMINO]BENZENEACETIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；294 K；BTP, PEG 3350, NaAc
|
Resolution 2.70 Å
R-free 0.237
|
|
5U2V
Structure of human MR1-HMB in complex with human MAIT A-F7 TCR
Deposited 2016-12-01
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
PRO PROLINE × 1
7WQ 2-hydroxy-5-methoxybenzaldehyde × 1
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；294 K；BTP, PEG 3350, NaAc
|
Resolution 2.20 Å
R-free 0.221
|
|
5U2V
Structure of human MR1-HMB in complex with human MAIT A-F7 TCR
Deposited 2016-12-01
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain D
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
7WQ 2-hydroxy-5-methoxybenzaldehyde × 1
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；294 K；BTP, PEG 3350, NaAc
|
Resolution 2.20 Å
R-free 0.221
|
|
5U6Q
Structure of human MR1-3-F-SA in complex with human MAIT A-F7 TCR
Deposited 2016-12-08
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain F
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
7ZS 3-methanoyl-2-oxidanyl-benzoic acid × 1
GOL GLYCEROL × 1
ACT ACETATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；294 K；BTP, PEG 3350, NaAc
|
Resolution 1.90 Å
R-free 0.222
|
|
5U6Q
Structure of human MR1-3-F-SA in complex with human MAIT A-F7 TCR
Deposited 2016-12-08
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain H
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
7ZS 3-methanoyl-2-oxidanyl-benzoic acid × 1
ACT ACETATE ION × 1
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；294 K；BTP, PEG 3350, NaAc
|
Resolution 1.90 Å
R-free 0.222
|
|
5U72
Structure of human MR1-5OH-DCF in complex with human MAIT A-F7 TCR
Deposited 2016-12-10
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain H
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
ACT ACETATE ION × 2
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；294 K；BTP, PEG 3350, NaAc
|
Resolution 2.50 Å
R-free 0.231
|
|
5U72
Structure of human MR1-5OH-DCF in complex with human MAIT A-F7 TCR
Deposited 2016-12-10
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain F
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
ACT ACETATE ION × 1
7ZV 5-hydroxydiclofenac × 1
DMS DIMETHYL SULFOXIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；294 K；BTP, PEG 3350, NaAc
|
Resolution 2.50 Å
R-free 0.231
|
|
5U98
The crystal structure of a self-peptide complexed to Abacavir and HLA-B*57:01
Deposited 2016-12-15
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
1KX {(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；289 K；0.1M NACACODYLATE, 0.1MNAACETATE, 25% PEG 8,000, 15% GLYCEROL
|
Resolution 2.00 Å
R-free 0.216
|
|
5U98
The crystal structure of a self-peptide complexed to Abacavir and HLA-B*57:01
Deposited 2016-12-15
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
1KX {(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；289 K；0.1M NACACODYLATE, 0.1MNAACETATE, 25% PEG 8,000, 15% GLYCEROL
|
Resolution 2.00 Å
R-free 0.216
|
|
5V5L
Crystal structure of HLA-B*5801 complex with HIV-1 gag derived peptide TW10
Deposited 2017-03-14
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；290 K；15-20% w/v PEG 4000, 20% w/v 2-propanol, 0.1 M MES pH 6.5
|
Resolution 2.00 Å
R-free 0.214
|
|
5V5L
Crystal structure of HLA-B*5801 complex with HIV-1 gag derived peptide TW10
Deposited 2017-03-14
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；290 K；15-20% w/v PEG 4000, 20% w/v 2-propanol, 0.1 M MES pH 6.5
|
Resolution 2.00 Å
R-free 0.214
|
|
5V5M
Crystal structure of HLA-B*5701 complex with HIV-1 gag derived peptide TW10
Deposited 2017-03-14
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；290 K；15-20% w/v PEG 4000, 20% w/v 2-propanol, 0.1 M MES pH 6.5
|
Resolution 2.88 Å
R-free 0.244
|
|
5V5M
Crystal structure of HLA-B*5701 complex with HIV-1 gag derived peptide TW10
Deposited 2017-03-14
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；290 K；15-20% w/v PEG 4000, 20% w/v 2-propanol, 0.1 M MES pH 6.5
|
Resolution 2.88 Å
R-free 0.244
|
|
5VGD
Crystal Structure of HLA-C*0501 in complex with SAE
Deposited 2017-04-11
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；277 K；1.8M NaMalonate pH7
|
Resolution 2.32 Å
R-free 0.297
|
|
5VGE
Crystal structure of HLA-C*07:02 in complex with RYR peptide
Deposited 2017-04-11
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
ZN ZINC ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；298 K；0.1 M HEPES pH 8.5
2 mM ZnSO4
28 % jeffamine ED-2001 (Hampton)
|
Resolution 2.60 Å
R-free 0.221
|
|
5VUD
HLA-B*57:01 presenting LSSPVTKSW
Deposited 2017-05-19
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.4；298 K；12 -20 % PEG 4000, 0.2 M ammonium acetate and 0.1 M tri-sodium citrate pH 5.4
|
Resolution 2.00 Å
R-free 0.209
|
|
5VUE
HLA-B*57:01 presenting LTVQVARVW
Deposited 2017-05-19
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.4；298 K；12 -20 % PEG 4000, 0.2 M ammonium acetate and 0.1 M tri-sodium citrate pH 5.4
|
Resolution 1.80 Å
R-free 0.207
|
|
5VUF
HLA-B*57:01 presenting LTVQVARVY
Deposited 2017-05-19
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.4；298 K；12 -20 % PEG 4000, 0.2 M ammonium acetate and 0.1 M tri-sodium citrate pH 5.4
|
Resolution 1.90 Å
R-free 0.216
|
|
5VVP
HLA-B*57:03 presenting LSSPVTKSW
Deposited 2017-05-19
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.4；298 K；12 -20 % PEG 4000, 0.2 M ammonium acetate and 0.1 M tri-sodium citrate pH 5.4
|
Resolution 2.00 Å
R-free 0.202
|
|
5VWD
HLA-B*57:03 presenting LTVQVARVW
Deposited 2017-05-21
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.4；298 K；12 -20 % PEG 4000, 0.2 M ammonium acetate and 0.1 M tri-sodium citrate pH 5.4
|
Resolution 1.80 Å
R-free 0.208
|
|
5VWF
HLA-B*58:03 presenting LTVQVARVY
Deposited 2017-05-21
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.4；298 K；12 -20 % PEG 4000, 0.2 M ammonium acetate and 0.1 M tri-sodium citrate pH 5.4
|
Resolution 1.80 Å
R-free 0.196
|
|
5VWH
HLA-B*58:01 presenting LSSPVTKSW
Deposited 2017-05-21
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.4；298 K；12 -20 % PEG 4000, 0.2 M ammonium acetate and 0.1 M tri-sodium citrate pH 5.4
|
Resolution 1.65 Å
R-free 0.199
|
|
5VWJ
HLA-B*58:01 presenting LTVQVARVW
Deposited 2017-05-22
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.4；298 K；12 -20 % PEG 4000, 0.2 M ammonium acetate and 0.1 M tri-sodium citrate pH 5.4
|
Resolution 2.00 Å
R-free 0.214
|
|
5VZ5
Crystal structure of an anaplastic lymphoma kinase-derived neuroblastoma tumor antigen bound to the Human Major Histocompatibility Complex Class I molecule HLA-B*1501
Deposited 2017-05-26
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 7
SO4 SULFATE ION × 5
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；295 K；0.1M Hepes (7.5)
2M Ammonium sulfate
2% PEG400
|
Resolution 2.59 Å
R-free 0.265
|
|
5W1V
Structure of the HLA-E-VMAPRTLIL/GF4 TCR complex
Deposited 2017-06-04
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.2M K, Na tartrate, 20% PEG 3350
|
Resolution 3.31 Å
R-free 0.268
|
|
5W1V
Structure of the HLA-E-VMAPRTLIL/GF4 TCR complex
Deposited 2017-06-04
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.2M K, Na tartrate, 20% PEG 3350
|
Resolution 3.31 Å
R-free 0.268
|
|
5W1V
Structure of the HLA-E-VMAPRTLIL/GF4 TCR complex
Deposited 2017-06-04
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain L
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.2M K, Na tartrate, 20% PEG 3350
|
Resolution 3.31 Å
R-free 0.268
|
|
5W1V
Structure of the HLA-E-VMAPRTLIL/GF4 TCR complex
Deposited 2017-06-04
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain Q
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.2M K, Na tartrate, 20% PEG 3350
|
Resolution 3.31 Å
R-free 0.268
|
|
5W1W
Structure of the HLA-E-VMAPRTLVL/GF4 TCR complex
Deposited 2017-06-05
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.2 m Na.K tartrate, 20% PEG 3350
|
Resolution 3.10 Å
R-free 0.263
|
|
5W1W
Structure of the HLA-E-VMAPRTLVL/GF4 TCR complex
Deposited 2017-06-05
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.2 m Na.K tartrate, 20% PEG 3350
|
Resolution 3.10 Å
R-free 0.263
|
|
5W1W
Structure of the HLA-E-VMAPRTLVL/GF4 TCR complex
Deposited 2017-06-05
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain L
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.2 m Na.K tartrate, 20% PEG 3350
|
Resolution 3.10 Å
R-free 0.263
|
|
5W1W
Structure of the HLA-E-VMAPRTLVL/GF4 TCR complex
Deposited 2017-06-05
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain Q
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.2 m Na.K tartrate, 20% PEG 3350
|
Resolution 3.10 Å
R-free 0.263
|
|
5W67
HLA-C*06:02 presenting VRSRR(ABA)LRL
Deposited 2017-06-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 6
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.5；298 K；0.1M Na acetate pH 4.5 and 1.8 M ammonium citrate
|
Resolution 2.30 Å
R-free 0.235
|
|
5W69
HLA-C*06:02 presenting ARFNDLRFV
Deposited 2017-06-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；298 K；0.1 M Tris pH 8.5, 0.2 M Na acetate and 20 % PEG 3350
|
Resolution 2.80 Å
R-free 0.223
|
|
5W69
HLA-C*06:02 presenting ARFNDLRFV
Deposited 2017-06-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；298 K；0.1 M Tris pH 8.5, 0.2 M Na acetate and 20 % PEG 3350
|
Resolution 2.80 Å
R-free 0.223
|
|
5W69
HLA-C*06:02 presenting ARFNDLRFV
Deposited 2017-06-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain F
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；298 K；0.1 M Tris pH 8.5, 0.2 M Na acetate and 20 % PEG 3350
|
Resolution 2.80 Å
R-free 0.223
|
|
5W69
HLA-C*06:02 presenting ARFNDLRFV
Deposited 2017-06-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain H
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；298 K；0.1 M Tris pH 8.5, 0.2 M Na acetate and 20 % PEG 3350
|
Resolution 2.80 Å
R-free 0.223
|
|
5W6A
HLA-C*06:02 presenting ARTELYRSL
Deposited 2017-06-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；0.1 M Bis-Tris propane pH 7.0, 0.1 M Na fluoride and 20 % PEG 8000
|
Resolution 1.74 Å
R-free 0.201
|
|
5W6A
HLA-C*06:02 presenting ARTELYRSL
Deposited 2017-06-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；0.1 M Bis-Tris propane pH 7.0, 0.1 M Na fluoride and 20 % PEG 8000
|
Resolution 1.74 Å
R-free 0.201
|
|
5WER
Crystal Structure of TAPBPR and H2-Dd complex
Deposited 2017-07-10
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：residues 21-119
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 1
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.8；291 K；1.0 M ammonium sulfate, 0.1 M TRIS pH 8.8, 0.2 M NaCl, 0.15-0.20 M sodium citrate, 2%-5% PEG 400
|
Resolution 3.41 Å
R-free 0.269
|
|
5WER
Crystal Structure of TAPBPR and H2-Dd complex
Deposited 2017-07-10
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
Fragment：residues 21-119
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 1
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.8；291 K；1.0 M ammonium sulfate, 0.1 M TRIS pH 8.8, 0.2 M NaCl, 0.15-0.20 M sodium citrate, 2%-5% PEG 400
|
Resolution 3.41 Å
R-free 0.269
|
|
5WER
Crystal Structure of TAPBPR and H2-Dd complex
Deposited 2017-07-10
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain H
21–119（99 aa）
Fragment：residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.8；291 K；1.0 M ammonium sulfate, 0.1 M TRIS pH 8.8, 0.2 M NaCl, 0.15-0.20 M sodium citrate, 2%-5% PEG 400
|
Resolution 3.41 Å
R-free 0.269
|
|
5WER
Crystal Structure of TAPBPR and H2-Dd complex
Deposited 2017-07-10
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain K
21–119（99 aa）
Fragment：residues 21-119
|
Not recorded
|
GOL GLYCEROL × 1
1PE PENTAETHYLENE GLYCOL × 1
CIT CITRIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.8；291 K；1.0 M ammonium sulfate, 0.1 M TRIS pH 8.8, 0.2 M NaCl, 0.15-0.20 M sodium citrate, 2%-5% PEG 400
|
Resolution 3.41 Å
R-free 0.269
|
|
5WHK
Crystal structure of Fab fragment of antibody DX-2507 bound to FcRn-B2M
Deposited 2017-07-17
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
1–119（119 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 2
NHE 2-[N-CYCLOHEXYLAMINO]ETHANE SULFONIC ACID × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；289 K；DX-2507 Fab FcRn B2M complex at 6.6 mg/mL at 70 uM against an optimization screen against JCSG+ A7 18% PEG 8000, 0.1 M CHES pH 9.8 with seeding from an earlier crystal obtained under similar conditions, supplemented with 20% ethylene glycol as cro-protectant
|
Resolution 2.50 Å
R-free 0.225
|
|
5WJL
Crystal Structure of HLA-A*11:01 with GTS1 peptide
Deposited 2017-07-23
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
CL CHLORIDE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；1.4-1.8M NH4SO4, 0.1M Na-cacodylate pH6.5, 200mM NaCl, 2% Ethylen glycol
|
Resolution 3.15 Å
R-free 0.231
|
|
5WJL
Crystal Structure of HLA-A*11:01 with GTS1 peptide
Deposited 2017-07-23
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
CL CHLORIDE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；1.4-1.8M NH4SO4, 0.1M Na-cacodylate pH6.5, 200mM NaCl, 2% Ethylen glycol
|
Resolution 3.15 Å
R-free 0.231
|
|
5WJL
Crystal Structure of HLA-A*11:01 with GTS1 peptide
Deposited 2017-07-23
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain H
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；1.4-1.8M NH4SO4, 0.1M Na-cacodylate pH6.5, 200mM NaCl, 2% Ethylen glycol
|
Resolution 3.15 Å
R-free 0.231
|
|
5WJN
Crystal Structure of HLA-A*11:01-GTS3
Deposited 2017-07-23
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
K POTASSIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 8.5；277 K；1.4-1.8M NH4SO4, 0.1M Na-cacodylate pH6.5, 200mM NaCl, 2% Ethylen glycol
|
Resolution 2.85 Å
R-free 0.230
|
|
5WJN
Crystal Structure of HLA-A*11:01-GTS3
Deposited 2017-07-23
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 8.5；277 K；1.4-1.8M NH4SO4, 0.1M Na-cacodylate pH6.5, 200mM NaCl, 2% Ethylen glycol
|
Resolution 2.85 Å
R-free 0.230
|
|
5WJN
Crystal Structure of HLA-A*11:01-GTS3
Deposited 2017-07-23
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain H
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 8.5；277 K；1.4-1.8M NH4SO4, 0.1M Na-cacodylate pH6.5, 200mM NaCl, 2% Ethylen glycol
|
Resolution 2.85 Å
R-free 0.230
|
|
5WKE
Crystal Structure of Human CD1b in Complex with PS
Deposited 2017-07-25
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
CUY tetracosyl octadecanoate × 1
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
EDO 1,2-ETHANEDIOL × 3
CL CHLORIDE ION × 7
P50 (19S,22S,25R)-25-amino-22-hydroxy-16,22,26-trioxo-17,21,23-trioxa-22lambda~5~-phosphahexacosan-19-yl (9Z)-octadec-9-enoate × 1
NA SODIUM ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；27% PEG 3350, 0.2M Sodium Malonate
|
Resolution 1.69 Å
R-free 0.239
|
|
5WKF
D30 TCR in complex with HLA-A*11:01-GTS1
Deposited 2017-07-25
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.5；277 K；17%PEG8000, 2% Ethylen glycol, 0.1M HEPES pH7.5
|
Resolution 2.95 Å
R-free 0.253
|
|
5WKF
D30 TCR in complex with HLA-A*11:01-GTS1
Deposited 2017-07-25
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.5；277 K；17%PEG8000, 2% Ethylen glycol, 0.1M HEPES pH7.5
|
Resolution 2.95 Å
R-free 0.253
|
|
5WKG
Crystal Structure of Human CD1b in Complex with PA
Deposited 2017-07-25
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
D21 (2R)-1-(hexadecanoyloxy)-3-(phosphonooxy)propan-2-yl (9Z)-octadec-9-enoate × 1
CUY tetracosyl octadecanoate × 1
PEG DI(HYDROXYETHYL)ETHER × 1
CL CHLORIDE ION × 4
EDO 1,2-ETHANEDIOL × 1
IOD IODIDE ION × 3
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；27% PET 3350, 0.2M Sodium malonate
|
Resolution 2.06 Å
R-free 0.224
|
|
5WKH
D30 TCR in complex with HLA-A*11:01-GTS3
Deposited 2017-07-25
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.5；277 K；17%PEG8000, 2% Ethylen glycol, 0.1M HEPES pH7.5
|
Resolution 3.20 Å
R-free 0.246
|
|
5WKH
D30 TCR in complex with HLA-A*11:01-GTS3
Deposited 2017-07-25
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.5；277 K；17%PEG8000, 2% Ethylen glycol, 0.1M HEPES pH7.5
|
Resolution 3.20 Å
R-free 0.246
|
|
5WKI
Crystal structure of PG90 TCR-CD1b-PG complex
Deposited 2017-07-25
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
CUY tetracosyl octadecanoate × 1
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
EDO 1,2-ETHANEDIOL × 12
NA SODIUM ION × 2
D3D (19S,22R,25R)-22,25,26-trihydroxy-16,22-dioxo-17,21,23-trioxa-22lambda~5~-phosphahexacosan-19-yl (9E)-octadec-9-enoate × 1
ACT ACETATE ION × 2
CL CHLORIDE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.8；293 K；12% PEG8K, 0.2M Zinc Acetate, 0.1M MES pH 6.2
|
Resolution 2.75 Å
R-free 0.252
|
|
5WL1
Crystal Structure of Human CD1b in Complex with PG
Deposited 2017-07-25
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
CUY tetracosyl octadecanoate × 1
IOD IODIDE ION × 1
CL CHLORIDE ION × 1
NA SODIUM ION × 2
EDO 1,2-ETHANEDIOL × 3
D3D (19S,22R,25R)-22,25,26-trihydroxy-16,22-dioxo-17,21,23-trioxa-22lambda~5~-phosphahexacosan-19-yl (9E)-octadec-9-enoate × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；26% PEG 3350, 0.2M Sodium Malonate
|
Resolution 1.38 Å
R-free 0.206
|
|
5WMN
Crystal Structure of HLA-B7 in complex with SPI, an influenza peptide
Deposited 2017-07-30
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；18-24%PEG4000, 0.2 NH4 Acetate, 0.1M Na-cacodylate pH 6.5
|
Resolution 1.82 Å
R-free 0.222
|
|
5WMN
Crystal Structure of HLA-B7 in complex with SPI, an influenza peptide
Deposited 2017-07-30
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；18-24%PEG4000, 0.2 NH4 Acetate, 0.1M Na-cacodylate pH 6.5
|
Resolution 1.82 Å
R-free 0.222
|
|
5WMO
Crystal Structure of HLA-B7 in complex with RPP, an EBV peptide
Deposited 2017-07-30
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；18-24%PEG4000, 0.2 NH4 Acetate, 0.1M Na-cacodylate pH 6.5
|
Resolution 1.62 Å
R-free 0.200
|
|
5WMP
Crystal Structure of HLA-B7 in complex with TPR, a CMV peptide
Deposited 2017-07-30
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
IOD IODIDE ION × 4
NA SODIUM ION × 1
CL CHLORIDE ION × 4
PEG DI(HYDROXYETHYL)ETHER × 1
ZN ZINC ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；18-24%PEG4000, 0.2 NH4 Acetate, 0.1M Na-cacodylate pH 6.5
|
Resolution 1.60 Å
R-free 0.199
|
|
5WMQ
Crystal Structure of HLA-B8 in complex with ELR, an Influenza A virus peptide
Deposited 2017-07-31
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；18-24%PEG4000, 0.2 NH4 Acetate, 0.1M Na-cacodylate pH 6.5
|
Resolution 1.40 Å
R-free 0.216
|
|
5WMR
Crystal Structure of HLA-B8 in complex with QIK, a CMV peptide
Deposited 2017-07-31
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；18-24%PEG4000, 0.2 NH4 Acetate, 0.1M Na-cacodylate pH 6.5
|
Resolution 1.58 Å
R-free 0.228
|
|
5WSH
Structure of HLA-A2 P130
Deposited 2016-12-07
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
PEG DI(HYDROXYETHYL)ETHER × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；0.1mol/L bis-tris(pH6.5), 20%(wt/vol) polyethylene glycol 3350
|
Resolution 2.00 Å
R-free 0.196
|
|
5WWI
Crystal Structure of HLA-A*2402 in complex with avian influenza A(H7N9) virus-derived peptide H7-25 (data set 1)
Deposited 2017-01-01
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
20–119（100 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；291 K；0.1 M MES monohydrate pH 6.0, 14% w/v Polyethylene glycol 4000
|
Resolution 3.19 Å
R-free 0.309
|
|
5WWJ
Crystal Structure of HLA-A*2402 in complex with avian influenza A(H7N9) virus-derived peptide H7-25 (data set 1)
Deposited 2017-01-01
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；291 K；0.1 M Imidazole pH 7.0, 12% w/v Polyethylene glycol 20000
|
Resolution 2.29 Å
R-free 0.210
|
|
5WWJ
Crystal Structure of HLA-A*2402 in complex with avian influenza A(H7N9) virus-derived peptide H7-25 (data set 1)
Deposited 2017-01-01
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；291 K；0.1 M Imidazole pH 7.0, 12% w/v Polyethylene glycol 20000
|
Resolution 2.29 Å
R-free 0.210
|
|
5WWU
Crystal Structure of HLA-A*2402 in complex with 2009 pandemic influenza A(H1N1) virus and avian influenza A(H5N1) virus-derived peptide H1-25
Deposited 2017-01-05
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；291 K；0.1 M MES monohydrate pH 6.0, 14% w/v Polyethylene glycol 4000
|
Resolution 2.79 Å
R-free 0.284
|
|
5WXC
Crystal Structure of HLA-A*2402 in complex with avian influenza A(H7N9) virus-derived peptide H7-25 (data set 2)
Deposited 2017-01-07
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
20–119（100 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；291 K；0.1 M MES monohydrate pH 6.0, 14% w/v Polyethylene glycol 4000
|
Resolution 2.29 Å
R-free 0.224
|
|
5WXC
Crystal Structure of HLA-A*2402 in complex with avian influenza A(H7N9) virus-derived peptide H7-25 (data set 2)
Deposited 2017-01-07
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
20–119（100 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；291 K；0.1 M MES monohydrate pH 6.0, 14% w/v Polyethylene glycol 4000
|
Resolution 2.29 Å
R-free 0.224
|
|
5WXD
Crystal Structure of HLA-A*2402 in complex with avian influenza A(H7N9) virus-derived peptide H7-25 (data set 1)
Deposited 2017-01-07
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
20–119（100 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；291 K；0.1 M Imidazole pH 7.0, 12% w/v Polyethylene glycol 20000
|
Resolution 3.29 Å
R-free 0.254
|
|
5XOS
Crystal structure of HLA-B35 in complex with a pepetide antigen
Deposited 2017-05-31
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；288 K；0.1M MES monohydrate, pH 6.5, 12%(w/v) PEG20000
|
Resolution 1.70 Å
R-free 0.184
|
|
5XOT
Crystal structure of pHLA-B35 in complex with TU55 T cell receptor
Deposited 2017-05-31
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；288 K；5% v/v Tacsimate pH 7.0, 0.1 M HEPES, pH 7.3, 10% w/v polyethylene glycol monomethyl either 5000
|
Resolution 2.79 Å
R-free 0.254
|
|
5XOV
Crystal structure of peptide-HLA-A24 bound to S19-2 V-delta/V-beta TCR
Deposited 2017-05-31
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；288 K；5%(v/v) Tacsimate pH 7.0, 0.1M HEPES, pH 7.3, 10%(w/v) polyethylene glycol monomethyl either 5000
|
Resolution 2.68 Å
R-free 0.245
|
|
5XOV
Crystal structure of peptide-HLA-A24 bound to S19-2 V-delta/V-beta TCR
Deposited 2017-05-31
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain E
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；288 K；5%(v/v) Tacsimate pH 7.0, 0.1M HEPES, pH 7.3, 10%(w/v) polyethylene glycol monomethyl either 5000
|
Resolution 2.68 Å
R-free 0.245
|
|
6AEE
Crystal structure of the four Ig-like domains of LILRB1 complexed with HLA-G
Deposited 2018-08-04
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；277 K；0.2M imidazole malate, 15%(w/v) PEG4000, pH 6.0
|
Resolution 3.30 Å
R-free 0.267
|
|
6AEE
Crystal structure of the four Ig-like domains of LILRB1 complexed with HLA-G
Deposited 2018-08-04
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain E
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；277 K；0.2M imidazole malate, 15%(w/v) PEG4000, pH 6.0
|
Resolution 3.30 Å
R-free 0.267
|
|
6AM5
Crystal structure of DMF5 TCR bound to HLA-A2 presenting synthetic peptide SMLGIGIVPV
Deposited 2017-08-09
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.1；298 K；13% PEG3350, 0.25 M magnesium chloride, 0.1 M Tris
|
Resolution 2.39 Å
R-free 0.244
|
|
6AMT
Human Class I MHC HLA-A2 in complex with synthetic peptide MMWDRGLGMM
Deposited 2017-08-11
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.4；298 K；25% PEG1000, 0.01% sodium azide, 0.1 M MES
|
Resolution 2.50 Å
R-free 0.249
|
|
6AMT
Human Class I MHC HLA-A2 in complex with synthetic peptide MMWDRGLGMM
Deposited 2017-08-11
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.4；298 K；25% PEG1000, 0.01% sodium azide, 0.1 M MES
|
Resolution 2.50 Å
R-free 0.249
|
|
6AMU
Crystal structure of DMF5 TCR bound to HLA-A2 presenting synthetic peptide MMWDRGLGMM
Deposited 2017-08-11
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.9；298 K；18% PEG3350, 0.25 M magnesium chloride, 0.1 M HEPES
|
Resolution 2.15 Å
R-free 0.226
|
|
6APN
HLA-A*0201 single chain trimer with HPV.16 E7 peptide LLMGTLGIV
Deposited 2017-08-17
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；295 K；0.1 M MES, pH 6,5, 25% PEG 2000 MME
|
Resolution 2.22 Å
R-free 0.260
|
|
6APN
HLA-A*0201 single chain trimer with HPV.16 E7 peptide LLMGTLGIV
Deposited 2017-08-17
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；295 K；0.1 M MES, pH 6,5, 25% PEG 2000 MME
|
Resolution 2.22 Å
R-free 0.260
|
|
6AT5
Crystal structure of HLA-B*07:02 in complex with an NY-ESO-1 peptide
Deposited 2017-08-27
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
1–119（119 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277 K；0.2 M NaCl and 20 % PEG 3350
|
Resolution 1.50 Å
R-free 0.230
|
|
6AT9
Crystal structure of an anaplastic lymphoma kinase-derived neuroblastoma tumor antigen bound to the Human Major Histocompatibility Complex Class I molecule HLA-A*0101
Deposited 2017-08-28
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；295 K；0.18M MgCl2, 0.1M Na-HEPES(7.5),27%PEG400, 10%Glycerol
|
Resolution 2.95 Å
R-free 0.307
|
|
6AVF
Crystal structure of the KFJ5 TCR-NY-ESO-1-HLA-B*07:02 complex
Deposited 2017-09-02
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain M
21–119（99 aa）
Fragment：UNP residues 13-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；0.1 M MIB pH 7.0 and 25 % (w/v) PEG 1500
|
Resolution 2.03 Å
R-free 0.256
|
|
6AVG
Crystal structure of the KFJ37 TCR-NY-ESO-1-HLA-B*07:02 complex
Deposited 2017-09-02
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain H
13–119（107 aa）
Fragment：UNP residues 13-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.8；293 K；0.1 M BTP pH 8.8, 0.2 M Na-Iodide, 14 % w/v PEG 3350 and 2 % w/v PEG 20000
|
Resolution 2.60 Å
R-free 0.248
|
|
6AVG
Crystal structure of the KFJ37 TCR-NY-ESO-1-HLA-B*07:02 complex
Deposited 2017-09-02
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain A
13–119（107 aa）
Fragment：UNP residues 13-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.8；293 K；0.1 M BTP pH 8.8, 0.2 M Na-Iodide, 14 % w/v PEG 3350 and 2 % w/v PEG 20000
|
Resolution 2.60 Å
R-free 0.248
|
|
6BJ2
TCR589 in complex with HIV(Pol448-456)/HLA-B35
Deposited 2017-11-03
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
ZN ZINC ION × 3
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 8；295 K；0.1 M Tris, pH 8.0, 20% PEG3350, 0.002 M zinc chloride
|
Resolution 3.35 Å
R-free 0.276
|
|
6BJ3
TCR55 in complex with HIV(Pol448-456)/HLA-B35
Deposited 2017-11-03
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 3
SO4 SULFATE ION × 5
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；295 K；PEG4000, 0.1 M sodium cacodylate, pH 6.0, 0.2 M ammonium sulfate
|
Resolution 1.90 Å
R-free 0.216
|
|
6BJ8
TCR55 in complex with Pep20/HLA-B35
Deposited 2017-11-05
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 27
PO4 PHOSPHATE ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；295 K；0.04 M potassium phosphate monobasic, 16% w/v PEG8000, 20% v/v glycerol
|
Resolution 1.75 Å
R-free 0.183
|
|
6BXP
Crystal Structure of HLA-B*57:01 with a modified HIV peptide RKV-Kyn
Deposited 2017-12-18
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
ACT ACETATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；18%PEG4000, 0.2M NH4 Ac, 0.1M NaCitrate
|
Resolution 1.45 Å
R-free 0.194
|
|
6BXQ
Crystal Structure of HLA-B*57:01 with an HIV peptide RKV
Deposited 2017-12-18
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain C
21–119（99 aa）
Fragment：residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；18%PEG4000, 0.2M NH4 Ac, 0.1M NaCitrate
|
Resolution 1.58 Å
R-free 0.203
|
|
6C09
Ternary crystal structure of the 3C8 TCR-CD1c-monoacylglycerol complex
Deposited 2017-12-28
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
EKG (2R)-2,3-dihydroxypropyl hexadecanoate × 1
D10 DECANE × 2
K POTASSIUM ION × 3
EDO 1,2-ETHANEDIOL × 3
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；20% PEG 3350, 0.2M potassium thiocynate
|
Resolution 2.95 Å
R-free 0.208
|
|
6C15
CD1c in complex with phosphatidylcholine
Deposited 2018-01-03
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3
D12 DODECANE × 1
6PL (4S,7R)-4-HYDROXY-N,N,N-TRIMETHYL-9-OXO-7-[(PALMITOYLOXY)METHYL]-3,5,8-TRIOXA-4-PHOSPHAHEXACOSAN-1-AMINIUM 4-OXIDE × 1
NA SODIUM ION × 1
SO4 SULFATE ION × 1
BME BETA-MERCAPTOETHANOL × 1
EDO 1,2-ETHANEDIOL × 1
MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；10% Dioxane; 1.6 M Ammonium sulfate; 10 mM MES, pH 6.5
|
Resolution 3.21 Å
R-free 0.242
|
|
6C97
Crystal structure of FcRn at pH3
Deposited 2018-01-25
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 3；289 K；APO FCRN CRYSTALS WERE PRODUCED BY SITTING DROP VAPOR DIFFUSION WITH AN EQUAL VOLUME COMBINATION OF THE PROTEIN COMPLEX, PROVIDED IN A
PROTEIN SOLUTION CONTAINING 50MM HEPES PH 7.0 AND 75MM NACL,
AND AN OPTIMIZATION SCREEN CONTAINING 0.1M CITRIC ACID/NAOH PH
3.01-3.09 AND 12-16% W/V PEG 6,000.
|
Resolution 2.00 Å
R-free 0.210
|
|
6C97
Crystal structure of FcRn at pH3
Deposited 2018-01-25
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 3；289 K；APO FCRN CRYSTALS WERE PRODUCED BY SITTING DROP VAPOR DIFFUSION WITH AN EQUAL VOLUME COMBINATION OF THE PROTEIN COMPLEX, PROVIDED IN A
PROTEIN SOLUTION CONTAINING 50MM HEPES PH 7.0 AND 75MM NACL,
AND AN OPTIMIZATION SCREEN CONTAINING 0.1M CITRIC ACID/NAOH PH
3.01-3.09 AND 12-16% W/V PEG 6,000.
|
Resolution 2.00 Å
R-free 0.210
|
|
6C98
Crystal structure of FcRn bound to UCB-84
Deposited 2018-01-25
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
CYS CYSTEINE × 1
ER7 1-[7-(3-fluorophenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl]ethan-1-one × 1
GOL GLYCEROL × 1
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 3；289 K；APO FCRN CRYSTALS WERE PRODUCED BY SITTING DROP VAPOR DIFFUSION WITH AN EQUAL VOLUME COMBINATION OF THE PROTEIN COMPLEX, PROVIDED IN A PROTEIN SOLUTION CONTAINING 50MM HEPES PH 7.0 AND 75MM NACL,
AND AN OPTIMIZATION SCREEN CONTAINING 0.1M CITRIC ACID/NAOH PH
3.0 AND 20% W/V PEG 6,000. CRYSTALS OF FCRN WERE SOAKED FOR
THREE DAYS IN BUFFER CONTAINING 0.1M CITRIC ACID/NAOH PH 3.0,
20% W/V PEG 6,000, AND 20% GLYCEROL AND 20MM UCB-84).
|
Resolution 1.85 Å
R-free 0.213
|
|
6C98
Crystal structure of FcRn bound to UCB-84
Deposited 2018-01-25
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
CYS CYSTEINE × 1
ER7 1-[7-(3-fluorophenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl]ethan-1-one × 1
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 3；289 K；APO FCRN CRYSTALS WERE PRODUCED BY SITTING DROP VAPOR DIFFUSION WITH AN EQUAL VOLUME COMBINATION OF THE PROTEIN COMPLEX, PROVIDED IN A PROTEIN SOLUTION CONTAINING 50MM HEPES PH 7.0 AND 75MM NACL,
AND AN OPTIMIZATION SCREEN CONTAINING 0.1M CITRIC ACID/NAOH PH
3.0 AND 20% W/V PEG 6,000. CRYSTALS OF FCRN WERE SOAKED FOR
THREE DAYS IN BUFFER CONTAINING 0.1M CITRIC ACID/NAOH PH 3.0,
20% W/V PEG 6,000, AND 20% GLYCEROL AND 20MM UCB-84).
|
Resolution 1.85 Å
R-free 0.213
|
|
6C99
Crystal structure of FcRn bound to UCB-303
Deposited 2018-01-25
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EQY methyl 7-(3,5-difluorophenyl)-5-(pyridin-3-yl)[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxylate × 1
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
GOL GLYCEROL × 5
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 3；289 K；APO FCRN CRYSTALS WERE PRODUCED BY SITTING DROP VAPOR DIFFUSION WITH AN EQUAL VOLUME COMBINATION OF THE PROTEIN COMPLEX, PROVIDED IN A
PROTEIN SOLUTION CONTAINING 50MM HEPES PH 7.0 AND 75MM NACL,
AND AN OPTIMIZATION SCREEN CONTAINING 0.1M CITRIC ACID/NAOH PH
3.01-3.09 AND 12-16% W/V PEG 6,000. CRYSTALS OF FCRN WERE SOAKED FOR THREE DAYS IN BUFFER CONTAINING 0.1M CITRIC ACID/NAOH PH 3.0, 20% W/V PEG6,000, AND 20% GLYCEROL AND 12.5MM UCB-303.
|
Resolution 2.00 Å
R-free 0.220
|
|
6C99
Crystal structure of FcRn bound to UCB-303
Deposited 2018-01-25
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
EQY methyl 7-(3,5-difluorophenyl)-5-(pyridin-3-yl)[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxylate × 1
CIT CITRIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 3；289 K；APO FCRN CRYSTALS WERE PRODUCED BY SITTING DROP VAPOR DIFFUSION WITH AN EQUAL VOLUME COMBINATION OF THE PROTEIN COMPLEX, PROVIDED IN A
PROTEIN SOLUTION CONTAINING 50MM HEPES PH 7.0 AND 75MM NACL,
AND AN OPTIMIZATION SCREEN CONTAINING 0.1M CITRIC ACID/NAOH PH
3.01-3.09 AND 12-16% W/V PEG 6,000. CRYSTALS OF FCRN WERE SOAKED FOR THREE DAYS IN BUFFER CONTAINING 0.1M CITRIC ACID/NAOH PH 3.0, 20% W/V PEG6,000, AND 20% GLYCEROL AND 12.5MM UCB-303.
|
Resolution 2.00 Å
R-free 0.220
|
|
6CUG
Crystal structure of BC8B TCR-CD1b-PC complex
Deposited 2018-03-26
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
CUY tetracosyl octadecanoate × 1
POV (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate × 1
CL CHLORIDE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.2；293 K；PEG 3350, Tris-HCl
|
Resolution 2.40 Å
R-free 0.229
|
|
6D29
HLA-B*57:01 presenting TSMSFVPRPW
Deposited 2018-04-13
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.4；294 K；18 % PEG 4000, 0.2 M ammonium acetate and 0.1 M tri-sodium citrate pH 5.4.
|
Resolution 1.88 Å
R-free 0.222
|
|
6D2B
HLA-B*57:01 presenting LSDSTARDVTW
Deposited 2018-04-13
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.4；294 K；18 % PEG 4000, 0.2 M ammonium acetate and 0.1 M tri-sodium citrate pH 5.4.
|
Resolution 2.04 Å
R-free 0.212
|
|
6D2R
HLA-B*57:01 presenting GSFDYSGVHLW
Deposited 2018-04-13
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.4；294 K；18 % PEG 4000, 0.2 M ammonium acetate and 0.1 M tri-sodium citrate pH 5.4.
|
Resolution 1.83 Å
R-free 0.207
|
|
6D2T
HLA-B*57:01 presenting LALLTGVRW
Deposited 2018-04-13
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.4；294 K；18 % PEG 4000, 0.2 M ammonium acetate and 0.1 M tri-sodium citrate pH 5.4.
|
Resolution 1.90 Å
R-free 0.203
|
|
6D64
Crystal Structure of Human CD1b in Complex with POPC
Deposited 2018-04-20
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
POV (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate × 1
CUY tetracosyl octadecanoate × 1
CL CHLORIDE ION × 7
EDO 1,2-ETHANEDIOL × 3
NA SODIUM ION × 1
IOD IODIDE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG 3350, 0.2M Sodium Iodide, Ethylene Glycol
|
Resolution 1.70 Å
R-free 0.211
|
|
6D78
The complex between high-affinity TCR DMF5(alpha-D26Y,beta-L98W) and human Class I MHC HLA-A2 with the bound MART-1(27-35)peptide
Deposited 2018-04-24
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；0.1 M Tris, 12% PEG6000, 0.2 M magnesium chloride
|
Resolution 2.35 Å
R-free 0.255
|
|
6D7G
Structure of 5F3 TCR in complex with HLA-A2/MART-1
Deposited 2018-04-24
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain A
21–119（99 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；295.15 K；PEG 550 MME, TRIS, VAPOR DIFFUSION,
SITTING DROP, TEMPERATURE 295K
|
Resolution 2.75 Å
R-free 0.237
|
|
6DKP
The complex among DMF5(alpha-D26Y, alpha-Y50A,beta-L98W) TCR, human Class I MHC HLA-A2 and MART-1(26-35)(A27L) peptide
Deposited 2018-05-30
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；12% Peg 3350, 250mM MgCl2, 0.1M HEPES
|
Resolution 2.97 Å
R-free 0.286
|
|
6EI2
Crystal Structure of HLA-A68 presenting a C-terminally extended peptide
Deposited 2017-09-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 6
NI NICKEL (II) ION × 3
CD CADMIUM ION × 2
CO COBALT (II) ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；298 K；12% PEG3350
0.005M cobalt chloride
0.005M cadmium chloride
0.005M nickel chloride
0.005M magnesium chloride
0.1M HEPES pH 7.5
|
Resolution 1.61 Å
R-free 0.181
|
|
6ENY
Structure of the human PLC editing module
Deposited 2017-10-07
|
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 5.80 Å
|
|
6EQA
HLA class I histocompatibility antigen
Deposited 2017-10-12
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.1 M HEPES pH 7.5, 25% PEG 4000 and 15% glycerol
|
Resolution 3.16 Å
R-free 0.263
|
|
6EQB
HLA class I histocompatibility antigen
Deposited 2017-10-12
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 2
SO4 SULFATE ION × 4
EDO 1,2-ETHANEDIOL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.1 M HEPES pH 7.0, 20% PEG 4000 and 15% glycerol
|
Resolution 2.81 Å
R-free 0.251
|
|
6EWA
Crystal structure of HLA-A2 in complex with LILRB1
Deposited 2017-11-03
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；17.5% PEG 3350, 0.2M Ammonium acetate, 0.1M Tris HCL
|
Resolution 2.39 Å
R-free 0.279
|
|
6EWA
Crystal structure of HLA-A2 in complex with LILRB1
Deposited 2017-11-03
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain F
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；17.5% PEG 3350, 0.2M Ammonium acetate, 0.1M Tris HCL
|
Resolution 2.39 Å
R-free 0.279
|
|
6EWC
Crystal structure of non-phosphorylated form of RLS PHOSPHOPEPTIDE BOUND TO HLA-A2 in complex with LILRB1
Deposited 2017-11-03
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；298 K；12.8% PEG 3350, 3% Tacsimate, 10% dimethyl sulphoxide
|
Resolution 3.20 Å
R-free 0.246
|
|
6EWC
Crystal structure of non-phosphorylated form of RLS PHOSPHOPEPTIDE BOUND TO HLA-A2 in complex with LILRB1
Deposited 2017-11-03
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain F
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；298 K；12.8% PEG 3350, 3% Tacsimate, 10% dimethyl sulphoxide
|
Resolution 3.20 Å
R-free 0.246
|
|
6EWO
Crystal structure of non-phosphorylated form of RTF PHOSPHOPEPTIDE BOUND TO HLA-A2 in complex with LILRB1
Deposited 2017-11-06
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；20% PEG 3350, 0.2M Potassium sodium tartrate
|
Resolution 2.30 Å
R-free 0.276
|
|
6EWO
Crystal structure of non-phosphorylated form of RTF PHOSPHOPEPTIDE BOUND TO HLA-A2 in complex with LILRB1
Deposited 2017-11-06
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain F
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；20% PEG 3350, 0.2M Potassium sodium tartrate
|
Resolution 2.30 Å
R-free 0.276
|
|
6FGB
Human FcRn extra-cellular domain complexed with Fab fragment of Rozanolixizumab
Deposited 2018-01-10
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
CL CHLORIDE ION × 2
NA SODIUM ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；291.15 K；0.1M Sodium citrate pH 5.5, 11% PEG6000
|
Resolution 2.90 Å
R-free 0.284
|
|
6G3J
MHC A02 Allele presenting MTSAIGILVP
Deposited 2018-03-26
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K
|
Resolution 2.45 Å
R-free 0.270
|
|
6G3J
MHC A02 Allele presenting MTSAIGILVP
Deposited 2018-03-26
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K
|
Resolution 2.45 Å
R-free 0.270
|
|
6G3K
MHC A02 Allele presenting MTSAIGILPV
Deposited 2018-03-26
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K
|
Resolution 2.90 Å
R-free 0.287
|
|
6G3K
MHC A02 Allele presenting MTSAIGILPV
Deposited 2018-03-26
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K
|
Resolution 2.90 Å
R-free 0.287
|
|
6GGM
HLA-E*01:03 in complex with the Mtb44 peptide variant: Mtb44*P2-Phe.
Deposited 2018-05-03
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
ZN ZINC ION × 3
SO4 SULFATE ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293.5 K；2.0 M Ammonium Sulphate, 0.1 M MES, 1mM ZnSO4
|
Resolution 2.73 Å
R-free 0.221
|
|
6GGM
HLA-E*01:03 in complex with the Mtb44 peptide variant: Mtb44*P2-Phe.
Deposited 2018-05-03
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
ZN ZINC ION × 1
SO4 SULFATE ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293.5 K；2.0 M Ammonium Sulphate, 0.1 M MES, 1mM ZnSO4
|
Resolution 2.73 Å
R-free 0.221
|
|
6GH1
HLA-E*01:03 in complex with Mtb44
Deposited 2018-05-04
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293.5 K；2.4 M Ammonium Sulphate, 0.1 M MES, pH 6
|
Resolution 2.10 Å
R-free 0.229
|
|
6GH1
HLA-E*01:03 in complex with Mtb44
Deposited 2018-05-04
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain H
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 2
ZN ZINC ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293.5 K；2.4 M Ammonium Sulphate, 0.1 M MES, pH 6
|
Resolution 2.10 Å
R-free 0.229
|
|
6GH1
HLA-E*01:03 in complex with Mtb44
Deposited 2018-05-04
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293.5 K；2.4 M Ammonium Sulphate, 0.1 M MES, pH 6
|
Resolution 2.10 Å
R-free 0.229
|
|
6GH1
HLA-E*01:03 in complex with Mtb44
Deposited 2018-05-04
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain F
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293.5 K；2.4 M Ammonium Sulphate, 0.1 M MES, pH 6
|
Resolution 2.10 Å
R-free 0.229
|
|
6GH4
HLA-E*01:03 in complex with the Mtb44 peptide variant: Mtb44*P2-Gln.
Deposited 2018-05-04
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；293.5 K；2.4 M Ammonium Sulphate, 0.1 M HEPES, pH 7
|
Resolution 2.16 Å
R-free 0.242
|
|
6GH4
HLA-E*01:03 in complex with the Mtb44 peptide variant: Mtb44*P2-Gln.
Deposited 2018-05-04
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 3
ZN ZINC ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；293.5 K；2.4 M Ammonium Sulphate, 0.1 M HEPES, pH 7
|
Resolution 2.16 Å
R-free 0.242
|
|
6GH4
HLA-E*01:03 in complex with the Mtb44 peptide variant: Mtb44*P2-Gln.
Deposited 2018-05-04
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain F
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；293.5 K；2.4 M Ammonium Sulphate, 0.1 M HEPES, pH 7
|
Resolution 2.16 Å
R-free 0.242
|
|
6GH4
HLA-E*01:03 in complex with the Mtb44 peptide variant: Mtb44*P2-Gln.
Deposited 2018-05-04
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain H
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；293.5 K；2.4 M Ammonium Sulphate, 0.1 M HEPES, pH 7
|
Resolution 2.16 Å
R-free 0.242
|
|
6GHN
HLA-E*01:03 in complex with the Mtb44 peptide variant: Mtb44*P9-Phe.
Deposited 2018-05-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；293.5 K；2.4 M Ammonium Sulphate, 0.1 M HEPES, pH 7
|
Resolution 2.54 Å
R-free 0.264
|
|
6GHN
HLA-E*01:03 in complex with the Mtb44 peptide variant: Mtb44*P9-Phe.
Deposited 2018-05-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；293.5 K；2.4 M Ammonium Sulphate, 0.1 M HEPES, pH 7
|
Resolution 2.54 Å
R-free 0.264
|
|
6GK3
Two protofilament beta-2-microglobulin amyloid fibril
Deposited 2018-05-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 8
PDB declaration: octameric
|
Chain A
42–105（64 aa）
Chain B
42–105（64 aa）
Chain C
42–105（64 aa）
Chain D
42–105（64 aa）
Chain E
42–105（64 aa）
Chain F
42–105（64 aa）
Chain G
42–105（64 aa）
Chain H
42–105（64 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 2.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.98 Å
|
|
6GL1
HLA-E*01:03 in complex with the HIV epitope, RL9HIV
Deposited 2018-05-22
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293.5 K；2.4 M Ammonium Sulphate, 0.1 M MES, pH 6, 0.05% dichloromethane
|
Resolution 2.62 Å
R-free 0.273
|
|
6GL1
HLA-E*01:03 in complex with the HIV epitope, RL9HIV
Deposited 2018-05-22
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293.5 K；2.4 M Ammonium Sulphate, 0.1 M MES, pH 6, 0.05% dichloromethane
|
Resolution 2.62 Å
R-free 0.273
|
|
6GL1
HLA-E*01:03 in complex with the HIV epitope, RL9HIV
Deposited 2018-05-22
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain F
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293.5 K；2.4 M Ammonium Sulphate, 0.1 M MES, pH 6, 0.05% dichloromethane
|
Resolution 2.62 Å
R-free 0.273
|
|
6GL1
HLA-E*01:03 in complex with the HIV epitope, RL9HIV
Deposited 2018-05-22
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain H
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 1
ZN ZINC ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293.5 K；2.4 M Ammonium Sulphate, 0.1 M MES, pH 6, 0.05% dichloromethane
|
Resolution 2.62 Å
R-free 0.273
|
|
6ID4
Defining the structural basis for human alloantibody binding to human leukocyte antigen allele HLA-A*11:01
Deposited 2018-09-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 3
PEG DI(HYDROXYETHYL)ETHER × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；1,4-Dioxane, Tris pH 8.2, Polyethylene glycol 3,350
|
Resolution 2.40 Å
R-free 0.246
|
|
6ID4
Defining the structural basis for human alloantibody binding to human leukocyte antigen allele HLA-A*11:01
Deposited 2018-09-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain F
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 2
PEG DI(HYDROXYETHYL)ETHER × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；1,4-Dioxane, Tris pH 8.2, Polyethylene glycol 3,350
|
Resolution 2.40 Å
R-free 0.246
|
|
6IEX
Crystal structure of HLA-B*4001 in complex with SARS-CoV derived peptide N216-225 GETALALLLL
Deposited 2018-09-17
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；0.1M sodium citrate tribasic dehydrate, pH 6.5 and 18% w-v polyethylene glycol 3350
|
Resolution 2.31 Å
R-free 0.261
|
|
6ILM
Cryo-EM structure of Echovirus 6 complexed with its uncoating receptor FcRn at PH 7.4
Deposited 2018-10-19
|
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 360
PDB declaration: 540-meric
|
Chain F
21–119（99 aa）
|
Not recorded
|
SPH SPHINGOSINE × 60
K POTASSIUM ION × 60
NA SODIUM ION × 60
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.40 Å
|
|
6ILM
Cryo-EM structure of Echovirus 6 complexed with its uncoating receptor FcRn at PH 7.4
Deposited 2018-10-19
|
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 6
PDB declaration: nonameric
|
Chain F
21–119（99 aa）
|
Not recorded
|
SPH SPHINGOSINE × 1
K POTASSIUM ION × 1
NA SODIUM ION × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.40 Å
|
|
6ILM
Cryo-EM structure of Echovirus 6 complexed with its uncoating receptor FcRn at PH 7.4
Deposited 2018-10-19
|
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 30
PDB declaration: 45-meric
|
Chain F
21–119（99 aa）
|
Not recorded
|
SPH SPHINGOSINE × 5
K POTASSIUM ION × 5
NA SODIUM ION × 5
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.40 Å
|
|
6ILM
Cryo-EM structure of Echovirus 6 complexed with its uncoating receptor FcRn at PH 7.4
Deposited 2018-10-19
|
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 36
PDB declaration: 54-meric
|
Chain F
21–119（99 aa）
|
Not recorded
|
SPH SPHINGOSINE × 6
K POTASSIUM ION × 6
NA SODIUM ION × 6
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.40 Å
|
|
6ILM
Cryo-EM structure of Echovirus 6 complexed with its uncoating receptor FcRn at PH 7.4
Deposited 2018-10-19
|
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 5
Protein heterocomplex
Heteromer；Protein × 6
PDB declaration: nonameric
|
Chain F
21–119（99 aa）
|
Not recorded
|
SPH SPHINGOSINE × 1
K POTASSIUM ION × 1
NA SODIUM ION × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.40 Å
|
|
6J1V
The structure of HLA-A*3003/RT313
Deposited 2018-12-29
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；291 K；0.1 M HEPES (pH 7.5), 25% (w/v) polyethylene glycol 3350
|
Resolution 2.00 Å
R-free 0.217
|
|
6J1W
The structure of HLA-A*3001/RT313
Deposited 2018-12-29
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；291 K；0.1 M sodium citrate tribasic dehydrate (pH 5.5)
|
Resolution 1.50 Å
R-free 0.205
|
|
6J29
The structure of HLA-A*3003/MTB
Deposited 2018-12-31
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.6；291 K；0.2M Potassium Sodium Tartrate tetrahydrate, 0.1M Tri-Sodium Citrate dihydrate(pH 5.6), 2.0M Ammonium Sulfate
|
Resolution 1.60 Å
R-free 0.197
|
|
6J2A
The structure of HLA-A*3003/NP44
Deposited 2018-12-31
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.6；291 K；0.1M Tri-Sodium Citrate dihydrate (pH 5.6), 1.0M Lithium Sulfate monohydrate
|
Resolution 1.40 Å
R-free 0.195
|
|
6J2E
Crystal structure of bat (Pteropus Alecto) MHC class I Ptal-N*01:01 in complex with Ebola virus-derived peptide EBOV-NP1
Deposited 2019-01-01
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.1M succinic acid pH 7.0, 15%(w/v) polyethylene glycol 3,350
|
Resolution 2.10 Å
R-free 0.257
|
|
6J2E
Crystal structure of bat (Pteropus Alecto) MHC class I Ptal-N*01:01 in complex with Ebola virus-derived peptide EBOV-NP1
Deposited 2019-01-01
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.1M succinic acid pH 7.0, 15%(w/v) polyethylene glycol 3,350
|
Resolution 2.10 Å
R-free 0.257
|
|
6J2G
Crystal structure of bat (Pteropus Alecto) MHC class I Ptal-N*01:01 in complex with Ebola virus-derived peptide EBOV-NP2
Deposited 2019-01-01
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.2 M ammonium acetate, 0.1 M Tris pH 8.0, 16% w/v polyethylene glycol 10,000
|
Resolution 2.41 Å
R-free 0.233
|
|
6J2G
Crystal structure of bat (Pteropus Alecto) MHC class I Ptal-N*01:01 in complex with Ebola virus-derived peptide EBOV-NP2
Deposited 2019-01-01
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.2 M ammonium acetate, 0.1 M Tris pH 8.0, 16% w/v polyethylene glycol 10,000
|
Resolution 2.41 Å
R-free 0.233
|
|
6J2H
Crystal structure of bat (Pteropus Alecto) MHC class I Ptal-N*01:01 mutant (Met52 Asp53 Leu54 deleted) in complex with Hendra virus-derived peptide HeV1
Deposited 2019-01-01
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.2M sodium formate, 20%(w/v) polyethylene glycol 3,350
|
Resolution 2.30 Å
R-free 0.228
|
|
6J2H
Crystal structure of bat (Pteropus Alecto) MHC class I Ptal-N*01:01 mutant (Met52 Asp53 Leu54 deleted) in complex with Hendra virus-derived peptide HeV1
Deposited 2019-01-01
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.2M sodium formate, 20%(w/v) polyethylene glycol 3,350
|
Resolution 2.30 Å
R-free 0.228
|
|
6J2I
Crystal structure of bat (Pteropus Alecto) MHC class I Ptal-N*01:01 in complex with H17N10 influenza-like virus-derivrd peptide H17N10-NP
Deposited 2019-01-01
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.075 M HEPES pH 7.5, 15% w/v polyethylene glycol 10,000, 25% v/v glycerol.
|
Resolution 2.30 Å
R-free 0.253
|
|
6J2I
Crystal structure of bat (Pteropus Alecto) MHC class I Ptal-N*01:01 in complex with H17N10 influenza-like virus-derivrd peptide H17N10-NP
Deposited 2019-01-01
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.075 M HEPES pH 7.5, 15% w/v polyethylene glycol 10,000, 25% v/v glycerol.
|
Resolution 2.30 Å
R-free 0.253
|
|
6J2J
Crystal structure of bat (Pteropus Alecto) MHC class I Ptal-N*01:01 in complex with MERS-CoV-derived peptide MERS-CoV-S3
Deposited 2019-01-01
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.2 M sodium acetate trihydrate, 20% w/v polyethylene glycol 3,350
|
Resolution 2.50 Å
R-free 0.267
|
|
6J2J
Crystal structure of bat (Pteropus Alecto) MHC class I Ptal-N*01:01 in complex with MERS-CoV-derived peptide MERS-CoV-S3
Deposited 2019-01-01
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.2 M sodium acetate trihydrate, 20% w/v polyethylene glycol 3,350
|
Resolution 2.50 Å
R-free 0.267
|
|
6JOZ
Crystal structure of BRLF peptide from EBV in complex with HLA-A1101.
Deposited 2019-03-25
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 7
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；289 K；0.2M LITHIUM SULFATE MONOHYDRATE,
0.1M TRIS-HCL, 30% PEG 4000
|
Resolution 1.35 Å
R-free 0.189
|
|
6JP3
Crystal structure of peptide in complex with HLA-A1101.
Deposited 2019-03-25
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5；289 K；0.2M Sodium malonate, 20% PEG 3350
|
Resolution 1.66 Å
R-free 0.194
|
|
6JTN
Crystal structure of HLA-C08 in complex with a tumor mut10m peptide
Deposited 2019-04-11
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–118（98 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；0.2M ammonium acetate, 0.1M HEPES (pH 7.5), 25% w/v polyethylene glycol 3350
|
Resolution 1.90 Å
R-free 0.200
|
|
6JTO
Crystal structure of HLA-C05 in complex with a tumor mut10m peptide
Deposited 2019-04-11
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–118（98 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；0.2M ammonium acetate, 0.1M HEPES (pH 7.5), 25% w/v polyethylene glycol 3350
|
Resolution 1.70 Å
R-free 0.208
|
|
6JTP
Crystal structure of HLA-C08 in complex with a tumor mut9m peptide
Deposited 2019-04-11
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–118（98 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；0.2M ammonium acetate, 0.1M HEPES (pH 7.5), 25% w/v polyethylene glycol 3350
|
Resolution 1.90 Å
R-free 0.283
|
|
6K60
Structural and functional basis for HLA-G isoform recognition of immune checkpoint receptor LILRBs
Deposited 2019-05-31
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
IOD IODIDE ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；0.2M sodium iodide, 0.1M Bis Tris propane (pH 8.5), 20% PEG 3350
|
Resolution 3.15 Å
R-free 0.289
|
|
6K60
Structural and functional basis for HLA-G isoform recognition of immune checkpoint receptor LILRBs
Deposited 2019-05-31
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain F
21–119（99 aa）
|
Not recorded
|
IOD IODIDE ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；0.2M sodium iodide, 0.1M Bis Tris propane (pH 8.5), 20% PEG 3350
|
Resolution 3.15 Å
R-free 0.289
|
|
6K7T
Crystal structure of bat (Pteropus Alecto) MHC class I Ptal-N*01:01 in complex with Hendra virus-derived peptide HeV1--human beta-2 microglobulin
Deposited 2019-06-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.1 M HEPES pH 7.0, 2% w/v Polyethylene glycol 3350
|
Resolution 1.60 Å
R-free 0.234
|
|
6LA6
Cryo-EM structure of echovirus 11 complexed with its uncoating receptor FcRn at pH 7.4
Deposited 2019-11-12
|
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 360
PDB declaration: 360-meric
|
Chain F
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.39 Å
|
|
6LA6
Cryo-EM structure of echovirus 11 complexed with its uncoating receptor FcRn at pH 7.4
Deposited 2019-11-12
|
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain F
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.39 Å
|
|
6LA6
Cryo-EM structure of echovirus 11 complexed with its uncoating receptor FcRn at pH 7.4
Deposited 2019-11-12
|
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 30
PDB declaration: 30-meric
|
Chain F
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.39 Å
|
|
6LA6
Cryo-EM structure of echovirus 11 complexed with its uncoating receptor FcRn at pH 7.4
Deposited 2019-11-12
|
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 36
PDB declaration: 36-meric
|
Chain F
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.39 Å
|
|
6LA6
Cryo-EM structure of echovirus 11 complexed with its uncoating receptor FcRn at pH 7.4
Deposited 2019-11-12
|
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 5
Protein heterocomplex
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain F
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.39 Å
|
|
6LA7
Cryo-EM structure of echovirus 11 complexed with its uncoating receptor FcRn at pH 5.5
Deposited 2019-11-12
|
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 360
PDB declaration: 360-meric
|
Chain F
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 5.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.82 Å
|
|
6LA7
Cryo-EM structure of echovirus 11 complexed with its uncoating receptor FcRn at pH 5.5
Deposited 2019-11-12
|
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain F
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 5.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.82 Å
|
|
6LA7
Cryo-EM structure of echovirus 11 complexed with its uncoating receptor FcRn at pH 5.5
Deposited 2019-11-12
|
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 30
PDB declaration: 30-meric
|
Chain F
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 5.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.82 Å
|
|
6LA7
Cryo-EM structure of echovirus 11 complexed with its uncoating receptor FcRn at pH 5.5
Deposited 2019-11-12
|
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 36
PDB declaration: 36-meric
|
Chain F
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 5.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.82 Å
|
|
6LA7
Cryo-EM structure of echovirus 11 complexed with its uncoating receptor FcRn at pH 5.5
Deposited 2019-11-12
|
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 5
Protein heterocomplex
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain F
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 5.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.82 Å
|
|
6M1B
A new V27M variant of beta 2 microglobulin induced amyloidosis in a patient with long-term hemodialysis
Deposited 2020-02-25
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 4
MG MAGNESIUM ION × 2
CA CALCIUM ION × 2
PO4 PHOSPHATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG 4000, ammonium acetate, glycerol, Phosphate buffer
|
Resolution 1.88 Å
R-free 0.246
|
|
6M24
Uncommon structural features of rabbit MHC class I (RLA-A1) complexed with rabbit haemorrhagic disease virus (RHDV) derived peptide, VP60-2
Deposited 2020-02-26
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5；291 K；0.2M magnesium chloride hexahydrate, 0.1M sodium citrate tribasic, pH 5.0, 10% w/v polyethylene glycol 20000
|
Resolution 2.29 Å
R-free 0.246
|
|
6M2J
Uncommon structural features of rabbit MHC class I (RLA-A1) complexed with rabbit haemorrhagic disease virus (RHDV) derived peptide, VP60-1
Deposited 2020-02-27
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；291 K；0.1M imidazole (pH 7.0), 12% w/v polyethylene glycol 2000
|
Resolution 2.20 Å
R-free 0.256
|
|
6M2K
Uncommon structural features of rabbit MHC class I (RLA-A1) complexed with rabbit haemorrhagic disease virus (RHDV) derived peptide, VP60-10
Deposited 2020-02-27
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；291 K；0.1 M BIS-TRIS PH 6.5, 20% w/v PEG 5000
|
Resolution 2.59 Å
R-free 0.294
|
|
6MPP
HLA-A*01:01 complex with NRAS Q61K peptide by NMR
Deposited 2018-10-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain C
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
SOLUTION NMR
NMR measurement conditions
pH 7.2；298 K；Ionic strength (raw mmCIF value) 20；Pressure 1
NMR sample composition
300 uM [U-99% 13C; U-99% 15N] MHC-I HLA-A01:01, 300 uM NRAS Q16K, 300 uM Hb2M, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition
180 uM [U-15N; U-2H]; [U-15N; U-2H; Methyl-1H; Methyl-13C]-Ala, Ile, Leu & Val MHC-I HLA-A01:01, 180 uM NRAS Q16K, 180 uM Hb2M, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition
210 uM [U-15N; U-2H]; [U-15N; U-2H; Methyl-1H; Methyl-13C]-Ala, Ile, Leu & Val; [U-13C; U-15N]-Phe & Tyr MHC-I HLA-A01:01, 210 uM [U-15N] NRAS Q16K, 210 uM [U-2H] Hb2M, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition
170 uM [U-15N; U-2H]; [U-15N; U-2H; Methyl-1H; Methyl-13C]-Ala, Ile, Leu & Val MHC-I HLA-A01:01, 170 uM NRAS Q16K, 170 uM Hb2M, 100% D2O | 100% D2O
|
Resolution not provided
|
|
6MT3
Crystal Structure of HLA-B*18:01 in complex with NP338 influenza peptide
Deposited 2018-10-19
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain C
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；20% PEG6000, 0.2M NaCl, 0.1M Na citrate pH 6.5
|
Resolution 1.21 Å
R-free 0.214
|
|
6MT4
Crystal Structure of HLA-B*37:01 in complex with NP338-L7S influenza peptide
Deposited 2018-10-19
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；20% PEG6000, 0.2M NaCl, 0.1M Na citrate pH 6.5
|
Resolution 1.55 Å
R-free 0.251
|
|
6MT5
Crystal Structure of HLA-B*37:01 in complex with NP338-V6L influenza peptide
Deposited 2018-10-19
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；20% PEG6000, 0.2M NaCl, 0.1M Na citrate pH 6.5
|
Resolution 1.55 Å
R-free 0.207
|
|
6MT6
Crystal Structure of HLA-B*37:01 in complex with NP338 influenza peptide
Deposited 2018-10-19
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain C
21–119（99 aa）
|
Not recorded
|
ACT ACETATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；20% PEG6000, 0.2M NaCl, 0.1M Na citrate pH 6.5
|
Resolution 1.31 Å
R-free 0.193
|
|
6MTL
Crystal Structure of HLA-B*44:05 in complex with NP338 influenza peptide
Deposited 2018-10-19
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
ACT ACETATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；20% PEG6000, 0.2M NaCl, 0.1M Na citrate pH 6.5
|
Resolution 1.35 Å
R-free 0.210
|
|
6MTM
Crystal Structure of EM2 TCR in complex with HLA-B*37:01-NP338
Deposited 2018-10-19
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；277 K；19% PEG 3350, 0.2 ammonium tartrate
|
Resolution 3.00 Å
R-free 0.301
|
|
6MWR
Recognition of MHC-like molecule
Deposited 2018-10-30
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
2LJ 1-deoxy-1-({2,6-dioxo-5-[(E)-propylideneamino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-ribitol × 1
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；15-17% PEG3350
0.2M CaCl2
|
Resolution 3.30 Å
R-free 0.261
|
|
6NCA
HLA-A2 (A*02:01) bound to a peptide from the Epstein-Barr virus BRLF1 protein
Deposited 2018-12-11
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain i
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；10.5% (w/v) PEG 4000, 35 mM Tris base/ HCl (pH 8.5), 70 mM Li2SO4
|
Resolution 3.30 Å
R-free 0.303
|
|
6NCA
HLA-A2 (A*02:01) bound to a peptide from the Epstein-Barr virus BRLF1 protein
Deposited 2018-12-11
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 10
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain r
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；10.5% (w/v) PEG 4000, 35 mM Tris base/ HCl (pH 8.5), 70 mM Li2SO4
|
Resolution 3.30 Å
R-free 0.303
|
|
6NCA
HLA-A2 (A*02:01) bound to a peptide from the Epstein-Barr virus BRLF1 protein
Deposited 2018-12-11
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 11
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain h
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；10.5% (w/v) PEG 4000, 35 mM Tris base/ HCl (pH 8.5), 70 mM Li2SO4
|
Resolution 3.30 Å
R-free 0.303
|
|
6NCA
HLA-A2 (A*02:01) bound to a peptide from the Epstein-Barr virus BRLF1 protein
Deposited 2018-12-11
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 12
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain q
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；10.5% (w/v) PEG 4000, 35 mM Tris base/ HCl (pH 8.5), 70 mM Li2SO4
|
Resolution 3.30 Å
R-free 0.303
|
|
6NCA
HLA-A2 (A*02:01) bound to a peptide from the Epstein-Barr virus BRLF1 protein
Deposited 2018-12-11
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 13
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain g
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；10.5% (w/v) PEG 4000, 35 mM Tris base/ HCl (pH 8.5), 70 mM Li2SO4
|
Resolution 3.30 Å
R-free 0.303
|
|
6NCA
HLA-A2 (A*02:01) bound to a peptide from the Epstein-Barr virus BRLF1 protein
Deposited 2018-12-11
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 14
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain d
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；10.5% (w/v) PEG 4000, 35 mM Tris base/ HCl (pH 8.5), 70 mM Li2SO4
|
Resolution 3.30 Å
R-free 0.303
|
|
6NCA
HLA-A2 (A*02:01) bound to a peptide from the Epstein-Barr virus BRLF1 protein
Deposited 2018-12-11
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 15
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain n
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；10.5% (w/v) PEG 4000, 35 mM Tris base/ HCl (pH 8.5), 70 mM Li2SO4
|
Resolution 3.30 Å
R-free 0.303
|
|
6NCA
HLA-A2 (A*02:01) bound to a peptide from the Epstein-Barr virus BRLF1 protein
Deposited 2018-12-11
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 16
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain a
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；10.5% (w/v) PEG 4000, 35 mM Tris base/ HCl (pH 8.5), 70 mM Li2SO4
|
Resolution 3.30 Å
R-free 0.303
|
|
6NCA
HLA-A2 (A*02:01) bound to a peptide from the Epstein-Barr virus BRLF1 protein
Deposited 2018-12-11
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 17
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain k
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；10.5% (w/v) PEG 4000, 35 mM Tris base/ HCl (pH 8.5), 70 mM Li2SO4
|
Resolution 3.30 Å
R-free 0.303
|
|
6NCA
HLA-A2 (A*02:01) bound to a peptide from the Epstein-Barr virus BRLF1 protein
Deposited 2018-12-11
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 18
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain c
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；10.5% (w/v) PEG 4000, 35 mM Tris base/ HCl (pH 8.5), 70 mM Li2SO4
|
Resolution 3.30 Å
R-free 0.303
|
|
6NCA
HLA-A2 (A*02:01) bound to a peptide from the Epstein-Barr virus BRLF1 protein
Deposited 2018-12-11
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 19
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain s
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；10.5% (w/v) PEG 4000, 35 mM Tris base/ HCl (pH 8.5), 70 mM Li2SO4
|
Resolution 3.30 Å
R-free 0.303
|
|
6NCA
HLA-A2 (A*02:01) bound to a peptide from the Epstein-Barr virus BRLF1 protein
Deposited 2018-12-11
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain b
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；10.5% (w/v) PEG 4000, 35 mM Tris base/ HCl (pH 8.5), 70 mM Li2SO4
|
Resolution 3.30 Å
R-free 0.303
|
|
6NCA
HLA-A2 (A*02:01) bound to a peptide from the Epstein-Barr virus BRLF1 protein
Deposited 2018-12-11
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 20
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain m
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；10.5% (w/v) PEG 4000, 35 mM Tris base/ HCl (pH 8.5), 70 mM Li2SO4
|
Resolution 3.30 Å
R-free 0.303
|
|
6NCA
HLA-A2 (A*02:01) bound to a peptide from the Epstein-Barr virus BRLF1 protein
Deposited 2018-12-11
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain l
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；10.5% (w/v) PEG 4000, 35 mM Tris base/ HCl (pH 8.5), 70 mM Li2SO4
|
Resolution 3.30 Å
R-free 0.303
|
|
6NCA
HLA-A2 (A*02:01) bound to a peptide from the Epstein-Barr virus BRLF1 protein
Deposited 2018-12-11
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain j
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；10.5% (w/v) PEG 4000, 35 mM Tris base/ HCl (pH 8.5), 70 mM Li2SO4
|
Resolution 3.30 Å
R-free 0.303
|
|
6NCA
HLA-A2 (A*02:01) bound to a peptide from the Epstein-Barr virus BRLF1 protein
Deposited 2018-12-11
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 5
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain t
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；10.5% (w/v) PEG 4000, 35 mM Tris base/ HCl (pH 8.5), 70 mM Li2SO4
|
Resolution 3.30 Å
R-free 0.303
|
|
6NCA
HLA-A2 (A*02:01) bound to a peptide from the Epstein-Barr virus BRLF1 protein
Deposited 2018-12-11
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 6
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain f
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；10.5% (w/v) PEG 4000, 35 mM Tris base/ HCl (pH 8.5), 70 mM Li2SO4
|
Resolution 3.30 Å
R-free 0.303
|
|
6NCA
HLA-A2 (A*02:01) bound to a peptide from the Epstein-Barr virus BRLF1 protein
Deposited 2018-12-11
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 7
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain p
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；10.5% (w/v) PEG 4000, 35 mM Tris base/ HCl (pH 8.5), 70 mM Li2SO4
|
Resolution 3.30 Å
R-free 0.303
|
|
6NCA
HLA-A2 (A*02:01) bound to a peptide from the Epstein-Barr virus BRLF1 protein
Deposited 2018-12-11
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 8
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain o
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；10.5% (w/v) PEG 4000, 35 mM Tris base/ HCl (pH 8.5), 70 mM Li2SO4
|
Resolution 3.30 Å
R-free 0.303
|
|
6NCA
HLA-A2 (A*02:01) bound to a peptide from the Epstein-Barr virus BRLF1 protein
Deposited 2018-12-11
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 9
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain e
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；10.5% (w/v) PEG 4000, 35 mM Tris base/ HCl (pH 8.5), 70 mM Li2SO4
|
Resolution 3.30 Å
R-free 0.303
|
|
6NHA
Crystal structure of SYNT001, a human FcRn blocking monoclonal antibody
Deposited 2018-12-21
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
NHE 2-[N-CYCLOHEXYLAMINO]ETHANE SULFONIC ACID × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 9.5；277.15 K；0.1M CHES pH 9.5
50% polyethylene glycol 200
|
Resolution 2.38 Å
R-free 0.245
|
|
6NPR
Crystal structure of H-2Dd with C84-C139 disulfide in complex with gp120 derived peptide P18-I10
Deposited 2019-01-18
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；295 K；0.2M Ammonium acetate, 0.1M Bis-Tris (5.5) and 25%PEG 3350
|
Resolution 2.37 Å
R-free 0.251
|
|
6NPR
Crystal structure of H-2Dd with C84-C139 disulfide in complex with gp120 derived peptide P18-I10
Deposited 2019-01-18
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；295 K；0.2M Ammonium acetate, 0.1M Bis-Tris (5.5) and 25%PEG 3350
|
Resolution 2.37 Å
R-free 0.251
|
|
6NUX
CD1a-lipid binary complex
Deposited 2019-02-03
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
FOF (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol × 1
EDO 1,2-ETHANEDIOL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；20-25% PEG 1500, 0.1M MMT pH 5.5
|
Resolution 2.20 Å
R-free 0.248
|
|
6O4Y
Structure of HLA-A2:01 with peptide MM91
Deposited 2019-03-01
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 3
NA SODIUM ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；295.15 K；30% PEG 4000, 0.1M TRIS-HCL PH 8.5,
0.2M LITHIUM SULFATE
|
Resolution 1.58 Å
R-free 0.205
|
|
6O4Z
Structure of HLA-A2:01 with peptide MM92
Deposited 2019-03-01
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 3
NA SODIUM ION × 6
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；295.15 K；30% PEG 4000, 0.1M TRIS-HCL PH 8.0,
0.2M LITHIUM SULFATE
|
Resolution 1.50 Å
R-free 0.193
|
|
6O51
Structure of HLA-A2:01 with peptide MM90
Deposited 2019-03-01
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 6
NA SODIUM ION × 5
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；295.15 K；30% PEG 4000, 0.1M TRIS-HCL PH 8.5,
0.2M LITHIUM SULFATE
|
Resolution 1.55 Å
R-free 0.225
|
|
6O53
Structure of HLA-A2:01 with peptide MM96
Deposited 2019-03-01
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 4
SO4 SULFATE ION × 1
NA SODIUM ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；295.15 K；30% PEG 4000, 0.1M TRIS-HCL PH 8.5,
0.2M LITHIUM SULFATE
|
Resolution 1.40 Å
R-free 0.210
|
|
6O9B
Crystal structure of HLA-A3*01 in complex with a wild-type beta-catenin peptide
Deposited 2019-03-13
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
1–119（119 aa）
|
Not recorded
|
PG4 TETRAETHYLENE GLYCOL × 2
MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 3
IMD IMIDAZOLE × 2
PEG DI(HYDROXYETHYL)ETHER × 4
EDO 1,2-ETHANEDIOL × 7
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；292 K；0.1 M MES/imidazole, pH 6.5, 0.03 M diethylene glycol, 0.03 M triethylene glycol, 0.03 M tetraethylene glycol, 0.03 M pentaethylene glycol, 20% PEG500 MME, 10% PEG20000
|
Resolution 2.20 Å
R-free 0.227
|
|
6O9C
Crystal structure of HLA-A3*01 in complex with a mutant beta-catenin peptide
Deposited 2019-03-13
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
1–119（119 aa）
|
Not recorded
|
MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 2
SO4 SULFATE ION × 10
PEG DI(HYDROXYETHYL)ETHER × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；292 K；0.1 M MES, pH 6.5, 0.2 M ammonium sulfate, 30% PEG5000 MME
|
Resolution 2.45 Å
R-free 0.259
|
|
6OPD
Crystal Structure of ILNAMIVKI peptide bound to HLA-A2
Deposited 2019-04-24
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
ACT ACETATE ION × 3
GOL GLYCEROL × 4
MG MAGNESIUM ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；298 K；20% PEG8000, 100 mM MES, pH 6.5, 200 mM magnesium acetate
|
Resolution 1.79 Å
R-free 0.204
|
|
6P23
Structure of a nested set of N-terminally extended MHC I-peptides provide novel insights into antigen processing presentation
Deposited 2019-05-20
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；298 K；0.2 M ammonium sulfate, 18% PEG4000, 0.1 M sodium cacodylate, pH 5.7
|
Resolution 1.59 Å
R-free 0.227
|
|
6P27
Structure of a nested set of N-terminally extended MHC I-peptides provides novel insights into antigen processing and presentation
Deposited 2019-05-21
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；0.2 M ammonium sulfate, 18% PEG4000, 0.1 M sodium cacodylate, pH 5.7
|
Resolution 1.59 Å
R-free 0.213
|
|
6P2C
Structure of a nested set of N-terminally extended MHC I-peptides provides novel insights into antigen processing and presentation
Deposited 2019-05-21
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；0.2 M ammonium sulfate, 18% PEG4000, 0.1 M sodium cacodylate, pH 5.7
|
Resolution 1.40 Å
R-free 0.210
|
|
6P2F
Structure of a nested set of N-terminally extended MHC I-peptides provides novel insights into antigen processing and presentation
Deposited 2019-05-21
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；0.2 M ammonium sulfate, 18% PEG4000, 0.1 M sodium cacodylate, pH 5.7
|
Resolution 1.48 Å
R-free 0.245
|
|
6P2S
Structure of a nested set of N-terminally extended MHC I-peptides provide novel insights into antigen processing and presentation
Deposited 2019-05-22
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；0.2 M ammonium sulfate, 18% PEG4000, 0.1 M sodium cacodylate, pH 5.7
|
Resolution 1.65 Å
R-free 0.214
|
|
6P64
Alpha-beta TCR Binding to Neoantigen KQWLVWLFL Presented by HLA-A206
Deposited 2019-05-31
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；295.5 K；8 mg/mL protein, 12.5% PEG3350, 0.1 M MOPS, pH 7.0, 0.25 M lithium nitrate
|
Resolution 3.05 Å
R-free 0.219
|
|
6P64
Alpha-beta TCR Binding to Neoantigen KQWLVWLFL Presented by HLA-A206
Deposited 2019-05-31
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；295.5 K；8 mg/mL protein, 12.5% PEG3350, 0.1 M MOPS, pH 7.0, 0.25 M lithium nitrate
|
Resolution 3.05 Å
R-free 0.219
|
|
6PA1
Killer cell immunoglobulin-like receptor 2DL2 in complex with HLA-C*07:02
Deposited 2019-06-11
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；0.2 M Sodium tartrate dibasic dihydrate and 20% w/v PEG 3350
|
Resolution 3.01 Å
R-free 0.310
|
|
6PA1
Killer cell immunoglobulin-like receptor 2DL2 in complex with HLA-C*07:02
Deposited 2019-06-11
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain F
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；0.2 M Sodium tartrate dibasic dihydrate and 20% w/v PEG 3350
|
Resolution 3.01 Å
R-free 0.310
|
|
6PAG
Killer cell immunoglobulin-like receptor 2DL3 in complex with HLA-C*07:02
Deposited 2019-06-11
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；293 K；0.2 M Ammonium acetate, 0.1 M Tris-HCl pH.8.0 and 25% PEG 3350.
|
Resolution 2.50 Å
R-free 0.254
|
|
6PBH
Crystal Structure of HLA-A*68:01 in complex with NP145-156, a 12 mer influenza peptide
Deposited 2019-06-13
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
IOD IODIDE ION × 1
MG MAGNESIUM ION × 3
SO4 SULFATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；277 K；8-14%PEG3350, 0.1M NaCl, 0.1M Hepes pH 7.4, 20mM MgCl2, 5mM CdCl2
|
Resolution 1.89 Å
R-free 0.234
|
|
6PTB
Crystal Structure of ILNAMIAKI peptide bound to HLA-A2
Deposited 2019-07-15
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；15% v/v PEG3350, 100 mM MES
|
Resolution 2.15 Å
R-free 0.232
|
|
6PTB
Crystal Structure of ILNAMIAKI peptide bound to HLA-A2
Deposited 2019-07-15
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；15% v/v PEG3350, 100 mM MES
|
Resolution 2.15 Å
R-free 0.232
|
|
6PTE
Crystal Structure of ILNAMITKI peptide bound to HLA-A2
Deposited 2019-07-15
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 3
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；296 K；20% v/v PEG3350, 100 mM HEPES, pH 7.5
|
Resolution 1.90 Å
R-free 0.185
|
|
6PTE
Crystal Structure of ILNAMITKI peptide bound to HLA-A2
Deposited 2019-07-15
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain F
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 3
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；296 K；20% v/v PEG3350, 100 mM HEPES, pH 7.5
|
Resolution 1.90 Å
R-free 0.185
|
|
6PTE
Crystal Structure of ILNAMITKI peptide bound to HLA-A2
Deposited 2019-07-15
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain I
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 3
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；296 K；20% v/v PEG3350, 100 mM HEPES, pH 7.5
|
Resolution 1.90 Å
R-free 0.185
|
|
6PTE
Crystal Structure of ILNAMITKI peptide bound to HLA-A2
Deposited 2019-07-15
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain L
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 3
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；296 K；20% v/v PEG3350, 100 mM HEPES, pH 7.5
|
Resolution 1.90 Å
R-free 0.185
|
|
6PUC
Structure of human MAIT A-F7 TCR in complex with human MR1-5-OP-RU
Deposited 2019-07-18
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
Q87 1-deoxy-1-({2,6-dioxo-5-[(E)-(2-oxopropylidene)amino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-ribitol × 1
GOL GLYCEROL × 1
CL CHLORIDE ION × 1
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；100 mM BTP (pH 6.0 - 6.5), 8-20% PEG3350 and 200 mM sodium acetate
|
Resolution 1.85 Å
R-free 0.178
|
|
6PUC
Structure of human MAIT A-F7 TCR in complex with human MR1-5-OP-RU
Deposited 2019-07-18
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain F
21–119（99 aa）
|
Not recorded
|
Q87 1-deoxy-1-({2,6-dioxo-5-[(E)-(2-oxopropylidene)amino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-ribitol × 1
GOL GLYCEROL × 2
CL CHLORIDE ION × 1
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；100 mM BTP (pH 6.0 - 6.5), 8-20% PEG3350 and 200 mM sodium acetate
|
Resolution 1.85 Å
R-free 0.178
|
|
6PUD
Structure of human MAIT A-F7 TCR in complex with human MR1-5'OH-Pentyl-5-OP-U
Deposited 2019-07-18
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
OYD 6-[(5-hydroxypentyl)amino]-5-[(E)-propylideneamino]pyrimidine-2,4(1H,3H)-dione × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；100 mM BTP (pH 6.0 - 6.5), 8-20% PEG3350 and 200 mM sodium acetate
|
Resolution 1.80 Å
R-free 0.200
|
|
6PUD
Structure of human MAIT A-F7 TCR in complex with human MR1-5'OH-Pentyl-5-OP-U
Deposited 2019-07-18
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain F
21–119（99 aa）
|
Not recorded
|
OYD 6-[(5-hydroxypentyl)amino]-5-[(E)-propylideneamino]pyrimidine-2,4(1H,3H)-dione × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；100 mM BTP (pH 6.0 - 6.5), 8-20% PEG3350 and 200 mM sodium acetate
|
Resolution 1.80 Å
R-free 0.200
|
|
6PUE
Structure of human MAIT A-F7 TCR in complex with human MR1-4'D-5-OP-RU
Deposited 2019-07-18
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 1
Q7J 1,4-dideoxy-1-({2,6-dioxo-5-[(E)-(2-oxopropylidene)amino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-erythro-pentitol × 1
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；100 mM BTP (pH 6.0 - 6.5), 8-20% PEG3350 and 200 mM sodium acetate
|
Resolution 1.90 Å
R-free 0.232
|
|
6PUE
Structure of human MAIT A-F7 TCR in complex with human MR1-4'D-5-OP-RU
Deposited 2019-07-18
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain F
21–119（99 aa）
|
Not recorded
|
Q7J 1,4-dideoxy-1-({2,6-dioxo-5-[(E)-(2-oxopropylidene)amino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-erythro-pentitol × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；100 mM BTP (pH 6.0 - 6.5), 8-20% PEG3350 and 200 mM sodium acetate
|
Resolution 1.90 Å
R-free 0.232
|
|
6PUF
Structure of human MAIT A-F7 TCR in complex with human MR1-5'D-5-OP-RU
Deposited 2019-07-18
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
2LJ 1-deoxy-1-({2,6-dioxo-5-[(E)-propylideneamino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-ribitol × 1
GOL GLYCEROL × 3
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；100 mM BTP (pH 6.0 - 6.5), 8-20% PEG3350 and 200 mM sodium acetate
|
Resolution 1.92 Å
R-free 0.221
|
|
6PUF
Structure of human MAIT A-F7 TCR in complex with human MR1-5'D-5-OP-RU
Deposited 2019-07-18
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain F
21–119（99 aa）
|
Not recorded
|
2LJ 1-deoxy-1-({2,6-dioxo-5-[(E)-propylideneamino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-ribitol × 1
GOL GLYCEROL × 3
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；100 mM BTP (pH 6.0 - 6.5), 8-20% PEG3350 and 200 mM sodium acetate
|
Resolution 1.92 Å
R-free 0.221
|
|
6PUG
Structure of human MAIT A-F7 TCR in complex with human MR1-2`OH-Ethyl-5-OP-U
Deposited 2019-07-18
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 1
OZD 6-[(2-hydroxyethyl)amino]-5-[(E)-(2-oxopropylidene)amino]pyrimidine-2,4(1H,3H)-dione × 1
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；100 mM BTP (pH 6.0 - 6.5), 8-20% PEG3350 and 200 mM sodium acetate
|
Resolution 1.80 Å
R-free 0.194
|
|
6PUG
Structure of human MAIT A-F7 TCR in complex with human MR1-2`OH-Ethyl-5-OP-U
Deposited 2019-07-18
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain F
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 2
OZD 6-[(2-hydroxyethyl)amino]-5-[(E)-(2-oxopropylidene)amino]pyrimidine-2,4(1H,3H)-dione × 1
CL CHLORIDE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；100 mM BTP (pH 6.0 - 6.5), 8-20% PEG3350 and 200 mM sodium acetate
|
Resolution 1.80 Å
R-free 0.194
|
|
6PUH
Structure of human MAIT A-F7 TCR in complex with human MR1-Ribityl-less
Deposited 2019-07-18
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain H
21–119（99 aa）
|
Not recorded
|
OYG 6-methyl-5-[(1E)-3-oxobut-1-en-1-yl]pyrimidine-2,4(1H,3H)-dione × 1
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；100 mM BTP (pH 6.0 - 6.5), 8-20% PEG3350 and 200 mM sodium acetate
|
Resolution 1.88 Å
R-free 0.195
|
|
6PUH
Structure of human MAIT A-F7 TCR in complex with human MR1-Ribityl-less
Deposited 2019-07-18
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain F
21–119（99 aa）
|
Not recorded
|
OYG 6-methyl-5-[(1E)-3-oxobut-1-en-1-yl]pyrimidine-2,4(1H,3H)-dione × 1
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；100 mM BTP (pH 6.0 - 6.5), 8-20% PEG3350 and 200 mM sodium acetate
|
Resolution 1.88 Å
R-free 0.195
|
|
6PUI
Structure of human MAIT A-F7 TCR in complex with human MR1-4'OH-Butyl-5-OP-U
Deposited 2019-07-18
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain H
21–119（99 aa）
|
Not recorded
|
Q7P 6-[(4-hydroxybutyl)amino]-5-[(E)-(2-oxopropylidene)amino]pyrimidine-2,4(1H,3H)-dione × 1
GOL GLYCEROL × 1
NA SODIUM ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；292 K；100 mM BTP (pH 6.0 - 6.5), 8-20% PEG3350 and 200 mM sodium acetate
|
Resolution 1.96 Å
R-free 0.200
|
|
6PUI
Structure of human MAIT A-F7 TCR in complex with human MR1-4'OH-Butyl-5-OP-U
Deposited 2019-07-18
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain F
21–119（99 aa）
|
Not recorded
|
Q7P 6-[(4-hydroxybutyl)amino]-5-[(E)-(2-oxopropylidene)amino]pyrimidine-2,4(1H,3H)-dione × 1
GOL GLYCEROL × 2
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；292 K；100 mM BTP (pH 6.0 - 6.5), 8-20% PEG3350 and 200 mM sodium acetate
|
Resolution 1.96 Å
R-free 0.200
|
|
6PUK
Structure of human MAIT A-F7 TCR in complex with human MR1-JYM72
Deposited 2019-07-18
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain H
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 1
OYV 1,2-dideoxy-1-{2,6-dioxo-5-[(1E)-3-oxobut-1-en-1-yl]-1,2,3,6-tetrahydropyrimidin-4-yl}-D-ribo-hexitol × 1
NA SODIUM ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；100 mM BTP (pH 6.0 - 6.5), 8-20% PEG3350 and 200 mM sodium acetate
|
Resolution 2.08 Å
R-free 0.202
|
|
6PUK
Structure of human MAIT A-F7 TCR in complex with human MR1-JYM72
Deposited 2019-07-18
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain F
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 2
OYV 1,2-dideoxy-1-{2,6-dioxo-5-[(1E)-3-oxobut-1-en-1-yl]-1,2,3,6-tetrahydropyrimidin-4-yl}-D-ribo-hexitol × 1
ACT ACETATE ION × 1
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；100 mM BTP (pH 6.0 - 6.5), 8-20% PEG3350 and 200 mM sodium acetate
|
Resolution 2.08 Å
R-free 0.202
|
|
6PUL
Structure of human MAIT A-F7 TCR in complex with human MR1 3'D-5-OP-RU
Deposited 2019-07-18
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain H
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 4
Q81 1,3-dideoxy-1-({2,6-dioxo-5-[(E)-(2-oxopropylidene)amino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-erythro-pentitol × 1
NA SODIUM ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；100 mM BTP (pH 6.0 - 6.5), 8-20% PEG3350 and 200 mM sodium acetate
|
Resolution 1.84 Å
R-free 0.184
|
|
6PUL
Structure of human MAIT A-F7 TCR in complex with human MR1 3'D-5-OP-RU
Deposited 2019-07-18
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain F
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 3
Q81 1,3-dideoxy-1-({2,6-dioxo-5-[(E)-(2-oxopropylidene)amino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-erythro-pentitol × 1
ACT ACETATE ION × 1
NA SODIUM ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；100 mM BTP (pH 6.0 - 6.5), 8-20% PEG3350 and 200 mM sodium acetate
|
Resolution 1.84 Å
R-free 0.184
|
|
6PUM
Structure of human MAIT A-F7 TCR in complex with human MR1-2'D-5-OP-RU
Deposited 2019-07-18
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 2
Q84 1,2-dideoxy-1-({2,6-dioxo-5-[(E)-(2-oxopropylidene)amino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-erythro-pentitol × 1
NA SODIUM ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；100 mM BTP (pH 6.0 - 6.5), 8-20% PEG3350 and 200 mM sodium acetate
|
Resolution 1.96 Å
R-free 0.190
|
|
6PUM
Structure of human MAIT A-F7 TCR in complex with human MR1-2'D-5-OP-RU
Deposited 2019-07-18
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain F
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 4
Q84 1,2-dideoxy-1-({2,6-dioxo-5-[(E)-(2-oxopropylidene)amino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-erythro-pentitol × 1
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；100 mM BTP (pH 6.0 - 6.5), 8-20% PEG3350 and 200 mM sodium acetate
|
Resolution 1.96 Å
R-free 0.190
|
|
6PVC
Structure of human MAIT A-F7 TCR in complex with human MR1-DB28
Deposited 2019-07-20
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 1
P1J N-(2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carbonyl)-beta-alanine × 1
ACT ACETATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；BTP (pH 6.0 - 6.5), PEG3350 and sodium acetate
|
Resolution 1.96 Å
R-free 0.212
|
|
6PVC
Structure of human MAIT A-F7 TCR in complex with human MR1-DB28
Deposited 2019-07-20
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain D
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 1
P1J N-(2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carbonyl)-beta-alanine × 1
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；BTP (pH 6.0 - 6.5), PEG3350 and sodium acetate
|
Resolution 1.96 Å
R-free 0.212
|
|
6PVD
Structure of human MAIT A-F7 TCR in complex with human MR1-NV18.1
Deposited 2019-07-20
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
N18 methyl N-(2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carbonyl)-beta-alaninate × 1
GOL GLYCEROL × 2
ACT ACETATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；BTP (pH 6.0 - 6.5), PEG3350 and sodium acetate
|
Resolution 2.14 Å
R-free 0.198
|
|
6PVD
Structure of human MAIT A-F7 TCR in complex with human MR1-NV18.1
Deposited 2019-07-20
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain F
21–119（99 aa）
|
Not recorded
|
N18 methyl N-(2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carbonyl)-beta-alaninate × 1
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；BTP (pH 6.0 - 6.5), PEG3350 and sodium acetate
|
Resolution 2.14 Å
R-free 0.198
|
|
6PYJ
Crystal Structure of HLA-B*2705 in complex with LRN, a self-peptide
Deposited 2019-07-30
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；277 K；20-30% PEG 4K, 0.2M Na Acetate and 0.1M Na Citrate pH 5.6
|
Resolution 1.44 Å
R-free 0.220
|
|
6PYL
Crystal Structure of HLA-B*2703 in complex with KK10, an HIV peptide
Deposited 2019-07-30
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
MG MAGNESIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；277 K；20-30% PEG 4K, 0.2M Na Acetate and 0.1M Na Citrate pH 5.6
|
Resolution 1.52 Å
R-free 0.230
|
|
6PYV
Crystal Structure of HLA-B*2703-P47G in complex with LRN, a self-peptide
Deposited 2019-07-31
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；277 K；20-30% PEG 4K, 0.2M Na Acetate and 0.1M Na Citrate pH 5.6
|
Resolution 1.45 Å
R-free 0.231
|
|
6PYW
Crystal Structure of HLA-B*2705-W60A in complex with LRN, a self-peptide
Deposited 2019-07-31
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；277 K；20-30% PEG 4K, 0.2M Na Acetate and 0.1M Na Citrate pH 5.6
|
Resolution 1.38 Å
R-free 0.220
|
|
6PZ5
Crystal Structure of HLA-B*2703 in complex with LRN, a self-peptide
Deposited 2019-07-31
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；277 K；20-30% PEG 4K, 0.2M Na Acetate and 0.1M Na Citrate pH 5.6
|
Resolution 1.53 Å
R-free 0.223
|
|
6Q3K
Engineered Human HLA_A2 MHC Class I molecule in complex with NV9 peptide
Deposited 2018-12-04
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 2
CO COBALT (II) ION × 7
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；5 mM cobalt chloride, 5 mM cadmium chloride, 5 mM magnesium chloride, 5 mM nickel chloride,
0.1 M HEPES pH 7.5, 12 % PEG 3350.
|
Resolution 1.50 Å
R-free 0.200
|
|
6Q3S
Engineered Human HLA_A2 MHC Class I molecule in complex with TCR and SV9 peptide
Deposited 2018-12-04
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 1
ACT ACETATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M ammonium acetate; 0.1 M bis-tris pH 5.5, 17 %(w/v) PEG 10.000
|
Resolution 2.50 Å
R-free 0.273
|
|
6QIO
Ternary complex of FcRn ectodomain, FcRn binding optimised human serum albumin and the human growth hormone derivative somapacitan
Deposited 2019-01-21
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain C
21–119（99 aa）
|
Not recorded
|
MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1
CYS CYSTEINE × 2
JG5 Somapacitan × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5；293 K；ammonium acetate, sodium acetate, PEG4000
|
Resolution 1.95 Å
R-free 0.226
|
|
6QIP
Ternary complex of FcRn ectodomain, FcRn binding optimised human serum albumin and the albumin-biniding side chain of the human growth hormone derivative somapacitan
Deposited 2019-01-21
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain C
21–119（99 aa）
|
Not recorded
|
MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1
JG5 Somapacitan × 1
BME BETA-MERCAPTOETHANOL × 1
CYS CYSTEINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；sodium cacodylate, PEG3350
|
Resolution 2.45 Å
R-free 0.259
|
|
6R2L
NYBR1-A2-SLSKILDTV
Deposited 2019-03-18
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
PEG DI(HYDROXYETHYL)ETHER × 1
EDO 1,2-ETHANEDIOL × 2
GOL GLYCEROL × 3
SO4 SULFATE ION × 8
EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；291 K；0.2 M NaCl, 0.1 M MES, 20% PEG 6000, pH 6.0 . Condition B07 from Molecular Dimensions PACT premier HT-96/FX-96, MD1-36
|
Resolution 2.30 Å
R-free 0.265
|
|
6RP9
Crystal structure of the T-cell receptor NYE_S3 bound to HLA A2*01-SLLMWITQV
Deposited 2019-05-14
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M ammonium sulphate, 15 % PEG8k, 0.1 M Tris pH7.5
|
Resolution 3.12 Å
R-free 0.250
|
|
6RP9
Crystal structure of the T-cell receptor NYE_S3 bound to HLA A2*01-SLLMWITQV
Deposited 2019-05-14
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M ammonium sulphate, 15 % PEG8k, 0.1 M Tris pH7.5
|
Resolution 3.12 Å
R-free 0.250
|
|
6RPA
Crystal structure of the T-cell receptor NYE_S2 bound to HLA A2*01-SLLMWITQV
Deposited 2019-05-14
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.02 M sodium/potassium phosphate, 20 % PEG 3350
|
Resolution 2.56 Å
R-free 0.293
|
|
6RPB
Crystal structure of the T-cell receptor NYE_S1 bound to HLA A2*01-SLLMWITQV
Deposited 2019-05-14
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M Ammonium sulfate, 25 %(w/v) PEG 4000, 0.1 M tri-Sodium citrate pH 5.6
|
Resolution 2.50 Å
R-free 0.273
|
|
6RPB
Crystal structure of the T-cell receptor NYE_S1 bound to HLA A2*01-SLLMWITQV
Deposited 2019-05-14
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M Ammonium sulfate, 25 %(w/v) PEG 4000, 0.1 M tri-Sodium citrate pH 5.6
|
Resolution 2.50 Å
R-free 0.273
|
|
6RPB
Crystal structure of the T-cell receptor NYE_S1 bound to HLA A2*01-SLLMWITQV
Deposited 2019-05-14
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain L
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M Ammonium sulfate, 25 %(w/v) PEG 4000, 0.1 M tri-Sodium citrate pH 5.6
|
Resolution 2.50 Å
R-free 0.273
|
|
6RPB
Crystal structure of the T-cell receptor NYE_S1 bound to HLA A2*01-SLLMWITQV
Deposited 2019-05-14
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain Q
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M Ammonium sulfate, 25 %(w/v) PEG 4000, 0.1 M tri-Sodium citrate pH 5.6
|
Resolution 2.50 Å
R-free 0.273
|
|
6RSY
The complex between TCR a7b2 and human Class I MHC HLA-A0201-WT1 with the bound RMFPNAPYL peptide.
Deposited 2019-05-22
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；297 K；7.5% PEG 8 K , 0.75 M NaCl , 50mM HEPES , pH 7.0
|
Resolution 2.95 Å
R-free 0.291
|
|
6RSY
The complex between TCR a7b2 and human Class I MHC HLA-A0201-WT1 with the bound RMFPNAPYL peptide.
Deposited 2019-05-22
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；297 K；7.5% PEG 8 K , 0.75 M NaCl , 50mM HEPES , pH 7.0
|
Resolution 2.95 Å
R-free 0.291
|
|
6SS7
Human Leukocyte Antigen Class I A02 Carrying LLWAGPMAV
Deposited 2019-09-06
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
NA SODIUM ION × 1
EDO 1,2-ETHANEDIOL × 2
SO4 SULFATE ION × 5
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.1 M Sodium Cacodylate pH 6.0, 0.2 M Ammonium Sulphate, 25% PEG 4000. A2/LLW-7I crystals were grown in 0.1 M Mes pH 7.0, 0.2 M Ammonium Sulphate, 25% PEG 8000
|
Resolution 2.50 Å
R-free 0.304
|
|
6SS7
Human Leukocyte Antigen Class I A02 Carrying LLWAGPMAV
Deposited 2019-09-06
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
NA SODIUM ION × 1
EDO 1,2-ETHANEDIOL × 5
SO4 SULFATE ION × 5
GOL GLYCEROL × 5
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.1 M Sodium Cacodylate pH 6.0, 0.2 M Ammonium Sulphate, 25% PEG 4000. A2/LLW-7I crystals were grown in 0.1 M Mes pH 7.0, 0.2 M Ammonium Sulphate, 25% PEG 8000
|
Resolution 2.50 Å
R-free 0.304
|
|
6SS8
Human Leukocyte Antigen Class I A02 Carrying LLWNGPIAV
Deposited 2019-09-06
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 3
EDO 1,2-ETHANEDIOL × 1
SO4 SULFATE ION × 6
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.1 M Mes pH 7.0, 0.2 M Amonium Sulphate, 25 % PEG 8000
|
Resolution 2.24 Å
R-free 0.277
|
|
6SS8
Human Leukocyte Antigen Class I A02 Carrying LLWNGPIAV
Deposited 2019-09-06
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 6
SO4 SULFATE ION × 5
PEG DI(HYDROXYETHYL)ETHER × 1
P4G 1-ETHOXY-2-(2-ETHOXYETHOXY)ETHANE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.1 M Mes pH 7.0, 0.2 M Amonium Sulphate, 25 % PEG 8000
|
Resolution 2.24 Å
R-free 0.277
|
|
6SS9
Human Leukocyte Antigen Class I A02 Carrying LLWNGPMHV
Deposited 2019-09-06
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
PEG DI(HYDROXYETHYL)ETHER × 2
SO4 SULFATE ION × 3
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.1 M Sodium Cacodylate pH 6.5, 0.2 M Ammonium Sulphate, 20 % PEG 4000
|
Resolution 2.70 Å
R-free 0.301
|
|
6SS9
Human Leukocyte Antigen Class I A02 Carrying LLWNGPMHV
Deposited 2019-09-06
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 2
GOL GLYCEROL × 1
EDO 1,2-ETHANEDIOL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.1 M Sodium Cacodylate pH 6.5, 0.2 M Ammonium Sulphate, 20 % PEG 4000
|
Resolution 2.70 Å
R-free 0.301
|
|
6SSA
Human Leukocyte Antigen Class I A02 Carrying LLWNGPMQV
Deposited 2019-09-06
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 1
GOL GLYCEROL × 1
PEG DI(HYDROXYETHYL)ETHER × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；291 K；0.1 M Sodium Cacodylate pH 6.5, 0.2 M Ammonium Sulphate, 20 % PEG 4000
|
Resolution 2.11 Å
R-free 0.271
|
|
6SSA
Human Leukocyte Antigen Class I A02 Carrying LLWNGPMQV
Deposited 2019-09-06
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 2
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；291 K；0.1 M Sodium Cacodylate pH 6.5, 0.2 M Ammonium Sulphate, 20 % PEG 4000
|
Resolution 2.11 Å
R-free 0.271
|
|
6SSA
Human Leukocyte Antigen Class I A02 Carrying LLWNGPMQV
Deposited 2019-09-06
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain H
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 1
GOL GLYCEROL × 4
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；291 K；0.1 M Sodium Cacodylate pH 6.5, 0.2 M Ammonium Sulphate, 20 % PEG 4000
|
Resolution 2.11 Å
R-free 0.271
|
|
6SSA
Human Leukocyte Antigen Class I A02 Carrying LLWNGPMQV
Deposited 2019-09-06
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain K
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 1
GOL GLYCEROL × 5
PEG DI(HYDROXYETHYL)ETHER × 1
CA CALCIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；291 K；0.1 M Sodium Cacodylate pH 6.5, 0.2 M Ammonium Sulphate, 20 % PEG 4000
|
Resolution 2.11 Å
R-free 0.271
|
|
6TDO
Crystal structure of the disulfide engineered HLA-A0201 molecule in complex with one GM dipeptide in the A pocket.
Deposited 2019-11-09
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GLY GLYCINE × 1
MET METHIONINE × 1
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.2 M magnesium acetate, 0.1 M sodium cacodylate pH 6.5, and 20% PEG
800
|
Resolution 1.65 Å
R-free 0.224
|
|
6TDP
Crystal structure of the disulfide engineered HLA-A0201 molecule in complex with one GL dipeptide in the A pocket.
Deposited 2019-11-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
NA SODIUM ION × 1
GLY GLYCINE × 1
LEU LEUCINE × 1
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.1 M HEPES pH 7.5,
20% PEG 10 000, 8% ethylene glycol
|
Resolution 1.40 Å
R-free 0.227
|
|
6TDQ
Crystal structure of the disulfide engineered HLA-A0201 molecule in complex with one GM dipeptide in the A pocket and one GM dipeptide in the F pocket.
Deposited 2019-11-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 5
GLY GLYCINE × 2
MET METHIONINE × 2
CL CHLORIDE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.1 M HEPES pH 7.5,
20% PEG 10 000, 8% ethylene glycol
|
Resolution 1.60 Å
R-free 0.214
|
|
6TDQ
Crystal structure of the disulfide engineered HLA-A0201 molecule in complex with one GM dipeptide in the A pocket and one GM dipeptide in the F pocket.
Deposited 2019-11-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 4
GLY GLYCINE × 2
MET METHIONINE × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.1 M HEPES pH 7.5,
20% PEG 10 000, 8% ethylene glycol
|
Resolution 1.60 Å
R-free 0.214
|
|
6TDR
Crystal structure of the disulfide engineered HLA-A0201 molecule devoid of peptide (annealed)
Deposited 2019-11-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 3
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.1 M HEPES pH 7.5,
20% PEG 10 000, 8% ethylene glycol
|
Resolution 1.75 Å
R-free 0.230
|
|
6TDR
Crystal structure of the disulfide engineered HLA-A0201 molecule devoid of peptide (annealed)
Deposited 2019-11-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 2
NA SODIUM ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.1 M HEPES pH 7.5,
20% PEG 10 000, 8% ethylene glycol
|
Resolution 1.75 Å
R-free 0.230
|
|
6TDS
Crystal structure of the disulfide engineered HLA-A0201 molecule without peptide bound after NaCl wash
Deposited 2019-11-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 4
NA SODIUM ION × 8
CL CHLORIDE ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.1 M HEPES pH 7.5,
20% PEG 10 000, 8% ethylene glycol
|
Resolution 1.70 Å
R-free 0.248
|
|
6TDS
Crystal structure of the disulfide engineered HLA-A0201 molecule without peptide bound after NaCl wash
Deposited 2019-11-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 3
NA SODIUM ION × 7
CL CHLORIDE ION × 5
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.1 M HEPES pH 7.5,
20% PEG 10 000, 8% ethylene glycol
|
Resolution 1.70 Å
R-free 0.248
|
|
6TMO
Structure determination of an enhanced affinity TCR, a24b17, in complex with HLA-A*02:01 presenting a MART-1 peptide, EAAGIGILTV
Deposited 2019-12-05
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 5
EDO 1,2-ETHANEDIOL × 7
SO4 SULFATE ION × 5
TAM TRIS(HYDROXYETHYL)AMINOMETHANE × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；291 K；0.1 M HEPES pH 7.5 0.2 M Ammonium Sulphate 15 % PEG 4000 8.7% Glycerol
|
Resolution 2.10 Å
R-free 0.209
|
|
6TRN
Crystal structure of HLA A2*01-AVYDGREHTV
Deposited 2019-12-19
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M potassium sodium tartrate, 0.1 M bis-tris propane pH6.5, 20 % PEG 3350
|
Resolution 1.35 Å
R-free 0.200
|
|
6TRO
Crystal structure of the T-cell receptor GVY01 bound to HLA A2*01-GVYDGREHTV
Deposited 2019-12-19
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；1 M succinic acid, 0.1 M HEPES pH 7.0, 1 % w/v PEG MME 2k
|
Resolution 3.00 Å
R-free 0.270
|
|
6UJ7
Crystal structure of HLA-B*07:02 with R140Q mutant IDH2 peptide
Deposited 2019-10-02
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
1–119（119 aa）
|
Not recorded
|
K POTASSIUM ION × 1
NA SODIUM ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；292 K；0.1 M Hepes pH 7.5, 0.2 M NaCl, 25% PEG4000
|
Resolution 1.90 Å
R-free 0.238
|
|
6UJ7
Crystal structure of HLA-B*07:02 with R140Q mutant IDH2 peptide
Deposited 2019-10-02
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
1–119（119 aa）
|
Not recorded
|
NA SODIUM ION × 1
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；292 K；0.1 M Hepes pH 7.5, 0.2 M NaCl, 25% PEG4000
|
Resolution 1.90 Å
R-free 0.238
|
|
6UJ8
Crystal structure of HLA-B*07:02 with wild-type IDH2 peptide
Deposited 2019-10-02
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
1–119（119 aa）
|
Not recorded
|
PEG DI(HYDROXYETHYL)ETHER × 4
1PE PENTAETHYLENE GLYCOL × 1
SO4 SULFATE ION × 2
PGE TRIETHYLENE GLYCOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；292 K；0.1 M MES pH 6.5, 0.2 M KI, 30% PEG4000
|
Resolution 2.25 Å
R-free 0.260
|
|
6UJ8
Crystal structure of HLA-B*07:02 with wild-type IDH2 peptide
Deposited 2019-10-02
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
1–119（119 aa）
|
Not recorded
|
PEG DI(HYDROXYETHYL)ETHER × 2
SO4 SULFATE ION × 1
PG4 TETRAETHYLENE GLYCOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；292 K；0.1 M MES pH 6.5, 0.2 M KI, 30% PEG4000
|
Resolution 2.25 Å
R-free 0.260
|
|
6UJ9
Crystal structure of HLA-B*07:02 with R140Q mutant IDH2 peptide in complex with Fab
Deposited 2019-10-02
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
1–119（119 aa）
|
Not recorded
|
PEG DI(HYDROXYETHYL)ETHER × 6
NHE 2-[N-CYCLOHEXYLAMINO]ETHANE SULFONIC ACID × 1
SO4 SULFATE ION × 8
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 9.5；292 K；0.1 M CHES, 20% PEG8000
|
Resolution 2.90 Å
R-free 0.287
|
|
6UJO
HHAT L75F Neoantigen Peptide KQWLVWLFL Presented by HLA-A206
Deposited 2019-10-03
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；295.5 K；10% PEG3350, 0.1 M magnesium chloride, 0.1 M sodium citrate, pH 6.5
|
Resolution 2.25 Å
R-free 0.222
|
|
6UJQ
HHAT Wild Type Peptide KQWLVWLLL Presented by HLA-A206
Deposited 2019-10-03
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.1；295.5 K；0.1 M Tris-HCl, pH 8.1, 30% PEG4000, 0.20 M ammonium sulfate
|
Resolution 2.55 Å
R-free 0.228
|
|
6UK2
Complex of T cell Receptor with HHAT Wild Type Peptide KQWLVWLLL Presented by HLA-A206
Deposited 2019-10-04
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.3；277 K；0.1 M sodium citrate, pH 6.3, 8.5% PEG6000, 0.20 M lithium nitrate
|
Resolution 3.14 Å
R-free 0.260
|
|
6UK4
Complex of T cell Receptor with HHAT Neoantigen Peptide KQWLVWLFL Presented by HLA-A206
Deposited 2019-10-04
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.3；277 K；0.1 M sodium citrate, pH 6.3, 7.5% PEG6000, 0.2 M lithium nitrate
|
Resolution 2.70 Å
R-free 0.252
|
|
6ULI
Molecular basis for tumor infiltrating TCR recognition of hotspot KRAS-G12D mutation
Deposited 2019-10-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；0.1 M Bis-Tris pH 6.5, 0.05M CaCl2 dihydrate, 30% PEG MME 500
|
Resolution 1.88 Å
R-free 0.226
|
|
6ULK
Molecular basis for tumor infiltrating TCR recognition of hotspot KRAS-G12D mutation
Deposited 2019-10-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；0.1 M Bis-Tris pH 6.5, 0.05M CaCl2 dihydrate, 30% PEG MME 500
|
Resolution 1.90 Å
R-free 0.270
|
|
6ULN
Molecular basis for tumor infiltrating TCR recognition of hotspot KRAS-G12D mutation
Deposited 2019-10-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 2
GOL GLYCEROL × 6
MG MAGNESIUM ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；22% PEG 3350, 0.1M MOPS pH 7.1 and 0.25M MgSO4
|
Resolution 2.01 Å
R-free 0.217
|
|
6ULR
Molecular basis for tumor infiltrating TCR recognition of hotspot KRAS-G12D mutation
Deposited 2019-10-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；22% PEG 3350, 0.1M MOPS pH 7.1 and 0.25M MgSO4
|
Resolution 3.20 Å
R-free 0.262
|
|
6UON
Molecular basis for tumor infiltrating TCR recognition of hotspot KRAS-G12D mutation
Deposited 2019-10-15
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；12.5% PEG 4000, 0.1M Na Cacodylate pH 5.8, 0.2M (NH4)2SO4 and 10% glycerol
|
Resolution 3.50 Å
R-free 0.294
|
|
6UON
Molecular basis for tumor infiltrating TCR recognition of hotspot KRAS-G12D mutation
Deposited 2019-10-15
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；12.5% PEG 4000, 0.1M Na Cacodylate pH 5.8, 0.2M (NH4)2SO4 and 10% glycerol
|
Resolution 3.50 Å
R-free 0.294
|
|
6UZ1
Noncanonical binding of single-chain A6 TCR variant S3-4 in complex with Tax/HLA-A2
Deposited 2019-11-14
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；298 K；10%w/v Polyethylene glycol 20,000, 100mMMES, pH 6.5
|
Resolution 3.14 Å
R-free 0.239
|
|
6UZ1
Noncanonical binding of single-chain A6 TCR variant S3-4 in complex with Tax/HLA-A2
Deposited 2019-11-14
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
|
Not recorded
|
MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；298 K；10%w/v Polyethylene glycol 20,000, 100mMMES, pH 6.5
|
Resolution 3.14 Å
R-free 0.239
|
|
6UZM
HLA-B*15:02 complexed with a synthetic peptide
Deposited 2019-11-15
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 2
EDO 1,2-ETHANEDIOL × 1
ACT ACETATE ION × 2
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；277 K；0.2 ammonium acetate, 0.M tri-sodium citrate dihydrate pH5.6, 30% w/v PEG4000
|
Resolution 1.80 Å
R-free 0.231
|
|
6UZN
HLA-B*15:02 complexed with a synthetic peptide
Deposited 2019-11-15
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 1
ACT ACETATE ION × 1
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；277 K；0.2 ammonium acetate, 0.M tri-sodium citrate dihydrate pH5.6, 30% w/v PEG4000
|
Resolution 2.22 Å
R-free 0.228
|
|
6UZO
HLA-B*15:02 complexed with a synthetic peptide
Deposited 2019-11-15
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；277 K；0.2 ammonium acetate, 0.M tri-sodium citrate dihydrate pH5.6, 30% w/v PEG4000
|
Resolution 2.35 Å
R-free 0.239
|
|
6UZP
HLA-B*15:01 complexed with a synthetic peptide
Deposited 2019-11-15
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 1
EDO 1,2-ETHANEDIOL × 4
ACT ACETATE ION × 2
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；277 K；0.2 ammonium acetate, 0.M tri-sodium citrate dihydrate pH5.6, 30% w/v PEG4000
|
Resolution 2.08 Å
R-free 0.248
|
|
6UZQ
HLA-B*15:01 complexed with a synthetic peptide
Deposited 2019-11-15
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
ACT ACETATE ION × 2
EDO 1,2-ETHANEDIOL × 1
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；277 K；0.2 ammonium acetate, 0.M tri-sodium citrate dihydrate pH5.6, 30% w/v PEG4000
|
Resolution 2.40 Å
R-free 0.253
|
|
6UZS
HLA-B*15:01 complexed with a synthetic peptide
Deposited 2019-11-15
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
ACT ACETATE ION × 2
GOL GLYCEROL × 4
EDO 1,2-ETHANEDIOL × 8
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；277 K；0.2 ammonium acetate, 0.M tri-sodium citrate dihydrate pH5.6, 30% w/v PEG4000
|
Resolution 1.90 Å
R-free 0.223
|
|
6V2O
HLA-B*57:01 presenting the peptide ASLNLPAVSW
Deposited 2019-11-25
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
ACT ACETATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.4；294 K；20 % PEG 4000, 0.2 M ammonium acetate, 0.1 M tri-sodium citrate pH 5.4
|
Resolution 1.27 Å
R-free 0.159
|
|
6V2P
HLA-B*57:03 presenting the peptide ASLNLPAVSW
Deposited 2019-11-25
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
PEG DI(HYDROXYETHYL)ETHER × 1
ACT ACETATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.4；294 K；20 % PEG 4000, 0.2 M ammonium acetate, 0.1 M tri-sodium citrate pH 5.4
|
Resolution 1.30 Å
R-free 0.163
|
|
6V2Q
HLA-B*57:03 presenting the peptide LSSPVTKSF
Deposited 2019-11-25
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
ACT ACETATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.4；294 K；20 % PEG 4000, 0.2 M ammonium acetate, 0.1 M tri-sodium citrate pH 5.4
|
Resolution 1.60 Å
R-free 0.194
|
|
6V3J
KIR3DL1 in complex with HLA-B*57:03 presenting the peptide LSSPVTKSF
Deposited 2019-11-25
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；294 K；14% PEG 3350, 2% tacsimate, pH 5.0, 0.1 M tri-sodium citrate pH 5.6
|
Resolution 1.98 Å
R-free 0.236
|
|
6V7Y
Human CD1d presenting alpha-Galactosylceramide in complex with VHH nanobody 1D5
Deposited 2019-12-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2
SO4 SULFATE ION × 5
AGH N-{(1S,2R,3S)-1-[(ALPHA-D-GALACTOPYRANOSYLOXY)METHYL]-2,3-DIHYDROXYHEPTADECYL}HEXACOSANAMIDE × 1
CL CHLORIDE ION × 5
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；2M Ammonium Sulphate, 0.1M Tris-HCl pH 7.0, 0.2M Lithium Sulphate
|
Resolution 2.40 Å
R-free 0.276
|
|
6V7Z
Human CD1d presenting alpha-Galactosylceramide in complex with VHH nanobody 1D22
Deposited 2019-12-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
AGH N-{(1S,2R,3S)-1-[(ALPHA-D-GALACTOPYRANOSYLOXY)METHYL]-2,3-DIHYDROXYHEPTADECYL}HEXACOSANAMIDE × 1
PEG DI(HYDROXYETHYL)ETHER × 2
CL CHLORIDE ION × 1
SO4 SULFATE ION × 1
BGC beta-D-glucopyranose × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.3；293 K；29% (v/v) PEG3350, 0.2M ammonium sulphate, 0.1M Bis-Tris (pH 5.3), 3% (v/v) glucose monohydrate
|
Resolution 2.75 Å
R-free 0.252
|
|
6V7Z
Human CD1d presenting alpha-Galactosylceramide in complex with VHH nanobody 1D22
Deposited 2019-12-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Other combination
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
AGH N-{(1S,2R,3S)-1-[(ALPHA-D-GALACTOPYRANOSYLOXY)METHYL]-2,3-DIHYDROXYHEPTADECYL}HEXACOSANAMIDE × 1
PEG DI(HYDROXYETHYL)ETHER × 1
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.3；293 K；29% (v/v) PEG3350, 0.2M ammonium sulphate, 0.1M Bis-Tris (pH 5.3), 3% (v/v) glucose monohydrate
|
Resolution 2.75 Å
R-free 0.252
|
|
6V80
Crystal structure of human CD1d presenting alpha-Galactosylceramide in complex with NKT12 TCR and VHH nanobody 1D12
Deposited 2019-12-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
AGH N-{(1S,2R,3S)-1-[(ALPHA-D-GALACTOPYRANOSYLOXY)METHYL]-2,3-DIHYDROXYHEPTADECYL}HEXACOSANAMIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；21 % (v/v) PEG 3350, 0.2 M tri-sodium citrate, 3% (v/v) D-(+)-trehalose dehydrate
|
Resolution 3.53 Å
R-free 0.254
|
|
6V80
Crystal structure of human CD1d presenting alpha-Galactosylceramide in complex with NKT12 TCR and VHH nanobody 1D12
Deposited 2019-12-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
|
Not recorded
|
AGH N-{(1S,2R,3S)-1-[(ALPHA-D-GALACTOPYRANOSYLOXY)METHYL]-2,3-DIHYDROXYHEPTADECYL}HEXACOSANAMIDE × 1
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；21 % (v/v) PEG 3350, 0.2 M tri-sodium citrate, 3% (v/v) D-(+)-trehalose dehydrate
|
Resolution 3.53 Å
R-free 0.254
|
|
6VB0
HLA-B*15:02 complexed with a synthetic peptide
Deposited 2019-12-18
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277 K；0.2M ammonium acetate, 0.1M tri-sodium citrate dihydrate pH5.6, 30% w/v PEG4000
|
Resolution 1.90 Å
R-free 0.213
|
|
6VB1
HLA-B*15:02 complexed with a synthetic peptide
Deposited 2019-12-18
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 3
GOL GLYCEROL × 1
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277 K；0.2 ammonium acetate, 0.M tri-sodium citrate dihydrate pH5.6, 30% w/v PEG4000
|
Resolution 1.75 Å
R-free 0.215
|
|
6VB2
HLA-B*15:02 complexed with a synthetic peptide
Deposited 2019-12-18
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
22–117（96 aa）
|
Not recorded
|
NA SODIUM ION × 1
GOL GLYCEROL × 2
ACT ACETATE ION × 2
EDO 1,2-ETHANEDIOL × 5
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277 K；0.2 ammonium acetate, 0.M tri-sodium citrate dihydrate pH5.6, 30% w/v PEG4000
|
Resolution 1.41 Å
R-free 0.232
|
|
6VB3
HLA-B*15:01 complexed with a synthetic peptide
Deposited 2019-12-18
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 1
NA SODIUM ION × 2
ACT ACETATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277 K；0.2 ammonium acetate, 0.M tri-sodium citrate dihydrate pH5.6, 30% w/v PEG4000
|
Resolution 2.00 Å
R-free 0.307
|
|
6VB4
HLA-B*15:02 complexed with a synthetic peptide
Deposited 2019-12-18
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–118（98 aa）
|
Not recorded
|
ACT ACETATE ION × 2
EDO 1,2-ETHANEDIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277 K；0.2 ammonium acetate, 0.M tri-sodium citrate dihydrate pH5.6, 30% w/v PEG4000
|
Resolution 2.33 Å
R-free 0.243
|
|
6VB5
HLA-B*15:02 complexed with a synthetic peptide
Deposited 2019-12-18
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–118（98 aa）
|
Not recorded
|
ACT ACETATE ION × 2
GOL GLYCEROL × 1
EDO 1,2-ETHANEDIOL × 3
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277 K；0.2 ammonium acetate, 0.M tri-sodium citrate dihydrate pH5.6, 30% w/v PEG4000
|
Resolution 2.15 Å
R-free 0.224
|
|
6VB6
HLA-B*15:02 complexed with a synthetic peptide
Deposited 2019-12-18
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 2
ACT ACETATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277 K；0.2 ammonium acetate, 0.M tri-sodium citrate dihydrate pH5.6, 30% w/v PEG4000
|
Resolution 2.15 Å
R-free 0.242
|
|
6VB7
HLA-B*15:02 complexed with a synthetic peptide
Deposited 2019-12-18
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
ACT ACETATE ION × 2
GOL GLYCEROL × 3
EDO 1,2-ETHANEDIOL × 2
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277 K；0.2 ammonium acetate, 0.M tri-sodium citrate dihydrate pH5.6, 30% w/v PEG4000
|
Resolution 2.10 Å
R-free 0.257
|
|
6VIU
HLA-B*15:02 complexed with a synthetic peptide
Deposited 2020-01-14
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
ACT ACETATE ION × 2
EDO 1,2-ETHANEDIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277 K；0.2 ammonium acetate, 0.M tri-sodium citrate dihydrate pH5.6, 30% w/v PEG4000
|
Resolution 2.33 Å
R-free 0.243
|
|
6VM7
SILv44 T cell receptor bound to HLA-A2 presenting gp100 peptide (ITDQVPFSV)
Deposited 2020-01-27
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；296 K；16% v/v PEG3350, 280 mM ammonium citrate dibasic
|
Resolution 2.41 Å
R-free 0.241
|
|
6VM8
SILv44 T cell receptor bound to HLA-A2 presenting gp100T2M peptide (IMDQVPFSV)
Deposited 2020-01-27
|
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Mutation：0
|
FLC CITRATE ANION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；296 K；20% v/v PEG3350, 236 mM ammonium citrate dibasic
|
Resolution 2.41 Å
R-free 0.221
|
|
6VM9
T4H2 T cell receptor bound to HLA-A2 presenting gp100T2M peptide (IMDQVPFSV)
Deposited 2020-01-27
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；296 K；18% v/v PEG10000, 16% v/v glycerol, 250 mM Tris pH 8.5, 60 mM sodium chloride, seeded with crushed crystals
|
Resolution 2.90 Å
R-free 0.250
|
|
6VMA
T4H2 T cell receptor bound to HLA-A2 presenting gp100 peptide (ITDQVPFSV)
Deposited 2020-01-27
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；296 K；18% v/v PEG10000, 16% v/v glycerol, 100 mM Tris pH 8.5, 100 mM sodium chloride
|
Resolution 2.75 Å
R-free 0.219
|
|
6VMC
T4H2 T cell receptor bound to HLA-A2 presenting gp100T2L peptide (ILDQVPFSV)
Deposited 2020-01-27
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；296 K；18% v/v PEG10000, 16% v/v glycerol, 250 mM Tris pH 8.5, 60 mM sodium chloride
|
Resolution 2.85 Å
R-free 0.238
|
|
6VMX
Structure of HD14 TCR in complex with HLA-B7 presenting an EBV epitope
Deposited 2020-01-28
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
PEG DI(HYDROXYETHYL)ETHER × 1
EDO 1,2-ETHANEDIOL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；293 K；8 mg/mL in 24% PEG 400, 0.1 M NaCl, 0.1 M sodium-citrate pH 6
|
Resolution 3.10 Å
R-free 0.242
|
|
6VMX
Structure of HD14 TCR in complex with HLA-B7 presenting an EBV epitope
Deposited 2020-01-28
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
|
Not recorded
|
PEG DI(HYDROXYETHYL)ETHER × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；293 K；8 mg/mL in 24% PEG 400, 0.1 M NaCl, 0.1 M sodium-citrate pH 6
|
Resolution 3.10 Å
R-free 0.242
|
|
6VPZ
HLA-B*27:05 presenting an HIV-1 11mer peptide
Deposited 2020-02-04
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.3；277 K；20 %w/v Polyethylene Glycol 3350, 0.2 M Ammonium Chloride
|
Resolution 2.10 Å
R-free 0.235
|
|
6VQ2
HLA-B*27:05 presenting an HIV-1 14mer peptide
Deposited 2020-02-04
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；277 K；20 %w/v Polyethylene Glycol 8000, 0.05 M Potassium di-Hydrogen Phosphate
|
Resolution 2.25 Å
R-free 0.230
|
|
6VQD
HLA-B*27:05 presenting an HIV-1 8mer peptide
Deposited 2020-02-05
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.8；277 K；20 %w/v Polyethylene Glycol 3350, 0.2 M Potassium di-Hydrogen Phosphate
|
Resolution 1.88 Å
R-free 0.206
|
|
6VQE
HLA-B*27:05 presenting an HIV-1 13mer peptide
Deposited 2020-02-05
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.8；277 K；20 %w/v Polyethylene Glycol 3350, 0.2 M Potassium di-Hydrogen Phosphate
|
Resolution 1.77 Å
R-free 0.186
|
|
6VQO
T cell receptor-p53-HLA-A2 complex
Deposited 2020-02-05
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 8；295 K；12% (w/v) PEG 8000, 0.1 M magnesium acetate
|
Resolution 3.00 Å
R-free 0.211
|
|
6VQO
T cell receptor-p53-HLA-A2 complex
Deposited 2020-02-05
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 8；295 K；12% (w/v) PEG 8000, 0.1 M magnesium acetate
|
Resolution 3.00 Å
R-free 0.211
|
|
6VQY
HLA-B*27:05 presenting an HIV-1 7mer peptide
Deposited 2020-02-06
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
ARG ARGININE × 1
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；30 %w/v Polyethylene Glycol Monomethyl Ether 5000, 0.2 M Ammonium Sulphate, 0.1 M MES pH 6.5
|
Resolution 2.57 Å
R-free 0.238
|
|
6VQY
HLA-B*27:05 presenting an HIV-1 7mer peptide
Deposited 2020-02-06
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
ARG ARGININE × 2
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；30 %w/v Polyethylene Glycol Monomethyl Ether 5000, 0.2 M Ammonium Sulphate, 0.1 M MES pH 6.5
|
Resolution 2.57 Å
R-free 0.238
|
|
6VQZ
HLA-B*27:05 presenting an HIV-1 6mer peptide
Deposited 2020-02-06
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
ARG ARGININE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；30 %w/v Polyethylene Glycol Monomethyl Ether 5000, 0.2 M Ammonium Sulphate, 0.1 M MES pH 6.5
|
Resolution 2.25 Å
R-free 0.244
|
|
6VQZ
HLA-B*27:05 presenting an HIV-1 6mer peptide
Deposited 2020-02-06
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
ARG ARGININE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；30 %w/v Polyethylene Glycol Monomethyl Ether 5000, 0.2 M Ammonium Sulphate, 0.1 M MES pH 6.5
|
Resolution 2.25 Å
R-free 0.244
|
|
6VR1
Complex of HLA-A2, a class I MHC, with a p53 peptide
Deposited 2020-02-06
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 8；296 K；15% PEG 8000, 0.1 M Tris-HCl, 0.2 M magnesium chloride
|
Resolution 2.37 Å
R-free 0.274
|
|
6VR1
Complex of HLA-A2, a class I MHC, with a p53 peptide
Deposited 2020-02-06
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 8；296 K；15% PEG 8000, 0.1 M Tris-HCl, 0.2 M magnesium chloride
|
Resolution 2.37 Å
R-free 0.274
|
|
6VR5
Complex of HLA-A2, a class I MHC, with a p53 peptide
Deposited 2020-02-06
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 8；295 K；15% PEG 8000, 0.1 M Tris-HCl, 0.2 M magnesium chloride
|
Resolution 2.38 Å
R-free 0.280
|
|
6VR5
Complex of HLA-A2, a class I MHC, with a p53 peptide
Deposited 2020-02-06
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 8；295 K；15% PEG 8000, 0.1 M Tris-HCl, 0.2 M magnesium chloride
|
Resolution 2.38 Å
R-free 0.280
|
|
6VRM
T cell receptor-p53-HLA-A2 complex
Deposited 2020-02-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7；295 K；20% (w/v) polyacrylic acid 5100, 0.1 M HEPES, 20 mM MgCl2
|
Resolution 2.61 Å
R-free 0.275
|
|
6VRN
T cell receptor-p53-HLA-A2 complex
Deposited 2020-02-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.7；295 K；20% (w/v) PEG 3350, 0.2 M ammonium tartrate dibasic
|
Resolution 2.46 Å
R-free 0.259
|
|
6W51
Structure of the antibody fragment H2 in complex with HLA-A*02:01/p53R175H
Deposited 2020-03-12
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
1–119（119 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；277 K；0.2 M Ammonium chloride, 20% w/v PEG 3350
|
Resolution 3.53 Å
R-free 0.283
|
|
6W51
Structure of the antibody fragment H2 in complex with HLA-A*02:01/p53R175H
Deposited 2020-03-12
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain E
1–119（119 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；277 K；0.2 M Ammonium chloride, 20% w/v PEG 3350
|
Resolution 3.53 Å
R-free 0.283
|
|
6W51
Structure of the antibody fragment H2 in complex with HLA-A*02:01/p53R175H
Deposited 2020-03-12
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain H
1–119（119 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；277 K；0.2 M Ammonium chloride, 20% w/v PEG 3350
|
Resolution 3.53 Å
R-free 0.283
|
|
6W51
Structure of the antibody fragment H2 in complex with HLA-A*02:01/p53R175H
Deposited 2020-03-12
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain K
1–119（119 aa）
|
Not recorded
|
PO4 PHOSPHATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；277 K；0.2 M Ammonium chloride, 20% w/v PEG 3350
|
Resolution 3.53 Å
R-free 0.283
|
|
6W9U
Structure of human MAIT A-F7 TCR in complex with patient MR1-R9H-Ac-6-FP
Deposited 2020-03-23
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
TKG 1-[[6-(1-$l^{1}-oxidanylethyl)-4-$l^{3}-oxidanylidene-2,3,6,8~{a}-tetrahydropteridin-2-yl]-$l^{2}-azanyl]ethanone × 1
GOL GLYCEROL × 2
CL CHLORIDE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.3；298 K；PEG3350, BTP, Cacl2
|
Resolution 1.89 Å
R-free 0.197
|
|
6W9U
Structure of human MAIT A-F7 TCR in complex with patient MR1-R9H-Ac-6-FP
Deposited 2020-03-23
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain F
21–119（99 aa）
|
Not recorded
|
TKG 1-[[6-(1-$l^{1}-oxidanylethyl)-4-$l^{3}-oxidanylidene-2,3,6,8~{a}-tetrahydropteridin-2-yl]-$l^{2}-azanyl]ethanone × 1
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.3；298 K；PEG3350, BTP, Cacl2
|
Resolution 1.89 Å
R-free 0.197
|
|
6W9V
Structure of human MAIT A-F7 TCR in complex with patient MR1-R9H without ligand
Deposited 2020-03-23
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
ACT ACETATE ION × 2
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.3；298 K；PEG3350, BTP, Cacl2
|
Resolution 1.95 Å
R-free 0.200
|
|
6W9V
Structure of human MAIT A-F7 TCR in complex with patient MR1-R9H without ligand
Deposited 2020-03-23
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain F
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.3；298 K；PEG3350, BTP, Cacl2
|
Resolution 1.95 Å
R-free 0.200
|
|
6WNA
Next generation monomeric IgG4 Fc
Deposited 2020-04-22
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；295 K；0.2 M magnesium chloride hexahydrate, 30% 1,5-diaminopentane dihydrochloride, 0.1 M MES, pH 6 and 20% PEG 6000 at a protein concentration of 6 mg/mL
|
Resolution 2.40 Å
R-free 0.263
|
|
6WOL
Next generation monomeric IgG4 Fc bound to neonatal Fc receptor
Deposited 2020-04-24
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6；295 K；0.2 M magnesium chloride hexahydrate, 1 M sodium iodide, 0.1 M MES, pH 6 and 20% PEG 6000 at a protein concentration of 6.35 mg/mL
|
Resolution 2.49 Å
R-free 0.270
|
|
6WZY
Structure of DbNA(10) peptides bound to H-2Db MHC-I
Deposited 2020-05-14
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 2
PEG DI(HYDROXYETHYL)ETHER × 2
PO4 PHOSPHATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.7；298 K；0.1M sodium citrate pH 5.7, 0.2M LiSO4 and 24-28% (w/v) PEG3350
|
Resolution 1.50 Å
R-free 0.204
|
|
6X00
Structure of DbNA(11) peptides bound to H-2Db MHC-I
Deposited 2020-05-14
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.7；298 K；0.1M sodium citrate pH 5.7, 0.2M Li2SO4 and 24-28% (w/v) PEG3350
|
Resolution 1.55 Å
R-free 0.215
|
|
6XQA
Crystal Structure of HLA A*2402 in complex with TYQWVLKNL, an 9-mer epitope from Influenza B virus
Deposited 2020-07-09
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；277 K；24% PEG8000, 0.1 HEPES pH 7.5, 2% isopropanol, 5% w/v Polyvinylpyrrolidone K15
|
Resolution 2.16 Å
R-free 0.229
|
|
6XQA
Crystal Structure of HLA A*2402 in complex with TYQWVLKNL, an 9-mer epitope from Influenza B virus
Deposited 2020-07-09
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
MG MAGNESIUM ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；277 K；24% PEG8000, 0.1 HEPES pH 7.5, 2% isopropanol, 5% w/v Polyvinylpyrrolidone K15
|
Resolution 2.16 Å
R-free 0.229
|
|
6XQP
Structure of human D462-E4 TCR in complex with human MR1-5-OP-RU
Deposited 2020-07-10
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
2LJ 1-deoxy-1-({2,6-dioxo-5-[(E)-propylideneamino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-ribitol × 1
GOL GLYCEROL × 2
BR BROMIDE ION × 1
NA SODIUM ION × 1
CL CHLORIDE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；293 K；18-26% PEG3350,
100 mM Bis-Tris Propane
200 mM Sodium Bromide
|
Resolution 2.90 Å
R-free 0.235
|
|
6XQP
Structure of human D462-E4 TCR in complex with human MR1-5-OP-RU
Deposited 2020-07-10
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain D
21–119（99 aa）
|
Not recorded
|
2LJ 1-deoxy-1-({2,6-dioxo-5-[(E)-propylideneamino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-ribitol × 1
GOL GLYCEROL × 5
BR BROMIDE ION × 1
CL CHLORIDE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；293 K；18-26% PEG3350,
100 mM Bis-Tris Propane
200 mM Sodium Bromide
|
Resolution 2.90 Å
R-free 0.235
|
|
6Y26
Crystal structure of HLA-B2705 complexed with the nona-peptide mA
Deposited 2020-02-15
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 4
CL CHLORIDE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；20% (w/v) PEG8000, 150 mM NaCl and 100 mM Tris-HCl, pH 7.0
|
Resolution 1.20 Å
R-free 0.174
|
|
6Y27
Crystal structure of HLA-B2709 complexed with the nona-peptide mA
Deposited 2020-02-15
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 3
CL CHLORIDE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；291 K；20% (w/v) PEG8000, 150 mM NaCl and 100 mM Tris-HCl, pH 7.0
|
Resolution 1.38 Å
R-free 0.194
|
|
6Y28
Crystal structure of HLA-B2705 complexed with the nona-peptide mE
Deposited 2020-02-15
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 6
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；291 K；20% (w/v) PEG8000, 150 mM NaCl and 100 mM Tris-HCl, pH 7.0
|
Resolution 1.69 Å
R-free 0.236
|
|
6Y29
Crystal structure of HLA-B2709 complexed with the nona-peptide mE
Deposited 2020-02-15
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；291 K；20% (w/v) PEG8000, 150 mM NaCl and 100 mM Tris-HCl, pH 7.0
|
Resolution 1.28 Å
R-free 0.169
|
|
6Y2A
Crystal structure of HLA-B2705 complexed with the nona-peptide mQ
Deposited 2020-02-15
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 5
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；291 K；20% (w/v) PEG8000, 150 mM NaCl and 100 mM Tris-HCl, pH 7.0
|
Resolution 1.25 Å
R-free 0.155
|
|
6Y2B
Crystal structure of HLA-B2709 complexed with the nona-peptide mQ
Deposited 2020-02-15
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；291 K；20% (w/v) PEG8000, 150 mM NaCl and 100 mM Tris-HCl, pH 7.0
|
Resolution 1.37 Å
R-free 0.181
|
|
6Z9V
Human Class I Major Histocompatibility Complex, A02 allele, presenting IIGWMWIPV
Deposited 2020-06-04
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 5
GOL GLYCEROL × 1
SO4 SULFATE ION × 3
NA SODIUM ION × 1
P4G 1-ETHOXY-2-(2-ETHOXYETHOXY)ETHANE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；295 K；PACT premier screen, condition G06: 0.2M Na Formate, 0.1M Bis-Tris Propane, 20% PEG 3350
|
Resolution 2.01 Å
R-free 0.216
|
|
6Z9V
Human Class I Major Histocompatibility Complex, A02 allele, presenting IIGWMWIPV
Deposited 2020-06-04
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 5
GOL GLYCEROL × 5
SO4 SULFATE ION × 1
P4G 1-ETHOXY-2-(2-ETHOXYETHOXY)ETHANE × 1
PE8 3,6,9,12,15,18,21-HEPTAOXATRICOSANE-1,23-DIOL × 1
CA CALCIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；295 K；PACT premier screen, condition G06: 0.2M Na Formate, 0.1M Bis-Tris Propane, 20% PEG 3350
|
Resolution 2.01 Å
R-free 0.216
|
|
6Z9W
Human Class I Major Histocompatibility Complex, A02 allele, presenting LLGWVFAQV
Deposited 2020-06-04
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5；295 K；PACT premier screen, condition D02: 0.1M MMT buffer, 25% PEG 1500
|
Resolution 2.70 Å
R-free 0.281
|
|
6Z9W
Human Class I Major Histocompatibility Complex, A02 allele, presenting LLGWVFAQV
Deposited 2020-06-04
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5；295 K；PACT premier screen, condition D02: 0.1M MMT buffer, 25% PEG 1500
|
Resolution 2.70 Å
R-free 0.281
|
|
6Z9X
Human Class I Major Histocompatibility Complex, A02 allele, presenting LLS (t-butyl)Y FGTPT
Deposited 2020-06-04
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；25% PEG 4000, 0.1 M Cacodylate buffer, 5% glycerol
|
Resolution 2.68 Å
R-free 0.241
|
|
6Z9X
Human Class I Major Histocompatibility Complex, A02 allele, presenting LLS (t-butyl)Y FGTPT
Deposited 2020-06-04
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；25% PEG 4000, 0.1 M Cacodylate buffer, 5% glycerol
|
Resolution 2.68 Å
R-free 0.241
|
|
6ZKW
Crystal structure of InhA:01 TCR in complex with HLA-E bound to InhA (53-61)
Deposited 2020-06-30
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293.15 K；0.1 M TRIS pH 8.5, 25 % (w/v) PEG 4000, 15 % Glycerol
|
Resolution 2.26 Å
R-free 0.287
|
|
6ZKX
Crystal structure of InhA:01 TCR in complex with HLA-E (Y84C) bound to InhA (53-61 GCG)
Deposited 2020-06-30
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 8
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293.15 K；0.1 M Tris pH 8.5, 25% (w/v) PEG 4000, 15% Glycerol
|
Resolution 2.17 Å
R-free 0.244
|
|
6ZKY
Crystal structure of InhA:01 TCR in complex with HLA-E (S147C) bound to InhA (53-61 H3C)
Deposited 2020-06-30
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293.15 K；0.1 M Sodium chloride, 0.1 M BIS-TRIS pH 6.5, 1.5 M Ammonium sulfate
|
Resolution 2.65 Å
R-free 0.273
|
|
6ZKZ
Crystal structure of InhA:01 TCR in complex with HLA-E (F116C) bound to InhA (53-61 H4C)
Deposited 2020-06-30
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293.15 K；0.1 M Tris pH 8.5, 20% (w/v) PEG 4000, 15% Glycerol
|
Resolution 2.30 Å
R-free 0.267
|
|
7AFV
Crystal structure of tetrameric beta-2-microglobulin deltaN6 S52C stabilized by a covalent ligand
Deposited 2020-09-20
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 4
PDB declaration: tetramer
|
Chain A
27–116（90 aa）
Chain B
27–116（90 aa）
|
Not recorded
|
TRS 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 2
SJK 5-oxidanylidene-~{N}-(2-sulfanylethyl)-2,3-dihydro-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxamide × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；Drop protein volume 0.2 uL
Drop well volume 0.1 uL
0.04 M Porpheus Alcohol Mix (Complex ingredient)
0.1 M Morpheus Buffer System 3 pH 8.5 (Buffer)
31 %w/v Morpheus Precipitant Mix 4 (Precipitant)
Stock Solutions:
Porpheus Alcohol Mix
0.2 M 1,6-hexanediol, 0.2 M 1-butanol, 0.2 M (RS)-1,2-propanediol, 0.2 M 2-propanol, 0.2 M 1,4-butanediol, 0.2 M 1,3-propanediol
(for a final concentration of 6.7 mM of 1,6-hexanediol, 1-butanol, (RS)-1,2-propanediol, 2-propanol, 1,4-butanediol, 1,3-propanediol)
Morpheus Buffer System 3 pH 8.5
1M Tris and 1M BICINE
(for a final concentration of 39.1 mM Bicine pH = 5.03 and 60.9 M Tris pH = 10.83)
Morpheus Precipitant Mix
25% w/v PEG 3350, 25% w/v PEG 1000, 25% v/v MPD
(for a final concentration of 7.75% w/v PEG 1000, 7.75% w/v PEG 3350 and 7.75% v/v MPD)
|
Resolution 2.40 Å
R-free 0.288
|
|
7ALO
Structure of B*27:09/photoRL9
Deposited 2020-10-07
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 5
TRS 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1
1PE PENTAETHYLENE GLYCOL × 1
PGE TRIETHYLENE GLYCOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；291 K；20% (w/v) polyethylene glycol 3350, and 200 mM KSCN
|
Resolution 1.80 Å
R-free 0.266
|
|
7ALO
Structure of B*27:09/photoRL9
Deposited 2020-10-07
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 7
TRS 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；291 K；20% (w/v) polyethylene glycol 3350, and 200 mM KSCN
|
Resolution 1.80 Å
R-free 0.266
|
|
7B5F
Structure of echovirus 18 in complex with neonatal Fc receptor
Deposited 2020-12-03
|
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 6
PDB declaration: Hexameric
|
Chain H
21–119（99 aa）
|
Not recorded
|
PLM PALMITIC ACID × 1
GUN GUANINE × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.3；Mixed in 1:1 volume ratio
{20 mM Tris (pH=7.2), 100 mM NaCl} and {8 mM Na2HPO4, 2 mM KH2PO4 (pH=7.4), 137 mM NaCl, 2.7 mM KCl}=PBS
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.90 Å
R-free 0.311
|
|
7BBG
CRYSTAL STRUCTURE OF HLA-A2-WT1-RMF AND FAB 11D06
Deposited 2020-12-17
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
NA SODIUM ION × 5
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M Tris pH 8.0, 20% PEG 4000
|
Resolution 2.64 Å
R-free 0.230
|
|
7BH8
3H4-Fab HLA-E-VL9 co-complex
Deposited 2021-01-10
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 10
PDB declaration: decameric
|
Chain B
21–119（99 aa）
Chain D
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 10
CA CALCIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；293.5 K；20% PEG 8000, 0.1 M NA HEPES
|
Resolution 1.80 Å
R-free 0.232
|
|
7C9V
E30 F-particle in complex with FcRn
Deposited 2020-06-07
|
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 360
PDB declaration: 360-meric
|
Chain F
21–119（99 aa）
|
Not recorded
|
MYR MYRISTIC ACID × 60
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.30 Å
|
|
7C9V
E30 F-particle in complex with FcRn
Deposited 2020-06-07
|
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain F
21–119（99 aa）
|
Not recorded
|
MYR MYRISTIC ACID × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.30 Å
|
|
7C9V
E30 F-particle in complex with FcRn
Deposited 2020-06-07
|
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 30
PDB declaration: 30-meric
|
Chain F
21–119（99 aa）
|
Not recorded
|
MYR MYRISTIC ACID × 5
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.30 Å
|
|
7C9V
E30 F-particle in complex with FcRn
Deposited 2020-06-07
|
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 36
PDB declaration: 36-meric
|
Chain F
21–119（99 aa）
|
Not recorded
|
MYR MYRISTIC ACID × 6
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.30 Å
|
|
7C9V
E30 F-particle in complex with FcRn
Deposited 2020-06-07
|
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 5
Protein heterocomplex
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain F
21–119（99 aa）
|
Not recorded
|
MYR MYRISTIC ACID × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.30 Å
|
|
7C9V
E30 F-particle in complex with FcRn
Deposited 2020-06-07
|
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 6
Protein heterocomplex
Heteromer；Protein × 360
PDB declaration: 360-meric
|
Chain F
21–119（99 aa）
|
Not recorded
|
MYR MYRISTIC ACID × 60
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.30 Å
|
|
7CIQ
Phosphorylation modification of MHC I polypeptide
Deposited 2020-07-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；277.15 K；0.2MSodiumchloride,0.1MBis-Tris(pH6.5),25%(w/v)PEG
3,350
|
Resolution 1.59 Å
R-free 0.209
|
|
7CIR
Peptide phosphorylation modification of MHC class I molecules
Deposited 2020-07-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291.15 K；0.1M TRIS-HCl (PH7.9)
17.5%(w/v)PEG8000
|
Resolution 1.81 Å
R-free 0.208
|
|
7CIS
Peptide modification of MHC class I molecules
Deposited 2020-07-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291.15 K；0.1 M TRIS-HCl (pH 7.1), 20.5% (w/v) PEG 8,000
|
Resolution 2.10 Å
R-free 0.222
|
|
7DUU
Crystal structure of HLA molecule with an KIR receptor
Deposited 2021-01-11
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；277 K；0.2 M Lithium sulfate, 0.1 M Tris pH 8.5, 25% w/v PEG 3350
|
Resolution 2.51 Å
R-free 0.246
|
|
7DYN
Phosphorylation of MHC I peptide
Deposited 2021-01-22
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291.15 K；0.2 M Ammonium acetate, 0.1 M HEPES (pH 7.5), 25% (w/v) PEG 3,350
|
Resolution 2.00 Å
R-free 0.208
|
|
7DZM
Crystal Structure of the cross-restricted T18A TCR and HLAB8101 bound to HIV-1 Gag TL9 peptide
Deposited 2021-01-25
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298.15 K；0.2 M Potassium chloride, 0.05 M HEPES pH 7.5, 35% v/v Pentaerythritol propoxylate (5/4 PO/OH)
|
Resolution 2.25 Å
R-free 0.240
|
|
7DZN
Crystal Structure of the cross-restricted T18A TCR and HLAB4201 bound to HIV-1 Gag TL9 peptide
Deposited 2021-01-25
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298.15 K；0.1 M SPG pH 7.0, 25 % w/v PEG 1500
|
Resolution 2.63 Å
R-free 0.261
|
|
7EDO
First insight into marsupial MHC I peptide presentation: immune features of lower mammals paralleled with bats
Deposited 2021-03-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291.15 K；0.1 M Na citrate trisbasic dihydrate (pH 5.0) ,30%v/v Jeffamine ED-2001
|
Resolution 2.70 Å
R-free 0.239
|
|
7EDO
First insight into marsupial MHC I peptide presentation: immune features of lower mammals paralleled with bats
Deposited 2021-03-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291.15 K；0.1 M Na citrate trisbasic dihydrate (pH 5.0) ,30%v/v Jeffamine ED-2001
|
Resolution 2.70 Å
R-free 0.239
|
|
7EJL
Complex Structure of HLA-A*2402 with the Peptide from HCoV(CoV-2) spike protein
Deposited 2021-04-02
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.2；293 K；Na/K phosphate
|
Resolution 1.89 Å
R-free 0.255
|
|
7EJM
Complex Structure of HLA-A*2402 with the Peptide from HCoV(CoV-229E) spike protein
Deposited 2021-04-02
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；Na citrate, PEG 3350
|
Resolution 1.71 Å
R-free 0.221
|
|
7EJN
Complex Structure of HLA-A*2402 with the Peptide from HCoV(CoV-HKU1) spike protein
Deposited 2021-04-02
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；PEG 3350, Tris-HCl
|
Resolution 2.11 Å
R-free 0.264
|
|
7EU2
Complex structure of HLA0201 with recognizing SARS-CoV-2 epitope S1
Deposited 2021-05-15
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 9；287 K；26% PEG 4000, 0.2 M Sodium acetate, and 0.1 M Tris-HCl pH9.0
|
Resolution 2.80 Å
R-free 0.266
|
|
7EU2
Complex structure of HLA0201 with recognizing SARS-CoV-2 epitope S1
Deposited 2021-05-15
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 9；287 K；26% PEG 4000, 0.2 M Sodium acetate, and 0.1 M Tris-HCl pH9.0
|
Resolution 2.80 Å
R-free 0.266
|
|
7F4W
Complex structure of HLA2402 with recognizing SARS-CoV-2 epitope pep4
Deposited 2021-06-21
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.1；287 K；0.1 M HEPES pH8.1
22%(v/v) PEG8000
|
Resolution 2.90 Å
R-free 0.298
|
|
7F4W
Complex structure of HLA2402 with recognizing SARS-CoV-2 epitope pep4
Deposited 2021-06-21
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.1；287 K；0.1 M HEPES pH8.1
22%(v/v) PEG8000
|
Resolution 2.90 Å
R-free 0.298
|
|
7JWI
Crystal structure of B17.R2 TCR in complex with H2D-b-NP366
Deposited 2020-08-25
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；298 K；20% PEG3350, 0.2 M potassium/sodium tartrate, 0.1 M Bis-tris propane
|
Resolution 3.02 Å
R-free 0.281
|
|
7JYU
Crystal Structure of HLA-A*2402 in complex with IYFSPIRVTF, an 10-mer epitope from Influenza B virus
Deposited 2020-09-01
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
MG MAGNESIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；277 K；20% PEG 8000, 0.2 MgCl2, 0.1 Tris-HCl pH 8.5
|
Resolution 2.75 Å
R-free 0.259
|
|
7JYU
Crystal Structure of HLA-A*2402 in complex with IYFSPIRVTF, an 10-mer epitope from Influenza B virus
Deposited 2020-09-01
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；277 K；20% PEG 8000, 0.2 MgCl2, 0.1 Tris-HCl pH 8.5
|
Resolution 2.75 Å
R-free 0.259
|
|
7JYV
Crystal Structure of HLA A*2402 in complex with YFSPIRVTF, an 9-mer influenza epitope
Deposited 2020-09-01
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
MG MAGNESIUM ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；277 K；19% PEG 3350, 0.2 MgCl2
|
Resolution 1.51 Å
R-free 0.206
|
|
7JYW
Crystal Structure of HLA A*2402 in complex with TYQWIIRNW, an 9-mer influenza epitope
Deposited 2020-09-01
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
CA CALCIUM ION × 1
NA SODIUM ION × 2
NI NICKEL (II) ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；277 K；20% PEG3350, 0.2M Na acetate
|
Resolution 2.90 Å
R-free 0.275
|
|
7JYX
Crystal Structure of HLA A*2402 in complex with TYQWIIRNWET, an 11-mer epitope from Influenza
Deposited 2020-09-01
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；277 K；24% PEG8000, 0.1 HEPES pH 7.5, 5% v/v Ethyl acetate
|
Resolution 2.95 Å
R-free 0.275
|
|
7JYX
Crystal Structure of HLA A*2402 in complex with TYQWIIRNWET, an 11-mer epitope from Influenza
Deposited 2020-09-01
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；277 K；24% PEG8000, 0.1 HEPES pH 7.5, 5% v/v Ethyl acetate
|
Resolution 2.95 Å
R-free 0.275
|
|
7K80
KIR3DL1*001 in complex with HLA-A*24:02 presenting the RYPLTFGW peptide
Deposited 2020-09-24
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
FMT FORMIC ACID × 1
ACT ACETATE ION × 1
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；298 K；14% PEG 3350, 2% tacsimate, pH 5.0, and 0.1 M trisodium citrate, pH 5.6
|
Resolution 2.40 Å
R-free 0.249
|
|
7K80
KIR3DL1*001 in complex with HLA-A*24:02 presenting the RYPLTFGW peptide
Deposited 2020-09-24
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain E
21–119（99 aa）
|
Not recorded
|
ACT ACETATE ION × 4
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；298 K；14% PEG 3350, 2% tacsimate, pH 5.0, and 0.1 M trisodium citrate, pH 5.6
|
Resolution 2.40 Å
R-free 0.249
|
|
7K81
KIR3DL1*005 in complex with HLA-A*24:02 presenting the RYPLTFGW peptide
Deposited 2020-09-24
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；298 K；14% PEG 3350, 2% tacsimate, pH 5.0, and 0.1 M trisodium citrate, pH 5.6
|
Resolution 2.00 Å
R-free 0.243
|
|
7KGO
Crystal Structure of HLA-A*0201in complex with SARS-CoV-2 N351-359
Deposited 2020-10-18
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
3NI NICKEL (III) ION × 3
CL CHLORIDE ION × 3
CD CADMIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；277 K；20% PEG3350 w/v, 0.2 M NaFormate, 1 mM CdCl2
|
Resolution 2.15 Å
R-free 0.229
|
|
7KGP
Crystal Structure of HLA-A*0201 in complex with SARS-CoV-2 N316-324
Deposited 2020-10-18
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
ACT ACETATE ION × 1
CD CADMIUM ION × 2
NA SODIUM ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；277 K；20% 3350, 0.2M NaFluoride, 1 mM CdCl2
|
Resolution 1.40 Å
R-free 0.203
|
|
7KGQ
Crystal Structure of HLA-A*0201in complex with SARS-CoV-2 N222-230
Deposited 2020-10-18
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
CD CADMIUM ION × 2
CA CALCIUM ION × 2
EDO 1,2-ETHANEDIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；277 K；20% PEG3350, 0.2M KFormate, 1mM CaCl2
|
Resolution 1.34 Å
R-free 0.198
|
|
7KGR
Crystal Structure of HLA-A*0201in complex with SARS-CoV-2 N159-167
Deposited 2020-10-18
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；277 K；20% PEG3350 w/v, 0.2 M NaFormate
|
Resolution 1.55 Å
R-free 0.221
|
|
7KGS
Crystal Structure of HLA-A*0201 in complex with SARS-CoV-2 N138-146
Deposited 2020-10-18
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
CD CADMIUM ION × 2
ACT ACETATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；277 K；20% PEG3350 w/v, 0.2 M NaFormate, 1 mM CdCl2
|
Resolution 1.58 Å
R-free 0.197
|
|
7KGT
Crystal Structure of HLA-A*0201 in complex with SARS-CoV-2 N226-234
Deposited 2020-10-18
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
CD CADMIUM ION × 2
NA SODIUM ION × 1
ACT ACETATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；277 K；20% PEG3350 w/v, 0.2M KFormate, 1mM CdCl2
|
Resolution 1.90 Å
R-free 0.205
|
|
7KOZ
CD1a-36:2 SM binary complex
Deposited 2020-11-10
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
20–119（100 aa）
|
Not recorded
|
WU7 (4S,7S,17Z)-4-hydroxy-7-[(1S,2E)-1-hydroxyhexadec-2-en-1-yl]-N,N,N-trimethyl-4,9-dioxo-3,5-dioxa-8-aza-4lambda~5~-phosphahexacos-17-en-1-aminium × 1
EDO 1,2-ETHANEDIOL × 4
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；20-25% PEG 1500, 0.1M MMT pH 5.5
|
Resolution 2.25 Å
R-free 0.246
|
|
7KP0
CD1a-42:1 SM binary complex
Deposited 2020-11-10
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
20–119（100 aa）
|
Not recorded
|
WUA (4R,7S)-4-hydroxy-7-[(1S,2E)-1-hydroxyhexadec-2-en-1-yl]-N,N,N-trimethyl-4,9-dioxo-3,5-dioxa-8-aza-4lambda~5~-phosphadotriacontan-1-aminium × 1
EDO 1,2-ETHANEDIOL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；20-25% PEG 1500, 0.1M MMT pH 5.5
|
Resolution 2.40 Å
R-free 0.264
|
|
7KP1
CD1a-42:2 SM binary complex
Deposited 2020-11-10
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
20–119（100 aa）
|
Not recorded
|
FO4 sphingomyelin × 1
MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；20-25% PEG 1500, 0.1M MMT pH 5.5
|
Resolution 2.02 Å
R-free 0.226
|
|
7L1B
Crystal structure of HLA-A*03:01 in complex with a wild-type PIK3CA peptide
Deposited 2020-12-14
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；277.15 K；10.00 % w/v Polyethylene glycol 8,000,
200 mM Calcium acetate,
100 mM HEPES; pH 7.5
|
Resolution 2.04 Å
R-free 0.221
|
|
7L1C
Crystal structure of HLA-A*03:01 in complex with a mutant PIK3CA peptide
Deposited 2020-12-14
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 5
FMT FORMIC ACID × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.6；277.15 K；20% w/v Polyethylene glycol 3,350,
200 mM Ammonium formate, pH 6.6
|
Resolution 1.96 Å
R-free 0.205
|
|
7L1D
Crystal structure of human 21LT2-2 TCR bound to HLA-A*03:01 in complex with a mutant PIK3CA peptide
Deposited 2020-12-14
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
ACT ACETATE ION × 1
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277.15 K；10% w/v Polyethylene glycol 8,000,
200mM Magnesium acetate
|
Resolution 3.11 Å
R-free 0.250
|
|
7LFZ
Human leukocyte antigen B*07:02 in complex with SARS-CoV2 epitope IPRRNVATL
Deposited 2021-01-19
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；290 K；0.1 M sodium citrate, pH 8.0, 20% PEG4000, 20% isopropanol
|
Resolution 1.90 Å
R-free 0.224
|
|
7LG0
Human leukocyte antigen B*07:02 in complex with SARS-CoV2 epitope SPRWYFYYL
Deposited 2021-01-19
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP RESIDUES 21-119
|
Not recorded
|
P6G HEXAETHYLENE GLYCOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；290 K；0.1 M HEPES-NaOH, pH 7.5, 2 M ammonium sulfate
|
Resolution 2.30 Å
R-free 0.268
|
|
7LG2
Human leukocyte antigen A*0201 in complex with SARS-CoV2 epitope ALWEIQQVV
Deposited 2021-01-19
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 3
PGE TRIETHYLENE GLYCOL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；290 K；25% PEG3350, 0.1 M Bis-Tris, pH 5.5, 0.2 M magnesium chloride
|
Resolution 2.40 Å
R-free 0.254
|
|
7LG3
Human leukocyte antigen A*0201 in complex with SARS-CoV2 epitope KLWAQCVQL
Deposited 2021-01-19
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.6；290 K；20% PEG4000, 0.1 M sodium acetate, pH 5.6, 20% isopropanol
|
Resolution 2.30 Å
R-free 0.248
|
|
7LGD
HLA-B*07:02 in complex with SARS-CoV-2 nucleocapsid peptide N105-113
Deposited 2021-01-20
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
CL CHLORIDE ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；277 K；2M Ammonium Sulfate, 0.1M HEPES pH 7.5
|
Resolution 2.88 Å
R-free 0.269
|
|
7LGD
HLA-B*07:02 in complex with SARS-CoV-2 nucleocapsid peptide N105-113
Deposited 2021-01-20
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
CL CHLORIDE ION × 2
SO4 SULFATE ION × 4
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；277 K；2M Ammonium Sulfate, 0.1M HEPES pH 7.5
|
Resolution 2.88 Å
R-free 0.269
|
|
7LGT
HLA-B*07:02 in complex with 229E-derived coronavirus nucleocapsid peptide N75-83
Deposited 2021-01-21
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
ZN ZINC ION × 7
NA SODIUM ION × 1
CL CHLORIDE ION × 8
K POTASSIUM ION × 8
BR BROMIDE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277 K；18% PEG 3350, 0.2 M KI
|
Resolution 1.97 Å
R-free 0.246
|
|
7LGT
HLA-B*07:02 in complex with 229E-derived coronavirus nucleocapsid peptide N75-83
Deposited 2021-01-21
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
ZN ZINC ION × 4
NA SODIUM ION × 3
CL CHLORIDE ION × 1
K POTASSIUM ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277 K；18% PEG 3350, 0.2 M KI
|
Resolution 1.97 Å
R-free 0.246
|
|
7LLI
Stimulatory immune receptor protein complex
Deposited 2021-02-04
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain D
21–119（99 aa）
|
Not recorded
|
2LJ 1-deoxy-1-({2,6-dioxo-5-[(E)-propylideneamino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-ribitol × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；30-40% PEG 400, 0.1/0.2 HEPES pH 7.5, 0.2M MgCl2
|
Resolution 3.20 Å
R-free 0.263
|
|
7LLI
Stimulatory immune receptor protein complex
Deposited 2021-02-04
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
2LJ 1-deoxy-1-({2,6-dioxo-5-[(E)-propylideneamino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-ribitol × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；30-40% PEG 400, 0.1/0.2 HEPES pH 7.5, 0.2M MgCl2
|
Resolution 3.20 Å
R-free 0.263
|
|
7LLJ
Inhibitory immune receptor protein complex
Deposited 2021-02-04
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain D
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
30W N-(6-formyl-4-oxo-3,4-dihydropteridin-2-yl)acetamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；30-40% PEG 400, 0.1/0.2 HEPES pH 7.5, 0.2M MgCl2
|
Resolution 3.15 Å
R-free 0.276
|
|
7LLJ
Inhibitory immune receptor protein complex
Deposited 2021-02-04
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain F
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
30W N-(6-formyl-4-oxo-3,4-dihydropteridin-2-yl)acetamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；30-40% PEG 400, 0.1/0.2 HEPES pH 7.5, 0.2M MgCl2
|
Resolution 3.15 Å
R-free 0.276
|
|
7M8S
Crystal Structure of HLA-A*02:01 in complex with KLNDLCFTNV, an 10-mer epitope from SARS-CoV-2 Spike (S386-395)
Deposited 2021-03-30
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.6；277 K；0.2 Ammonium tantrate, 0.001 Cadmium chloride, 14% PEG 3350
|
Resolution 2.35 Å
R-free 0.247
|
|
7M8S
Crystal Structure of HLA-A*02:01 in complex with KLNDLCFTNV, an 10-mer epitope from SARS-CoV-2 Spike (S386-395)
Deposited 2021-03-30
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.6；277 K；0.2 Ammonium tantrate, 0.001 Cadmium chloride, 14% PEG 3350
|
Resolution 2.35 Å
R-free 0.247
|
|
7M8T
Crystal Structure of HLA-A*11:01 in complex with NSASFSTFK, an 9-mer epitope from SARS-CoV-2 spike (S370-378)
Deposited 2021-03-30
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 1
SO4 SULFATE ION × 2
NA SODIUM ION × 2
CL CHLORIDE ION × 2
CA CALCIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；2M Ammonium Sulfate, 0.1M Calcium cacodylate pH 6.5, 0.2M sodium chloride
|
Resolution 1.50 Å
R-free 0.219
|
|
7M8U
Crystal Structure of HLA-B*35:01 in complex with IPFAMQMAY, an 9-mer epitope from SARS-CoV-2 spike (S896-904)
Deposited 2021-03-30
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
PO4 PHOSPHATE ION × 2
NA SODIUM ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；0.2 sodium fluoride, 18% PEG 3350
|
Resolution 1.45 Å
R-free 0.229
|
|
7MJ6
HLA-A*02:01 bound to Neuroblastoma Derived IGFBPL1 peptide
Deposited 2021-04-19
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；295 K；1M Sodium Citrate Dibasic, 0.1M Sodium Cacodylate pH 6.5
|
Resolution 1.95 Å
R-free 0.196
|
|
7MJ7
HLA-A*02:01 bound to Neuroblastoma Derived IGFBPL1 peptide
Deposited 2021-04-19
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；295 K；1M Sodium Citrate Dibasic, 0.1M Sodium Cacodylate pH 6.5
|
Resolution 1.60 Å
R-free 0.192
|
|
7MJ8
HLA-A*02:01 bound to Neuroblastoma Derived IGFBPL1 peptide
Deposited 2021-04-19
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；295 K；1M Sodium Citrate Dibasic, 0.1M Sodium Cacodylate pH 6.5
|
Resolution 1.79 Å
R-free 0.190
|
|
7MJ9
HLA-A*02:01 bound to Neuroblastoma Derived mutant IGFBPL1 peptide
Deposited 2021-04-19
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；295 K；0.2 M Magnesium Chloride, 0.1 M HEPES pH 7, 20 % PEG 6000
|
Resolution 1.75 Å
R-free 0.194
|
|
7MJA
HLA-A*24:02 bound to Neuroblastoma derived PHOX2B peptide
Deposited 2021-04-19
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；295 K；0.1 M HEPES pH 7.0, 10% PEG 6000
|
Resolution 1.69 Å
R-free 0.199
|
|
7MKB
Human leukocyte antigen A*0201 in complex with SARS-CoV-2 epitope YLQPRTFLL
Deposited 2021-04-22
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；290 K；17% PEG10000, 0.1 M Bis-Tris, pH 5.5, 0.1 M ammonium acetate
|
Resolution 1.90 Å
R-free 0.209
|
|
7MLE
Crystal Structure of HLA-A*03:01 in complex with VVRPSVASK, an 9-mer epitope from Influenza B virus
Deposited 2021-04-28
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.6；277 K；1M trisodium citrate, 0.1M sodium cacodylate pH 6.5
|
Resolution 2.20 Å
R-free 0.264
|
|
7MX4
CD1c with antigen analogue 1
Deposited 2021-05-18
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
20–119（100 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
ZPD (4S,8R,12S,16S,20S)-4,8,12,16,20-pentamethylheptacosyl (1R,2S,3S,4R,5R)-2,3,4-trihydroxy-5-(hydroxymethyl)cyclohexyl hydrogen (R)-phosphate × 1
D12 DODECANE × 1
ZP7 (2S)-2,3-dihydroxypropyl hexadecanoate × 1
NHE 2-[N-CYCLOHEXYLAMINO]ETHANE SULFONIC ACID × 1
MLA MALONIC ACID × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 9.4；293 K；100 mM CHES, 1.05 M sodium citrate, 25 mM triglycine
|
Resolution 1.73 Å
R-free 0.239
|
|
7MXF
CD1c with antigen analogue 2
Deposited 2021-05-19
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
20–119（100 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
NHE 2-[N-CYCLOHEXYLAMINO]ETHANE SULFONIC ACID × 1
ZQ4 2,6-anhydro-1-deoxy-1-[(S)-hydroxy{[(4R,8S,12R,16R,20S)-4,8,12,16,20-pentamethylheptacosyl]oxy}phosphoryl]-D-glycero-D-galacto-heptitol × 1
D12 DODECANE × 1
ZP7 (2S)-2,3-dihydroxypropyl hexadecanoate × 1
MLA MALONIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 9.4；293 K；100 mM CHES, 1.05 M sodium citrate, 25 mM triglycine
|
Resolution 2.00 Å
R-free 0.242
|
|
7MXH
CD1c with antigen analogue 3
Deposited 2021-05-19
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
20–119（100 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
ZQ7 2,6-anhydro-1-deoxy-1,1-difluoro-1-[(R)-hydroxy{[(4S,8S,12S,16S,20S)-4,8,12,16,20-pentamethylheptacosyl]oxy}phosphoryl]-D-glycero-D-galacto-heptitol × 1
D12 DODECANE × 1
ZP7 (2S)-2,3-dihydroxypropyl hexadecanoate × 1
MLA MALONIC ACID × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 9.4；293 K；100 mM CHES, 1.05 M sodium citrate, 25 mM triglycine
|
Resolution 2.11 Å
R-free 0.255
|
|
7N1A
SARS-CoV-2 YLQ peptide binds to HLA-A2
Deposited 2021-05-27
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
PG4 TETRAETHYLENE GLYCOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；295 K；0.2M Potassium thiocyanate (pH 7.0), 22% (w/v) PEG 3350
|
Resolution 2.06 Å
R-free 0.241
|
|
7N1A
SARS-CoV-2 YLQ peptide binds to HLA-A2
Deposited 2021-05-27
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
PG4 TETRAETHYLENE GLYCOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；295 K；0.2M Potassium thiocyanate (pH 7.0), 22% (w/v) PEG 3350
|
Resolution 2.06 Å
R-free 0.241
|
|
7N1B
SARS-CoV-2 RLQ peptide binds to HLA-A2
Deposited 2021-05-27
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；295 K；0.2M Ammonium sulfate, 0.1M MES (pH 6.5), 20% (w/v) PEG 8000 by micro-seeding
|
Resolution 2.81 Å
R-free 0.269
|
|
7N1B
SARS-CoV-2 RLQ peptide binds to HLA-A2
Deposited 2021-05-27
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；295 K；0.2M Ammonium sulfate, 0.1M MES (pH 6.5), 20% (w/v) PEG 8000 by micro-seeding
|
Resolution 2.81 Å
R-free 0.269
|
|
7N1E
SARS-CoV-2 RLQ peptide-specific TCR pRLQ3 binds to RLQ-HLA-A2
Deposited 2021-05-27
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；295 K；0.2M Ammonium sulfate, 0.1M MES (pH 6.0), 12% (w/v) PEG 4000
|
Resolution 2.30 Å
R-free 0.258
|
|
7N1F
SARS-CoV-2 YLQ peptide-specific TCR pYLQ7 binds to YLQ-HLA-A2
Deposited 2021-05-27
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5；295 K；in 0.1M Ammonium sulfate, 0.3M Sodium formate, 0.1M Sodium acetate (pH 5.0), 3% (w/v) Gama-PGA (Na+ form, LM), 3% (w/v) PEG 20000
|
Resolution 2.39 Å
R-free 0.236
|
|
7N2N
TCR-antigen complex AS4.2-PRPF3-HLA*B27
Deposited 2021-05-29
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 4
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；20% PEG3350 with 0.2M Potassium phosphate monobasic
|
Resolution 2.60 Å
R-free 0.291
|
|
7N2O
AS4.2-YEIH-HLA*B27
Deposited 2021-05-29
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 2
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；20% PEG3350 with 0.2M Ammonium acetate
|
Resolution 2.30 Å
R-free 0.267
|
|
7N2P
AS4.3-RNASEH2b-HLA*B27
Deposited 2021-05-29
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 6
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 4
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；20% PEG3350 with 0.2M Magnesium formate dihydrate
|
Resolution 2.50 Å
R-free 0.288
|
|
7N2Q
AS4.3-YEIH-HLA*B27
Deposited 2021-05-29
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；25% PEG3350 with 0.2M Ammonium sulfate and 0.1M BIS-TRIS pH 6.5
|
Resolution 2.70 Å
R-free 0.264
|
|
7N2Q
AS4.3-YEIH-HLA*B27
Deposited 2021-05-29
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain I
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3
SO4 SULFATE ION × 3
GOL GLYCEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；25% PEG3350 with 0.2M Ammonium sulfate and 0.1M BIS-TRIS pH 6.5
|
Resolution 2.70 Å
R-free 0.264
|
|
7N2R
AS4.3-PRPF3-HLA*B27
Deposited 2021-05-29
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5
ASP ASPARTIC ACID × 1
SO4 SULFATE ION × 3
EDO 1,2-ETHANEDIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；25% PEG3350 with 0.2M Ammonium sulfate and 0.1M BIS-TRIS pH 6.5
|
Resolution 2.28 Å
R-free 0.288
|
|
7N2S
AS3.1-PRPF3-HLA*B27
Deposited 2021-05-29
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 1
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；25% PEG3350 with 0.2M Ammonium tartrate dibasic dihydrate
|
Resolution 2.37 Å
R-free 0.311
|
|
7N4K
6218 TCR in complex with H2-Db PA 224
Deposited 2021-06-04
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
NA SODIUM ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；293 K；20% PEG3350, 0.2 M NaF, 0.05 M NaForm, 1% 1,5-Diaminopentane dihydrochloride
|
Resolution 1.85 Å
R-free 0.214
|
|
7N5C
6218 TCR in complex with H2Db PA with an engineered TCR-pMHC disulfide bond
Deposited 2021-06-05
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；293 K；20% PEG3350, 0.2M NaF, 0.05M NaForm, 1% 1,5-Diaminopentane dihydrochloride
|
Resolution 1.87 Å
R-free 0.233
|
|
7N5P
6218 TCR in complex with H2-Db PA224-233 with a cysteine mutant
Deposited 2021-06-06
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
NA SODIUM ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；293 K；20% PEG3350, 0.2M NaF, 0.05M NaForm, 1% 1,5-Diaminopentane dihydrochloride
|
Resolution 2.09 Å
R-free 0.236
|
|
7N5Q
Peptide-MHC complex of mouse H2-Db presenting PA224 with E4C mutation
Deposited 2021-06-06
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
NA SODIUM ION × 8
ACT ACETATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；293 K；20% PEG2000, 0.1M KSCN, 2% MPD
|
Resolution 1.76 Å
R-free 0.218
|
|
7N5Q
Peptide-MHC complex of mouse H2-Db presenting PA224 with E4C mutation
Deposited 2021-06-06
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain G
21–119（99 aa）
|
Not recorded
|
NA SODIUM ION × 3
ACT ACETATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；293 K；20% PEG2000, 0.1M KSCN, 2% MPD
|
Resolution 1.76 Å
R-free 0.218
|
|
7N6D
HLA peptide complex
Deposited 2021-06-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293.15 K；20% PEG3350, 0.2 M sodium thiocyanate
|
Resolution 2.30 Å
R-free 0.247
|
|
7N6D
HLA peptide complex
Deposited 2021-06-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain F
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293.15 K；20% PEG3350, 0.2 M sodium thiocyanate
|
Resolution 2.30 Å
R-free 0.247
|
|
7N6D
HLA peptide complex
Deposited 2021-06-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain J
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 5
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293.15 K；20% PEG3350, 0.2 M sodium thiocyanate
|
Resolution 2.30 Å
R-free 0.247
|
|
7N6D
HLA peptide complex
Deposited 2021-06-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain N
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293.15 K；20% PEG3350, 0.2 M sodium thiocyanate
|
Resolution 2.30 Å
R-free 0.247
|
|
7N6E
TCR peptide HLA-A2 complex
Deposited 2021-06-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；293.15 K；20% PEG3350, 0.2 M sodium thiocyanate, 100 mM Tris-Cl
|
Resolution 3.20 Å
R-free 0.294
|
|
7N6E
TCR peptide HLA-A2 complex
Deposited 2021-06-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；293.15 K；20% PEG3350, 0.2 M sodium thiocyanate, 100 mM Tris-Cl
|
Resolution 3.20 Å
R-free 0.294
|
|
7N9J
Crystal structure of H2DB in complex with HSF2 melanoma neoantigen
Deposited 2021-06-18
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；290 K；25% PEG3350, 0.1 M Tris-HCl, pH 8.5, 0.2 M sodium acetate, 30% PEG4000
|
Resolution 1.74 Å
R-free 0.213
|
|
7NA5
Structure of the H2DB-TCR ternary complex with HSF2 melanoma neoantigen
Deposited 2021-06-19
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 13
SO4 SULFATE ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；290 K；25% PEG3350, 0.1 M Bis-Tris, pH 5.5, 0.2 M lithium sulfate, 15% glycerol
|
Resolution 2.50 Å
R-free 0.249
|
|
7NDQ
Gag:02 TCR in complex with HLA-E.
Deposited 2021-02-02
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain BBB
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；23.2% (w/v) PEG 1500, 93 mM MMT pH 9.0
|
Resolution 2.55 Å
R-free 0.296
|
|
7NDT
UL40:01 TCR in complex with HLA-E with a non-natural amino acid
Deposited 2021-02-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 10
PDB declaration: decameric
|
Chain BBB
21–119（99 aa）
Chain GGG
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；12% (w/v) PEG 8000, 55 mM MOPS pH 6.5
|
Resolution 3.00 Å
R-free 0.269
|
|
7NDU
Gag:02 TCR in complex with HLA-E featuring a non-natural amino acid
Deposited 2021-02-02
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain BBB
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；22.3% (w/v) PEG 1500, 89 mM MMT pH 9.0
|
Resolution 2.90 Å
R-free 0.301
|
|
7NMC
Crystal structure of beta-2-microglobulin D76E mutant
Deposited 2021-02-23
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain AAA
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 2
PGE TRIETHYLENE GLYCOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293.15 K；100 nL mother liquor / 200 nL protein
15% Glycerol, 0.1 M NaAcetate pH 4.5-5.5, 28-32%PEG 4000, 0.2 M NH4Acetate
|
Resolution 1.20 Å
R-free 0.179
|
|
7NMD
Human Major Histocompatibility Complex A24 Allele presenting QLPRLFPLL
Deposited 2021-02-23
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 4
PEG DI(HYDROXYETHYL)ETHER × 4
SO4 SULFATE ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；20% PEG 4000, 0.1 M TRIS (pH 7.5), 15% glycerol.
|
Resolution 2.25 Å
R-free 0.265
|
|
7NMD
Human Major Histocompatibility Complex A24 Allele presenting QLPRLFPLL
Deposited 2021-02-23
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 4
PEG DI(HYDROXYETHYL)ETHER × 2
SO4 SULFATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；20% PEG 4000, 0.1 M TRIS (pH 7.5), 15% glycerol.
|
Resolution 2.25 Å
R-free 0.265
|
|
7NME
Human MHC Class I, A24 Allele presenting QLPRLFPLL, Complex with 4C6 TCR
Deposited 2021-02-23
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
BTB 2-[BIS-(2-HYDROXY-ETHYL)-AMINO]-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1
SO4 SULFATE ION × 1
EDO 1,2-ETHANEDIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 9；291 K；Molecular Dimensions Pact Premier C06:
0.1M PCTCP buffer, 25% PEG 1500, pH 9.0
|
Resolution 2.20 Å
R-free 0.274
|
|
7NMF
Human MHC Class I, A24 Allele presenting QLPRLFPLL, Complex with 4C6 TCR, monoclinic form
Deposited 2021-02-23
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1
EDO 1,2-ETHANEDIOL × 1
SO4 SULFATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；291 K；0.1M Sodium Bromide, 0.1 M bis-tris Propane, pH 7.5, 20% PEG 3350
|
Resolution 2.98 Å
R-free 0.259
|
|
7NMG
Human MHC Class I, A24 Allele presenting LWM, Complex with 4C6 TCR
Deposited 2021-02-23
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 3
EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 1
EDO 1,2-ETHANEDIOL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；25% PEG 1500, 0.1M PCTP Buffer, pH 9.0
|
Resolution 2.48 Å
R-free 0.271
|
|
7NMO
Crystal structure of beta-2-microglobulin D76A mutant
Deposited 2021-02-23
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain AAA
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293.15 K；100 nL mother liquor / 200 nL protein
15% Glycerol, 0.1 M NaAcetate pH 4.5-5.5, 28-32%PEG 4000, 0.2 M NH4Acetate
|
Resolution 1.20 Å
R-free 0.159
|
|
7NMR
Crystal structure of beta-2-microglobulin D76S mutant
Deposited 2021-02-23
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain AAA
21–117（97 aa）
|
Not recorded
|
GOL GLYCEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293.15 K；100 nL mother liquor / 200 nL protein
15% Glycerol, 0.1 M NaAcetate pH 4.5-5.5, 28-32%PEG 4000, 0.2 M NH4Acetate
|
Resolution 1.15 Å
R-free 0.182
|
|
7NMT
Crystal structure of beta-2-microglobulin D76G mutant
Deposited 2021-02-23
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain AAA
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293.15 K；100 nL mother liquor / 200 nL protein
15% Glycerol, 0.1 M NaAcetate pH 4.5-5.5, 28-32%PEG 4000, 0.2 M NH4Acetate
|
Resolution 1.20 Å
R-free 0.174
|
|
7NMV
Crystal structure of beta-2-microglobulin D76Q mutant
Deposited 2021-02-23
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain AAA
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293.15 K；100 nL mother liquor / 200 nL protein
15% Glycerol, 0.1 M NaAcetate pH 4.5-5.5, 28-32%PEG 4000, 0.2 M NH4Acetate
|
Resolution 1.51 Å
R-free 0.266
|
|
7NMY
Crystal structure of beta-2-microglobulin D76Y mutant
Deposited 2021-02-23
|
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain AAA
21–119（99 aa）
|
Mutation：D76Y
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293.15 K；100 nL mother liquor / 200 nL protein
15% Glycerol, 0.1 M NaAcetate pH 4.5-5.5, 28-32%PEG 4000, 0.2 M NH4Acetate
|
Resolution 1.25 Å
R-free 0.227
|
|
7NN5
Crystal structure of beta-2-microglobulin D76K mutant
Deposited 2021-02-24
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain AAA
21–118（98 aa）
|
Mutation：D76K
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293.15 K；100 nL mother liquor / 200 nL protein
15% Glycerol, 0.1 M NaAcetate pH 4.5-5.5, 28-32%PEG 4000, 0.2 M NH4Acetate
|
Resolution 1.24 Å
R-free 0.230
|
|
7NUI
Crystal structure of HLA-B*08:01 in complex with ELRSRYWAI viral peptide
Deposited 2021-03-12
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 4
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；289.15 K；0.2 M sodium iodide, 0.1 M Bis-Tris propane, 20 % w/v PEG 3350
|
Resolution 2.00 Å
R-free 0.282
|
|
7OW3
Crystal structure of HLA-A*11:01 in complex with KRAS peptide (VVVGAGGVGK)
Deposited 2021-06-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M Ammonium sulfate, 0.1 M Sodium cacodylate pH 6, 25% PEG 4000
|
Resolution 2.46 Å
R-free 0.260
|
|
7OW3
Crystal structure of HLA-A*11:01 in complex with KRAS peptide (VVVGAGGVGK)
Deposited 2021-06-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M Ammonium sulfate, 0.1 M Sodium cacodylate pH 6, 25% PEG 4000
|
Resolution 2.46 Å
R-free 0.260
|
|
7OW3
Crystal structure of HLA-A*11:01 in complex with KRAS peptide (VVVGAGGVGK)
Deposited 2021-06-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain H
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M Ammonium sulfate, 0.1 M Sodium cacodylate pH 6, 25% PEG 4000
|
Resolution 2.46 Å
R-free 0.260
|
|
7OW3
Crystal structure of HLA-A*11:01 in complex with KRAS peptide (VVVGAGGVGK)
Deposited 2021-06-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain K
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M Ammonium sulfate, 0.1 M Sodium cacodylate pH 6, 25% PEG 4000
|
Resolution 2.46 Å
R-free 0.260
|
|
7OW4
Crystal structure of HLA-A*11:01 in complex with KRAS G12D peptide (VVVGADGVGK)
Deposited 2021-06-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M Lithium sulfate, 0.1 M Bis-Tris pH 5.5, 25% w/v PEG 3500
|
Resolution 1.81 Å
R-free 0.249
|
|
7OW4
Crystal structure of HLA-A*11:01 in complex with KRAS G12D peptide (VVVGADGVGK)
Deposited 2021-06-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M Lithium sulfate, 0.1 M Bis-Tris pH 5.5, 25% w/v PEG 3500
|
Resolution 1.81 Å
R-free 0.249
|
|
7OW4
Crystal structure of HLA-A*11:01 in complex with KRAS G12D peptide (VVVGADGVGK)
Deposited 2021-06-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain H
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M Lithium sulfate, 0.1 M Bis-Tris pH 5.5, 25% w/v PEG 3500
|
Resolution 1.81 Å
R-free 0.249
|
|
7OW4
Crystal structure of HLA-A*11:01 in complex with KRAS G12D peptide (VVVGADGVGK)
Deposited 2021-06-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain K
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M Lithium sulfate, 0.1 M Bis-Tris pH 5.5, 25% w/v PEG 3500
|
Resolution 1.81 Å
R-free 0.249
|
|
7OW5
Crystal structure of a TCR in complex with HLA-A*11:01 bound to KRAS peptide (VVVGAGGVGK)
Deposited 2021-06-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M Ammonium citrate tribasic pH 7.0, 20% w/v PEG 3350
|
Resolution 2.58 Å
R-free 0.274
|
|
7OW6
Crystal structure of a TCR in complex with HLA-A*11:01 bound to KRAS G12D peptide (VVVGADGVGK)
Deposited 2021-06-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M Ammonium sulfate, 20% w/v PEG 3350
|
Resolution 2.64 Å
R-free 0.268
|
|
7P3D
MHC I A02 Allele presenting YLQPRTFLL
Deposited 2021-07-07
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 6
ACT ACETATE ION × 1
CA CALCIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M sodium nitrate, 0.1 M Bis Tris propane pH 7.5, and 20 % w/v PEG 3350
|
Resolution 1.67 Å
R-free 0.231
|
|
7P3E
MHC I A02 Allele presenting YLQLRTFLL
Deposited 2021-07-07
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
IOD IODIDE ION × 12
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；0.2 M sodium iodide, 0.1 M Bis Tris propane pH 7.5, and 20 % w/v PEG 3350
|
Resolution 2.00 Å
R-free 0.248
|
|
7P3E
MHC I A02 Allele presenting YLQLRTFLL
Deposited 2021-07-07
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
IOD IODIDE ION × 12
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；0.2 M sodium iodide, 0.1 M Bis Tris propane pH 7.5, and 20 % w/v PEG 3350
|
Resolution 2.00 Å
R-free 0.248
|
|
7P49
HLA-E*01:03 in complex with Mtb14
Deposited 2021-07-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 4
SO4 SULFATE ION × 8
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；3 M AS, 0.1 M MES pH 6
|
Resolution 2.05 Å
R-free 0.279
|
|
7P49
HLA-E*01:03 in complex with Mtb14
Deposited 2021-07-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 5
SO4 SULFATE ION × 7
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；3 M AS, 0.1 M MES pH 6
|
Resolution 2.05 Å
R-free 0.279
|
|
7P49
HLA-E*01:03 in complex with Mtb14
Deposited 2021-07-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain F
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 1
SO4 SULFATE ION × 6
ZN ZINC ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；3 M AS, 0.1 M MES pH 6
|
Resolution 2.05 Å
R-free 0.279
|
|
7P49
HLA-E*01:03 in complex with Mtb14
Deposited 2021-07-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain H
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 1
SO4 SULFATE ION × 6
ZN ZINC ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；3 M AS, 0.1 M MES pH 6
|
Resolution 2.05 Å
R-free 0.279
|
|
7P4B
HLA-E*01:03 in complex with IL9
Deposited 2021-07-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 1
SO4 SULFATE ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293.5 K；2.2 M AS 0.1 M MES pH 5.8
|
Resolution 1.72 Å
R-free 0.237
|
|
7P4B
HLA-E*01:03 in complex with IL9
Deposited 2021-07-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 7
SO4 SULFATE ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293.5 K；2.2 M AS 0.1 M MES pH 5.8
|
Resolution 1.72 Å
R-free 0.237
|
|
7P4B
HLA-E*01:03 in complex with IL9
Deposited 2021-07-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain F
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 2
ZN ZINC ION × 1
PO4 PHOSPHATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293.5 K；2.2 M AS 0.1 M MES pH 5.8
|
Resolution 1.72 Å
R-free 0.237
|
|
7P4B
HLA-E*01:03 in complex with IL9
Deposited 2021-07-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain H
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 2
SO4 SULFATE ION × 7
ZN ZINC ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293.5 K；2.2 M AS 0.1 M MES pH 5.8
|
Resolution 1.72 Å
R-free 0.237
|
|
7PB2
Crystal structure of JDI TCR in complex with HLA-A*11:01 bound to KRAS G12D peptide (VVVGADGVGK)
Deposited 2021-07-30
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M ammonium sulfate, 0.1 M Tris pH 8.5, 20 % PEG 8000
|
Resolution 3.41 Å
R-free 0.254
|
|
7PB2
Crystal structure of JDI TCR in complex with HLA-A*11:01 bound to KRAS G12D peptide (VVVGADGVGK)
Deposited 2021-07-30
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M ammonium sulfate, 0.1 M Tris pH 8.5, 20 % PEG 8000
|
Resolution 3.41 Å
R-free 0.254
|
|
7PBC
Crystal structure of engineered TCR (796) complexed to HLA-A*02:01 presenting MAGE-A10 9-mer peptide
Deposited 2021-08-02
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain DDD
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 3
CL CHLORIDE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293.15 K；0.2M Sodium bromide, 0.1M Bis-Tris propane pH 8.5, 20% w/v PEG 3350
|
Resolution 2.04 Å
R-free 0.236
|
|
7PBE
Emergence of immune escape at dominant SARS-CoV-2 killer T-cell epitope
Deposited 2021-08-02
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
PEG DI(HYDROXYETHYL)ETHER × 1
SO4 SULFATE ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；291 K；0.2 M ammonium sulphate, 0.1 M Tris, pH 8.5, and 25 % w/v PEG 4000
|
Resolution 3.00 Å
R-free 0.296
|
|
7PBE
Emergence of immune escape at dominant SARS-CoV-2 killer T-cell epitope
Deposited 2021-08-02
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
|
Not recorded
|
PEG DI(HYDROXYETHYL)ETHER × 1
SO4 SULFATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；291 K；0.2 M ammonium sulphate, 0.1 M Tris, pH 8.5, and 25 % w/v PEG 4000
|
Resolution 3.00 Å
R-free 0.296
|
|
7PDW
Crystal structure of parent TCR (728) complexed to HLA-A*02:01 presenting MAGE-A10 9-mer peptide
Deposited 2021-08-09
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain DDD
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293.15 K；0.02M Sodium/potassium phosphate, 0.1M Bis-Tris propane pH 6.5, 20% w/v PEG 3350
|
Resolution 1.82 Å
R-free 0.229
|
|
7PDW
Crystal structure of parent TCR (728) complexed to HLA-A*02:01 presenting MAGE-A10 9-mer peptide
Deposited 2021-08-09
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain III
21–119（99 aa）
|
Not recorded
|
PO4 PHOSPHATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293.15 K；0.02M Sodium/potassium phosphate, 0.1M Bis-Tris propane pH 6.5, 20% w/v PEG 3350
|
Resolution 1.82 Å
R-free 0.229
|
|
7PHR
Structure of a fully assembled T-cell receptor engaging a tumor-associated peptide-MHC I
Deposited 2021-08-18
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 11
PDB declaration: undecameric
|
Chain L
20–119（100 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 6
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.08 Å
|
|
7Q15
Crystal structure of FcRn and beta-2-microglobulin in complex with IgG1-Fc-MST-HN (efgartigimod)
Deposited 2021-10-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain B
1–119（119 aa）
Chain D
1–119（119 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；294 K；0.1 M Sodium Cacodylate pH 7
|
Resolution 3.30 Å
R-free 0.231
|
|
7Q98
MHC Class I A02 Allele presenting NLSALGIFST
Deposited 2021-11-12
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
PEG DI(HYDROXYETHYL)ETHER × 3
SO4 SULFATE ION × 2
EDO 1,2-ETHANEDIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；25% PEG 8000, 0.2 M Ammonium Sulphate, Sodium Cacodylate buffer 0.1 M, pH 6.5
|
Resolution 2.50 Å
R-free 0.274
|
|
7Q98
MHC Class I A02 Allele presenting NLSALGIFST
Deposited 2021-11-12
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
PEG DI(HYDROXYETHYL)ETHER × 4
SO4 SULFATE ION × 9
EDO 1,2-ETHANEDIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；25% PEG 8000, 0.2 M Ammonium Sulphate, Sodium Cacodylate buffer 0.1 M, pH 6.5
|
Resolution 2.50 Å
R-free 0.274
|
|
7Q98
MHC Class I A02 Allele presenting NLSALGIFST
Deposited 2021-11-12
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain H
21–119（99 aa）
|
Not recorded
|
PEG DI(HYDROXYETHYL)ETHER × 4
SO4 SULFATE ION × 5
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；25% PEG 8000, 0.2 M Ammonium Sulphate, Sodium Cacodylate buffer 0.1 M, pH 6.5
|
Resolution 2.50 Å
R-free 0.274
|
|
7Q98
MHC Class I A02 Allele presenting NLSALGIFST
Deposited 2021-11-12
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain K
21–119（99 aa）
|
Not recorded
|
PEG DI(HYDROXYETHYL)ETHER × 2
SO4 SULFATE ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；25% PEG 8000, 0.2 M Ammonium Sulphate, Sodium Cacodylate buffer 0.1 M, pH 6.5
|
Resolution 2.50 Å
R-free 0.274
|
|
7Q98
MHC Class I A02 Allele presenting NLSALGIFST
Deposited 2021-11-12
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 5
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain N
21–119（99 aa）
|
Not recorded
|
PEG DI(HYDROXYETHYL)ETHER × 2
SO4 SULFATE ION × 1
EDO 1,2-ETHANEDIOL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；25% PEG 8000, 0.2 M Ammonium Sulphate, Sodium Cacodylate buffer 0.1 M, pH 6.5
|
Resolution 2.50 Å
R-free 0.274
|
|
7Q99
MHC Class I A02 Allele presenting NLSALGIFST, in complex with Mel5 TCR
Deposited 2021-11-12
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；0.1M HEPES, 25% PEG 4000, 15% Glycerol, pH 7.5
|
Resolution 2.55 Å
R-free 0.272
|
|
7Q9A
MHC Class I A02 Allele presenting LLLGIGILVL, in complex with Mel5 TCR
Deposited 2021-11-12
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；0.1M TRIS, 15% PEG 8000, 15% Glycerol, pH 7.5
|
Resolution 2.10 Å
R-free 0.243
|
|
7Q9B
MHC Class I A02 Allele presenting EAAGIGILTV, in complex with Mel8 TCR
Deposited 2021-11-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 10
PDB declaration: decameric
|
Chain BBB
21–119（99 aa）
Chain GGG
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K
|
Resolution 3.24 Å
R-free 0.277
|
|
7QNG
Structure of a MHC I-Tapasin-ERp57 complex
Deposited 2021-12-20
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain D
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291.15 K；100 mM Gly-Gly, AMPD, pH 8.5, 300 mM lithium sulfate, 300 mM sodium sulfate, 300 mM potassium sulfate, 20% (v/v) PEG8000, 40% (v/v) 1,5-pentanediol
|
Resolution 2.70 Å
R-free 0.229
|
|
7QPD
Structure of the human MHC I peptide-loading complex editing module
Deposited 2022-01-03
|
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.73 Å
|
|
7QPJ
Crystal structure of engineered TCR (756) complexed to HLA-A*02:01 presenting MAGE-A10 9-mer peptide
Deposited 2022-01-04
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain D
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293.15 K；0.2M Sodium chloride, 0.1M MES pH 6.0, 20% w/v PEG 6000
|
Resolution 1.54 Å
R-free 0.236
|
|
7R7V
Crystal structure of HLA-B*5301 complex with an HIV-1 Gag-derived epitope QW9
Deposited 2021-06-25
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；290 K；30% w/v PEG8000, 0.1 M sodium cacodylate trihydrate, pH 6.5
|
Resolution 1.60 Å
R-free 0.199
|
|
7R7W
Crystal structure of HLA-B*5301 complex with an HIV-1 Gag-derived epitope QW9 S3T variant
Deposited 2021-06-25
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；290 K；30% w/v PEG8000, 0.2 M sodium acetate, 0.1 M sodium cacodylate trihydrate, pH 6.5
|
Resolution 1.17 Å
R-free 0.158
|
|
7R7X
Crystal structure of HLA-B*5701 complex with an HIV-1 Gag-derived epitope QW9
Deposited 2021-06-25
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1
IPA ISOPROPYL ALCOHOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；290 K；15-20% w/v PEG4000, 20% w/v 2-propanol, 0.1 M MES, pH 6.5
|
Resolution 2.10 Å
R-free 0.219
|
|
7R7X
Crystal structure of HLA-B*5701 complex with an HIV-1 Gag-derived epitope QW9
Deposited 2021-06-25
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；290 K；15-20% w/v PEG4000, 20% w/v 2-propanol, 0.1 M MES, pH 6.5
|
Resolution 2.10 Å
R-free 0.219
|
|
7R7Y
Crystal structure of HLA-B*5701 complex with an HIV-1 Gag-derived epitope QW9 S3T variant
Deposited 2021-06-25
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
22–119（98 aa）
Fragment：UNP residues 22-119
|
Not recorded
|
GOL GLYCEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；290 K；30% w/v PEG8000, 0.2 M ammonium sulfate, 0.1 M sodium cacodylate trihydrate, pH 6.5
|
Resolution 1.60 Å
R-free 0.189
|
|
7R80
Crystal structure of C3 TCR complex with QW9-bound HLA-B*5301
Deposited 2021-06-25
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain D
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；290 K；0.1 M Tris, pH 8.5, 21-23% PEG3350
|
Resolution 2.90 Å
R-free 0.287
|
|
7RE7
TCR mimic antibody (Fab fragment) in complex with AFP/HLA-A*02
Deposited 2021-07-12
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain E
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 1
GOL GLYCEROL × 4
PG4 TETRAETHYLENE GLYCOL × 2
PGE TRIETHYLENE GLYCOL × 1
1PE PENTAETHYLENE GLYCOL × 1
FMT FORMIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.2；296.15 K；18% v/v PEG 3350 and 0.2 M sodium formate solution, pH 7.2
|
Resolution 2.55 Å
R-free 0.220
|
|
7RE7
TCR mimic antibody (Fab fragment) in complex with AFP/HLA-A*02
Deposited 2021-07-12
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 2
GOL GLYCEROL × 3
PG4 TETRAETHYLENE GLYCOL × 2
P6G HEXAETHYLENE GLYCOL × 1
PGE TRIETHYLENE GLYCOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.2；296.15 K；18% v/v PEG 3350 and 0.2 M sodium formate solution, pH 7.2
|
Resolution 2.55 Å
R-free 0.220
|
|
7RE8
Class I MHC (HLA-A*02) presenting alpha fetoprotein peptide (AFP)
Deposited 2021-07-12
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
PGE TRIETHYLENE GLYCOL × 3
PEG DI(HYDROXYETHYL)ETHER × 5
1PE PENTAETHYLENE GLYCOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277.15 K；25 mM MES pH6.5, 150 mM NaCl, 25% v/v PEG 3350
|
Resolution 2.82 Å
R-free 0.239
|
|
7RE8
Class I MHC (HLA-A*02) presenting alpha fetoprotein peptide (AFP)
Deposited 2021-07-12
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
PGE TRIETHYLENE GLYCOL × 3
PEG DI(HYDROXYETHYL)ETHER × 5
1PE PENTAETHYLENE GLYCOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277.15 K；25 mM MES pH6.5, 150 mM NaCl, 25% v/v PEG 3350
|
Resolution 2.82 Å
R-free 0.239
|
|
7RK7
The complex between TIL 1383i TCR and human Class I MHC HLA-A2 with the bound Tyrosinase(369-377)(N371D) nonameric peptide
Deposited 2021-07-22
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；298 K；16% PEG 3350, 2% tacsimate, 100mM Tris (pH 8.5)
|
Resolution 2.54 Å
R-free 0.255
|
|
7RM4
Neoantigen p53R175H-specific TCR 6-11 binds to p53R175H-HLA-A2
Deposited 2021-07-26
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；293 K；20% (w/v) PEG 3350, 0.1 M Bis-Tris propane (pH 8.5), and 0.2 M Potassium thiocyanate
|
Resolution 3.33 Å
R-free 0.295
|
|
7RM4
Neoantigen p53R175H-specific TCR 6-11 binds to p53R175H-HLA-A2
Deposited 2021-07-26
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；293 K；20% (w/v) PEG 3350, 0.1 M Bis-Tris propane (pH 8.5), and 0.2 M Potassium thiocyanate
|
Resolution 3.33 Å
R-free 0.295
|
|
7RM4
Neoantigen p53R175H-specific TCR 6-11 binds to p53R175H-HLA-A2
Deposited 2021-07-26
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain L
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；293 K；20% (w/v) PEG 3350, 0.1 M Bis-Tris propane (pH 8.5), and 0.2 M Potassium thiocyanate
|
Resolution 3.33 Å
R-free 0.295
|
|
7RM4
Neoantigen p53R175H-specific TCR 6-11 binds to p53R175H-HLA-A2
Deposited 2021-07-26
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain Q
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；293 K；20% (w/v) PEG 3350, 0.1 M Bis-Tris propane (pH 8.5), and 0.2 M Potassium thiocyanate
|
Resolution 3.33 Å
R-free 0.295
|
|
7RRG
Crystal structure of human 0606T1-2 TCR bound to HLA-A*03:01 in complex with a mutant PIK3CA peptide
Deposited 2021-08-09
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 13
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；277.15 K；12% w/v Polyethylene glycol 3,350,
100 mM Succinic acid
|
Resolution 2.12 Å
R-free 0.221
|
|
7RTD
SARS-CoV-2 Spike-derived peptide S269-277 (YLQPRTFLL) presented by HLA-A*02:01
Deposited 2021-08-13
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；20% PEG 3350, 0.2M NaFluoride
|
Resolution 2.05 Å
R-free 0.235
|
|
7RTR
YLQ-SG3 TCR in complex with SARS-CoV-2 Spike-derived peptide S269-277 (YLQPRTFLL) presented by HLA-A*02:01
Deposited 2021-08-14
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
NA SODIUM ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；20% PEG3350, 0.05 M Zinc Acetate
|
Resolution 2.60 Å
R-free 0.235
|
|
7RYM
CD1a-endo-gdTCR complex
Deposited 2021-08-25
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
PEG DI(HYDROXYETHYL)ETHER × 1
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；20% PEG3350,
0.2M Ammonium Sulfate
|
Resolution 3.20 Å
R-free 0.286
|
|
7RYN
CD1a-sulfatide-gdTCR complex
Deposited 2021-08-25
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
CIS (15Z)-N-((1S,2R,3E)-2-HYDROXY-1-{[(3-O-SULFO-BETA-D-GALACTOPYRANOSYL)OXY]METHYL}HEPTADEC-3-ENYL)TETRACOS-15-ENAMIDE × 1
EDO 1,2-ETHANEDIOL × 6
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
PEG DI(HYDROXYETHYL)ETHER × 1
SO4 SULFATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；15% PEG 4000,
0.15M Ammonium Sulfate,
0.1M MES pH6
|
Resolution 2.70 Å
R-free 0.268
|
|
7RYO
CD1a-dideoxymycobactin-gdTCR complex
Deposited 2021-08-25
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 2
WGR dideoxymycobactin-838 × 1
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；20% PEG 3350,
0.2M Ammonium sulfate
|
Resolution 3.00 Å
R-free 0.267
|
|
7RZD
CRYSTAL STRUCTURE OF HLA-B*07:02 IN COMPLEX WITH MLL(747-755) PEPTIDE
Deposited 2021-08-27
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 2
CL CHLORIDE ION × 1
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；291 K；18-24%PEG4000, 0.1M SODIUM CITRATE, 20% ISOPROPANOL, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 291K
|
Resolution 1.82 Å
R-free 0.236
|
|
7RZJ
CRYSTAL STRUCTURE OF HLA-B*07:02 IN COMPLEX WITH MLL(747-755) PHOSPHOPEPTIDE
Deposited 2021-08-27
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；290 K；18-24%PEG4000, 0.1 SODIUM CITRATE, 20% ISOPROPANOL, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 290K
|
Resolution 1.80 Å
R-free 0.217
|
|
7S79
STRUCTURE OF HLA-B*07:02 IN COMPLEX WITH SYNTHETIC PHOSPHONO-MLL PEPTIDE ANALOG
Deposited 2021-09-15
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 4
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；290 K；18-24% PEG4000, 0.1 SODIUM CITRATE, 20% ISOPROPANOL, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE
|
Resolution 1.53 Å
R-free 0.196
|
|
7S7D
STRUCTURE OF HLA-B*07:02 IN COMPLEX WITH SYNTHETIC SULFO-MLL PEPTIDE ANALOG
Deposited 2021-09-15
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；290 K；18-24% PEG4000, 0.1 SODIUM CITRATE, 20% ISOPROPANOL, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE
|
Resolution 1.56 Å
R-free 0.195
|
|
7S7E
STRUCTURE OF HLA-B*07:02 IN COMPLEX WITH DOT1L(998-1006) PEPTIDE
Deposited 2021-09-15
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；290 K；18-24% PEG4000, 0.1 SODIUM CITRATE, 20% ISOPROPANOL, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE
|
Resolution 2.04 Å
R-free 0.235
|
|
7S7F
STRUCTURE OF HLA-B*07:02 IN COMPLEX WITH DOT1L(998-1006) PHOSPHOPEPTIDE
Deposited 2021-09-15
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；290 K；18-24% PEG4000, 0.1 SODIUM CITRATE, 20% ISOPROPANOL, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE
|
Resolution 1.88 Å
R-free 0.217
|
|
7S8A
STRUCTURE OF HLA-B*07:02 IN COMPLEX WITH MLL(747-755) PHOSPHOPEPTIDE, CUBIC CRYSTAL FORM
Deposited 2021-09-17
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
12P DODECAETHYLENE GLYCOL × 1
PE8 3,6,9,12,15,18,21-HEPTAOXATRICOSANE-1,23-DIOL × 1
PGE TRIETHYLENE GLYCOL × 2
PEG DI(HYDROXYETHYL)ETHER × 1
PG4 TETRAETHYLENE GLYCOL × 1
ACT ACETATE ION × 1
1PE PENTAETHYLENE GLYCOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；290 K；35% PEG4000, 0.1M TRIS-HCL, PH 8.5, 0.2M SODIUM ACETATE, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE
|
Resolution 2.10 Å
R-free 0.206
|
|
7S8E
STRUCTURE OF HLA-B*07:02 IN COMPLEX WITH MLL(747-755) PHOSPHOPEPTIDE AND BOUND GLYCEROL
Deposited 2021-09-17
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 7
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；290 K；18-24%PEG4000, 0.1 SODIUM CITRATE, 20% ISOPROPANOL, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE
|
Resolution 1.60 Å
R-free 0.195
|
|
7S8F
STRUCTURE OF HLA-B*07:02 IN COMPLEX WITH MLL(747-755) PEPTIDE AND BOUND GLYCEROL
Deposited 2021-09-17
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 5
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；290 K；18-26%PEG4000, 0.1 SODIUM CITRATE, 20% ISOPROPANOL, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE
|
Resolution 1.80 Å
R-free 0.206
|
|
7S8Q
Crystal Structure of HLA A*1101 in complex with KTNGNAFIGK, an 10-mer epitope from Influenza B
Deposited 2021-09-19
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；20% PEG 3350, 0.1M BisTris pH 6.5
|
Resolution 2.08 Å
R-free 0.217
|
|
7S8Q
Crystal Structure of HLA A*1101 in complex with KTNGNAFIGK, an 10-mer epitope from Influenza B
Deposited 2021-09-19
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；20% PEG 3350, 0.1M BisTris pH 6.5
|
Resolution 2.08 Å
R-free 0.217
|
|
7S8R
Crystal Structure of HLA A*1101 in complex with SALEWIKNK, an 9-mer epitope from Influenza B
Deposited 2021-09-19
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
MG MAGNESIUM ION × 1
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；2M Ammonium Sulfate, 0.1 Tris pH 8, 0.2 Lithium Sulfate, 2% PEG 400
|
Resolution 2.95 Å
R-free 0.278
|
|
7S8R
Crystal Structure of HLA A*1101 in complex with SALEWIKNK, an 9-mer epitope from Influenza B
Deposited 2021-09-19
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
MG MAGNESIUM ION × 2
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；2M Ammonium Sulfate, 0.1 Tris pH 8, 0.2 Lithium Sulfate, 2% PEG 400
|
Resolution 2.95 Å
R-free 0.278
|
|
7S8S
Crystal Structure of HLA A*1101 in complex with RVLVNGTFLK, an 10-mer epitope from Influenza B
Deposited 2021-09-19
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；26% PEG 3350, 0.1M BisTris pH 6.3, 0.2M Lithium Sulfate
|
Resolution 1.87 Å
R-free 0.225
|
|
7SA2
SARS-CoV-2 spike-derived peptide S1060-1068 (VVFLHVTYV) presented by HLA-A*02:01
Deposited 2021-09-21
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
CD CADMIUM ION × 2
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；20% PEG 3350, 0.2 M K formate, 1 mM CdCl2
|
Resolution 1.85 Å
R-free 0.196
|
|
7SH4
CD1a-phosphatidylglycerol binary structure
Deposited 2021-10-07
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
MW9 (21R,24R,27S)-24,27,28-trihydroxy-18,24-dioxo-19,23,25-trioxa-24lambda~5~-phosphaoctacosan-21-yl (9Z)-octadec-9-enoate × 1
EDO 1,2-ETHANEDIOL × 2
MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1
PEG DI(HYDROXYETHYL)ETHER × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；20-25% PEG 1500, 0.1M MMT pH 5.5
|
Resolution 2.00 Å
R-free 0.230
|
|
7SIF
Crystal Structure of HLA B*3505 in complex with NPDIVIYQY, an 9-mer epitope from HIV-I
Deposited 2021-10-14
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
PEG DI(HYDROXYETHYL)ETHER × 2
TRS 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1
BTB 2-[BIS-(2-HYDROXY-ETHYL)-AMINO]-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；0.1M BIS-TRIS, 25% PEG3350
|
Resolution 1.73 Å
R-free 0.230
|
|
7SIG
Crystal Structure of HLA B*3501 in complex with NPDIVIYQY, an 9-mer epitope from HIV-I
Deposited 2021-10-14
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
FLC CITRATE ANION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；0.2M Ammonium Acetate, 20% PEG4000
|
Resolution 1.74 Å
R-free 0.216
|
|
7SIH
Crystal Structure of HLA B*3503 in complex with NPDIVIYQY, an 9-mer epitope from HIV-I
Deposited 2021-10-14
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；0.1M HEPES, 20% PEG8000
|
Resolution 1.90 Å
R-free 0.232
|
|
7SIS
SARS-CoV-2 Spike-derived peptide S976-984 (VLNDILSRL) presented by HLA-A*02:01
Deposited 2021-10-14
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
ACT ACETATE ION × 1
CD CADMIUM ION × 1
ZN ZINC ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；293 K；20% PEG 3350, 0.2M Ammonium Formate, 1 mM CdCl2
|
Resolution 1.90 Å
R-free 0.206
|
|
7STF
Structure of KRAS G12V/HLA-A*03:01 in complex with antibody fragment V2
Deposited 2021-11-12
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
19–119（101 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.14 Å
|
|
7SU9
KRAS-G12D specific TCR9a in complex with C*05-GADGVGKSL
Deposited 2021-11-16
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
MG MAGNESIUM ION × 2
GOL GLYCEROL × 2
SO4 SULFATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.1；293 K；22% PEG 3350, 0.1 M Mops and 0.25 M MgSO4
|
Resolution 1.99 Å
R-free 0.214
|
|
7T0L
HLA-B*27:05 in complex with the pan-HLA-Ia monoclonal antibody W6/32
Deposited 2021-11-29
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；298 K；PEG 5000 MME, 0.1 M Bis-Tris pH 6.0
|
Resolution 3.00 Å
R-free 0.252
|
|
7T0L
HLA-B*27:05 in complex with the pan-HLA-Ia monoclonal antibody W6/32
Deposited 2021-11-29
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；298 K；PEG 5000 MME, 0.1 M Bis-Tris pH 6.0
|
Resolution 3.00 Å
R-free 0.252
|
|
7T5M
Structure of HLA-A*02:01-FLPTPEELGLLGPPRPQVLA complex
Deposited 2021-12-12
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
TRS 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1
MG MAGNESIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；273 K；0.12M Monosaccharides (D-Glucose; D-Mannose; D-Galactose; L-Fucose; D-Xylose; N-Acetyl-D-Glucosamine), 0.1M of Na-HEPES and MOPS buffer at pH 7.5, 20% W/V Glycerol and 10% W/V PEG 4000
|
Resolution 1.67 Å
R-free 0.208
|
|
7T5M
Structure of HLA-A*02:01-FLPTPEELGLLGPPRPQVLA complex
Deposited 2021-12-12
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
MG MAGNESIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；273 K；0.12M Monosaccharides (D-Glucose; D-Mannose; D-Galactose; L-Fucose; D-Xylose; N-Acetyl-D-Glucosamine), 0.1M of Na-HEPES and MOPS buffer at pH 7.5, 20% W/V Glycerol and 10% W/V PEG 4000
|
Resolution 1.67 Å
R-free 0.208
|
|
7TLT
SARS-CoV-2 Spike-derived peptide S489-497 (YFPLQSYGF) presented by HLA-A*29:02
Deposited 2022-01-18
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
SO4 SULFATE ION × 3
MG MAGNESIUM ION × 2
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；1.9 M Ammonium Sulfate, 20 mM Magnesium chloride, 0.1M Bis-tris propane, 2% Ethylene glycol, 2% 2-Methyl-2,4-pentanediol
|
Resolution 2.30 Å
R-free 0.238
|
|
7TLT
SARS-CoV-2 Spike-derived peptide S489-497 (YFPLQSYGF) presented by HLA-A*29:02
Deposited 2022-01-18
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
SO4 SULFATE ION × 2
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；1.9 M Ammonium Sulfate, 20 mM Magnesium chloride, 0.1M Bis-tris propane, 2% Ethylene glycol, 2% 2-Methyl-2,4-pentanediol
|
Resolution 2.30 Å
R-free 0.238
|
|
7TR4
MA2-MART1-HLAA0201
Deposited 2022-01-27
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
22–119（98 aa）
|
Not recorded
|
GOL GLYCEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；20% PEG-6000
0.1M Tris (pH8)
0.2M MgCl2
|
Resolution 2.30 Å
R-free 0.267
|
|
7TUC
Crystal structure of HLA-B*44:05 (T73C) with 9mer EEFGRAFSF
Deposited 2022-02-02
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 2
EDO 1,2-ETHANEDIOL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；291 K；16% PEG 3350, 0.1M Tris, 0.2M Ca Acetate
|
Resolution 1.25 Å
R-free 0.195
|
|
7TUD
Crystal structure of HLA-B*44:05 (T73C) with 6mer EEFGRC and dipeptide GL
Deposited 2022-02-02
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 2
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；291 K；25% PEG 1500, 0.1M SPG (Succinic acid, Sodium phosphate monobasic monohydrate and Glycine)
|
Resolution 1.45 Å
R-free 0.213
|
|
7TUE
Crystal structure of Tapasin in complex with HLA-B*44:05 (T73C)
Deposited 2022-02-02
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；291 K；2.0M AmSO4, 0.1M Tris
|
Resolution 3.10 Å
R-free 0.309
|
|
7U1R
SARS-CoV-2 Spike-derived peptide S1185-1193 K1191N mutant (RLNEVANNL) presented by HLA-A*02:01
Deposited 2022-02-22
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
CD CADMIUM ION × 1
ZN ZINC ION × 1
NA SODIUM ION × 1
ACT ACETATE ION × 1
CL CHLORIDE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；18% P4000, 0.1M HEPES 7.6, 0.1M MgCl2, 1 mM CdCl2
|
Resolution 1.80 Å
R-free 0.196
|
|
7U21
Human Class I MHC HLA-A2 in complex with AVGSYVYSV peptide
Deposited 2022-02-22
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；15% PEG 3350, 0.1M MES pH 6.5
|
Resolution 1.90 Å
R-free 0.214
|
|
7U21
Human Class I MHC HLA-A2 in complex with AVGSYVYSV peptide
Deposited 2022-02-22
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；15% PEG 3350, 0.1M MES pH 6.5
|
Resolution 1.90 Å
R-free 0.214
|
|
7UC5
Crystal Structure of HLA A*0301 in complex with ILRGSVAHK, a 9-mer epitope from Influenza A
Deposited 2022-03-16
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
SO4 SULFATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.6；277 K；0.2 Ammonium Sulfate, 0.1 Bis-Tris propane pH 6.5, 22% PEG 3350
|
Resolution 1.95 Å
R-free 0.229
|
|
7UC5
Crystal Structure of HLA A*0301 in complex with ILRGSVAHK, a 9-mer epitope from Influenza A
Deposited 2022-03-16
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
SO4 SULFATE ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.6；277 K；0.2 Ammonium Sulfate, 0.1 Bis-Tris propane pH 6.5, 22% PEG 3350
|
Resolution 1.95 Å
R-free 0.229
|
|
7UFJ
Structure of human MR1-ethylvanillin in complex with human MAIT A-F7 TCR
Deposited 2022-03-22
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
PRO PROLINE × 1
N36 3-ethoxy-4-hydroxybenzaldehyde × 1
GOL GLYCEROL × 6
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；BTP
PEG 3350
NaAc
|
Resolution 2.50 Å
R-free 0.238
|
|
7UFJ
Structure of human MR1-ethylvanillin in complex with human MAIT A-F7 TCR
Deposited 2022-03-22
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain D
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
PRO PROLINE × 1
N36 3-ethoxy-4-hydroxybenzaldehyde × 1
GOL GLYCEROL × 7
ACT ACETATE ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；BTP
PEG 3350
NaAc
|
Resolution 2.50 Å
R-free 0.238
|
|
7UM2
SARS-CoV-2 Spike-derived peptide S417-425 K417T mutant (TIADYNYKL) presented by HLA-A*02:01
Deposited 2022-04-06
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
ZN ZINC ION × 1
CD CADMIUM ION × 1
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；14% P3350; 0.1M NaFlu; 2% EG; 1 mM CdCl2
|
Resolution 1.63 Å
R-free 0.195
|
|
7UMG
Crystal structure of human CD8aa-MR1-Ac-6-FP complex
Deposited 2022-04-06
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
30W N-(6-formyl-4-oxo-3,4-dihydropteridin-2-yl)acetamide × 1
PO4 PHOSPHATE ION × 1
CL CHLORIDE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；298 K；Na K Phosphate, PEG 1K and NaCl
|
Resolution 2.40 Å
R-free 0.218
|
|
7UR1
SARS-CoV-2 Spike-derived peptide S1215-1224 (YIWLGFIAGL) presented by HLA-A*02:01
Deposited 2022-04-21
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；20% P3350; 0.2 M K Acet
|
Resolution 2.17 Å
R-free 0.277
|
|
7WJ2
Crystal structure of HLA-C*1402 complexed with 8-mer HIV gag peptide
Deposited 2022-01-05
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
20–119（100 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 7
NA SODIUM ION × 1
ACT ACETATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.5；293 K；100 mM sodium acetate, 20 % PEG Smear Low
|
Resolution 1.28 Å
R-free 0.178
|
|
7WJ3
Crystal structure of HLA-C*1402 complexed with 4-mer lipopeptide
Deposited 2022-01-05
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
20–119（100 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 18
MYR MYRISTIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.7；277 K；200 mM ammonium acetate, 100 mM sodium acetate, 5 % ethylene glycol, 25 % PEG Smear Low
|
Resolution 1.56 Å
R-free 0.187
|
|
7WKJ
A COVID-19 T-cell response detection method based on a newly identified human CD8+ T cell epitope from SARS-CoV-2-Hubei Province, 2021.
Deposited 2022-01-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；2.0 M Ammonium sulfate
|
Resolution 1.50 Å
R-free 0.242
|
|
7WT3
Crystal structure of HLA-A*2402 complexed with 4-mer lipopeptide
Deposited 2022-02-03
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
20–119（100 aa）
|
Not recorded
|
TRS 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1
ACT ACETATE ION × 2
ZN ZINC ION × 2
EDO 1,2-ETHANEDIOL × 26
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；277 K；2mM ZnCL2, 100mM Tris, 20% PEG 6000
|
Resolution 1.89 Å
R-free 0.235
|
|
7WT3
Crystal structure of HLA-A*2402 complexed with 4-mer lipopeptide
Deposited 2022-02-03
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
20–119（100 aa）
|
Not recorded
|
ACT ACETATE ION × 1
ZN ZINC ION × 1
EDO 1,2-ETHANEDIOL × 11
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；277 K；2mM ZnCL2, 100mM Tris, 20% PEG 6000
|
Resolution 1.89 Å
R-free 0.235
|
|
7WT4
Crystal structure of HLA-A*2402 complexed with 8-mer Influenza PB1 peptide
Deposited 2022-02-03
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
20–119（100 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 33
ZN ZINC ION × 2
TRS 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 2
ACT ACETATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.8；293 K；100mM Tris, 20% PEG 6000
|
Resolution 1.89 Å
R-free 0.232
|
|
7WT4
Crystal structure of HLA-A*2402 complexed with 8-mer Influenza PB1 peptide
Deposited 2022-02-03
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
20–119（100 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 13
ZN ZINC ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.8；293 K；100mM Tris, 20% PEG 6000
|
Resolution 1.89 Å
R-free 0.232
|
|
7WT5
Crystal structure of HLA-A*2450 complexed with 8-mer model peptide
Deposited 2022-02-03
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
20–119（100 aa）
|
Not recorded
|
ZN ZINC ION × 1
TRS 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1
EDO 1,2-ETHANEDIOL × 35
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.8；277 K；100mM Tris, 20 % PEG 8000
|
Resolution 2.10 Å
R-free 0.228
|
|
7WT5
Crystal structure of HLA-A*2450 complexed with 8-mer model peptide
Deposited 2022-02-03
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
20–119（100 aa）
|
Not recorded
|
ZN ZINC ION × 2
EDO 1,2-ETHANEDIOL × 12
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.8；277 K；100mM Tris, 20 % PEG 8000
|
Resolution 2.10 Å
R-free 0.228
|
|
7WZZ
Crystal structure of peptide KAGQVVTIW in complex with HLA-B5801
Deposited 2022-02-20
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.9；293 K；0.2M Sodium thiocyanate, 20%(w/v) Polyethylene glycol 3,350
|
Resolution 1.30 Å
R-free 0.169
|
|
7X00
Crystal structure of peptide VSFIEFVGW in complex with HLA-B5801
Deposited 2022-02-20
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.4；293 K；0.04 M Citric acid, 0.06 M BIS-TRIS propane, 20% w/v Polyethylene glycol 3350
|
Resolution 1.45 Å
R-free 0.168
|
|
7X1B
Crystal structure of peptide KAGQVVTI in complex with HLA-B5801
Deposited 2022-02-23
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.9；293 K；0.2 M Sodium thiocyanate, 20% w/v Polyethylene glycol 3350
|
Resolution 1.40 Å
R-free 0.179
|
|
7X1C
Crystal structure of peptide VSFIEFVI in complex with HLA-B5801
Deposited 2022-02-23
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.4；293 K；0.04 M Citric acid, 0.06 M BIS-TRIS propane, 20% w/v Polyethylene glycol 3350
|
Resolution 1.41 Å
R-free 0.180
|
|
7XF3
The structure of HLA-B*1501/BM58-66AF9
Deposited 2022-03-31
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；277 K；20% w/v PEG 2000, 0.1M MES
|
Resolution 1.91 Å
R-free 0.232
|
|
7YG3
Crystal structure of HLA-B*13:01
Deposited 2022-07-11
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain C
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；289.15 K；0.1 M HEPES pH 6.5, 20% PEG 4000, 0.2 M NaCl
|
Resolution 1.50 Å
R-free 0.195
|
|
7ZT2
Structure of E8 TCR in complex with human MR1 bound to 5-OP-RU
Deposited 2022-05-09
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
2LJ 1-deoxy-1-({2,6-dioxo-5-[(E)-propylideneamino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-ribitol × 1
EDO 1,2-ETHANEDIOL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M Potassium thiocyanate, 0.1 M Bis-Tris Propane pH 8.5, 20 % PEG 3350
|
Resolution 2.40 Å
R-free 0.276
|
|
7ZT3
Structure of E8 TCR in complex in human MR1 K43A
Deposited 2022-05-09
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M Magnesium chloride hexahydrate, 0.1 M Tris pH 8.5, 15 % PEG 4000
|
Resolution 2.40 Å
R-free 0.236
|
|
7ZT4
Structure of E8 TCR in complex with human MR1 bound to 6FP
Deposited 2022-05-09
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
JSO 2-azanyl-6-methyl-3~{H}-pteridin-4-one × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M Sodium iodide, 0.1 M Bis-Tris propane pH 8.5 and 20 % w/v PEG 3350
|
Resolution 2.02 Å
R-free 0.268
|
|
7ZT5
Structure of E8 TCR in complex in human MR1 bound to 3FSA
Deposited 2022-05-09
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
7ZS 3-methanoyl-2-oxidanyl-benzoic acid × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M Sodium malonate dibasic monohydrate, 0.1 M Bis-Tris Propane pH 8.5, 20% PEG 3350
|
Resolution 2.09 Å
R-free 0.266
|
|
7ZT7
Structure of E8 TCR in complex in human MR1 bound to 5FSA
Deposited 2022-05-09
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
54G 2-hydroxy-5-methylbenzoic acid × 1
EDO 1,2-ETHANEDIOL × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M Sodium fluoride, 0.1 M Bis-Tris propane pH 8.5, 20% PEG 3350
|
Resolution 1.84 Å
R-free 0.255
|
|
7ZT8
Structure of E8 TCR in complex in human MR1 bound to 3FBA
Deposited 2022-05-09
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
OVV 3-methylbenzoic acid × 1
EDO 1,2-ETHANEDIOL × 1
MPO 3[N-MORPHOLINO]PROPANE SULFONIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M Magnesium acetate tetrahydrate, 0.1 M MOPS pH 7.5, 12 % PEG 8000
|
Resolution 2.29 Å
R-free 0.263
|
|
7ZT9
Structure of E8 TCR in complex in human MR1 bound to 4FBA
Deposited 2022-05-09
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
4MA 4-METHYLBENZOIC ACID × 1
EDO 1,2-ETHANEDIOL × 6
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M HEPES pH 7.5, 20% PEG 4000, 15% Glycerol
|
Resolution 2.13 Å
R-free 0.244
|
|
7ZUC
Human Major Histocompatibility Complex A2 allele presenting LLLGIGILV
Deposited 2022-05-12
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；20% PEG 3,350, 0.2 M Potassium Thiocyanate, 0.1 M BIS-TRIS Propane pH 7.5
|
Resolution 1.89 Å
R-free 0.247
|
|
7ZUC
Human Major Histocompatibility Complex A2 allele presenting LLLGIGILV
Deposited 2022-05-12
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；20% PEG 3,350, 0.2 M Potassium Thiocyanate, 0.1 M BIS-TRIS Propane pH 7.5
|
Resolution 1.89 Å
R-free 0.247
|
|
8A7O
beta-2-microglobulin DeltaN6 amyloid fibril form 2PFa
Deposited 2022-06-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 6
PDB declaration: hexameric
|
Chain A
27–119（93 aa）
Chain B
27–119（93 aa）
Chain C
27–119（93 aa）
Chain D
27–119（93 aa）
Chain E
27–119（93 aa）
Chain F
27–119（93 aa）
|
Mutation：deltaN6, K6M
Mutation：deltaN6, K6M
Mutation：deltaN6, K6M
Mutation：deltaN6, K6M
Mutation：deltaN6, K6M
Mutation：deltaN6, K6M
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 6.2
cryo-EM vitrification conditions
Cryogen ETHANE；6s blot
|
Resolution 3.00 Å
|
|
8A7P
beta-2-microglobulin DeltaN6 amyloid fibril form 2PFb
Deposited 2022-06-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 6
PDB declaration: hexameric
|
Chain A
27–119（93 aa）
Chain B
27–119（93 aa）
Chain C
27–119（93 aa）
Chain D
27–119（93 aa）
Chain E
27–119（93 aa）
Chain F
27–119（93 aa）
|
Mutation：deltaN6, K6M
Mutation：deltaN6, K6M
Mutation：deltaN6, K6M
Mutation：deltaN6, K6M
Mutation：deltaN6, K6M
Mutation：deltaN6, K6M
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 6.2
cryo-EM vitrification conditions
Cryogen ETHANE；6s blot
|
Resolution 3.40 Å
|
|
8A7Q
beta-2-microglobulin V27M amyloid fibril form 4PF
Deposited 2022-06-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 12
PDB declaration: dodecameric
|
Chain A
21–119（99 aa）
Chain B
21–119（99 aa）
Chain C
21–119（99 aa）
Chain D
21–119（99 aa）
Chain E
21–119（99 aa）
Chain F
21–119（99 aa）
Chain G
21–119（99 aa）
Chain H
21–119（99 aa）
Chain I
21–119（99 aa）
Chain J
21–119（99 aa）
Chain K
21–119（99 aa）
Chain L
21–119（99 aa）
|
Mutation：V27M
Mutation：V27M
Mutation：V27M
Mutation：V27M
Mutation：V27M
Mutation：V27M
Mutation：V27M
Mutation：V27M
Mutation：V27M
Mutation：V27M
Mutation：V27M
Mutation：V27M
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 6.2
cryo-EM vitrification conditions
Cryogen ETHANE；6s blot
|
Resolution 2.80 Å
|
|
8A7T
beta-2-microglobulin D76N amyloid fibril form 2PFa
Deposited 2022-06-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 6
PDB declaration: hexameric
|
Chain A
21–119（99 aa）
Chain B
21–119（99 aa）
Chain C
21–119（99 aa）
Chain D
21–119（99 aa）
Chain E
21–119（99 aa）
Chain F
21–119（99 aa）
|
Mutation：D76N
Mutation：D76N
Mutation：D76N
Mutation：D76N
Mutation：D76N
Mutation：D76N
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 6.2
cryo-EM vitrification conditions
Cryogen ETHANE；6s blot
|
Resolution 3.00 Å
|
|
8BP6
Structure of MHC-class I related molecule MR1 with bound M3Ade.
Deposited 2022-11-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
21–119（99 aa）
|
Not recorded
|
R8F (1R,5S)-8-(9H-purin-6-yl)-2-oxa-8-azabicyclo[3.3.1]nona-3,6-diene-4,6-dicarbaldehyde × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；Morpheus-F9
|
Resolution 2.80 Å
R-free 0.247
|
|
8BP6
Structure of MHC-class I related molecule MR1 with bound M3Ade.
Deposited 2022-11-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
R8F (1R,5S)-8-(9H-purin-6-yl)-2-oxa-8-azabicyclo[3.3.1]nona-3,6-diene-4,6-dicarbaldehyde × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；Morpheus-F9
|
Resolution 2.80 Å
R-free 0.247
|
|
8CX4
TCR-antigen complex AS8.4-YEIH-HLA*B27
Deposited 2022-05-19
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；25% PEG3350 and 0.1M HEPES pH 7.5
|
Resolution 2.20 Å
R-free 0.264
|
|
8DNT
SARS-CoV-2 specific T cell receptor
Deposited 2022-07-11
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain F
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 8.5；295 K；13.5% (w/v) PEG 20,000, 0.1 M Tris-HCl
|
Resolution 3.18 Å
R-free 0.313
|
|
8DNT
SARS-CoV-2 specific T cell receptor
Deposited 2022-07-11
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain L
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 8.5；295 K；13.5% (w/v) PEG 20,000, 0.1 M Tris-HCl
|
Resolution 3.18 Å
R-free 0.313
|
|
8DNT
SARS-CoV-2 specific T cell receptor
Deposited 2022-07-11
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain T
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 8.5；295 K；13.5% (w/v) PEG 20,000, 0.1 M Tris-HCl
|
Resolution 3.18 Å
R-free 0.313
|
|
8DNT
SARS-CoV-2 specific T cell receptor
Deposited 2022-07-11
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain Z
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 8.5；295 K；13.5% (w/v) PEG 20,000, 0.1 M Tris-HCl
|
Resolution 3.18 Å
R-free 0.313
|
|
8DV3
Crystal structure of human CD1b presenting Phosphatidylinositol C34:1
Deposited 2022-07-28
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 6
CL CHLORIDE ION × 6
NA SODIUM ION × 2
6UL TETRACOSYL PALMITATE × 1
IOD IODIDE ION × 2
PIE 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoinositol × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；24% PEG 3350, 0.2M Sodium Iodide, 2% ethylene glycol
|
Resolution 1.90 Å
R-free 0.253
|
|
8DV4
Crystal structure of the BC8B TCR-CD1b-PI complex
Deposited 2022-07-28
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 2
GOL GLYCEROL × 2
MAN alpha-D-mannopyranose × 1
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
CUY tetracosyl octadecanoate × 1
CL CHLORIDE ION × 1
NA SODIUM ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；24 %(w/v) PEG 4000, 0.02 M Tris-HCl (pH 7.0), 2% ethylene glycol
|
Resolution 2.40 Å
R-free 0.255
|
|
8DVG
Structure of KRAS WT(7-16)-HLA-A*03:01
Deposited 2022-07-28
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
1–119（119 aa）
|
Not recorded
|
SO4 SULFATE ION × 13
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；0.2M ammonium sulfate
0.1M sodium cacodylate pH 6.5
30 % w/v PEG 8,000
|
Resolution 2.59 Å
R-free 0.228
|
|
8E13
Structures of HLA-B8E76C loaded with long peptides reveal novel features at the N-terminus of the groove
Deposited 2022-08-09
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 5.6；298 K；0.2 M ammonium acetate, 18% PEG 4000, 0.1 M sodium citrate,
|
Resolution 1.37 Å
R-free 0.210
|
|
8E2Z
Structures of HLA-B8E76C loaded with long peptides reveal novel features at the N-terminus of the groove
Deposited 2022-08-16
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；277 K；0.2 M ammonium acetate, 15% PEG 4000, 0.1 M sodium citrate, pH5.6,
|
Resolution 1.13 Å
R-free 0.217
|
|
8E8I
Structures of HLA-B8E76C loaded with long peptides reveal novel features at the N-terminus of the groove
Deposited 2022-08-25
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 5.8；298 K；0.2 M ammonium acetate, 15% PEG 1000, 0.1 M sodium citrate
|
Resolution 1.49 Å
R-free 0.211
|
|
8EB2
Structure of HLA-A*02:01 in complex with NY-ESO-1 peptide and PA2.1 Fab
Deposited 2022-08-30
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；295 K；0.2M L-Proline, 0.1M HEPES pH 7.5, 13% PEG3350
|
Resolution 2.90 Å
R-free 0.284
|
|
8EB2
Structure of HLA-A*02:01 in complex with NY-ESO-1 peptide and PA2.1 Fab
Deposited 2022-08-30
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain E
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；295 K；0.2M L-Proline, 0.1M HEPES pH 7.5, 13% PEG3350
|
Resolution 2.90 Å
R-free 0.284
|
|
8EB2
Structure of HLA-A*02:01 in complex with NY-ESO-1 peptide and PA2.1 Fab
Deposited 2022-08-30
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain H
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；295 K；0.2M L-Proline, 0.1M HEPES pH 7.5, 13% PEG3350
|
Resolution 2.90 Å
R-free 0.284
|
|
8EC5
Structures of HLA-B8E76C loaded with long peptides reveal novel features at the N-terminus of the groove
Deposited 2022-09-01
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；pH 5.8；298 K；0.2 M ammonium acetate, 15% PEG 10000, 0.1 M sodium citrate
|
Resolution 1.22 Å
R-free 0.212
|
|
8EK5
Engineered scFv 10LH bound to PHOX2B/HLA-A24:02
Deposited 2022-09-20
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 2
NO3 NITRATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；20% PEG 3350, 0.2M Sodium Nitrate
|
Resolution 2.11 Å
R-free 0.212
|
|
8ELG
Crystal Structure of HLA-B*15:01 in complex with spike derived peptide NQKLIANAF from OC43 virus
Deposited 2022-09-24
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
ACT ACETATE ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；2% ethylene glycol, 20% w/v PEG3350
|
Resolution 1.65 Å
R-free 0.220
|
|
8ELH
Crystal Structure of HLA-B*15:01 in complex with spike derived peptide NQKLIANQF from SARS-CoV-2 virus
Deposited 2022-09-24
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
ACT ACETATE ION × 1
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；0.2 M sodium formate, pH 7.0, 20% w/v PEG3350
|
Resolution 1.85 Å
R-free 0.223
|
|
8EMF
Crystal structure of a HLA-B*35:01-NP6 epitope from 1977 H1N1 influenza strain
Deposited 2022-09-27
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；297 K；PEG
|
Resolution 1.80 Å
R-free 0.203
|
|
8EMG
Crystal structure of a HLA-B*35:01-NP7 epitope from 2002 H2N1 influenza strain
Deposited 2022-09-27
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
ACT ACETATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；297 K；PEG
|
Resolution 1.83 Å
R-free 0.206
|
|
8EMI
Crystal structure of a HLA-B*35:01-NP8 epitope from 2005 H1N1 influenza strain
Deposited 2022-09-27
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
ACT ACETATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4；297 K；PEG
|
Resolution 1.57 Å
R-free 0.208
|
|
8EMJ
Crystal structure of HLA-B*35:01-NP9 epitope from 2006 H1N1 influenza strain
Deposited 2022-09-27
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；297 K；PEG, Acetate
|
Resolution 1.75 Å
R-free 0.214
|
|
8EMK
Crystal structure of HLA-B*35:01-NP3 epitope from 1957 H2N2 influenza strain
Deposited 2022-09-27
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
NA SODIUM ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；297 K；PEG, NA ACETATE
|
Resolution 1.67 Å
R-free 0.206
|
|
8EN8
Cross-reactive 3180 TCR recognition of HLA-B*35:01-NP4 epitope from 1972 influenza strain
Deposited 2022-09-29
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；297 K；PEG
|
Resolution 2.70 Å
R-free 0.249
|
|
8EN8
Cross-reactive 3180 TCR recognition of HLA-B*35:01-NP4 epitope from 1972 influenza strain
Deposited 2022-09-29
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；297 K；PEG
|
Resolution 2.70 Å
R-free 0.249
|
|
8ENH
Cross-reactive 3180 TCR recognition of HLA-B*35:01-NP7 epitope from 2002 H3N2 influenza strain
Deposited 2022-09-30
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；297 K；PEG, ACETATE
|
Resolution 2.50 Å
R-free 0.230
|
|
8ENH
Cross-reactive 3180 TCR recognition of HLA-B*35:01-NP7 epitope from 2002 H3N2 influenza strain
Deposited 2022-09-30
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；297 K；PEG, ACETATE
|
Resolution 2.50 Å
R-free 0.230
|
|
8ENH
Cross-reactive 3180 TCR recognition of HLA-B*35:01-NP7 epitope from 2002 H3N2 influenza strain
Deposited 2022-09-30
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain L
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；297 K；PEG, ACETATE
|
Resolution 2.50 Å
R-free 0.230
|
|
8ENH
Cross-reactive 3180 TCR recognition of HLA-B*35:01-NP7 epitope from 2002 H3N2 influenza strain
Deposited 2022-09-30
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain Q
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；297 K；PEG, ACETATE
|
Resolution 2.50 Å
R-free 0.230
|
|
8EO8
Cross-reactive 3180 TCR recognition of HLA-B*35:01-NP8 epitope from 2005 H1N1 influenza strain
Deposited 2022-10-02
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；297 K；PEG, ACETATE
|
Resolution 2.30 Å
R-free 0.219
|
|
8EO8
Cross-reactive 3180 TCR recognition of HLA-B*35:01-NP8 epitope from 2005 H1N1 influenza strain
Deposited 2022-10-02
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；297 K；PEG, ACETATE
|
Resolution 2.30 Å
R-free 0.219
|
|
8EO8
Cross-reactive 3180 TCR recognition of HLA-B*35:01-NP8 epitope from 2005 H1N1 influenza strain
Deposited 2022-10-02
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain L
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；297 K；PEG, ACETATE
|
Resolution 2.30 Å
R-free 0.219
|
|
8EO8
Cross-reactive 3180 TCR recognition of HLA-B*35:01-NP8 epitope from 2005 H1N1 influenza strain
Deposited 2022-10-02
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain Q
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；297 K；PEG, ACETATE
|
Resolution 2.30 Å
R-free 0.219
|
|
8ERX
Structure of chimeric HLA-A*11:01-A*02:01 bound to HIV-1 RT peptide
Deposited 2022-10-13
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；294.15 K；0.02 Sodium/Potassium phosphate, 0.1 M BIS-TRIS propane pH 8.5, 18-22% PEG 3350
|
Resolution 2.07 Å
R-free 0.231
|
|
8ES8
CryoEM structure of PN45545 TCR-CD3 in complex with HLA-A2 MAGEA4 (230-239)
Deposited 2022-10-13
|
Different construct
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 11
PDB declaration: undecameric
|
Chain M
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
Y01 CHOLESTEROL HEMISUCCINATE × 1
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.65 Å
|
|
8ES9
CryoEM structure of PN45428 TCR-CD3 in complex with HLA-A2 MAGEA4
Deposited 2022-10-13
|
Different construct
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 11
PDB declaration: undecameric
|
Chain M
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 6
Y01 CHOLESTEROL HEMISUCCINATE × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.25 Å
|
|
8ESH
Structure of chimeric HLA-A*02:01 bound to CMV peptide
Deposited 2022-10-14
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；294.15 K；0.2 M Sodium Fluoride, 0.1 M BIS-TRIS propane pH 8.5, 20-24% PEG 3350
|
Resolution 2.72 Å
R-free 0.260
|
|
8F5A
Crystal Structure of KS1 TCR in complex with HLA-B*57:01-TW10
Deposited 2022-11-12
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
ACT ACETATE ION × 1
NA SODIUM ION × 1
CL CHLORIDE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；8 % tacsimate, 20 % PEG3350
|
Resolution 1.95 Å
R-free 0.237
|
|
8F7M
Crystal Structure of HLA-B*57:01-TW10-T242N complex
Deposited 2022-11-18
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
PEG DI(HYDROXYETHYL)ETHER × 1
ACT ACETATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；293 K；20 % w/v PEG4000, 0.2 M ammonium acetate, 0.1 M sodium cacodylate
|
Resolution 1.88 Å
R-free 0.220
|
|
8FJA
CryoEM structure of HLA-A2 MAGEA4 (230-239) in complex with REGN6972 Fab
Deposited 2022-12-19
|
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.00 Å
|
|
8FJB
CryoEM structure of HLA-A2 MAGEA4 (286-294) in complex with H2aM31345N Fab
Deposited 2022-12-19
|
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.06 Å
|
|
8FRT
X-ray crystal structure of the N-terminal region from HCMV US11 binding to HLA-A*02:01
Deposited 2023-01-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；30% (w/v) PEG3350, 0.1 M DL-malic acid pH 7.0, 83 mM cesium chloride
|
Resolution 1.80 Å
R-free 0.239
|
|
8FU4
HCMV US11 peptide binding to HLA-A*02:01
Deposited 2023-01-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 2
CD CADMIUM ION × 1
PGE TRIETHYLENE GLYCOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；26% (w/v) PEG3350 and 0.1 M DL-malic acid pH 7.0, 83 mM cesium chloride
|
Resolution 1.60 Å
R-free 0.204
|
|
8GLE
Crystal Structure of Human CD1b in Complex with Lysosulfatide
Deposited 2023-03-22
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
SGF (2S,3R,4E)-2-amino-3-hydroxyoctadec-4-en-1-yl 3-O-sulfo-beta-D-galactopyranoside × 1
CUY tetracosyl octadecanoate × 1
IOD IODIDE ION × 1
EDO 1,2-ETHANEDIOL × 4
CL CHLORIDE ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；26% PEG3350, 0.1 M sodium iodide, 2% ethylene glycol
|
Resolution 1.85 Å
R-free 0.229
|
|
8GLF
Crystal Structure of Human CD1b in Complex with Sphingomyelin C34:2
Deposited 2023-03-22
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 2
3LY [(~{Z},2~{R},3~{S})-2-(hexadecanoylamino)-3-oxidanyl-octadec-4-enyl] 2-(trimethyl-$l^{4}-azanyl)ethyl hydrogen phosphate × 1
6UL TETRACOSYL PALMITATE × 1
CL CHLORIDE ION × 4
IOD IODIDE ION × 2
NI NICKEL (II) ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；28% PEG3350, 0.2 M sodium iodide
|
Resolution 2.00 Å
R-free 0.231
|
|
8GLG
Crystal Structure of Human CD1b in Complex with Phosphatidylethanolamine C34:1
Deposited 2023-03-22
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
L9Q (1S)-2-{[(S)-(2-aminoethoxy)(hydroxy)phosphoryl]oxy}-1-[(octadecanoyloxy)methyl]ethyl (9Z)-octadec-9-enoate × 1
NI NICKEL (II) ION × 1
CUY tetracosyl octadecanoate × 1
CL CHLORIDE ION × 4
IOD IODIDE ION × 2
EDO 1,2-ETHANEDIOL × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；27% PEG3350, 0.1 M sodium iodide
|
Resolution 1.60 Å
R-free 0.209
|
|
8GLH
Crystal Structure of Human CD1b in Complex with Endogenous PC C40:5
Deposited 2023-03-22
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
IOD IODIDE ION × 3
3IV (11E)-hexadec-11-enoic acid × 1
3IY [(2~{R})-1-dodecanoyloxy-3-[oxidanyl-[2-(trimethyl-$l^{4}-azanyl)ethoxy]phosphoryl]oxy-propan-2-yl] (8~{Z},11~{Z},14~{Z},24~{Z},27~{Z})-triaconta-8,11,14,24,27-pentaenoate × 1
EDO 1,2-ETHANEDIOL × 4
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；24% PEG3350, 0.2 M sodium iodide, 2% ethylene glycol
|
Resolution 1.83 Å
R-free 0.221
|
|
8GLI
Crystal Structure of Human CD1b in Complex with Mycobacterial C85-GMM
Deposited 2023-03-22
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
ZR2 6-O-[(2R,3R)-3-hydroxy-20-{(1R,2S)-2-[(17R,18R)-17-methoxy-18-methyldotriacontyl]cyclopropyl}-2-pentadecylicosanoyl]-alpha-L-galactopyranose × 1
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
CL CHLORIDE ION × 1
IOD IODIDE ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293.15 K；26% PEG3350, 0.2 M sodium iodide, 2% ethylene glycol
|
Resolution 2.10 Å
R-free 0.267
|
|
8GOM
SARS-CoV-2 specific private TCR RLQ7 in complex with RLQ-HLA-A2
Deposited 2022-08-25
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
PG4 TETRAETHYLENE GLYCOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；293 K；0.1 M Tris-HCl pH 8.5, 0.01 M Trimethylamine hydrochloride, 15% PEG 6000.
|
Resolution 2.78 Å
R-free 0.248
|
|
8GON
SARS-CoV-2 specific private TCR RLQ7 in complex with RLQ-T1006I-HLA-A2
Deposited 2022-08-25
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
PG4 TETRAETHYLENE GLYCOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；293 K；0.1 M Tris-HCl pH 8.5, 15% PEG 6000
|
Resolution 2.60 Å
R-free 0.253
|
|
8GVB
The complex between public TCR TD08 and HLA-A24 bound to HIV-1 Nef138-8 peptide
Deposited 2022-09-14
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain L
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.06 M divalent ions (MgCl2, CaCl2), 0.1 M Tris (pH 8.5), 0.1 M Bicine (pH 8.5)
|
Resolution 3.20 Å
R-free 0.321
|
|
8GVG
The complex between public TCR TD08 and HLA-A24 bound to HIV-1 Nef138-8 (2F) peptide
Deposited 2022-09-15
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain L
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.2 M Sodium sulfate, 0.1 M Bis-Tris Propane (pH 7.5), 20% PEG 3350
|
Resolution 3.37 Å
R-free 0.320
|
|
8GVI
The complex between H25-11 TCR and HLA-A24 bound to HIV-1 Nef138-8 peptide
Deposited 2022-09-15
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain L
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.1 M Potassium chloride, 0.1 M tris (pH 8.0), 15% PEG2000 MME
|
Resolution 3.30 Å
R-free 0.314
|
|
8HN4
Complex structure of HLA2402 with recognizing SARS-CoV-2 epitope QYIKWPWYI
Deposited 2022-12-07
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；287 K；30% PEG 4000, 0.2 M Sodium acetate, and 0.1 M Tris-HCl pH8.5
|
Resolution 2.85 Å
R-free 0.251
|
|
8I5C
Crystal structure of a TCR in complex with HLA-A*11:01 bound to KRAS peptide (VVGAVGVGK)
Deposited 2023-01-24
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291.15 K；1.0 M Ammonium citrate tribasic pH 7.0, 0.1 M BIS-TRIS propane pH 7.0
|
Resolution 3.34 Å
R-free 0.258
|
|
8I5C
Crystal structure of a TCR in complex with HLA-A*11:01 bound to KRAS peptide (VVGAVGVGK)
Deposited 2023-01-24
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 10
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain u
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291.15 K；1.0 M Ammonium citrate tribasic pH 7.0, 0.1 M BIS-TRIS propane pH 7.0
|
Resolution 3.34 Å
R-free 0.258
|
|
8I5C
Crystal structure of a TCR in complex with HLA-A*11:01 bound to KRAS peptide (VVGAVGVGK)
Deposited 2023-01-24
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291.15 K；1.0 M Ammonium citrate tribasic pH 7.0, 0.1 M BIS-TRIS propane pH 7.0
|
Resolution 3.34 Å
R-free 0.258
|
|
8I5C
Crystal structure of a TCR in complex with HLA-A*11:01 bound to KRAS peptide (VVGAVGVGK)
Deposited 2023-01-24
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain L
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291.15 K；1.0 M Ammonium citrate tribasic pH 7.0, 0.1 M BIS-TRIS propane pH 7.0
|
Resolution 3.34 Å
R-free 0.258
|
|
8I5C
Crystal structure of a TCR in complex with HLA-A*11:01 bound to KRAS peptide (VVGAVGVGK)
Deposited 2023-01-24
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain Q
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291.15 K；1.0 M Ammonium citrate tribasic pH 7.0, 0.1 M BIS-TRIS propane pH 7.0
|
Resolution 3.34 Å
R-free 0.258
|
|
8I5C
Crystal structure of a TCR in complex with HLA-A*11:01 bound to KRAS peptide (VVGAVGVGK)
Deposited 2023-01-24
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 5
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain V
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291.15 K；1.0 M Ammonium citrate tribasic pH 7.0, 0.1 M BIS-TRIS propane pH 7.0
|
Resolution 3.34 Å
R-free 0.258
|
|
8I5C
Crystal structure of a TCR in complex with HLA-A*11:01 bound to KRAS peptide (VVGAVGVGK)
Deposited 2023-01-24
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 6
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain a
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291.15 K；1.0 M Ammonium citrate tribasic pH 7.0, 0.1 M BIS-TRIS propane pH 7.0
|
Resolution 3.34 Å
R-free 0.258
|
|
8I5C
Crystal structure of a TCR in complex with HLA-A*11:01 bound to KRAS peptide (VVGAVGVGK)
Deposited 2023-01-24
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 7
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain f
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291.15 K；1.0 M Ammonium citrate tribasic pH 7.0, 0.1 M BIS-TRIS propane pH 7.0
|
Resolution 3.34 Å
R-free 0.258
|
|
8I5C
Crystal structure of a TCR in complex with HLA-A*11:01 bound to KRAS peptide (VVGAVGVGK)
Deposited 2023-01-24
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 8
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain k
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291.15 K；1.0 M Ammonium citrate tribasic pH 7.0, 0.1 M BIS-TRIS propane pH 7.0
|
Resolution 3.34 Å
R-free 0.258
|
|
8I5C
Crystal structure of a TCR in complex with HLA-A*11:01 bound to KRAS peptide (VVGAVGVGK)
Deposited 2023-01-24
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 9
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain p
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291.15 K；1.0 M Ammonium citrate tribasic pH 7.0, 0.1 M BIS-TRIS propane pH 7.0
|
Resolution 3.34 Å
R-free 0.258
|
|
8I5D
Crystal structure of a TCR in complex with HLA-A*11:01 bound to KRAS peptide (VVGAVGVGK)
Deposited 2023-01-25
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain L
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291.15 K；0.1 M HEPES pH 7.5, 10% w/v PEG 8000/ 8% v/v Ethylene glycol.
|
Resolution 3.30 Å
R-free 0.256
|
|
8I5E
Crystal structure of HLA-A*11:01 in complex with KRAS peptide (VVGAGGVGK)
Deposited 2023-01-25
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain L
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291.15 K；0.1 M Tris. 8.0. 25% v/v PEG 350 MME.
|
Resolution 2.20 Å
R-free 0.235
|
|
8ISN
HLA-A24 in complex with modified 9mer WT1 peptide
Deposited 2023-03-21
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 5
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M Ammonium tartrate dibasic, 20 % (w/v) PEG 3350
|
Resolution 2.48 Å
R-free 0.258
|
|
8ISN
HLA-A24 in complex with modified 9mer WT1 peptide
Deposited 2023-03-21
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M Ammonium tartrate dibasic, 20 % (w/v) PEG 3350
|
Resolution 2.48 Å
R-free 0.258
|
|
8K4T
Crystal structure of HLA-A*11:01 in complex with KRAS G12C peptide (VVVGACGVGK)
Deposited 2023-07-20
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；293.15 K；Ammonium sulfate,Sodium cacodylate pH 6.0, PEG 4000
|
Resolution 2.30 Å
R-free 0.316
|
|
8K4T
Crystal structure of HLA-A*11:01 in complex with KRAS G12C peptide (VVVGACGVGK)
Deposited 2023-07-20
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；293.15 K；Ammonium sulfate,Sodium cacodylate pH 6.0, PEG 4000
|
Resolution 2.30 Å
R-free 0.316
|
|
8K4V
Crystal structure of HLA-A*11:01 in complex with KRAS G12R peptide (VVVGARGVGK)
Deposited 2023-07-20
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；293.15 K；Ammonium sulfate, Sodium cacodylate, PEG 4000
|
Resolution 3.10 Å
R-free 0.347
|
|
8K4V
Crystal structure of HLA-A*11:01 in complex with KRAS G12R peptide (VVVGARGVGK)
Deposited 2023-07-20
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；293.15 K；Ammonium sulfate, Sodium cacodylate, PEG 4000
|
Resolution 3.10 Å
R-free 0.347
|
|
8K4V
Crystal structure of HLA-A*11:01 in complex with KRAS G12R peptide (VVVGARGVGK)
Deposited 2023-07-20
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain H
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；293.15 K；Ammonium sulfate, Sodium cacodylate, PEG 4000
|
Resolution 3.10 Å
R-free 0.347
|
|
8K4V
Crystal structure of HLA-A*11:01 in complex with KRAS G12R peptide (VVVGARGVGK)
Deposited 2023-07-20
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain K
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；293.15 K；Ammonium sulfate, Sodium cacodylate, PEG 4000
|
Resolution 3.10 Å
R-free 0.347
|
|
8K50
Crystal structure of HLA-A*11:01 in complex with KRAS G12V peptide (VVVGARGVGK)
Deposited 2023-07-20
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；293.15 K；Ammonium sulfate, Sodium cacodylate, PEG 4000
|
Resolution 2.80 Å
R-free 0.281
|
|
8K50
Crystal structure of HLA-A*11:01 in complex with KRAS G12V peptide (VVVGARGVGK)
Deposited 2023-07-20
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；293.15 K；Ammonium sulfate, Sodium cacodylate, PEG 4000
|
Resolution 2.80 Å
R-free 0.281
|
|
8K50
Crystal structure of HLA-A*11:01 in complex with KRAS G12V peptide (VVVGARGVGK)
Deposited 2023-07-20
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain H
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；293.15 K；Ammonium sulfate, Sodium cacodylate, PEG 4000
|
Resolution 2.80 Å
R-free 0.281
|
|
8K50
Crystal structure of HLA-A*11:01 in complex with KRAS G12V peptide (VVVGARGVGK)
Deposited 2023-07-20
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain K
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；293.15 K；Ammonium sulfate, Sodium cacodylate, PEG 4000
|
Resolution 2.80 Å
R-free 0.281
|
|
8QFY
Crystal structure of high affinity TCR in complex with pHLA harbouring bacterial peptide
Deposited 2023-09-05
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain BBB
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.2 M calcium acetate, 0.1 M imidazole pH 8.0, 10% PEG 8000
|
Resolution 2.33 Å
R-free 0.289
|
|
8QFY
Crystal structure of high affinity TCR in complex with pHLA harbouring bacterial peptide
Deposited 2023-09-05
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain GGG
21–119（99 aa）
|
Not recorded
|
ACT ACETATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.2 M calcium acetate, 0.1 M imidazole pH 8.0, 10% PEG 8000
|
Resolution 2.33 Å
R-free 0.289
|
|
8RBU
Crystal structure of HLA-A*11:01 in complex with SVLNDILARL, an 10-mer epitope from SARS-CoV-2 Spike (S975-984)
Deposited 2023-12-05
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
PEG DI(HYDROXYETHYL)ETHER × 1
EDO 1,2-ETHANEDIOL × 8
CL CHLORIDE ION × 2
SO4 SULFATE ION × 2
NA SODIUM ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；25% PEG3350, 0.2M NaCl and 0.1M Tris HCl pH8.5
|
Resolution 2.70 Å
R-free 0.252
|
|
8RBV
SARS-CoV-2 Spike-derived peptide S976-984 S982A mutant (VLNDILARL) presented by HLA-A*02:01
Deposited 2023-12-05
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
ACT ACETATE ION × 2
EDO 1,2-ETHANEDIOL × 2
CD CADMIUM ION × 2
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；13% P3350; 0.1M NaFlu; 2% EG; 1 mM CdCl2
|
Resolution 1.80 Å
R-free 0.211
|
|
8RCV
Crystal structure of HLA B*13:01 in complex with SVLNDIFSRL, an 10-mer epitope from SARS-CoV-2 Spike (S975-984)
Deposited 2023-12-07
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 3
NA SODIUM ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；14% PEG3350 and 0.1M NaFormate
|
Resolution 1.65 Å
R-free 0.201
|
|
8REF
Crystal structure of HLA B*13:01 in complex with SVLNDILARL, an 10-mer epitope from SARS-CoV-2 Spike (S975-984)
Deposited 2023-12-11
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
PEG DI(HYDROXYETHYL)ETHER × 3
EDO 1,2-ETHANEDIOL × 4
NA SODIUM ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；20% PEG3350 and 2% EG
|
Resolution 1.90 Å
R-free 0.221
|
|
8RH6
Crystal structure of HLA-A*11:01 in complex with SVLNDILSRL, an 10-mer epitope from SARS-CoV-2 Spike (S975-984)
Deposited 2023-12-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 9
PDB declaration: nonameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
Chain D
21–119（99 aa）
Fragment：UNP residues 21-119
Chain F
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
PEG DI(HYDROXYETHYL)ETHER × 1
EDO 1,2-ETHANEDIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；25% PEG3350, 0.2M NaCl and 0.1M Tris HCl pH8.5
|
Resolution 3.32 Å
R-free 0.251
|
|
8RHQ
Crystal structure of HLA-A*11:01 in complex with SVLNDIFSRL, an 10-mer epitope from SARS-CoV-2 Spike (S975-984)
Deposited 2023-12-16
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 9
PDB declaration: nonameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
Chain D
21–119（99 aa）
Fragment：UNP residues 21-119
Chain F
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 17
NA SODIUM ION × 3
PEG DI(HYDROXYETHYL)ETHER × 1
CL CHLORIDE ION × 3
MG MAGNESIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；20% PEG3350, 0.2M Sodium acetate tihydrate pH 7.0
|
Resolution 2.00 Å
R-free 0.244
|
|
8RJ5
P1-15 T-cell Receptor bound to HLA A*2402-NF9 pMHC complex
Deposited 2023-12-20
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；di-Sodium malonate, 0.1M
HEPES pH7, 0.1M
Poly(acrylic acid sodium salt) 2,100, 30% w/v
|
Resolution 3.02 Å
R-free 0.260
|
|
8RJ5
P1-15 T-cell Receptor bound to HLA A*2402-NF9 pMHC complex
Deposited 2023-12-20
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；di-Sodium malonate, 0.1M
HEPES pH7, 0.1M
Poly(acrylic acid sodium salt) 2,100, 30% w/v
|
Resolution 3.02 Å
R-free 0.260
|
|
8RJH
HLA A*2402-NF9_6F pMHC complex
Deposited 2023-12-21
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；Glycerol 15% v/v
Polyethylene Glycol 4,000, 20% w/v
MES, 0.1 M, pH7
|
Resolution 2.60 Å
R-free 0.264
|
|
8RJH
HLA A*2402-NF9_6F pMHC complex
Deposited 2023-12-21
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；Glycerol 15% v/v
Polyethylene Glycol 4,000, 20% w/v
MES, 0.1 M, pH7
|
Resolution 2.60 Å
R-free 0.264
|
|
8RJH
HLA A*2402-NF9_6F pMHC complex
Deposited 2023-12-21
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain H
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；Glycerol 15% v/v
Polyethylene Glycol 4,000, 20% w/v
MES, 0.1 M, pH7
|
Resolution 2.60 Å
R-free 0.264
|
|
8RJH
HLA A*2402-NF9_6F pMHC complex
Deposited 2023-12-21
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain K
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；Glycerol 15% v/v
Polyethylene Glycol 4,000, 20% w/v
MES, 0.1 M, pH7
|
Resolution 2.60 Å
R-free 0.264
|
|
8RJH
HLA A*2402-NF9_6F pMHC complex
Deposited 2023-12-21
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 5
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain N
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；Glycerol 15% v/v
Polyethylene Glycol 4,000, 20% w/v
MES, 0.1 M, pH7
|
Resolution 2.60 Å
R-free 0.264
|
|
8RJH
HLA A*2402-NF9_6F pMHC complex
Deposited 2023-12-21
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 6
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain Q
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；Glycerol 15% v/v
Polyethylene Glycol 4,000, 20% w/v
MES, 0.1 M, pH7
|
Resolution 2.60 Å
R-free 0.264
|
|
8RJI
HLA A*2402-NF9_5R pMHC complex
Deposited 2023-12-21
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；Glycerol 15% v/v
Polyethylene glycol 4000, 20% w/v
Sodium Cacodylate, 0.1 M, pH 6
|
Resolution 2.30 Å
R-free 0.265
|
|
8RJI
HLA A*2402-NF9_5R pMHC complex
Deposited 2023-12-21
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；Glycerol 15% v/v
Polyethylene glycol 4000, 20% w/v
Sodium Cacodylate, 0.1 M, pH 6
|
Resolution 2.30 Å
R-free 0.265
|
|
8RJI
HLA A*2402-NF9_5R pMHC complex
Deposited 2023-12-21
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain H
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；Glycerol 15% v/v
Polyethylene glycol 4000, 20% w/v
Sodium Cacodylate, 0.1 M, pH 6
|
Resolution 2.30 Å
R-free 0.265
|
|
8RJI
HLA A*2402-NF9_5R pMHC complex
Deposited 2023-12-21
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain K
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；Glycerol 15% v/v
Polyethylene glycol 4000, 20% w/v
Sodium Cacodylate, 0.1 M, pH 6
|
Resolution 2.30 Å
R-free 0.265
|
|
8RLT
TCR in complex with HLA-E*01:03 bound to HBV envelope 371-379 index peptide
Deposited 2024-01-03
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；20% (w/v) PEG 3350, 100 mM BIS-TRIS propane pH 8.5, 200 mM sodium sulfate
|
Resolution 2.25 Å
R-free 0.252
|
|
8RLT
TCR in complex with HLA-E*01:03 bound to HBV envelope 371-379 index peptide
Deposited 2024-01-03
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；20% (w/v) PEG 3350, 100 mM BIS-TRIS propane pH 8.5, 200 mM sodium sulfate
|
Resolution 2.25 Å
R-free 0.252
|
|
8RLU
TCR in complex with HLA-E*01:03 bound to HBV envelope 371-379 S3N peptide
Deposited 2024-01-03
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；20% (w/v) PEG 3350, 100 mM BIS-TRIS propane pH 8.5, 200 mM sodium sulfate
|
Resolution 2.35 Å
R-free 0.261
|
|
8RLU
TCR in complex with HLA-E*01:03 bound to HBV envelope 371-379 S3N peptide
Deposited 2024-01-03
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；20% (w/v) PEG 3350, 100 mM BIS-TRIS propane pH 8.5, 200 mM sodium sulfate
|
Resolution 2.35 Å
R-free 0.261
|
|
8RLV
TCR in complex with HLA-E*01:03 bound to HBV envelope 371-379 L6I peptide
Deposited 2024-01-03
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；20% (w/v) PEG 3350, 100 mM BIS-TRIS propane pH 8.5, 200 mM sodium sulfate
Collection Temp: 100
|
Resolution 2.61 Å
R-free 0.251
|
|
8RLV
TCR in complex with HLA-E*01:03 bound to HBV envelope 371-379 L6I peptide
Deposited 2024-01-03
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；20% (w/v) PEG 3350, 100 mM BIS-TRIS propane pH 8.5, 200 mM sodium sulfate
Collection Temp: 100
|
Resolution 2.61 Å
R-free 0.251
|
|
8RNE
HLA-E*01:03 in complex with SARS-CoV-2 Nsp13 peptide, VMPLSAPTL
Deposited 2024-01-09
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293.15 K；0.15 M potassium bromide, 20% w/v of PEG 2000 MME
|
Resolution 1.71 Å
R-free 0.243
|
|
8RNE
HLA-E*01:03 in complex with SARS-CoV-2 Nsp13 peptide, VMPLSAPTL
Deposited 2024-01-09
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293.15 K；0.15 M potassium bromide, 20% w/v of PEG 2000 MME
|
Resolution 1.71 Å
R-free 0.243
|
|
8RNE
HLA-E*01:03 in complex with SARS-CoV-2 Nsp13 peptide, VMPLSAPTL
Deposited 2024-01-09
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain G
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293.15 K；0.15 M potassium bromide, 20% w/v of PEG 2000 MME
|
Resolution 1.71 Å
R-free 0.243
|
|
8RNF
HLA-E*01:03 in complex with SARS-CoV-2 Omicron Nsp13 peptide, VIPLSAPTL
Deposited 2024-01-09
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293.15 K；0.15 M DL malic acid and 20% w/v of PEG3350
|
Resolution 1.87 Å
R-free 0.220
|
|
8RNF
HLA-E*01:03 in complex with SARS-CoV-2 Omicron Nsp13 peptide, VIPLSAPTL
Deposited 2024-01-09
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293.15 K；0.15 M DL malic acid and 20% w/v of PEG3350
|
Resolution 1.87 Å
R-free 0.220
|
|
8RNF
HLA-E*01:03 in complex with SARS-CoV-2 Omicron Nsp13 peptide, VIPLSAPTL
Deposited 2024-01-09
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain G
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293.15 K；0.15 M DL malic acid and 20% w/v of PEG3350
|
Resolution 1.87 Å
R-free 0.220
|
|
8RNG
Crystal structure of HLA B*18:01 in complex with TEVETYVL, an 8-mer epitope from Influenza A
Deposited 2024-01-10
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 1
MG MAGNESIUM ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M Potassium Nitrate, 20% w/v PEG 3350 at pH 6.5
|
Resolution 1.45 Å
R-free 0.203
|
|
8RNH
Crystal structure of HLA B*18:01 in complex with EEIEITTHF, an 9-mer epitope from Influenza A
Deposited 2024-01-10
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
PEG DI(HYDROXYETHYL)ETHER × 1
EDO 1,2-ETHANEDIOL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M Lithium Acetate, 20% w/v PEG 3350, and 10 mM MgCl2
|
Resolution 1.60 Å
R-free 0.234
|
|
8RNI
HLA-A*03:01 with KRAS-G12V-10mer
Deposited 2024-01-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 6
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.1M ammonium citrate tribasic pH7, 12% PEG 3350
|
Resolution 2.49 Å
R-free 0.276
|
|
8ROO
Crystal structure of HLA B*18:01 in complex with YERMCNIL, an 8-mer epitope from Influenza A
Deposited 2024-01-11
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain C
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 9
MG MAGNESIUM ION × 1
K POTASSIUM ION × 3
SO4 SULFATE ION × 1
NO3 NITRATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M Potassium Nitrate, 20% w/v PEG 3350 at pH 6.5
|
Resolution 1.40 Å
R-free 0.189
|
|
8ROP
Crystal structure of HLA B*18:01 in complex with QEIRTFSF, an 8-mer epitope from Influenza A
Deposited 2024-01-12
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 3
CL CHLORIDE ION × 2
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M Lithium Acetate, 20% w/v PEG 3350, and 10 mM MgCl2
|
Resolution 1.15 Å
R-free 0.168
|
|
8RRO
G12V-TCR complex with HLA-A3
Deposited 2024-01-23
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain D
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；298 K；0.1M Bis-Tris Propane (pH 6.5), 0.2M Na2SO4, 14-20% PEG 3350
|
Resolution 3.50 Å
R-free 0.286
|
|
8RRO
G12V-TCR complex with HLA-A3
Deposited 2024-01-23
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain I
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；298 K；0.1M Bis-Tris Propane (pH 6.5), 0.2M Na2SO4, 14-20% PEG 3350
|
Resolution 3.50 Å
R-free 0.286
|
|
8RRO
G12V-TCR complex with HLA-A3
Deposited 2024-01-23
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain N
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；298 K；0.1M Bis-Tris Propane (pH 6.5), 0.2M Na2SO4, 14-20% PEG 3350
|
Resolution 3.50 Å
R-free 0.286
|
|
8RRO
G12V-TCR complex with HLA-A3
Deposited 2024-01-23
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain S
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；298 K；0.1M Bis-Tris Propane (pH 6.5), 0.2M Na2SO4, 14-20% PEG 3350
|
Resolution 3.50 Å
R-free 0.286
|
|
8RRO
G12V-TCR complex with HLA-A3
Deposited 2024-01-23
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 5
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain X
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；298 K；0.1M Bis-Tris Propane (pH 6.5), 0.2M Na2SO4, 14-20% PEG 3350
|
Resolution 3.50 Å
R-free 0.286
|
|
8RRO
G12V-TCR complex with HLA-A3
Deposited 2024-01-23
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 6
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain c
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；298 K；0.1M Bis-Tris Propane (pH 6.5), 0.2M Na2SO4, 14-20% PEG 3350
|
Resolution 3.50 Å
R-free 0.286
|
|
8RRO
G12V-TCR complex with HLA-A3
Deposited 2024-01-23
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 7
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain h
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；298 K；0.1M Bis-Tris Propane (pH 6.5), 0.2M Na2SO4, 14-20% PEG 3350
|
Resolution 3.50 Å
R-free 0.286
|
|
8RRO
G12V-TCR complex with HLA-A3
Deposited 2024-01-23
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 8
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain m
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；298 K；0.1M Bis-Tris Propane (pH 6.5), 0.2M Na2SO4, 14-20% PEG 3350
|
Resolution 3.50 Å
R-free 0.286
|
|
8RYM
Structure of S2 TCR in complex with HLA-A*03:01 bound to ELFSYLIEK peptide
Deposited 2024-02-09
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；50 mM HEPES pH 7.0, 13 % w/v PEG 8000
|
Resolution 2.34 Å
R-free 0.272
|
|
8RYN
Structure of S2 TCR in complex with HLA-A*11:01 bound to ELFSYLIEK peptide
Deposited 2024-02-09
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M Amino acids (0.02 M Sodium Glutamate; 0.02 M Alanine; 0.02 M Glycine; 0.02 M Lysine hydrochloride; 0.02 M Serine), 0.1 M Buffer system 1 (Imidazole; MES monohydrate) pH 6.5, 50 % Precipitant mix 2 (20% v/v Ethylene glycol; 10 % w/v PEG 8000)
|
Resolution 1.97 Å
R-free 0.251
|
|
8RYO
Structure of S2-198 TCR in complex with HLA-A*03:01 bound to ELFSYLIEK peptide
Deposited 2024-02-09
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
TOE 2-[2-(2-METHOXY-ETHOXY)-ETHOXY]-ETHOXYL × 1
EDO 1,2-ETHANEDIOL × 2
PO4 PHOSPHATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；50 mM MOPS pH 6.7, 14 % w/v PEG 8000
|
Resolution 2.05 Å
R-free 0.244
|
|
8RYP
Structure of S8 TCR in complex with HLA-A*03:01 bound to ELFSYLIEK peptide
Deposited 2024-02-09
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；50 mM Magnesium acetate, 20 mM MOPS pH 7.2, 50 mM Sodium chloride, 12 % w/v PEG 8000
|
Resolution 1.81 Å
R-free 0.241
|
|
8RYQ
Structure of S8-9F3 TCR in complex with HLA-A*11:01 bound to ELFSYLIEK peptide
Deposited 2024-02-09
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；150 mM Magnesium acetate, 20 mM MOPS pH 7.2, 12 % w/v PEG 8000
|
Resolution 2.49 Å
R-free 0.283
|
|
8RYQ
Structure of S8-9F3 TCR in complex with HLA-A*11:01 bound to ELFSYLIEK peptide
Deposited 2024-02-09
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；150 mM Magnesium acetate, 20 mM MOPS pH 7.2, 12 % w/v PEG 8000
|
Resolution 2.49 Å
R-free 0.283
|
|
8SBK
Structure of HLA-A*24:02 in complex with peptide, LYLPVRVLI (ATG2A).
Deposited 2023-04-03
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 2
SO4 SULFATE ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；294 K；2 M Ammonium sulfate, 0.1 M Sodium cacodylate pH 6.5
|
Resolution 1.80 Å
R-free 0.219
|
|
8SBL
Structure of HLA-A*24:02 in complex with peptide, LYLPVRVLI
Deposited 2023-04-03
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；294 K；0.05M MES monohydrate pH 6.5, 22.5% Polyethylene Glycol w/v 3350
|
Resolution 3.00 Å
R-free 0.270
|
|
8SBL
Structure of HLA-A*24:02 in complex with peptide, LYLPVRVLI
Deposited 2023-04-03
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；294 K；0.05M MES monohydrate pH 6.5, 22.5% Polyethylene Glycol w/v 3350
|
Resolution 3.00 Å
R-free 0.270
|
|
8SBL
Structure of HLA-A*24:02 in complex with peptide, LYLPVRVLI
Deposited 2023-04-03
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain H
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；294 K；0.05M MES monohydrate pH 6.5, 22.5% Polyethylene Glycol w/v 3350
|
Resolution 3.00 Å
R-free 0.270
|
|
8SBL
Structure of HLA-A*24:02 in complex with peptide, LYLPVRVLI
Deposited 2023-04-03
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain K
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；294 K；0.05M MES monohydrate pH 6.5, 22.5% Polyethylene Glycol w/v 3350
|
Resolution 3.00 Å
R-free 0.270
|
|
8SGB
Crystal Structure of CD1d-lipid complexed with Beta-2-Microglobulin, TCR Alpha-Chain and TCR Beta-Chain
Deposited 2023-04-12
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2
FO4 sphingomyelin × 1
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG3350, sodium citrate, citrate-bis-Tris pH7
|
Resolution 2.80 Å
R-free 0.249
|
|
8SGM
Crystal Structure of CD1d-lipid complexed with Beta-2-Microglobulin, TCR Alpha-Chain and TCR Beta-Chain
Deposited 2023-04-12
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
GOL GLYCEROL × 1
A1AHF N-[(2S)-3-oxo-1-(beta-L-talopyranosyloxy)octadecan-2-yl]docosanamide × 1
SO4 SULFATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG3350, sodium citrate, citrate-bis-Tris pH7
|
Resolution 2.50 Å
R-free 0.234
|
|
8SHI
Valpha3S1 Vbeta13S1 HLA C 0602 VRSRRCLRL
Deposited 2023-04-14
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；297 K；20% w/v polyethylene glycol 3350, 0.2M NaSO4.
|
Resolution 2.90 Å
R-free 0.291
|
|
8SHI
Valpha3S1 Vbeta13S1 HLA C 0602 VRSRRCLRL
Deposited 2023-04-14
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain E
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；297 K；20% w/v polyethylene glycol 3350, 0.2M NaSO4.
|
Resolution 2.90 Å
R-free 0.291
|
|
8SOS
Human CD1d presenting sphingomyelin C24:1 in complex with VHH nanobody 1D17
Deposited 2023-04-29
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
Chain F
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
FO4 sphingomyelin × 2
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.2；293 K；12% PEG8000, 0.05 M zinc acetate, 0.05 M MES, pH 6.2
|
Resolution 2.33 Å
R-free 0.230
|
|
8T6M
Human leukocyte antigen bound by two alloreactive antibody Fabs
Deposited 2023-06-16
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 7
PDB declaration: heptameric
|
Chain F
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.14 Å
|
|
8T7R
Crystal structure of human leukocyte antigen A*0101 in complex with the Fab of alloreactive antibody E07
Deposited 2023-06-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 50
PDB declaration: 50-meric
|
Chain D
21–119（99 aa）
Chain H
21–119（99 aa）
Chain L
21–119（99 aa）
Chain P
21–119（99 aa）
Chain T
21–119（99 aa）
Chain X
21–119（99 aa）
Chain b
21–119（99 aa）
Chain f
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；294 K；sodium citrate tribasic dihydrate, sodium cacodylate
|
Resolution 3.84 Å
R-free 0.263
|
|
8TBV
Human Class I MHC HLA-A2 in complex with sorting nexin 24 (127-135) neoantigen KLSHQLVLL
Deposited 2023-06-29
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
PEG DI(HYDROXYETHYL)ETHER × 1
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277.15 K；Purified protein complexes were concentrated to 7.4 mg/mL before crystallization. The crystals were grown in 12.5% PEG 4000 and 0.1 M MES (pH 6.5) via hanging drop vapor diffusion. Crystals were harvested and cryoprotected in 8% glycerol/92% mother liquor and immediately stored in liquid nitrogen
|
Resolution 2.64 Å
R-free 0.274
|
|
8TBV
Human Class I MHC HLA-A2 in complex with sorting nexin 24 (127-135) neoantigen KLSHQLVLL
Deposited 2023-06-29
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277.15 K；Purified protein complexes were concentrated to 7.4 mg/mL before crystallization. The crystals were grown in 12.5% PEG 4000 and 0.1 M MES (pH 6.5) via hanging drop vapor diffusion. Crystals were harvested and cryoprotected in 8% glycerol/92% mother liquor and immediately stored in liquid nitrogen
|
Resolution 2.64 Å
R-free 0.274
|
|
8TBW
Human Class I MHC HLA-A2 in complex with sorting nexin 24 (127-135) peptide KLSHQPVLL
Deposited 2023-06-29
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
NO3 NITRATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277.15 K；Purified protein complexes were concentrated to 7.4 mg/mL before crystallization. The crystals were grown in 12.5% PEG 4000 and 0.1 M MES (pH 6.5) via hanging drop vapor diffusion. Crystals were harvested and cryoprotected in 8% glycerol/92% mother liquor and immediately stored in liquid nitrogen
|
Resolution 2.08 Å
R-free 0.205
|
|
8TBW
Human Class I MHC HLA-A2 in complex with sorting nexin 24 (127-135) peptide KLSHQPVLL
Deposited 2023-06-29
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
NO3 NITRATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277.15 K；Purified protein complexes were concentrated to 7.4 mg/mL before crystallization. The crystals were grown in 12.5% PEG 4000 and 0.1 M MES (pH 6.5) via hanging drop vapor diffusion. Crystals were harvested and cryoprotected in 8% glycerol/92% mother liquor and immediately stored in liquid nitrogen
|
Resolution 2.08 Å
R-free 0.205
|
|
8TMU
HLA-B*73:01 bound to a 10mer peptide in complex with KIR2DL2
Deposited 2023-07-31
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 4
PEG DI(HYDROXYETHYL)ETHER × 1
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；Tris-HCl pH 8.75 and 20% PEG 8000
|
Resolution 2.90 Å
R-free 0.258
|
|
8TQ5
Crystal structure of Fab DX17 in complex with MHC-I (HLA-B*44:05)
Deposited 2023-08-06
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；291 K；12% PEG20000, 0.1 M MES, pH 6.5
|
Resolution 2.30 Å
R-free 0.234
|
|
8TQ6
Crystal structure of Fab.B1.23.2 in complex with MHC-I (HLA-B*44:05)
Deposited 2023-08-06
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.8；291 K；16% PEG3350, 0.04 M sodium citrate, 0.06 M Bis-Tris, pH 8.8
|
Resolution 3.20 Å
R-free 0.268
|
|
8TQ6
Crystal structure of Fab.B1.23.2 in complex with MHC-I (HLA-B*44:05)
Deposited 2023-08-06
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain D
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.8；291 K；16% PEG3350, 0.04 M sodium citrate, 0.06 M Bis-Tris, pH 8.8
|
Resolution 3.20 Å
R-free 0.268
|
|
8TUB
HLA B7:02 with HPNGYKSLSTL
Deposited 2023-08-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain A
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 3
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG
|
Resolution 2.40 Å
R-free 0.238
|
|
8TUB
HLA B7:02 with HPNGYKSLSTL
Deposited 2023-08-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG
|
Resolution 2.40 Å
R-free 0.238
|
|
8TUB
HLA B7:02 with HPNGYKSLSTL
Deposited 2023-08-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG
|
Resolution 2.40 Å
R-free 0.238
|
|
8TUB
HLA B7:02 with HPNGYKSLSTL
Deposited 2023-08-16
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain I
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG
|
Resolution 2.40 Å
R-free 0.238
|
|
8TUH
HLA B7:02 with RPIIRPATL
Deposited 2023-08-16
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 7
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG
|
Resolution 2.20 Å
R-free 0.245
|
|
8U9G
Human Class I MHC HLA-A2 bound to sorting nexin 24 (127-135) neoantigen KLSHQLVLL
Deposited 2023-09-19
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277.15 K；Purified protein complexes were concentrated to 7.4 mg/mL before crystallization. The crystals were grown in 12.5% PEG 4000 and 0.1 M MES (pH 6.5) via hanging drop vapor diffusion. Crystals were harvested and cryoprotected in 8% glycerol/92% mother liquor and immediately stored in liquid nitrogen
|
Resolution 2.87 Å
R-free 0.245
|
|
8U9G
Human Class I MHC HLA-A2 bound to sorting nexin 24 (127-135) neoantigen KLSHQLVLL
Deposited 2023-09-19
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277.15 K；Purified protein complexes were concentrated to 7.4 mg/mL before crystallization. The crystals were grown in 12.5% PEG 4000 and 0.1 M MES (pH 6.5) via hanging drop vapor diffusion. Crystals were harvested and cryoprotected in 8% glycerol/92% mother liquor and immediately stored in liquid nitrogen
|
Resolution 2.87 Å
R-free 0.245
|
|
8UDR
Structure of the P1B7 antibody bound to the Sotorasib-modified KRas G12C peptide presented by the A*03:01 MHC I complex
Deposited 2023-09-28
|
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
MOV AMG 510 (bound form) × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5；20mM HEPES ph 7.5, 100 mM KCl
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.10 Å
|
|
8UTC
HUMAN LEUKOCYTE ANTIGEN B*07:02 IN COMPLEX WITH SARS-COV2 EPITOPE N105-113 (Y111F mutant)
Deposited 2023-10-30
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
PGE TRIETHYLENE GLYCOL × 1
PG4 TETRAETHYLENE GLYCOL × 1
CL CHLORIDE ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；289 K；0.1 M HEPES-NaOH, pH 7.5, 25% PEG 3350
|
Resolution 2.40 Å
R-free 0.240
|
|
8UTC
HUMAN LEUKOCYTE ANTIGEN B*07:02 IN COMPLEX WITH SARS-COV2 EPITOPE N105-113 (Y111F mutant)
Deposited 2023-10-30
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
PG4 TETRAETHYLENE GLYCOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；289 K；0.1 M HEPES-NaOH, pH 7.5, 25% PEG 3350
|
Resolution 2.40 Å
R-free 0.240
|
|
8V4Z
Crystal structure of a HLA-B*35:01-NP7 with D1 TCR
Deposited 2023-11-29
|
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Mutation：M1
|
PO4 PHOSPHATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG
|
Resolution 2.40 Å
R-free 0.252
|
|
8V4Z
Crystal structure of a HLA-B*35:01-NP7 with D1 TCR
Deposited 2023-11-29
|
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
|
Mutation：M1
|
PO4 PHOSPHATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG
|
Resolution 2.40 Å
R-free 0.252
|
|
8V4Z
Crystal structure of a HLA-B*35:01-NP7 with D1 TCR
Deposited 2023-11-29
|
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain L
21–119（99 aa）
|
Mutation：M1
|
PO4 PHOSPHATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG
|
Resolution 2.40 Å
R-free 0.252
|
|
8V4Z
Crystal structure of a HLA-B*35:01-NP7 with D1 TCR
Deposited 2023-11-29
|
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain Q
21–119（99 aa）
|
Mutation：M1
|
PO4 PHOSPHATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG
|
Resolution 2.40 Å
R-free 0.252
|
|
8V50
Crystal structure of a HLA-B*35:01-NP6 with D1 TCR
Deposited 2023-11-30
|
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Mutation：artificial starting M
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG
|
Resolution 2.65 Å
R-free 0.265
|
|
8V50
Crystal structure of a HLA-B*35:01-NP6 with D1 TCR
Deposited 2023-11-30
|
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
|
Mutation：artificial starting M
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG
|
Resolution 2.65 Å
R-free 0.265
|
|
8V50
Crystal structure of a HLA-B*35:01-NP6 with D1 TCR
Deposited 2023-11-30
|
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain L
21–119（99 aa）
|
Mutation：artificial starting M
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG
|
Resolution 2.65 Å
R-free 0.265
|
|
8V50
Crystal structure of a HLA-B*35:01-NP6 with D1 TCR
Deposited 2023-11-30
|
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain Q
21–119（99 aa）
|
Mutation：artificial starting M
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG
|
Resolution 2.65 Å
R-free 0.265
|
|
8V51
Crystal structure of a HLA-B*35:01-NP10 with D1 TCR
Deposited 2023-11-30
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 1
NA SODIUM ION × 1
PO4 PHOSPHATE ION × 5
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG
|
Resolution 2.10 Å
R-free 0.244
|
|
8V8Q
HUMAN LEUKOCYTE ANTIGEN B*07:02 IN COMPLEX WITH MERS-COV EPITOPE N95-103 (A95S mutant)
Deposited 2023-12-05
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
BCT BICARBONATE ION × 2
PEG DI(HYDROXYETHYL)ETHER × 2
CL CHLORIDE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；289 K；0.1 M HEPES: NaOH, pH 7.5, 25 % PEG 3350
|
Resolution 1.85 Å
R-free 0.210
|
|
8VCL
Crystal structure of HLA-A*03:01 in complex with a mutant PIK3CA peptide
Deposited 2023-12-14
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
FMT FORMIC ACID × 4
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；277.15 K；12% w/v Polyethylene glycol 3,350, 4% v/v TacsimateTM, pH 6.0
|
Resolution 2.40 Å
R-free 0.230
|
|
8VJZ
HLA-A*03:01 with WT KRAS-10mer
Deposited 2024-01-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；295 K；0.1M ammonium citrate tribasic pH7, 12% PEG 3350
|
Resolution 1.90 Å
R-free 0.214
|
|
8VR9
Structure of a synthetic antibody in complex with a class I MHC presenting a hapten-peptide conjugate
Deposited 2024-01-20
|
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
MOV AMG 510 (bound form) × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.06 Å
|
|
8VRA
Structure of a synthetic antibody in complex with a class I MHC presenting a hapten-peptide conjugate
Deposited 2024-01-20
|
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
MOV AMG 510 (bound form) × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.12 Å
|
|
8VRB
Structure of a synthetic antibody in complex with a class I MHC presenting a hapten-peptide conjugate
Deposited 2024-01-20
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
20–119（100 aa）
Fragment：UNP residues 20-119
|
Not recorded
|
MOV AMG 510 (bound form) × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.25 Å
|
|
8WTE
Crystal structure of TCR in complex with HLA-A*11:01 bound to KRAS-G12V peptide (VVGAVGVGK)
Deposited 2023-10-18
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain I
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；289.15 K；20% (w/v) PEG 3350
0.2 M sodium citrate.
|
Resolution 2.17 Å
R-free 0.216
|
|
8WTE
Crystal structure of TCR in complex with HLA-A*11:01 bound to KRAS-G12V peptide (VVGAVGVGK)
Deposited 2023-10-18
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain F
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；289.15 K；20% (w/v) PEG 3350
0.2 M sodium citrate.
|
Resolution 2.17 Å
R-free 0.216
|
|
8WUL
Crystal structure of affinity enhanced TCR in complex with HLA-A*11:01 bound to KRAS-G12V peptide (VVGAVGVGK)
Deposited 2023-10-20
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain M
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；289.15 K；20% (w/v) PEG 3350, 0.2M ammonium citrate tribasic at pH 7.0
|
Resolution 2.36 Å
R-free 0.235
|
|
8WUL
Crystal structure of affinity enhanced TCR in complex with HLA-A*11:01 bound to KRAS-G12V peptide (VVGAVGVGK)
Deposited 2023-10-20
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain J
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；289.15 K；20% (w/v) PEG 3350, 0.2M ammonium citrate tribasic at pH 7.0
|
Resolution 2.36 Å
R-free 0.235
|
|
8WUL
Crystal structure of affinity enhanced TCR in complex with HLA-A*11:01 bound to KRAS-G12V peptide (VVGAVGVGK)
Deposited 2023-10-20
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain P
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；289.15 K；20% (w/v) PEG 3350, 0.2M ammonium citrate tribasic at pH 7.0
|
Resolution 2.36 Å
R-free 0.235
|
|
8WUL
Crystal structure of affinity enhanced TCR in complex with HLA-A*11:01 bound to KRAS-G12V peptide (VVGAVGVGK)
Deposited 2023-10-20
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain S
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；289.15 K；20% (w/v) PEG 3350, 0.2M ammonium citrate tribasic at pH 7.0
|
Resolution 2.36 Å
R-free 0.235
|
|
8XES
The structure of HLA-A/L1-1
Deposited 2023-12-12
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；0.1M Bis-Tris, 20%w/v Polyethylene glycol monomethyl ether 5000
|
Resolution 1.78 Å
R-free 0.235
|
|
8XFZ
The structure of HLA-A/L1-2
Deposited 2023-12-14
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；277 K；0.1M Imidazole, 20%w/v PEG 6000
|
Resolution 2.32 Å
R-free 0.251
|
|
8XG2
The structure of HLA-A/Pep14
Deposited 2023-12-14
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；0.1M Bis-Tris, 20%w/v Polyethylene glycol monomethyl ether 5000
|
Resolution 1.84 Å
R-free 0.230
|
|
8XKC
The structure of HLA-A/Pep16
Deposited 2023-12-23
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；277 K；0.1M Imidazole, 20%w/v PEG 6000
|
Resolution 2.18 Å
R-free 0.291
|
|
8XKE
The structure of HLA-A/14-3-D
Deposited 2023-12-23
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；277 K；0.1M Bis-Tris, 20%w/v Polyethylene glycol monomethyl ether 5000
|
Resolution 1.92 Å
R-free 0.251
|
|
8Y6X
Crystal structure of ternary complex of human MR1, ligand #4, and MAIT-TCR A-F7
Deposited 2024-02-03
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
A1LXU 5-(2-oxidanylidenepropyl)-8-[(2~{S},3~{S},4~{R})-2,3,4,5-tetrakis(oxidanyl)pentyl]-1,7-dihydropteridine-2,4,6-trione × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.2；293 K；0.1M Tris (pH 8.2), 20mM Magnesium chloride, 22% (v/v) polyacrylic acid sodium salt 5,100
|
Resolution 3.40 Å
R-free 0.208
|
|
8YE4
The complex of TCR NYN-I and HLA-A24 bound to SARS-CoV-2 Spike448-456 peptide NYNYLYRLF
Deposited 2024-02-21
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；287 K；8% Tacsimate 7.0, 20% PEG3350
|
Resolution 3.20 Å
R-free 0.310
|
|
8YE4
The complex of TCR NYN-I and HLA-A24 bound to SARS-CoV-2 Spike448-456 peptide NYNYLYRLF
Deposited 2024-02-21
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain D
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；287 K；8% Tacsimate 7.0, 20% PEG3350
|
Resolution 3.20 Å
R-free 0.310
|
|
8YIV
N17.1.2 recognition of NRAS neoantigens
Deposited 2024-02-29
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 8
EDO 1,2-ETHANEDIOL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；10mg/ml, 8% TacsimateTM pH7.0, 20% PEG4K
|
Resolution 2.10 Å
R-free 0.226
|
|
8YJ2
N17.1.2 recognition of NRAS neoantigens
Deposited 2024-02-29
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；10mg/ml, 0.2 M NH4 citrate tribasic, 16% PEG3350, pH 7.4
|
Resolution 2.26 Å
R-free 0.229
|
|
8YZR
The structure of HLA-A*2402 complex with peptide from SARS-CoV-2 S448-456 NYNYLYRLL(EG.5.1)
Deposited 2024-04-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；277 K；0.1 M MES monohydrate pH 6.0, 20% (w/v) Polyethylene glycol 2,000
|
Resolution 1.80 Å
R-free 0.262
|
|
8YZW
The structure of HLA-A*2402 complex with peptide from SARS-CoV-2 S448-456 NYDYWYRLF(BA.2.86)
Deposited 2024-04-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；277 K；0.1 M Sodium citrate tribasic dihydrate , 18% (w/v) Polyethylene glycol 3350
|
Resolution 2.36 Å
R-free 0.278
|
|
8YZW
The structure of HLA-A*2402 complex with peptide from SARS-CoV-2 S448-456 NYDYWYRLF(BA.2.86)
Deposited 2024-04-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；277 K；0.1 M Sodium citrate tribasic dihydrate , 18% (w/v) Polyethylene glycol 3350
|
Resolution 2.36 Å
R-free 0.278
|
|
8YZZ
The structure of HLA-A*2402 complex with peptide from SARS-CoV-2 S448-456 NYNYLYRLF(Prototype)
Deposited 2024-04-08
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；277 K；0.1M Sodium citrate tribasic dihydrate ,18%w/v Polyethylene glycol 3350
|
Resolution 1.88 Å
R-free 0.224
|
|
8Z05
The structure of HLA-A*0201 complex with peptide from SARS-CoV-2 N222-230 LLLDRLNKL(BA.2.86/JN.1)
Deposited 2024-04-09
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；277 K；0.1 M sodium citrate tribasic dihydrate pH 5.5, 18% (w/v) Polyethylene glycol 3,350
|
Resolution 1.96 Å
R-free 0.275
|
|
8Z06
The structure of HLA-A*2402 complex with peptide from SARS-CoV-2 S448-456 NYDYWYRSF(JN.1)
Deposited 2024-04-09
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；0.1 M MES monohydrate pH 6.0, 14% (w/v) Polyethylene glycol 4,000
|
Resolution 2.39 Å
R-free 0.232
|
|
8Z07
The structure of HLA-A*2402 complex with peptide from SARS-CoV-2 S448-456 NYNYRYRLF(Delta/BA.5.2)
Deposited 2024-04-09
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；0.1 M MES monohydrate pH 6.0, 14% (w/v) Polyethylene glycol 4,000
|
Resolution 2.70 Å
R-free 0.289
|
|
8Z08
The structure of HLA-A*2402 complex with peptide from SARS-CoV-2 S448-456 NYNYQYRLF(BA.2.12.1)
Deposited 2024-04-09
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；277 K；0.1M Bis-Tris, 20%w/v Polyethylene glycol monomethyl ether 5000
|
Resolution 2.01 Å
R-free 0.233
|
|
8ZV9
Complex structure of HLA2402 with recognizing SARS-CoV-2 Y453F epitope NYNYLFRLF
Deposited 2024-06-11
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；287 K；20% PEG8000, 0.1 M HEPES 7.5
|
Resolution 2.60 Å
R-free 0.289
|
|
8ZV9
Complex structure of HLA2402 with recognizing SARS-CoV-2 Y453F epitope NYNYLFRLF
Deposited 2024-06-11
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；287 K；20% PEG8000, 0.1 M HEPES 7.5
|
Resolution 2.60 Å
R-free 0.289
|
|
8ZV9
Complex structure of HLA2402 with recognizing SARS-CoV-2 Y453F epitope NYNYLFRLF
Deposited 2024-06-11
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain H
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；287 K；20% PEG8000, 0.1 M HEPES 7.5
|
Resolution 2.60 Å
R-free 0.289
|
|
9ASF
Crystal structure of HLA-A*03:01 in complex with a wild-type PIK3CA peptide analogue (Trp-6 Bta)
Deposited 2024-02-25
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277.15 K；15% w/v Polyethylene glycol 6,000, 50 mM Potassium chloride; 10 mM Magnesium chloride
|
Resolution 1.77 Å
R-free 0.237
|
|
9ASG
Crystal structure of HLA-A*03:01 in complex with a mutant PIK3CA peptide analogue (Trp-6 Bta)
Deposited 2024-02-25
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277.15 K；15% w/v Polyethylene glycol 3,350, 150mM Cesium chloride
|
Resolution 2.03 Å
R-free 0.238
|
|
9BL2
KIR3DL1*001 in complex with HLA-B*57:03 presenting the AW10 peptide
Deposited 2024-04-29
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；294 K；18% PEG-3350, 2% tacsimate pH 5.0, 0.1 M tri-sodium citrate pH 5.6
|
Resolution 2.10 Å
R-free 0.231
|
|
9BL3
KIR3DL1*114 in complex with HLA-B*57:03 presenting the AW10 peptide
Deposited 2024-04-29
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；294 K；16% PEG 3350, 2% tacsimate pH 5.0, 0.1 M tri-sodium citrate pH 5.6
|
Resolution 2.00 Å
R-free 0.229
|
|
9BL4
KIR3DL1*086 in complex with HLA-B*57:03 presenting the AW10 peptide
Deposited 2024-04-29
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；294 K；16% PEG 3350, 2% tacsimate pH 5.0, 0.1 M tri-sodium citrate pH 5.6
|
Resolution 1.75 Å
R-free 0.227
|
|
9BL5
KIR3DL1*001 in complex with HLA-A*24:02 presenting the TW9 peptide
Deposited 2024-04-29
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；294 K；16% PEG-3350, 2% tacsimate pH 5.0, 0.1 M tri-sodium citrate pH 5.6
|
Resolution 2.00 Å
R-free 0.231
|
|
9BL6
KIR3DL1*114 in complex with HLA-A*24:02 presenting the TW9 peptide
Deposited 2024-04-29
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；294 K；14% PEG 3550, 2% tacsimate pH 5.0, 0.1 M tri-sodium citrate pH 5.6
|
Resolution 2.40 Å
R-free 0.256
|
|
9BL9
KIR3DL1*114 in complex with HLA-A*24:02 presenting the NEF peptide
Deposited 2024-04-29
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；294 K；14% PEG 3350, 2% tacsimate pH 5.0, 0.1 M tri-sodium citrate pH 5.6
|
Resolution 2.60 Å
R-free 0.246
|
|
9BLA
KIR3DL1*086 in complex with HLA-A*24:02 presenting the NEF peptide
Deposited 2024-04-30
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；294 K；14% PEG 3350, 2% tacsimate pH 5.0, 0.1 M tri-sodium citrate pH 5.6
|
Resolution 3.00 Å
R-free 0.248
|
|
9BTX
Structure of human MAIT A-F7 TCR in complex with human MR1-3,4-dihydroxybenzaldehyde
Deposited 2024-05-15
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 4
H6N Protocatechuic aldehyde × 1
ACT ACETATE ION × 4
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；295 K；PEG3350, Na-acetate, BTP
|
Resolution 2.05 Å
R-free 0.218
|
|
9BTX
Structure of human MAIT A-F7 TCR in complex with human MR1-3,4-dihydroxybenzaldehyde
Deposited 2024-05-15
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain F
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 2
H6N Protocatechuic aldehyde × 1
ACT ACETATE ION × 3
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；295 K；PEG3350, Na-acetate, BTP
|
Resolution 2.05 Å
R-free 0.218
|
|
9BTY
Structure of human MAIT A-F7 TCR in complex with human MR1-veratraldehyde
Deposited 2024-05-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 8
PDB declaration: octameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
Chain F
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
XIK 3,4-dimethoxybenzaldehyde × 2
ACT ACETATE ION × 1
GOL GLYCEROL × 5
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；295 K；PEG 3350, Na acetate, BTP
|
Resolution 2.85 Å
R-free 0.223
|
|
9BTZ
Structure of human MAIT A-F7 TCR in complex with human MR1-nicotinaldehyde
Deposited 2024-05-15
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
XIE Nicotinaldehyde × 1
ACT ACETATE ION × 2
GOL GLYCEROL × 1
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；295 K；PEG 3350, Na acetate, BTP
|
Resolution 3.00 Å
R-free 0.255
|
|
9BTZ
Structure of human MAIT A-F7 TCR in complex with human MR1-nicotinaldehyde
Deposited 2024-05-15
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain F
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
XIE Nicotinaldehyde × 1
ACT ACETATE ION × 1
GOL GLYCEROL × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；295 K；PEG 3350, Na acetate, BTP
|
Resolution 3.00 Å
R-free 0.255
|
|
9BU0
Structure of human MAIT A-F7 TCR in complex with human MR1-salicylaldehyde
Deposited 2024-05-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 8
PDB declaration: octameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
Chain F
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
NK SALICYLALDEHYDE × 2
GOL GLYCEROL × 5
ACT ACETATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；295 K；PEG 3350, Na acetate, BTP
|
Resolution 2.89 Å
R-free 0.238
|
|
9BYS
Structure of human MAIT BV28 TCR in complex with human MR1-5-OP-RU
Deposited 2024-05-24
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain AAAD
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
Q87 1-deoxy-1-({2,6-dioxo-5-[(E)-(2-oxopropylidene)amino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-ribitol × 1
GOL GLYCEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；295 K；PEG3350, Na-acetate, BTP
|
Resolution 3.10 Å
R-free 0.252
|
|
9C3E
TCR - CD3 complex bound to HLA
Deposited 2024-05-31
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 9
PDB declaration: nonameric
|
Chain H
21–118（98 aa）
|
Mutation：C9V
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 8
CLR CHOLESTEROL × 2
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.50 Å
|
|
9C42
Structure of human MR1-ellagic acid in complex with human MAIT A-F7 TCR
Deposited 2024-06-02
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
REF 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione × 1
NA SODIUM ION × 3
ACY ACETIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；PEG 3350, bis-tris propane, sodium acetate
|
Resolution 2.69 Å
R-free 0.246
|
|
9C42
Structure of human MR1-ellagic acid in complex with human MAIT A-F7 TCR
Deposited 2024-06-02
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain F
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
REF 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione × 1
ACY ACETIC ACID × 2
CL CHLORIDE ION × 1
GOL GLYCEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；PEG 3350, bis-tris propane, sodium acetate
|
Resolution 2.69 Å
R-free 0.246
|
|
9C6V
Crystal Structure of a single chain trimer composed of HLA-B*39:06 Y84C variant, beta-2microglobulin, and NRVMLPKAA peptide from NLRP2 (1 molecule/asymmetric unit)
Deposited 2024-06-09
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
21–119（99 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 1
GOL GLYCEROL × 1
CL CHLORIDE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；20% PEG 3350, 0.2 M Potassium
sulfate
|
Resolution 1.70 Å
R-free 0.219
|
|
9C6W
Crystal Structure of a single chain trimer composed of HLA-B*39:06 Y84C variant, beta-2microglobulin, and NRVMLPKAA peptide from NLRP2 (2 molecules/asymmetric unit)
Deposited 2024-06-09
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 7
EDO 1,2-ETHANEDIOL × 8
PEG DI(HYDROXYETHYL)ETHER × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；291 K；2M Ammonuim sulfate,0.2 M Lithium sulfate, 0.1 M HEPES
|
Resolution 1.70 Å
R-free 0.215
|
|
9C6W
Crystal Structure of a single chain trimer composed of HLA-B*39:06 Y84C variant, beta-2microglobulin, and NRVMLPKAA peptide from NLRP2 (2 molecules/asymmetric unit)
Deposited 2024-06-09
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 8
EDO 1,2-ETHANEDIOL × 9
CL CHLORIDE ION × 2
P3G 3,6,9,12,15-PENTAOXAHEPTADECANE × 1
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；291 K；2M Ammonuim sulfate,0.2 M Lithium sulfate, 0.1 M HEPES
|
Resolution 1.70 Å
R-free 0.215
|
|
9C6X
Crystal Structure of a single chain trimer composed of HLA-B*39:01 Y84C variant, beta-2microglobulin, and NRVMLPKAA peptide from NLRP2
Deposited 2024-06-09
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
21–119（99 aa）
|
Not recorded
|
P4G 1-ETHOXY-2-(2-ETHOXYETHOXY)ETHANE × 1
EDO 1,2-ETHANEDIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；291 K；25% PEG 3350 and 0.1 M Tris
|
Resolution 1.70 Å
R-free 0.232
|
|
9C96
Cryo-EM structure of TAP binding protein related (TAPBPR) in complex with HLA-A*02:01 bound to a suboptimal peptide.
Deposited 2024-06-13
|
Different construct
Different mutation/modification
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–118（98 aa）
|
Mutation：H31C
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.00 Å
|
|
9C9D
Protein receptor
Deposited 2024-06-13
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
30W N-(6-formyl-4-oxo-3,4-dihydropteridin-2-yl)acetamide × 1
GOL GLYCEROL × 3
SO4 SULFATE ION × 8
MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1
CL CHLORIDE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；295 K；PEG 8K, (NH4)2SO4, MES
|
Resolution 2.90 Å
R-free 0.215
|
|
9CGR
Structure of human MAIT A-F7 TCR in complex with human MR1-Pyridoxal
Deposited 2024-06-30
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
PXL 3-HYDROXY-5-(HYDROXYMETHYL)-2-METHYLISONICOTINALDEHYDE × 1
GOL GLYCEROL × 3
ACY ACETIC ACID × 2
CL CHLORIDE ION × 1
CA CALCIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；295 K；PEG 3350, BTP, Ca acetate
|
Resolution 2.40 Å
R-free 0.216
|
|
9CGR
Structure of human MAIT A-F7 TCR in complex with human MR1-Pyridoxal
Deposited 2024-06-30
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain F
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
PXL 3-HYDROXY-5-(HYDROXYMETHYL)-2-METHYLISONICOTINALDEHYDE × 1
GOL GLYCEROL × 7
ACY ACETIC ACID × 3
CL CHLORIDE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；295 K；PEG 3350, BTP, Ca acetate
|
Resolution 2.40 Å
R-free 0.216
|
|
9CGS
Structure of human MAIT A-F7 TCR in complex with human MR1-Pyridoxal-5'-phosphate
Deposited 2024-06-30
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 2
ACY ACETIC ACID × 1
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；296 K；PEG 3350, BTP, Ca acetate
|
Resolution 2.00 Å
R-free 0.200
|
|
9CGS
Structure of human MAIT A-F7 TCR in complex with human MR1-Pyridoxal-5'-phosphate
Deposited 2024-06-30
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain F
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 1
ACY ACETIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；296 K；PEG 3350, BTP, Ca acetate
|
Resolution 2.00 Å
R-free 0.200
|
|
9CWY
Crystal structure of HLA-A*03:02 in complex with a wild-type PIK3CA peptide
Deposited 2024-07-30
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
ACT ACETATE ION × 2
FMT FORMIC ACID × 7
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；277.15 K；12% w/v polyethylene glycol 3,350, 4% v/v Tacsimate (Hampton Research)
|
Resolution 1.98 Å
R-free 0.224
|
|
9CWZ
Crystal structure of HLA-A*03:02 in complex with a mutant PIK3CA peptide
Deposited 2024-07-30
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 10
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.1；277.15 K；20% w/v polyethylene glycol 3,350, 200 mM lithium nitrate
|
Resolution 2.05 Å
R-free 0.238
|
|
9CX0
Crystal structure of HLA-A*03:01 E152V mutant in complex with a mutant PIK3CA peptide
Deposited 2024-07-30
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；277.15 K；12% w/v polyethylene glycol 3,350, 100 mM sodium malonate
|
Resolution 1.92 Å
R-free 0.242
|
|
9CX1
Crystal structure of HLA-A*03:01 L156Q mutant in complex with a mutant PIK3CA peptide
Deposited 2024-07-30
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；277.15 K；20% w/v polyethylene glycol 3,350, 200 mM sodium malonate
|
Resolution 2.00 Å
R-free 0.221
|
|
9CX2
Crystal structure of HLA-A*03:01 L156Q mutant in complex with a mutant PIK3CA peptide
Deposited 2024-07-30
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277.15 K；10% w/v polyethylene glycol 20,000, 100 mM MES
|
Resolution 2.30 Å
R-free 0.219
|
|
9D73
CryoEM structure of anti-MHC-I mAb B1.23.2 complex with HLA-B44:05
Deposited 2024-08-16
|
Different construct
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.02 Å
|
|
9D74
CryoEM structure of anti-MHC-I Fab B1.23.2 complex with HLA-B44:05
Deposited 2024-08-16
|
Different construct
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.31 Å
|
|
9D95
TRAV35/TRBV20 TCR - HLA-B38 complex
Deposited 2024-08-21
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
SO4 SULFATE ION × 1
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 4
P6G HEXAETHYLENE GLYCOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293.15 K；0.1M Bis-Tris, pH6.5, 22%PEG3350, 0.2M (NH4)2SO4
|
Resolution 2.80 Å
R-free 0.235
|
|
9D95
TRAV35/TRBV20 TCR - HLA-B38 complex
Deposited 2024-08-21
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
SO4 SULFATE ION × 1
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2
P6G HEXAETHYLENE GLYCOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293.15 K；0.1M Bis-Tris, pH6.5, 22%PEG3350, 0.2M (NH4)2SO4
|
Resolution 2.80 Å
R-free 0.235
|
|
9D95
TRAV35/TRBV20 TCR - HLA-B38 complex
Deposited 2024-08-21
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain L
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
SO4 SULFATE ION × 2
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5
P6G HEXAETHYLENE GLYCOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293.15 K；0.1M Bis-Tris, pH6.5, 22%PEG3350, 0.2M (NH4)2SO4
|
Resolution 2.80 Å
R-free 0.235
|
|
9D95
TRAV35/TRBV20 TCR - HLA-B38 complex
Deposited 2024-08-21
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain Q
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
SO4 SULFATE ION × 1
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3
P6G HEXAETHYLENE GLYCOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293.15 K；0.1M Bis-Tris, pH6.5, 22%PEG3350, 0.2M (NH4)2SO4
|
Resolution 2.80 Å
R-free 0.235
|
|
9D96
KIR3DL1 - HLA-B38-YHL complex
Deposited 2024-08-21
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293.15 K；15% PEG 3350, 2% Tacsimate, pH 5.0, and 0.1 M trisodium citrate, pH 5.6
|
Resolution 2.40 Å
R-free 0.238
|
|
9D96
KIR3DL1 - HLA-B38-YHL complex
Deposited 2024-08-21
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293.15 K；15% PEG 3350, 2% Tacsimate, pH 5.0, and 0.1 M trisodium citrate, pH 5.6
|
Resolution 2.40 Å
R-free 0.238
|
|
9D97
KIR3DL1 - HLA-B*38-YHE complex
Deposited 2024-08-21
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293.15 K；15% PEG 3350, 2% Tacsimate, pH 5.0, 0.1 M Na3citrate, pH 5.6
|
Resolution 1.60 Å
R-free 0.195
|
|
9D97
KIR3DL1 - HLA-B*38-YHE complex
Deposited 2024-08-21
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293.15 K；15% PEG 3350, 2% Tacsimate, pH 5.0, 0.1 M Na3citrate, pH 5.6
|
Resolution 1.60 Å
R-free 0.195
|
|
9DBT
Crystal structure of human astrovirus 1 capsid spike bound to human neonatal Fc receptor
Deposited 2024-08-23
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain D
21–119（99 aa）
Chain G
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.1；295.15 K；Sodium chloride, Ammonium sulfate, BIS-TRIS
|
Resolution 3.40 Å
R-free 0.263
|
|
9DBT
Crystal structure of human astrovirus 1 capsid spike bound to human neonatal Fc receptor
Deposited 2024-08-23
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain B
21–119（99 aa）
Chain J
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.1；295.15 K；Sodium chloride, Ammonium sulfate, BIS-TRIS
|
Resolution 3.40 Å
R-free 0.263
|
|
9DL1
Crystal Structure of HLA-A*02:01/NY-ESO-1 (SLLMWITQV) and a target specific TRACeR-I
Deposited 2024-09-10
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 8
PDB declaration: octameric
|
Chain C
21–119（99 aa）
Fragment：UNP residues 21-119
Chain G
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
SO4 SULFATE ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M Sodium Sulfate and 20% w/v PEG 3350
|
Resolution 2.30 Å
R-free 0.265
|
|
9DY8
Crystal structure of HLA-B*18:01 in complex with PEMTFFSVK, an 9-mer epitope from Influenza B
Deposited 2024-10-13
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
PEG DI(HYDROXYETHYL)ETHER × 5
NA SODIUM ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2M Lithium Acetate and 20% polyethylene glycol 3350
|
Resolution 2.00 Å
R-free 0.248
|
|
9EK6
Crystal structure of MAIT TCR in complex with MR1-5FU
Deposited 2024-12-01
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
TDR THYMINE × 1
GOL GLYCEROL × 3
ACT ACETATE ION × 1
CA CALCIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；295 K；PEG3350, sodium acetate, BTP
|
Resolution 2.22 Å
R-free 0.210
|
|
9EK6
Crystal structure of MAIT TCR in complex with MR1-5FU
Deposited 2024-12-01
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain F
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
TDR THYMINE × 1
GOL GLYCEROL × 4
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；295 K；PEG3350, sodium acetate, BTP
|
Resolution 2.22 Å
R-free 0.210
|
|
9EK7
Crystal structure of MAIT TCR in complex with MR1-5FdU
Deposited 2024-12-01
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain H
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
YC6 1-(2-deoxy-alpha-D-erythro-pentofuranosyl)-5-methylpyrimidine-2,4(1H,3H)-dione × 1
GOL GLYCEROL × 3
ACT ACETATE ION × 3
CL CHLORIDE ION × 1
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；295 K；PEG3350, sodium acetate, BTP
|
Resolution 2.15 Å
R-free 0.206
|
|
9EK7
Crystal structure of MAIT TCR in complex with MR1-5FdU
Deposited 2024-12-01
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain F
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 4
ACT ACETATE ION × 2
THM THYMIDINE × 1
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；295 K；PEG3350, sodium acetate, BTP
|
Resolution 2.15 Å
R-free 0.206
|
|
9F13
Crystal structure of HLA-C*12:02 in complex with KAYNVTQAF (KF9), a 9-mer epitope from SARS-CoV-2 Nucleocapsid (N266-274)
Deposited 2024-04-18
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；2% PEG400, 20% PEG3350
|
Resolution 1.61 Å
R-free 0.231
|
|
9FE1
Cryo-EM structure of the ternary DARPin NY_1/HLA-A0201/NY-ESO1 complex.
Deposited 2024-05-17
|
Different construct
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4；25 mM HEPES, 150 mM NaCl, pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.10 Å
|
|
9GV6
Structure of TCR in complex with peptide-HLA
Deposited 2024-09-23
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M Sodium citrate tribasic dihydrate, 0.1 M Bis-Tris propane pH 7.5, and 20 % w/v PEG 3350
|
Resolution 2.77 Å
R-free 0.274
|
|
9GV6
Structure of TCR in complex with peptide-HLA
Deposited 2024-09-23
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain H
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M Sodium citrate tribasic dihydrate, 0.1 M Bis-Tris propane pH 7.5, and 20 % w/v PEG 3350
|
Resolution 2.77 Å
R-free 0.274
|
|
9GV7
Structure of reverse docking TCR in complex with peptide-HLA
Deposited 2024-09-23
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M MMT pH 9, 25% PEG 1500
|
Resolution 1.86 Å
R-free 0.212
|
|
9HI7
Structure of MC.7.G5 T cell receptor in complex with MR1 R9H
Deposited 2024-11-24
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；50 mM HEPES pH 7.0, 250 mM NaCl and 11% PEG 8000
|
Resolution 2.81 Å
R-free 0.296
|
|
9HI7
Structure of MC.7.G5 T cell receptor in complex with MR1 R9H
Deposited 2024-11-24
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain G
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；50 mM HEPES pH 7.0, 250 mM NaCl and 11% PEG 8000
|
Resolution 2.81 Å
R-free 0.296
|
|
9HKQ
Structure of VHH5 targeting NY-ESO-1(SLLMWITQC)/HLA-A*02:01
Deposited 2024-12-04
|
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain C
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.30 Å
|
|
9HLJ
Crystal structure of GV37-TCR in complex with HLA-C*12:02 with KAYNVTQAF (KF9), a 9-mer epitope from SARS-CoV-2 Nucleocapsid (N266-274)
Deposited 2024-12-05
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 2
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M Magnesium formate dihydrate, 20% PEG3350
|
Resolution 2.54 Å
R-free 0.257
|
|
9IKY
Crystal structure of 1-2C-T96F TCR in complex with HLA-A*11:01 bound to KRAS-G12V peptide (VVGAVGVGK)
Deposited 2024-06-29
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain p
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.1 M Magnesium chloride hexahydrate,
0.1 M Sodium HEPES (pH 7.0)
15% w/v PEG 4000.
|
Resolution 3.45 Å
R-free 0.234
|
|
9IKY
Crystal structure of 1-2C-T96F TCR in complex with HLA-A*11:01 bound to KRAS-G12V peptide (VVGAVGVGK)
Deposited 2024-06-29
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 10
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain k
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.1 M Magnesium chloride hexahydrate,
0.1 M Sodium HEPES (pH 7.0)
15% w/v PEG 4000.
|
Resolution 3.45 Å
R-free 0.234
|
|
9IKY
Crystal structure of 1-2C-T96F TCR in complex with HLA-A*11:01 bound to KRAS-G12V peptide (VVGAVGVGK)
Deposited 2024-06-29
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 11
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain u
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.1 M Magnesium chloride hexahydrate,
0.1 M Sodium HEPES (pH 7.0)
15% w/v PEG 4000.
|
Resolution 3.45 Å
R-free 0.234
|
|
9IKY
Crystal structure of 1-2C-T96F TCR in complex with HLA-A*11:01 bound to KRAS-G12V peptide (VVGAVGVGK)
Deposited 2024-06-29
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.1 M Magnesium chloride hexahydrate,
0.1 M Sodium HEPES (pH 7.0)
15% w/v PEG 4000.
|
Resolution 3.45 Å
R-free 0.234
|
|
9IKY
Crystal structure of 1-2C-T96F TCR in complex with HLA-A*11:01 bound to KRAS-G12V peptide (VVGAVGVGK)
Deposited 2024-06-29
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.1 M Magnesium chloride hexahydrate,
0.1 M Sodium HEPES (pH 7.0)
15% w/v PEG 4000.
|
Resolution 3.45 Å
R-free 0.234
|
|
9IKY
Crystal structure of 1-2C-T96F TCR in complex with HLA-A*11:01 bound to KRAS-G12V peptide (VVGAVGVGK)
Deposited 2024-06-29
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain L
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.1 M Magnesium chloride hexahydrate,
0.1 M Sodium HEPES (pH 7.0)
15% w/v PEG 4000.
|
Resolution 3.45 Å
R-free 0.234
|
|
9IKY
Crystal structure of 1-2C-T96F TCR in complex with HLA-A*11:01 bound to KRAS-G12V peptide (VVGAVGVGK)
Deposited 2024-06-29
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 5
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain Q
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.1 M Magnesium chloride hexahydrate,
0.1 M Sodium HEPES (pH 7.0)
15% w/v PEG 4000.
|
Resolution 3.45 Å
R-free 0.234
|
|
9IKY
Crystal structure of 1-2C-T96F TCR in complex with HLA-A*11:01 bound to KRAS-G12V peptide (VVGAVGVGK)
Deposited 2024-06-29
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 6
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain V
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.1 M Magnesium chloride hexahydrate,
0.1 M Sodium HEPES (pH 7.0)
15% w/v PEG 4000.
|
Resolution 3.45 Å
R-free 0.234
|
|
9IKY
Crystal structure of 1-2C-T96F TCR in complex with HLA-A*11:01 bound to KRAS-G12V peptide (VVGAVGVGK)
Deposited 2024-06-29
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 7
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain a
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.1 M Magnesium chloride hexahydrate,
0.1 M Sodium HEPES (pH 7.0)
15% w/v PEG 4000.
|
Resolution 3.45 Å
R-free 0.234
|
|
9IKY
Crystal structure of 1-2C-T96F TCR in complex with HLA-A*11:01 bound to KRAS-G12V peptide (VVGAVGVGK)
Deposited 2024-06-29
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 8
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain f
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.1 M Magnesium chloride hexahydrate,
0.1 M Sodium HEPES (pH 7.0)
15% w/v PEG 4000.
|
Resolution 3.45 Å
R-free 0.234
|
|
9IKY
Crystal structure of 1-2C-T96F TCR in complex with HLA-A*11:01 bound to KRAS-G12V peptide (VVGAVGVGK)
Deposited 2024-06-29
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 9
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain f
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.1 M Magnesium chloride hexahydrate,
0.1 M Sodium HEPES (pH 7.0)
15% w/v PEG 4000.
|
Resolution 3.45 Å
R-free 0.234
|
|
9J4S
Structural basis for recognition of SARS-CoV-2 conserved nucleocapside epitopes by dominant T cell receptors
Deposited 2024-08-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain H
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 5
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；291 K；0.1M Tris-base/hydrochloric acid (pH 7.0), 0.2 M lithium sulfate, and 1.9 M ammonium sulfate
|
Resolution 2.95 Å
R-free 0.238
|
|
9J4S
Structural basis for recognition of SARS-CoV-2 conserved nucleocapside epitopes by dominant T cell receptors
Deposited 2024-08-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain D
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；291 K；0.1M Tris-base/hydrochloric acid (pH 7.0), 0.2 M lithium sulfate, and 1.9 M ammonium sulfate
|
Resolution 2.95 Å
R-free 0.238
|
|
9J4S
Structural basis for recognition of SARS-CoV-2 conserved nucleocapside epitopes by dominant T cell receptors
Deposited 2024-08-10
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 10
PDB declaration: decameric
|
Chain D
21–119（99 aa）
Chain H
21–119（99 aa）
|
Not recorded
|
SO4 SULFATE ION × 9
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；291 K；0.1M Tris-base/hydrochloric acid (pH 7.0), 0.2 M lithium sulfate, and 1.9 M ammonium sulfate
|
Resolution 2.95 Å
R-free 0.238
|
|
9J4T
Structural basis for recognition of SARS-CoV-2 conserved nucleocapside epitopes by dominant T cell receptors
Deposited 2024-08-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；0.1 M ammonium citrate dibasic, and 20% (w/v) PEG 3350
|
Resolution 2.04 Å
R-free 0.232
|
|
9J4U
Structural basis for recognition of SARS-CoV-2 conserved nucleocapside epitopes by dominant T cell receptors
Deposited 2024-08-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；0.2 M potassium sodium tartrate tetrahydrate, and 20% (w/v) PEG 3350
|
Resolution 2.17 Å
R-free 0.239
|
|
9J4V
Structural basis for recognition of SARS-CoV-2 conserved nucleocapside epitopes by dominant T cell receptors
Deposited 2024-08-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
P6G HEXAETHYLENE GLYCOL × 1
PEG DI(HYDROXYETHYL)ETHER × 1
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；0.1 HEPES (pH 7.5), 0.2 M ammonium acetate, and 24% (w/v) PEG 3350
|
Resolution 1.98 Å
R-free 0.243
|
|
9J4V
Structural basis for recognition of SARS-CoV-2 conserved nucleocapside epitopes by dominant T cell receptors
Deposited 2024-08-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
21–119（99 aa）
|
Not recorded
|
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；0.1 HEPES (pH 7.5), 0.2 M ammonium acetate, and 24% (w/v) PEG 3350
|
Resolution 1.98 Å
R-free 0.243
|
|
9K2I
Rac1 epitope specific TCR 5934 binding to Rac1P29S-HLA-A2
Deposited 2024-10-17
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；0.2M Potassium Citrate, 21% PEG 4000, 0.1M Hepes, pH7.0
|
Resolution 3.05 Å
R-free 0.290
|
|
9K2I
Rac1 epitope specific TCR 5934 binding to Rac1P29S-HLA-A2
Deposited 2024-10-17
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；0.2M Potassium Citrate, 21% PEG 4000, 0.1M Hepes, pH7.0
|
Resolution 3.05 Å
R-free 0.290
|
|
9K2I
Rac1 epitope specific TCR 5934 binding to Rac1P29S-HLA-A2
Deposited 2024-10-17
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain L
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；0.2M Potassium Citrate, 21% PEG 4000, 0.1M Hepes, pH7.0
|
Resolution 3.05 Å
R-free 0.290
|
|
9K2I
Rac1 epitope specific TCR 5934 binding to Rac1P29S-HLA-A2
Deposited 2024-10-17
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain Q
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；0.2M Potassium Citrate, 21% PEG 4000, 0.1M Hepes, pH7.0
|
Resolution 3.05 Å
R-free 0.290
|
|
9K2R
Human T cell receptor (TRAV24*01/TRBV27*01) in complex with HLA-C*1202 and IY11 peptide
Deposited 2024-10-18
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；0.1M HEPES pH7.0, 1.6M ammonium sulfate, 0.2M sodium thiocyanate
|
Resolution 2.98 Å
R-free 0.233
|
|
9K2R
Human T cell receptor (TRAV24*01/TRBV27*01) in complex with HLA-C*1202 and IY11 peptide
Deposited 2024-10-18
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；0.1M HEPES pH7.0, 1.6M ammonium sulfate, 0.2M sodium thiocyanate
|
Resolution 2.98 Å
R-free 0.233
|
|
9K2R
Human T cell receptor (TRAV24*01/TRBV27*01) in complex with HLA-C*1202 and IY11 peptide
Deposited 2024-10-18
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain H
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；0.1M HEPES pH7.0, 1.6M ammonium sulfate, 0.2M sodium thiocyanate
|
Resolution 2.98 Å
R-free 0.233
|
|
9K2S
Killer cell immunoglobulin-like receptor 2DL2 in complex with HLA-C*1202 and IY10 peptide
Deposited 2024-10-18
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
1–119（119 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2M K/Na tartrate, 20% PEG 3350
|
Resolution 2.40 Å
R-free 0.299
|
|
9K2T
Crystal structure of HLA-C*1202 in complex with IY10 peptide
Deposited 2024-10-18
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；293 K；PEG
|
Resolution 2.20 Å
R-free 0.243
|
|
9K2U
Crystal structure of HLA-C*1202 in complex with IY11V9A peptide
Deposited 2024-10-18
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2M Sodium bromide, 20% (w/v) PEG 3350
|
Resolution 2.10 Å
R-free 0.247
|
|
9L47
Crystal structure of HLA-C*12:03-MY9
Deposited 2024-12-20
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277.15 K；0.2 M Lithium sulfate 0.1M Tris pH8.5 30% w/v PEG4,000
|
Resolution 2.80 Å
R-free 0.265
|
|
9L47
Crystal structure of HLA-C*12:03-MY9
Deposited 2024-12-20
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277.15 K；0.2 M Lithium sulfate 0.1M Tris pH8.5 30% w/v PEG4,000
|
Resolution 2.80 Å
R-free 0.265
|
|
9L48
Crystal structure of HLA-C*12:02-RV9
Deposited 2024-12-20
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
20–119（100 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277.15 K；0.2 M sodium citrate tribasic dihydrate, 20% w/v Polyethylene glycol 3,350
|
Resolution 1.90 Å
R-free 0.204
|
|
9L49
Crystal structure of HLA-C*12:03-RV9
Deposited 2024-12-20
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277.15 K；1.5 M Ammonium sulfate 0.1 M Sodium HEPES pH7.5 2% v/v PEG400
|
Resolution 3.00 Å
R-free 0.235
|
|
9L4A
Crystal structure of HLA-C*12:02-MY9
Deposited 2024-12-20
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277.15 K；0.2M Sodium formate 0.1M Bis-Tris propane pH8.5 20% w/v PEG3,350
|
Resolution 1.90 Å
R-free 0.207
|
|
9L4A
Crystal structure of HLA-C*12:02-MY9
Deposited 2024-12-20
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277.15 K；0.2M Sodium formate 0.1M Bis-Tris propane pH8.5 20% w/v PEG3,350
|
Resolution 1.90 Å
R-free 0.207
|
|
9L4G
Crystal structure of HLA-C*14:03 complexed with 8-mer HIV gag peptide
Deposited 2024-12-20
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
20–119（100 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；277.15 K；6% v/v 2-Propanol, 0.1 M Sodium acetate trihydrate pH 4.5 and 26% v/v Polyethylene glycol monomethyl ether 550
|
Resolution 2.70 Å
R-free 0.255
|
|
9L4H
Crystal structure of HLA-C*14:03 complexed with KIR2DL2
Deposited 2024-12-20
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
20–119（100 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277.15 K；0.2 M Potassium phosphate dibasic and 20% w/v Polyethylene glycol 3,350
|
Resolution 3.10 Å
R-free 0.252
|
|
9L4I
Crystal structure of HLA-C*14:02 complexed with KIR2DL2
Deposited 2024-12-20
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277.15 K；0.2 M Potassium citrate tribasic monohydrate and 20% w/v Polyethylene glycol 3,350
|
Resolution 2.50 Å
R-free 0.253
|
|
9MDA
Conformational flexibility in HLA-B8: peptide tuning structural and dynamical changes
Deposited 2024-12-05
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；12.5-16% PEG 4000,100mM citrate acid pH5.5 ,100mM ammonium acetate
|
Resolution 1.60 Å
R-free 0.239
|
|
9MEF
Conformational flexibility in HLA-B8: peptide tuning structural and dynamical changes
Deposited 2024-12-06
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；15% PEG4000, 0.1m citrate acid pH5.4, 0.2M ammonium acetate
|
Resolution 1.27 Å
R-free 0.227
|
|
9MEG
Conformational flexibility in HLA-B8: peptide tuning structural and dynamical changes
Deposited 2024-12-06
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；50% PEG4000, 20% citrate acid pH5.5, 0.1M ammonium acetate
|
Resolution 1.61 Å
R-free 0.227
|
|
9MI6
Crystal structure of human FcRn in complex with nipocalimab Fab fragment
Deposited 2024-12-12
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；277.15 K；10% PEG 1000, 10% PEG 8000
|
Resolution 2.41 Å
R-free 0.248
|
|
9MIN
Structure of a designed minibinder to NYESO1-A*02:01
Deposited 2024-12-13
|
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Mutation：insertion of MG at N-terminus - cloning artifact
|
GOL GLYCEROL × 10
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；0.2 M ammonium acetate
0.1 M bis-tris pH 5.5
25% PEG 3350
|
Resolution 2.05 Å
R-free 0.267
|
|
9MIN
Structure of a designed minibinder to NYESO1-A*02:01
Deposited 2024-12-13
|
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain G
21–119（99 aa）
|
Mutation：insertion of MG at N-terminus - cloning artifact
|
GOL GLYCEROL × 6
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；0.2 M ammonium acetate
0.1 M bis-tris pH 5.5
25% PEG 3350
|
Resolution 2.05 Å
R-free 0.267
|
|
9MS0
Structure of cord Blood MAIT A2 TCR in complex with human MR1-5-OP-RU
Deposited 2025-01-09
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–118（98 aa）
|
Not recorded
|
Q87 1-deoxy-1-({2,6-dioxo-5-[(E)-(2-oxopropylidene)amino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-ribitol × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；295 K；PEG3350, Na-acetate, BTP
|
Resolution 2.52 Å
R-free 0.213
|
|
9NAV
CryoEM structure of human astrovirus 1 spike in complex with human neonatal Fc receptor
Deposited 2025-02-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 10
PDB declaration: decameric
|
Chain H
21–119（99 aa）
Chain J
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.81 Å
|
|
9NFB
Structure of the cross-HLA supertype antibody R302 bound to a class I MHC presenting a divarasib-modified KRAS-G12C peptide on HLA-A*02
Deposited 2025-02-21
|
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
A1AWR 1-{(3S)-4-[(7M)-7-[6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl]-6-chloro-8-fluoro-2-{[(2S)-1-methylpyrrolidin-2-yl]methoxy}quinazolin-4-yl]-3-methylpiperazin-1-yl}propan-1-one × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE；blot time 4 s
blot force 5
|
Resolution 3.23 Å
|
|
9NFC
Structure of the cross-HLA supertype antibody R302 bound to a class I MHC presenting a divarasib-modified KRAS-G12C peptide on HLA-A*03
Deposited 2025-02-21
|
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
A1AWR 1-{(3S)-4-[(7M)-7-[6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl]-6-chloro-8-fluoro-2-{[(2S)-1-methylpyrrolidin-2-yl]methoxy}quinazolin-4-yl]-3-methylpiperazin-1-yl}propan-1-one × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE；blot time 4 s
blot force 5
|
Resolution 2.58 Å
|
|
9NKH
Conformational flexibility in HLA-B8: peptide tuning structural and dynamical changes
Deposited 2025-02-28
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.4；298 K；25% PEG3350, 0.1M Tris pH8.4, 0.1M (NH4)2SO4, 90mM Cesium chloride
|
Resolution 1.94 Å
R-free 0.259
|
|
9NKH
Conformational flexibility in HLA-B8: peptide tuning structural and dynamical changes
Deposited 2025-02-28
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.4；298 K；25% PEG3350, 0.1M Tris pH8.4, 0.1M (NH4)2SO4, 90mM Cesium chloride
|
Resolution 1.94 Å
R-free 0.259
|
|
9NMU
TCR156 bound to HLA A*02:01-PAP
Deposited 2025-03-04
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 7
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；295 K；0.2 M Sodium malonate, 0.1 M bis Tris-propane pH 7.5, 17% PEG 3500
|
Resolution 2.10 Å
R-free 0.227
|
|
9NMV
TCR156 S32Halpha bound to HLA A*02:01-PAP
Deposited 2025-03-04
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 6
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.5；295 K；0.2 M Sodium malonate, 0.1 M bis Tris-propane pH 7.5, 20% PEG3500
|
Resolution 1.97 Å
R-free 0.217
|
|
9NMW
TCR156 S30Ealpha S32Qalpha bound to HLA A*02:01-PAP
Deposited 2025-03-04
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 11
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.5；295 K；0.2 M Na2SO4, bis tris propane pH 7.5, 20% PEG 3350
|
Resolution 2.11 Å
R-free 0.232
|
|
9NMX
TCR156 S32Malpha variant bound to HLA A*02:01-PAP
Deposited 2025-03-04
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
MLI MALONATE ION × 2
GOL GLYCEROL × 12
NA SODIUM ION × 1
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.5；295 K；0.2 M Sodium malonate, 0.1 M bis Tris-propane pH 7.5, 17% PEG 3500
|
Resolution 2.19 Å
R-free 0.229
|
|
9NMY
TCR156 S32Qalpha bound to HLA A*02:01-PAP
Deposited 2025-03-04
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 9
MLI MALONATE ION × 1
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.3；295 K；0.2 M sodium malonat, 20% PEG 3350
|
Resolution 2.01 Å
R-free 0.227
|
|
9NNF
Cryo-EM structure of a de-novo designed binder NY1-B04 in complex with HLA-A*02:01 and NY-ESO-1-derived peptide SLLMWITQC
Deposited 2025-03-05
|
Different construct
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain C
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.80 Å
|
|
9NW6
CA147v24 Fab bound to HLA-E-VL9
Deposited 2025-03-21
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M potassium iodide, 0.1 M MES pH 6.5, 25% PEG 4000
|
Resolution 3.10 Å
R-free 0.258
|
|
9NW6
CA147v24 Fab bound to HLA-E-VL9
Deposited 2025-03-21
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain D
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M potassium iodide, 0.1 M MES pH 6.5, 25% PEG 4000
|
Resolution 3.10 Å
R-free 0.258
|
|
9NW7
CA117v2v8 Fab bound to HLA-E-VL9
Deposited 2025-03-21
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M ammonium acetate, 0.1 M HEPES pH 7.5, 25% PEG 3350
|
Resolution 2.10 Å
R-free 0.233
|
|
9NW8
CA117v2v8 Fab bound to HLA-E-Mtb44
Deposited 2025-03-21
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M magnesium acetate, 20% PEG 3350
|
Resolution 2.30 Å
R-free 0.246
|
|
9NW9
CA117v2v8 Fab bound to HLA-E-RL9HIV
Deposited 2025-03-21
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M magnesium chloride, 20% PEG 3350
|
Resolution 2.30 Å
R-free 0.239
|
|
9NYN
Conformational flexibility in HLA-B8: peptide tuning structural and dynamical changes
Deposited 2025-03-27
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.4；298 K；15% PEG 4000, 0.1M Sodium cacodylate pH 5.4, 0.2M ammonium acetate
|
Resolution 1.43 Å
R-free 0.215
|
|
9O05
Structure of human MAIT A-F7 TCR in complex with human MR1-riboflavin
Deposited 2025-04-02
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
RBF RIBOFLAVIN × 1
ACT ACETATE ION × 1
GOL GLYCEROL × 2
CL CHLORIDE ION × 1
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.3；298 K；Bis-Tris-propane, PEG3350 and sodium acetate
|
Resolution 1.95 Å
R-free 0.201
|
|
9O05
Structure of human MAIT A-F7 TCR in complex with human MR1-riboflavin
Deposited 2025-04-02
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain F
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
RBF RIBOFLAVIN × 1
ACT ACETATE ION × 1
GOL GLYCEROL × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.3；298 K；Bis-Tris-propane, PEG3350 and sodium acetate
|
Resolution 1.95 Å
R-free 0.201
|
|
9O06
Structure of human MAIT A-F7 TCR in complex with human MR1-10-formylmethylflavin
Deposited 2025-04-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 8
PDB declaration: octameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
Chain F
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
A1B7N (7,8-dimethyl-2,4-dioxo-3,4-dihydrobenzo[g]pteridin-10(2H)-yl)acetaldehyde × 2
GOL GLYCEROL × 4
NA SODIUM ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.3；298 K；Bis-Tris-propane, PEG3350 and sodium acetate
|
Resolution 2.00 Å
R-free 0.210
|
|
9O07
Structure of human MAIT A-F7 TCR in complex with human MR1-lumiflavin
Deposited 2025-04-02
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain F
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
LFN LUMIFLAVIN × 1
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.3；298 K；Bis-Tris-propane, PEG3350 and sodium acetate
|
Resolution 1.97 Å
R-free 0.195
|
|
9O07
Structure of human MAIT A-F7 TCR in complex with human MR1-lumiflavin
Deposited 2025-04-02
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain H
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
LFN LUMIFLAVIN × 1
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.3；298 K；Bis-Tris-propane, PEG3350 and sodium acetate
|
Resolution 1.97 Å
R-free 0.195
|
|
9O08
Structure of human MAIT A-F7 TCR in complex with human MR1-lumichrome
Deposited 2025-04-02
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 2
LUM LUMICHROME × 1
CL CHLORIDE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.3；298 K；Bis-Tris-propane, PEG3350 and sodium acetate
|
Resolution 2.20 Å
R-free 0.220
|
|
9O08
Structure of human MAIT A-F7 TCR in complex with human MR1-lumichrome
Deposited 2025-04-02
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain F
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
GOL GLYCEROL × 3
LUM LUMICHROME × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.3；298 K；Bis-Tris-propane, PEG3350 and sodium acetate
|
Resolution 2.20 Å
R-free 0.220
|
|
9O4X
Gamma delta T cell receptor bound to CD1d
Deposited 2025-04-09
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
FO4 sphingomyelin × 1
1PE PENTAETHYLENE GLYCOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；16% PEG 3350, 0.05M CBTP pH 5
|
Resolution 2.86 Å
R-free 0.255
|
|
9O5S
minibinder-antigen complex BXMart1-3-MART1-HLA*A02
Deposited 2025-04-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 15
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；0.2M potassium thiocyanate, 20% w/v PEG 3350
|
Resolution 2.27 Å
R-free 0.234
|
|
9O5S
minibinder-antigen complex BXMart1-3-MART1-HLA*A02
Deposited 2025-04-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain D
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 6
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；0.2M potassium thiocyanate, 20% w/v PEG 3350
|
Resolution 2.27 Å
R-free 0.234
|
|
9O5S
minibinder-antigen complex BXMart1-3-MART1-HLA*A02
Deposited 2025-04-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain I
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 12
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；0.2M potassium thiocyanate, 20% w/v PEG 3350
|
Resolution 2.27 Å
R-free 0.234
|
|
9O5S
minibinder-antigen complex BXMart1-3-MART1-HLA*A02
Deposited 2025-04-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain M
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 12
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；0.2M potassium thiocyanate, 20% w/v PEG 3350
|
Resolution 2.27 Å
R-free 0.234
|
|
9OC6
Crystal structure of receptor FcRn bound to Human Astrovirus 6 spike
Deposited 2025-04-23
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain D
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；0.1M HEPES, 30% 1,2-propanediol, 20% PEG-400
|
Resolution 2.97 Å
R-free 0.281
|
|
9OC7
Crystal structure of FcRn in complex with Human Astrovirus 2 spike
Deposited 2025-04-23
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain F
21–119（99 aa）
Chain Z
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.9；293 K；25% 1,2-propanediol, 10% glycerol, 5% PEG-3000, 0.1 M phosphate-citrate
|
Resolution 3.07 Å
R-free 0.239
|
|
9OHT
CD1c presenting GD3 ganglioside
Deposited 2025-05-05
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
20–119（100 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
A1CB5 (2S)-2,3-dihydroxypropyl heptadecanoate × 1
KZF 2-(cyclohexylazaniumyl)ethanesulfonate × 1
MLA MALONIC ACID × 2
A1CB4 (2S,3R,4E)-3-hydroxy-2-octadecanamidooctadec-4-en-1-yl 5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranonosyl-(2->8)-5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranonosyl-(2->3)-beta-D-galactopyranosyl-(1->4)-beta-D-glucopyranoside × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 9.46；293 K；0.1 M CHES pH 9.46
1.05 M tri-Na citrate
0.025 M tri-glycine
|
Resolution 2.98 Å
R-free 0.251
|
|
9OHU
CD1c presenting GM3 ganglioside
Deposited 2025-05-05
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
20–119（100 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
A1CB5 (2S)-2,3-dihydroxypropyl heptadecanoate × 1
KZF 2-(cyclohexylazaniumyl)ethanesulfonate × 1
MLA MALONIC ACID × 2
CL CHLORIDE ION × 2
A1CB6 (2S,3R,4E)-3-hydroxy-2-octadecanamidooctadec-4-en-1-yl 5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranonosyl-(2->3)-beta-D-galactopyranosyl-(1->4)-beta-D-glucopyranoside × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 9.46；293 K；0.1 M CHES pH 9.46
1.05 M tri-Na Citrate
0.025 M tri-glycine
|
Resolution 2.90 Å
R-free 0.272
|
|
9OHV
CD1c presenting dual lipids MPM and GD3 ganglioside
Deposited 2025-05-05
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–118（98 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
A1CB4 (2S,3R,4E)-3-hydroxy-2-octadecanamidooctadec-4-en-1-yl 5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranonosyl-(2->8)-5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranonosyl-(2->3)-beta-D-galactopyranosyl-(1->4)-beta-D-glucopyranoside × 1
MK0 1-O-[(S)-hydroxy{[(4S,8S,16S,20S)-4,8,12,16,20-pentamethylheptacosyl]oxy}phosphoryl]-beta-D-mannopyranose × 1
CL CHLORIDE ION × 1
KZF 2-(cyclohexylazaniumyl)ethanesulfonate × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 9.46；293 K；0.1 M CHES pH 9.46
1.05 M tri-Na Citrate
0.025 M tri-glycine
|
Resolution 2.12 Å
R-free 0.260
|
|
9OHW
CD1c presenting GM1 ganglioside
Deposited 2025-05-05
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
20–118（99 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
MK0 1-O-[(S)-hydroxy{[(4S,8S,16S,20S)-4,8,12,16,20-pentamethylheptacosyl]oxy}phosphoryl]-beta-D-mannopyranose × 1
GGG glycylglycylglycine × 3
KZF 2-(cyclohexylazaniumyl)ethanesulfonate × 3
MLA MALONIC ACID × 1
A1CB7 (2S,3R,4E)-3-hydroxy-2-octadecanamidooctadec-4-en-1-yl 5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranonosyl-(2->3)-[beta-D-galactopyranosyl-(1->3)-2-acetamido-2-deoxy-beta-D-galactopyranosyl-(1->4)]-beta-D-galactopyranosyl-(1->4)-beta-D-glucopyranoside × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 9.46；293 K；0.1 M CHES pH 9.46
1.05 M tri-Na Citrate
0.025 M tri-glycine
|
Resolution 2.50 Å
R-free 0.246
|
|
9OHX
CD1c presenting endogenous lipids
Deposited 2025-05-05
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
20–119（100 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
KZF 2-(cyclohexylazaniumyl)ethanesulfonate × 3
EKG (2R)-2,3-dihydroxypropyl hexadecanoate × 1
D10 DECANE × 1
D12 DODECANE × 1
R16 HEXADECANE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 9.4；293 K；100 mM CHES, 1.05 M sodium citrate, 25 mM triglycine
|
Resolution 1.68 Å
R-free 0.217
|
|
9OHY
CD1c presenting phosphomycoketide in its open conformation
Deposited 2025-05-05
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
20–119（100 aa）
|
Not recorded
|
Z7B (4S,8S,16S,20S)-4,8,12,16,20-pentamethylheptacosyl dihydrogen phosphate × 1
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
D12 DODECANE × 2
KZF 2-(cyclohexylazaniumyl)ethanesulfonate × 3
GGG glycylglycylglycine × 1
MLA MALONIC ACID × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 9.46；293 K；0.1 M CHES pH 9.46
1.05 M tri-Na Citrate
0.025 M tri-glycine
|
Resolution 2.20 Å
R-free 0.242
|
|
9OHZ
Crystal structure of CD1a presenting ganglioside GD3
Deposited 2025-05-05
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
20–119（100 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
A1CB9 N-{(2S,3R)-1-[(4-O-beta-D-galactopyranosyl-beta-D-glucopyranosyl)oxy]-3-hydroxyoctadecan-2-yl}tetracosanamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；21% PEG 1500, 0.1M MMT pH 5.5
|
Resolution 2.14 Å
R-free 0.247
|
|
9OI0
Crystal structure of CD1b presenting ganglioside GD3
Deposited 2025-05-05
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–118（98 aa）
|
Not recorded
|
IOD IODIDE ION × 4
CL CHLORIDE ION × 2
EDO 1,2-ETHANEDIOL × 3
A1CDL N-{(2S,3R,4E)-1-[(4-O-beta-D-galactopyranosyl-beta-D-glucopyranosyl)oxy]-3-hydroxyoctadec-4-en-2-yl}octadecanamide × 1
CUY tetracosyl octadecanoate × 1
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；22% PEG 3350, 0.1 M Sodium Iodide
|
Resolution 1.84 Å
R-free 0.266
|
|
9PBG
TCR 19.2 complex with YEIH-HLA B*27:05
Deposited 2025-06-26
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 9
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；295 K；0.2 M sodium malonate pH 6.4
17% PEG 3350
|
Resolution 2.00 Å
R-free 0.258
|
|
9PBH
AS19.2 TCR complex with PSG5-HLA B*27:05
Deposited 2025-06-26
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 2
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；295 K；0.2 M sodium formate; 20% PEG 3350
|
Resolution 2.13 Å
R-free 0.246
|
|
9PIX
Mur14 Fab with HBV c18V pMHC
Deposited 2025-07-11
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；300 K；0.2 M NH4F, 20% PEG3350
|
Resolution 2.35 Å
R-free 0.235
|
|
9PKC
Mur35 Fab with HBV c18V pMHC
Deposited 2025-07-14
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；300 K；0.15 M NH4F + 15% PEG3350
|
Resolution 2.50 Å
R-free 0.302
|
|
9PKF
Mur35 Fab with HBV c18I pMHC
Deposited 2025-07-14
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；300 K；0.2 M NH4F + 20% PEG3350
|
Resolution 2.60 Å
R-free 0.303
|
|
9PKV
HU-38 Fab with PRAME pMHC
Deposited 2025-07-14
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.72 Å
|
|
9QQE
Cryo-EM structure of the SN230G6 Fab - HLA-A*02:01 human alloantibody-HLA complex
Deposited 2025-03-31
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4；1X Phosphate-Buffered Saline (PBS)
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.78 Å
|
|
9QQF
Cryo-EM structure of the WIM8E5 Fab - HLA-A*11:01 human alloantibody-HLA complex
Deposited 2025-03-31
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
1–119（119 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4；1X Phosphate-Buffered Saline (PBS)
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.23 Å
|
|
9QWJ
Crystal structure of S2c TCR in complex with CD1c
Deposited 2025-04-14
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–118（98 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 4
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 4
BMA beta-D-mannopyranose × 1
D12 DODECANE × 2
CA CALCIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M Sodium cacodylate trihydrate pH 6.4, 0.2 M Calcium chloride dihydrate, 16 % (w/v) PEG 3350 and 3 % (w/v) 1,6-Hexanediol
|
Resolution 2.04 Å
R-free 0.235
|
|
9QWJ
Crystal structure of S2c TCR in complex with CD1c
Deposited 2025-04-14
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain N
21–118（98 aa）
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 3
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2
BMA beta-D-mannopyranose × 1
CA CALCIUM ION × 2
D10 DECANE × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M Sodium cacodylate trihydrate pH 6.4, 0.2 M Calcium chloride dihydrate, 16 % (w/v) PEG 3350 and 3 % (w/v) 1,6-Hexanediol
|
Resolution 2.04 Å
R-free 0.235
|
|
9QWK
Crystal structure of S2c-a5b6 TCR in complex with CD1c
Deposited 2025-04-14
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain A
21–118（98 aa）
Chain B
21–118（98 aa）
|
Not recorded
|
D10 DECANE × 2
EDO 1,2-ETHANEDIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M Sodium thiocyanate and 20 % (w/v) PEG 3350
|
Resolution 2.27 Å
R-free 0.253
|
|
9QWK
Crystal structure of S2c-a5b6 TCR in complex with CD1c
Deposited 2025-04-14
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain G
21–118（98 aa）
Chain J
21–118（98 aa）
|
Not recorded
|
D10 DECANE × 2
EDO 1,2-ETHANEDIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M Sodium thiocyanate and 20 % (w/v) PEG 3350
|
Resolution 2.27 Å
R-free 0.253
|
|
9QWK
Crystal structure of S2c-a5b6 TCR in complex with CD1c
Deposited 2025-04-14
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain L
21–118（98 aa）
Chain O
21–118（98 aa）
|
Not recorded
|
D10 DECANE × 2
EDO 1,2-ETHANEDIOL × 1
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
FUC alpha-L-fucopyranose × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M Sodium thiocyanate and 20 % (w/v) PEG 3350
|
Resolution 2.27 Å
R-free 0.253
|
|
9QWK
Crystal structure of S2c-a5b6 TCR in complex with CD1c
Deposited 2025-04-14
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain Q
21–118（98 aa）
Chain T
21–118（98 aa）
|
Not recorded
|
D10 DECANE × 2
EDO 1,2-ETHANEDIOL × 1
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M Sodium thiocyanate and 20 % (w/v) PEG 3350
|
Resolution 2.27 Å
R-free 0.253
|
|
9RCV
Structure of the Human Peptide-Loading Complex Arrested by HCMV US6
Deposited 2025-05-29
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 9
PDB declaration: nonameric
|
Chain D
1–119（119 aa）
Chain H
1–119（119 aa）
|
Not recorded
|
ATP ADENOSINE-5'-TRIPHOSPHATE × 1
MG MAGNESIUM ION × 2
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2
ADP ADENOSINE-5'-DIPHOSPHATE × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 6.5；20 mM HEPES-NaOH pH 6.5, 150 mM NaCl, 10 mM MgCl2, 2.5 mM biotin, 0.05% (w/v) glycodiosgenin
cryo-EM vitrification conditions
Cryogen ETHANE；Blot force 5, Blot time 5 s
|
Resolution 2.70 Å
|
|
9RUP
Cryo-EM structure of TCRpub/pMHC dimer
Deposited 2025-07-04
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 10
PDB declaration: decameric
|
Chain E
21–119（99 aa）
Chain e
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4；30 mM HEPES pH 7.4, 150 mM NaCl
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 4.11 Å
|
|
9RXM
Cryo-EM structure of TCRpriv/pMHC
Deposited 2025-07-11
|
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain F
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4；30 mM HEPES pH 7.4, 150 mM NaCl
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.00 Å
|
|
9SKO
Crystal structure of HLA-A0201 in complex with peptide LLWNGPMAVS
Deposited 2025-09-02
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
NA SODIUM ION × 8
GOL GLYCEROL × 4
CL CHLORIDE ION × 11
EDO 1,2-ETHANEDIOL × 10
PEG DI(HYDROXYETHYL)ETHER × 1
PG4 TETRAETHYLENE GLYCOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291.15 K；0.2 M Ammonium nitrate, 0.1M HEPES 7.5, 20% w/v PEG Smear Broad
BCS Screen E9
|
Resolution 1.49 Å
R-free 0.204
|
|
9SKP
Crystal structure of HLA-A0201 in complex with peptide SLLWNGPMAV
Deposited 2025-09-02
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
CL CHLORIDE ION × 5
EDO 1,2-ETHANEDIOL × 13
NA SODIUM ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；291.15 K；0.005M Nickel(II)chloride hexahydrate, 0.1 M TRIS 7.5 20% w/v PEG 4000
Clear Strategy 2 F9
|
Resolution 1.89 Å
R-free 0.229
|
|
9SL0
Crystal structure of HLA-A0201 in complex with peptide LLWNGPMAV
Deposited 2025-09-02
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
NA SODIUM ION × 2
EDO 1,2-ETHANEDIOL × 2
CL CHLORIDE ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291.15 K；0.005 M Cadmium chloride hemi(pentahydrate), 0.1 M Tris 8.5, 20% w/v PEG 4000
Clear-Strategy-Screen-II H3
|
Resolution 1.60 Å
R-free 0.264
|
|
9UV8
Crystal structure of HLA-A*11:01 in complex with KRAS G12D 9-mer peptide (VVGADGVGK)
Deposited 2025-05-09
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；27% PEG3350,0.1M Bis-Tris,0.2M Lithium sulfate,additve 0.1M Spermidine
|
Resolution 1.79 Å
R-free 0.231
|
|
9UVI
Crystal structure of beta 2 microglobulin in complex with antibody BBM.1
Deposited 2025-05-10
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain C
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277.15 K；0.2 M Sodium acetate trihydrate 0.1 M Bis-Tris propane 8.5 20 % w/v PEG 3350
|
Resolution 2.50 Å
R-free 0.246
|
|
9WBD
Crystal structure of HLA-B*07:02 in complex with SPR epitope and Q04 TCR
Deposited 2025-08-13
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain D
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；289 K；Tris-HCl, calcium chloride, PEG 3350
|
Resolution 2.75 Å
R-free 0.270
|
|
9WBD
Crystal structure of HLA-B*07:02 in complex with SPR epitope and Q04 TCR
Deposited 2025-08-13
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain I
21–119（99 aa）
|
Not recorded
|
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；289 K；Tris-HCl, calcium chloride, PEG 3350
|
Resolution 2.75 Å
R-free 0.270
|
|
9WBD
Crystal structure of HLA-B*07:02 in complex with SPR epitope and Q04 TCR
Deposited 2025-08-13
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain N
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；289 K；Tris-HCl, calcium chloride, PEG 3350
|
Resolution 2.75 Å
R-free 0.270
|
|
9WBD
Crystal structure of HLA-B*07:02 in complex with SPR epitope and Q04 TCR
Deposited 2025-08-13
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain S
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；289 K；Tris-HCl, calcium chloride, PEG 3350
|
Resolution 2.75 Å
R-free 0.270
|
|
9WVE
Crystal structure of HLA-A*11:01 in complex with KRAS G12A 10-mer peptide (VVVGAAGVGK)
Deposited 2025-09-19
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；23% PEG3350, 0.1M Bis-Tris, PH5.8, 0.2M Lithium sulfate
|
Resolution 2.80 Å
R-free 0.267
|
|
9WVE
Crystal structure of HLA-A*11:01 in complex with KRAS G12A 10-mer peptide (VVVGAAGVGK)
Deposited 2025-09-19
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；23% PEG3350, 0.1M Bis-Tris, PH5.8, 0.2M Lithium sulfate
|
Resolution 2.80 Å
R-free 0.267
|
|
9WVE
Crystal structure of HLA-A*11:01 in complex with KRAS G12A 10-mer peptide (VVVGAAGVGK)
Deposited 2025-09-19
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain H
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；23% PEG3350, 0.1M Bis-Tris, PH5.8, 0.2M Lithium sulfate
|
Resolution 2.80 Å
R-free 0.267
|
|
9WVE
Crystal structure of HLA-A*11:01 in complex with KRAS G12A 10-mer peptide (VVVGAAGVGK)
Deposited 2025-09-19
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain K
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；23% PEG3350, 0.1M Bis-Tris, PH5.8, 0.2M Lithium sulfate
|
Resolution 2.80 Å
R-free 0.267
|
|
9WVF
Crystal structure of HLA-A*11:01 in complex with KRAS G12S 10-mer peptide (VVVGASGVGK)
Deposited 2025-09-19
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；29% PEG3350,0.1M Bis-Tris,PH5.2,0.2M Lithium sulfate
|
Resolution 2.80 Å
R-free 0.291
|
|
9WVF
Crystal structure of HLA-A*11:01 in complex with KRAS G12S 10-mer peptide (VVVGASGVGK)
Deposited 2025-09-19
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；29% PEG3350,0.1M Bis-Tris,PH5.2,0.2M Lithium sulfate
|
Resolution 2.80 Å
R-free 0.291
|
|
9WVF
Crystal structure of HLA-A*11:01 in complex with KRAS G12S 10-mer peptide (VVVGASGVGK)
Deposited 2025-09-19
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain H
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；29% PEG3350,0.1M Bis-Tris,PH5.2,0.2M Lithium sulfate
|
Resolution 2.80 Å
R-free 0.291
|
|
9WVF
Crystal structure of HLA-A*11:01 in complex with KRAS G12S 10-mer peptide (VVVGASGVGK)
Deposited 2025-09-19
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain K
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；29% PEG3350,0.1M Bis-Tris,PH5.2,0.2M Lithium sulfate
|
Resolution 2.80 Å
R-free 0.291
|
|
9WYD
Crystal structure of HAstV8 spike and FcRn
Deposited 2025-09-26
|
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
21–119（99 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIQUID DIFFUSION；291.15 K；0.1 M BICINE pH 8.5, 8% w/v Polyethylene glycol monomethyl ether 5,000
|
Resolution 2.65 Å
R-free 0.232
|
|
9Y0T
Crystal structure of human MAIT A-F7 TCR-MR1*02-5-OP-RU complex
Deposited 2025-08-29
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain B
21–119（99 aa）
Chain F
21–119（99 aa）
|
Not recorded
|
Q87 1-deoxy-1-({2,6-dioxo-5-[(E)-(2-oxopropylidene)amino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-ribitol × 2
ACT ACETATE ION × 1
CL CHLORIDE ION × 1
GOL GLYCEROL × 2
NA SODIUM ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG 3350, BTP, Cacl2
|
Resolution 2.30 Å
R-free 0.218
|
|
9Y0U
Crystal structure of human MAIT A-F7 TCR-MR1*03-5-OP-RU complex
Deposited 2025-08-29
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 8
PDB declaration: octameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
Chain F
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
ACY ACETIC ACID × 2
Q87 1-deoxy-1-({2,6-dioxo-5-[(E)-(2-oxopropylidene)amino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-ribitol × 2
GOL GLYCEROL × 8
CL CHLORIDE ION × 1
NA SODIUM ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG 3350, BTP, CaCl2
|
Resolution 2.10 Å
R-free 0.187
|
|
9Y0V
Crystal Structure of human MAIT A-F7 TCR-MR1*04 complex
Deposited 2025-08-29
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG 6000, HEPES, Lithium Chloride
|
Resolution 3.00 Å
R-free 0.244
|
|
9Y0V
Crystal Structure of human MAIT A-F7 TCR-MR1*04 complex
Deposited 2025-08-29
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain F
21–119（99 aa）
|
Not recorded
|
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG 6000, HEPES, Lithium Chloride
|
Resolution 3.00 Å
R-free 0.244
|
|
9Y0W
Crystal Structure of human MAIT A-F7 TCR-MR1*05-5-OP-RU complex
Deposited 2025-08-29
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 8
PDB declaration: octameric
|
Chain B
21–119（99 aa）
Chain F
21–119（99 aa）
|
Not recorded
|
Q87 1-deoxy-1-({2,6-dioxo-5-[(E)-(2-oxopropylidene)amino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-ribitol × 2
GOL GLYCEROL × 3
NA SODIUM ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG 3350, BTP, CaCl2
|
Resolution 2.40 Å
R-free 0.217
|
|
9YTD
Designed antibody vAB66 targeting PAP-HLA A*02:01
Deposited 2025-10-20
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.3
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.50 Å
|
|
9YTF
TCR mimic antibody vAB-30 in complex with MAGE-A3 in HLA-A1
Deposited 2025-10-20
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain B
21–119（99 aa）
Fragment：UNP residues 21-119
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.60 Å
|
